var images_info;if (!images_info) images_info =[]; images_info["72"]={"72000":{"type":"graphic_diagnosticimage","displayName":"Pelvic neuroblastoma","title":"Pelvic neuroblastoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pelvic neuroblastoma</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/PEDS/72000_Pelvic_neuroblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI of a large pelvic neuroblastoma with extension into the spine.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.</div><div id=\"graphicVersion\">Graphic 72000 Version 3.0</div></div></div>"},"72001":{"type":"graphic_figure","displayName":"Breast quadrants","title":"Breast quadrants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast quadrants</div><div class=\"cntnt\"><img style=\"width:364px; height:230px;\" src=\"images/PC/72001_Breast_quadrants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The breasts are divided into four quadrants with nipple as the center.</div><div class=\"graphic_footnotes\">UO: upper outer; UI: upper inner; LO: lower outer; LI: lower inner.</div><div id=\"graphicVersion\">Graphic 72001 Version 1.0</div></div></div>"},"72002":{"type":"graphic_table","displayName":"Physical findings in edema","title":"Major physical findings in edematous states","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major physical findings in edematous states</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Disorder</td>\n\n      <td class=\"subtitle1\">Pulmonary edema</td>\n\n      <td class=\"subtitle1\">Central venous pressure</td>\n\n      <td class=\"subtitle1\">Ascites and/or pedal edema</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left-sided heart failure</td>\n\n      <td>+</td>\n\n      <td>Variable</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right-sided heart failure</td>\n\n      <td>-</td>\n\n      <td>&#8593;</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cirrhosis </td>\n\n      <td>-</td>\n\n      <td>&#8595;-Normal</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Renal disease</td>\n\n      <td>Variable</td>\n\n      <td>&#8593;</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Nephrotic syndrome </td>\n\n      <td>-</td>\n\n      <td>Variable</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Idiopathic edema</td>\n\n      <td>-</td>\n\n      <td>&#8595;-Normal</td>\n\n      <td>+</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Venous insufficiency </td>\n\n      <td>-</td>\n\n      <td>Normal</td>\n\n      <td>+, edema may be asymmetric</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72002 Version 1.0</div></div></div>"},"72006":{"type":"graphic_figure","displayName":"Expected height of the uterine fundus by month of pregnancy","title":"Expected height of the uterine fundus by month of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Expected height of the uterine fundus by month of pregnancy</div><div class=\"cntnt\"><img style=\"width:462px; height:355px;\" src=\"images/SURG/72006_Expect_ht_uterine_fundus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72006 Version 1.0</div></div></div>"},"72007":{"type":"graphic_figure","displayName":"BMD and fracture risk by age","title":"BMD and fracture risk by age","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">BMD and fracture risk by age</div><div class=\"cntnt\"><img style=\"width:606px; height:631px;\" src=\"images/ENDO/72007_BMDfracriskagePR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Bone loss begins in the third decade of life in both sexes. The data are from the Epidemiological Follow-up Study cohort of the NHANES I, a nationally representative sample of noninstitutionalized civilians who were followed for a maximum of 22 years. A cohort of 2879 Caucasian men (1437 in the bone density subsample) aged 45 to 74 years at baseline (1971 to 1975) were observed through 1992<SUP>[1]</SUP>.<br />(B) Age is a more critical determinant of fracture risk than bone mass in humans. Data are from a follow-up of 521 Caucasian women over an average of 6.5 years with repeated bone mass measurements at the radius. A total of 138 nonspinal fractures in 3388 person-years were detected, and the incident fractures were cross-classified by age and bone mass. The incidence of fracture was then fitted to a log-linear model in age and bone mass<SUP>[2]</SUP>.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; NHANES: National Health and Nutrition Examination Survey.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int 1998; 8:468.</li>&#xD;&#xA;    <li>Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81:1804.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Manolagas SC. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266. Copyright &copy; 2010 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 72007 Version 4.0</div></div></div>"},"72008":{"type":"graphic_picture","displayName":"Scrofuloderma ulcer","title":"Scrofuloderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scrofuloderma</div><div class=\"cntnt\"><img style=\"width:270px; height:270px;\" src=\"images/DERM/72008_Scrofuloderma_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A draining, ulcerated nodule is present on the flank.</div><div class=\"graphic_reference\">Courtesy of the Research Institute for Tropical Medicine, Philippines.</div><div id=\"graphicVersion\">Graphic 72008 Version 1.0</div></div></div>"},"72009":{"type":"graphic_diagnosticimage","displayName":"Dreiling tube","title":"Dreiling tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dreiling tube</div><div class=\"cntnt\"><img style=\"width:396px; height:383px;\" src=\"images/GAST/72009_Dreiling_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic image showing proper placement of the double-lumen gastroduodenal (Dreiling) collection tube for performance of direct pancreatic function testing. The proximal lumen is situated in the gastric antrum to collect and discard gastric secretion. The distal lumen is deep within the duodenum with the tip of the tube at the ligament of Treitz for continuous collection of duodenal fluid.</div><div class=\"graphic_reference\">Courtesy of Cleveland Clinic Foundation.</div><div id=\"graphicVersion\">Graphic 72009 Version 2.0</div></div></div>"},"72011":{"type":"graphic_picture","displayName":"Erythema ab igne","title":"Erythema ab igne","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema ab igne</div><div class=\"cntnt\"><img style=\"width:396px; height:338px;\" src=\"images/DERM/72011_Erythema_ab_igne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reticular, erythematous and hyperpigmented area on the back of a patient who used to sit in close proximity of a heating radiator.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer Health. Copyright Â© 2011.</div><div id=\"graphicVersion\">Graphic 72011 Version 3.0</div></div></div>"},"72012":{"type":"graphic_picture","displayName":"Laparoscopic Heller myotomy with Toupet fundoplication","title":"Laparoscopic Heller myotomy with Toupet fundoplication","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic Heller myotomy with Toupet fundoplication</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/72012_Laparo_Heller_myo_Toupet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an intraopertive photograph showing the edge of the Toupet fundoplication sutures to the edge of the myotomy. The procedure was performed laparoscopically.</div><div id=\"graphicVersion\">Graphic 72012 Version 2.0</div></div></div>"},"72013":{"type":"graphic_picture","displayName":"Distal subungual onychomycosis - toenail","title":"Distal subungual onychomycosis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Distal subungual onychomycosis</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/DERM/72013_Distal_sub_onych_toenail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail discoloration and subungual hyperkeratosis are present on the nail. The area immediately adjacent to the cuticle is not yet involved.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72013 Version 4.0</div></div></div>"},"72014":{"type":"graphic_table","displayName":"Microbiology CAP site of care","title":"Microbial etiology of community-acquired pneumonia by site of care*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbial etiology of community-acquired pneumonia by site of care*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Outpatients</td> <td class=\"subtitle1\" colspan=\"2\">Ward patients</td> <td class=\"subtitle1\" colspan=\"2\">Intensive care unit patients</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;Spain<sup>[1</sup><sup>]</sup></td> <td class=\"subtitle2\">Canada<sup>[2] </sup></td> <td class=\"subtitle2\">Spain<sup>[1]</sup></td> <td class=\"subtitle2\">United States<sup>[3]</sup></td> <td class=\"subtitle2\">Spain<sup>[1]</sup></td> <td class=\"subtitle2\">United States<sup>[3]</sup></td> </tr> <tr> <td>Total patients evaluated</td> <td>514</td> <td>507</td> <td>2521</td> <td>585</td> <td>488</td> <td>145</td> </tr> <tr> <td>Patients in whom a pathogen was identified</td> <td>161 (31.3)</td> <td>244 (48.1)</td> <td>1042 (41)</td> <td>120 (21)</td> <td>260 (53)</td> <td>57 (39)</td> </tr> <tr class=\"divider_bottom\"> <td>Patients in whom no pathogen was identified</td> <td>353 (68.7)</td> <td>263 (51.9)</td> <td>1479 (59)</td> <td>465 (79)</td> <td>228 (47)</td> <td>88 (61)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Pathogen<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"><em>Streptococcus pneumoniae</em></td> <td>56 (10.9)</td> <td>30 (5.9)</td> <td>447 (17.7)</td> <td>38 (6.5)</td> <td>110 (22.5)</td> <td>22 (15.2)</td> </tr> <tr> <td class=\"indent1\">Other <em>Streptococcus spp</em></td> <td>0</td> <td>5 (1.0)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus influenza</em></td> <td>8 (1.6)</td> <td>25 (4.9)</td> <td>54 (2.1)</td> <td>16 (2.7)</td> <td>8 (1.6)</td> <td>3 (2.1)</td> </tr> <tr> <td class=\"indent1\"><em>Haemophilus parainfluenzae</em></td> <td>0</td> <td>10 (2.0)</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Moraxella cattarrhalis</em></td> <td>0</td> <td>6 (1.2)</td> <td>4 (0.2)</td> <td>0</td> <td>1 (0.2)</td> <td>0</td> </tr> <tr> <td class=\"indent1\"><em>Legionella pneumophila</em></td> <td>10 (1.9)</td> <td>&#916;</td> <td>87 (3.5)</td> <td>&#9674;</td> <td>21 (4.3)</td> <td>&#9674;</td> </tr> <tr> <td class=\"indent1\"><em>Mycoplasma pneumoniae</em></td> <td>27 (5.3)<sup>&#167;</sup></td> <td>87 (17.2)<sup>&#167;</sup></td> <td>32 (1.3)<sup>&#167;</sup></td> <td>&#165;</td> <td>6 (1.2)<sup>&#167;</sup></td> <td>&#165;</td> </tr> <tr> <td class=\"indent1\"><em>Chlamydia pneumoniae</em></td> <td>10 (1.9)<sup>&#167;</sup></td> <td>72 (14.2)<sup>&#167;</sup></td> <td>32 (1.3)<sup>&#167;</sup></td> <td>&#165;</td> <td>8 (1.6)<sup>&#167;</sup></td> <td>&#165;</td> </tr> <tr> <td class=\"indent1\"><em>Coxiella burnetii</em></td> <td>11 (2.1)<sup>&#167;</sup></td> <td>&#916;</td> <td>17 (0.7)<sup>&#167;</sup></td> <td>&#165;</td> <td>2 (0.4)<sup>&#167;</sup></td> <td>&#165;</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>1 (0.2)</td> <td>6 (1.2)</td> <td>18 (0.7)</td> <td>25 (4.3)</td> <td>6 (1.2)</td> <td>12 (8.3)</td> </tr> <tr> <td class=\"indent1\">MSSA</td> <td>1 (0.2)</td> <td>NR</td> <td>9 (0.4)</td> <td>18 (3.1)</td> <td>4 (0.8)</td> <td>9 (6.2)</td> </tr> <tr> <td class=\"indent1\">MRSA</td> <td>0</td> <td>NR</td> <td>9 (0.4)</td> <td>7 (1.2)</td> <td>2 (0.4)</td> <td>3 (2.1)</td> </tr> <tr> <td class=\"indent1\">Gram-negative enteric bacilli</td> <td>1 (0.2)</td> <td>2 (0.4)</td> <td>23 (0.9)</td> <td>15 (2.6)</td> <td>3 (0.6)</td> <td>4 (2.8)</td> </tr> <tr> <td class=\"indent1\"><em>Pseudomonas aeruginosa</em></td> <td>1 (0.2)</td> <td>1 (0.2)</td> <td>37 (1.5)</td> <td>12 (2.1)</td> <td>12 (2.5)</td> <td>8 (5.5)</td> </tr> <tr> <td class=\"indent1\">Respiratory viruses<sup>&#135;</sup></td> <td>15 (2.9)<sup>&#167;</sup></td> <td>&#134;</td> <td>123 (4.9)<sup>&#167;</sup></td> <td>&#134;</td> <td>10 (2.0)<sup>&#167;</sup></td> <td>&#134;</td> </tr> <tr> <td class=\"indent1\">Other pathogen</td> <td>6 (1.2)</td> <td>14 (2.8)</td> <td>33 (1.3)</td> <td>8 (1.4)</td> <td>15 (3.1)</td> <td>3 (2.1)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#62;1 pathogen</td> <td>15 (2.9)</td> <td>**</td> <td>135 (5.4)</td> <td>6 (1.0)</td> <td>58 (11.9)</td> <td>7 (4.8)</td> </tr> <tr> <td><strong>Diagnostic methods</strong></td> <td>Cultures (sputum, blood, transthoracic needle aspirate, transbronchial aspirates, BAL fluid, protected specimen brush respiratory samples, pleural fluid), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, <em>L. pneumophila</em>, <em>C. burnetti</em>, influenza A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus), urinary antigen testing (for <em>S. pneumoniae</em> and <em>L. pneumophila</em>), immunofluorescence assay plus virus isolation or reverse transcriptase PCR for influenza A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus</td> <td>Cultures (sputum, blood), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>)</td> <td>Cultures (sputum, blood, transthoracic needle aspirate, transbronchial aspirates, BAL fluid, protected specimen brush respiratory samples, pleural fluid), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, <em>L. pneumophila</em>, <em>C. burnetti</em>, influenza A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus), urinary antigen testing (for <em>S. pneumoniae</em> and <em>L. pneumophila</em>), immunofluorescence assay plus virus isolation or reverse transcriptase PCR for influenza A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus</td> <td>Cultures (blood, endotracheal aspirates, protected specimen brush respiratory samples, BAL fluid, pleural fluid), urinary antigen (for <em>L. pneumophila</em>)</td> <td>Cultures (sputum, blood, transthoracic needle aspirate, transbronchial aspirates, BAL fluid, protected specimen brush respiratory samples, pleural fluid), serologic testing (for <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, <em>L. pneumophila</em>, <em>C. burnetti</em>, influenza A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus), urinary antigen testing (for <em>S. pneumoniae</em> and <em>L. pneumophila</em>), immunofluorescence assay plus virus isolation or reverse transcriptase PCR for influenza A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus</td> <td>Cultures (blood, endotracheal aspirates, protected specimen brush respiratory samples, BAL fluid, pleural fluid), urinary antigen testing (for <em>L. pneumophila</em>)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <EM>Staphylococcus aureus</EM>; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; NR: not reported; BAL: bronchoalveolar lavage; PCR: polymerase chain reaction.<br />* Results are reported as number of patients (percent). Different methods were used for diagnosis in each study, as described in the row on diagnostic methods.<br />Â¶ Results are reported as the number of patients with a given pathogen, followed by the percentage of patients in whom the pathogen was identified out of all of the patients in the study. For example, in the first column, <EM>S. pneumoniae</EM> was detected in 30 of 507 patients in the study (5.9 percent). Among the 244 patients in whom a pathogen was identified, <EM>S. pneumoniae</EM> was detected in 12.3 percent.<br />Î Testing for <EM>Legionella </EM>spp and <EM>C. burnetti</EM> was not performed.<br /><FONT class=lozenge>â</FONT> <EM>Legionella</EM> urinary antigen testing was performed in 35 ward patients and 26 intensive care unit patients, but all results were negative. <EM>Legionella</EM> culture was not performed.<br />Â§ Pathogens detected by serologic methods may represent recent infection rather than active infection.<br />Â¥ Testing for <EM>M. pneumoniae</EM>, <EM>C. pneumoniae</EM>, and <EM>C. burnetii</EM> was not performed.<br />â¡ Influenza viruses A or B, parainfluenza viruses 1 to 3, respiratory syncytial virus, adenovirus.<br />â  Testing for viruses was not performed.<br />** Some patients had &gt;1 pathogen isolated, but the details were not reported.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>CillÃ³niz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340. </LI>&#xD;&#xA;<LI>Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Bnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Resp Medicine 2005; 99:60.</LI>&#xD;&#xA;<LI>Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133:610. </LI></OL></div><div id=\"graphicVersion\">Graphic 72014 Version 10.0</div></div></div>"},"72015":{"type":"graphic_table","displayName":"Severity of community-acquired pneumonia in infants and children","title":"Severity of community-acquired pneumonia in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity of community-acquired pneumonia in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Clinical features of mild pneumonia</td>\r\n                    <td class=\"subtitle1\">Clinical features of severe pneumonia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Temperature &#60;38.5&#176;C (101.3&#176;F)</td>\r\n                    <td>Temperature &#8805;38.5&#176;C (101.3&#176;F)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>\r\n                    <p>Mild or absent respiratory distress:</p>\r\n                    <ul>\r\n                        <li>Increased RR, but less than the age-specific RR that defines moderate to severe respiratory distress </li>\r\n                        <li>Mild or absent retractions </li>\r\n                        <li>No grunting </li>\r\n                        <li>No nasal flaring </li>\r\n                        <li>No apnea </li>\r\n                        <li>Mild shortness of breath </li>\r\n                    </ul>\r\n                    </td>\r\n                    <td>\r\n                    <p>Moderate to severe respiratory distress:</p>\r\n                    <ul>\r\n                        <li>RR &#62;70 breaths/minute for infants; RR &#62;50 breaths/minute for older children </li>\r\n                        <li>Moderate/severe suprasternal, intercostal, or subcostal retractions (&#60;12 months) </li>\r\n                        <li>Severe difficulty breathing (&#8805;12 months) </li>\r\n                        <li>Grunting </li>\r\n                        <li>Nasal flaring </li>\r\n                        <li>Apnea </li>\r\n                        <li>Significant shortness of breath </li>\r\n                    </ul>\r\n                    </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normal color</td>\r\n                    <td>Cyanosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normal mental status</td>\r\n                    <td>Altered mental status</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normoxemia (oxygen saturation &#8805;92 percent in room air)</td>\r\n                    <td>Hypoxemia (sustained oxygen saturation &#60;90 percent in room air at sea level)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normal feeding (infants); no vomiting</td>\r\n                    <td>Not feeding (infants) or signs of dehydration (older children)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Normal heart rate</td>\r\n                    <td>Tachycardia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Capillary refill &#60;2 seconds</td>\r\n                    <td>Capillary refill &#8805;2 seconds</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=95630&#38;amp;Mode=Edit&quot;&#62;&#60;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&#62;Edit Table&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">RR: respiratory rate.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25. </LI>&#xD;&#xA;<LI>Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: Update 2011. Thorax 2011; 66:ii1. </LI></OL></div><div id=\"graphicVersion\">Graphic 72015 Version 4.0</div></div></div>"},"72016":{"type":"graphic_figure","displayName":"Stroop test","title":"Stroop test","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Stroop test</div><div class=\"cntnt\"><img style=\"width:466px; height:598px;\" src=\"images/NEURO/72016_Stroop-test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Stroop Color&#160;Word&#160;Interference Test examines the ability to direct attention. After first confirming that the subject can appropriately read the color names and name the colors (top two panels), he/she is asked to name the color of the ink that the&#160;word is printed in (third panel). As an example, the patient should say for the first row of the third panel &quot;Blue, Green, Blue, Blue, Red, Green.&quot; The test is scored based on speed and accuracy.</div><div id=\"graphicVersion\">Graphic 72016 Version 1.0</div></div></div>"},"72017":{"type":"graphic_table","displayName":"Forms of early pubertal development","title":"Clinical characteristics of forms of early pubertal development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of forms of early pubertal development</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Nonprogressive precocious puberty</td> <td class=\"subtitle1\">Central precocious puberty (CPP)</td> <td class=\"subtitle1\">Peripheral precocity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Physical examination: Advancement through pubertal stages (Tanner stage)</strong></td> <td>No progression in Tanner staging during 3 to 6 months of observation</td> <td>Progression to next pubertal stage in 3 to 6 months</td> <td>Progression</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Growth velocity</strong></td> <td>Normal for bone age</td> <td>Accelerated (&#62;6 cm per year)*</td> <td>Accelerated*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Bone age</strong></td> <td>Normal to mildly advanced</td> <td>Advanced for height age</td> <td>Advanced for height age</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Serum estradiol concentration (girls)</strong><sup>&#182;</sup></td> <td>Prepubertal<sup>&#916;</sup></td> <td>Prepubertal to pubertal</td> <td>Increased in ovarian causes of peripheral precocity, or with exogenous estrogen exposure</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Serum testosterone concentration (boys, or girls with virilization)</strong><sup>&#182;</sup></td> <td>Prepubertal<sup>&#916;</sup></td> <td>Prepubertal to pubertal</td> <td>Pubertal and increasing</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Basal (unstimulated) serum LH concentration</strong><sup>&#182;</sup></td> <td>Prepubertal<sup>&#916;&#9674;</sup></td> <td>Pubertal<sup>&#9674;</sup></td> <td>Suppressed or prepubertal<sup>&#9674;</sup></td> </tr> <tr> <td><strong><sup></sup>GnRH (or GnRHa) stimulation test</strong><sup>&#182;</sup></td> <td> <p>LH peak in the prepubertal range<sup>&#916;</sup><sup>&#167;</sup></p> Lower stimulated LH to FSH ratio<sup>&#165;</sup></td> <td> <p>LH peak elevated (in the pubertal range)<sup>&#167;</sup></p> Higher stimulated LH to FSH ratio<sup>&#165;</sup></td> <td>No change from baseline, or LH peak in the prepubertal range</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CPP: central precocious puberty (also known as gonadotropin-dependent precocious puberty); LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; GnRHa: gonadotropin-releasing hormone agonist; FSH: follicle-stimulating hormone.<br />* UNLESS the patient has concomitant growth hormone deficiency (as in the case of a neurogenic form of CPP), or has already passed his or her peak height velocity at the time of evaluation, in which case growth velocity may be normal or decreased for chronological age.<br />Â¶ Using most commercially available immunoassays, serum concentrations of gonadal steroids have poor sensitivity to differentiate between prepubertal and early pubertal concentrations.<br />Î In most cases these levels will be prepubertal, however in children with intermittently progressive CPP, these levels may reach pubertal concentrations during times of active development.<br />â Using ultrasensitive assays with detection limit of LH &lt;0.1 mIU/L, prepubertal basal LH concentrations are &lt;0.2 to 0.3 mIU/L.<br />Â§&nbsp;In most laboratories, the upper limit of normal for LH after GnRH stimulation is 3.3 to 5.0 mIU/mL. Stimulated LH concentrations above this normal range suggests CPP.<br />Â¥&nbsp;A peak stimulated LH/FSH ratio &lt;0.66 usually suggests non-progressive precocious puberty, whereas a ratio &gt;0.66 is typically seen with CPP.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Oerter KE, Uriarte MM, Rose SR, et al. Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990; 71:1251.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Drs. Mark Palmert and Jennifer Harrington.</div><div id=\"graphicVersion\">Graphic 72017 Version 9.0</div></div></div>"},"72018":{"type":"graphic_table","displayName":"Clinical manifestations of Lyme disease","title":"Clinical manifestations of Lyme disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of Lyme disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Early localized disease, occurring a few days to one month after the tick bite*</td> </tr> <tr> <td class=\"indent1\">Erythema migrans - occurs in approximately 80 percent of patients</td> </tr> <tr> <td class=\"indent1\">Associated symptoms and signs may include: fatigue, malaise, lethargy, mild headache, mild neck stiffness, myalgias, arthralgias, regional lymphadenopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Early disseminated disease<sup>&#182;</sup>, occurring weeks to months after the tick bite*<sup>&#916;</sup></td> </tr> <tr> <td class=\"sublist2_start\">Carditis - about 1 percent&nbsp;of patients reported to the CDC<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\">Manifestations include AV nodal block, mild cardiomyopathy or myopericarditis</td> </tr> <tr> <td class=\"sublist2_start\">Neurologic disease - occurs in approximately 15 percent of untreated patients<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\">Manifestations include lymphocytic meningitis, cranial neuropathy (most often facial, can be bilateral), peripheral neuropathy; rarely myelitis or encephalitis</td> </tr> <tr> <td class=\"sublist2_start\">Musculoskeletal involvement - occurs in approximately 60 percent of untreated patients<sup>&#9674;</sup></td> </tr> <tr> <td class=\"sublist2\">Manifestations include migratory arthralgias</td> </tr> <tr> <td class=\"indent1\">Skin involvement - multiple erythema migrans lesions<sup>&#916;</sup>, borrelial lymphocytoma (in Europe)</td> </tr> <tr> <td class=\"indent1\">Lymphadenopathy - regional or generalized</td> </tr> <tr> <td class=\"indent1\">Eye involvement<sup>&#167;</sup> - conjunctivitis, iritis, choroiditis, vitritis, retinitis</td> </tr> <tr> <td class=\"indent1\">Liver disease - liver function test abnormalities, hepatitis</td> </tr> <tr> <td class=\"indent1\">Kidney disease - microhematuria, asymptomatic proteinuria</td> </tr> <tr> <td class=\"subtitle1_single\">Late or chronic disease<sup>&#182;</sup>, occurring months to years after the tick bite*</td> </tr> <tr> <td class=\"indent1\">Musculoskeletal symptoms - approximately 60 percent of untreated patients develop intermittent monoarticular or oligoarticular arthritis; approximately 10 percent of untreated patients develop persistent monoarthritis, usually affecting the knee</td> </tr> <tr> <td class=\"sublist2_start\">Neurologic disease - incidence has not been established</td> </tr> <tr> <td class=\"sublist2\">Peripheral neuropathy or encephalomyelitis (both rare)</td> </tr> <tr> <td class=\"indent1\">Cutaneous involvement - acrodermatitis chronica atrophicans, morphea/localized scleroderma-like lesions (both described only in Europe)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Only about 25 percent of patients with erythema migrans recall the tick bite that transmitted Lyme disease.<br />Â¶&nbsp;Can occur in the absence of any prior features of Lyme disease.<br />Î The multiple erythema migrans lesions of early disseminated disease typically occur days to weeks following infection.<br /><FONT class=lozenge>â</FONT> Incidence following treated erythema migrans is not known but is very low.<br />Â§ Observation based on individual case reports.</div><div id=\"graphicVersion\">Graphic 72018 Version 9.0</div></div></div>"},"72019":{"type":"graphic_table","displayName":"Rx uncomplicated falciparum malaria","title":"Drug regimens for treatment of uncomplicated <EM>Plasmodium falciparum</EM> malaria (or species not identified) in nonpregnant adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug regimens for treatment of uncomplicated <EM>Plasmodium falciparum</EM> malaria (or species not identified) in nonpregnant adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adults</td> <td class=\"subtitle1\">Children</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chloroquine-resistant or unknown resistance</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">All malarious regions except those specified as chloroquine-sensitive listed below. Middle Eastern countries with chloroquine-resistant <em>P. falciparu</em>m include Iran, Oman, Saudi Arabia, and Yemen.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>A. Artemisinin combination therapy</strong></td> <td>Regimens and doses summarized in separate table.</td> <td>Regimens and doses summarized in separate table.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>B. Atovaquone-proguanil*</strong><br /> Adult tab = 250 mg atovaquone/100 mg proguanil<br /> Pediatric tab = 62.5 mg atovaquone/25 mg proguanil</td> <td>4 adult tabs orally once daily for three days</td> <td> <p>5 to 8 kg: 2 pediatric tabs orally once daily for three days</p> <p>9 to 10 kg: 3 pediatric tabs orally once daily for three days</p> <p>11 to 20 kg: 1 adult tab orally once daily for three days</p> <p>21 to 30 kg: 2 adult tabs orally once daily for three days</p> <p>31 to 40 kg: 3 adult tabs orally once daily for three days</p> &#62;40 kg: 4 adult tabs orally once daily for three days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"5\"><strong>C. Quinine<sup>&#182;</sup> PLUS one of the following: doxycycline<sup>&#916;</sup>, tetracycline<sup>&#916;</sup>, or clindamycin</strong></td> <td>Quinine<sup>&#182;</sup>: 542 mg base ( = 650 mg salt) orally three times daily for three or seven days<sup>&#9674;</sup></td> <td>Quinine: 8.3 mg base/kg ( = 10 mg salt/kg) orally three times daily for three or seven days<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>PLUS</strong> one of the following:</td> <td><strong>PLUS</strong> one of the following:</td> </tr> <tr> <td class=\"indent2\">Doxycycline: 100 mg orally twice daily for seven days</td> <td class=\"indent2\">Doxycycline<sup>&#916;</sup>: 2.2 mg/kg orally twice daily for seven days</td> </tr> <tr> <td class=\"indent2\">Tetracycline: 250 mg orally four times daily for seven days</td> <td class=\"indent2\">Tetracycline<sup>&#916;</sup>: 6.25 mg/kg orally four times daily for seven days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Clindamycin: 20 mg base/kg/day (up to 1.8 grams) orally divided three times daily for seven days</td> <td class=\"indent2\">Clindamycin: 6.7 mg base/kg orally every 8 hours for seven days</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>D. Mefloquine<strong><sup><span style=\"font-size: 13px;\">&#167;</span></sup></strong><sup><span style=\"font-size: 13px;\">&#165;</span></sup></strong></td> <td>684 mg base ( = 750 mg salt) orally as initial dose, followed by 456 mg base ( = 500 mg salt) orally given 6 to 12 hours after initial dose. Total dose = 1250 mg salt.&nbsp;</td> <td>13.7 mg base/kg ( = 15 mg salt/kg maximum 750 mg) orally as initial dose, followed by 9.1 mg base/kg ( = 10 mg salt/kg) orally given 6 to 12 hours after initial dose. Total dose = 25 mg salt/kg.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_left\" colspan=\"3\"><strong>Chloroquine-sensitive</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"3\">Central America west of Panama Canal; Haiti; the Dominican Republic; and most of the Middle East. Infections acquired in Korea and the states of the former Soviet Union have been uniformly caused by <em>Plasmodium vivax</em> to date and should therefore be treated as chloroquine-sensitive infections.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Chloroquine</strong></td> <td>600 mg base ( = 1000 mg salt) orally immediately, followed by 300 mg base ( = 500 mg salt) orally at 6, 24, and 48 hours. Total dose: 1500 mg base ( = 2500 mg salt).</td> <td>10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg. Maximum total dose 1500 mg base ( = 2500 mg salt).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>OR</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><strong>Hydroxychloroquine</strong></td> <td>620 mg base ( = 800 mg salt) orally immediately, followed by 310 mg base ( = 400 mg salt) orally at 6, 24, and 48 hours. Total dose: 1550 mg base ( = 2000 mg salt).</td> <td>10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg. Maximum total dose 1550 mg base ( = 2000 mg salt).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The dosing regimens listed in this table are generally consistent with the United States Centers for Disease Control and Prevention (CDC) guidelines for the treatment of uncomplicated malaria in the United States (as revised July 2013) and may differ from dosing recommended in approved product information.<br />There are four options (A, B, C, or D) available for treatment of uncomplicated malaria caused by chloroquine-resistant <em>P. falciparum</em>. The World Health Organization (WHO) recommends option A as the first-line treatment for uncomplicated malaria. The CDC recommends options A (artemether-lumefantrine), B, and C equally. For option C, because there is more data on the efficacy of quinine in combination with doxycycline or tetracycline, these treatment combinations are generally preferred to quinine in combination with clindamycin. In addition, option C has higher incidence of adverse effects than options A or B. Because of a higher rate of severe neuropsychiatric reactions seen at treatment doses, option D (mefloquine) is recommended only when the other options cannot be used.</div><div class=\"graphic_footnotes\">* Take with food or whole milk. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose. It is also acceptable to take one-half of the dose twice daily.<br />Â¶ United States-manufactured quinine sulfate capsule is only available in a 324 mg (salt) strength; therefore, 2 capsules should be sufficient for adult dosing. Pediatric dosing may be difficult due to unavailability of noncapsule forms of quinine in the United States.<br />Î Doxycycline and tetracycline are not indicated for use in children less than eight years old. For children less than eight years old with chloroquine-resistant <EM>P. falciparum</EM>, atovaquone-proguanil and artemether-lumefantrine are recommended treatment options; mefloquine can be considered if no other options are available.<br /><FONT class=lozenge>â</FONT> For infections acquired in Southeast Asia, quinine treatment should continue for seven days. For infections acquired elsewhere, quinine treatment should continue for three days.<br />Â§ Treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance.<br />Â¥ Mefloquine is not recommended for children &lt;15 kg.</div><div class=\"graphic_reference\">Adapted from United States Centers for Disease Control guidelines for treatment of malaria: <a href=\"http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf</a> (Accessed March 22, 2016). CDC Malaria Hotline: (770) 488-7788 Monday to Friday 8:00 am to 4:30 pm EST; (770) 488-7100 after hours, weekends, and holiday.</div><div id=\"graphicVersion\">Graphic 72019 Version 9.0</div></div></div>"},"72022":{"type":"graphic_figure","displayName":"APC and wnt signaling pathway","title":"The APC gene, and possible pathogenetic mechanisms in familial adenomatous polyposis","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">The APC gene, and possible pathogenetic mechanisms in familial adenomatous polyposis</div><div class=\"cntnt\"><img style=\"width:530px; height:343px;\" src=\"images/ONC/72022_APC_and_wnt_signaling_pathw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The APC (adenomatous polyposis coli) gene modulates &#946;-catenin, Tcf transcriptional activation, and Wnt signal transduction.<br> (A) In the presence of wildtype APC or in the absence of Wnt ligand, &#946;-catenin is localized to the adherens junction where it is associated with E-cadherin, &#945;-catenin, p120cas, and indirectly with the cytoskeleton. GSK3&#946; phosphorylates &#946;-catenin in a complex that contains &#946;-catenin, APC, and axin family members, and &#946;-catenin is rapidly degraded by ubiquination at the proteosome.<br> (B) When APC is mutated, &#946;-catenin accumulates in the cytoplasm and the nucleus. Similarly, binding of Wnt ligand to its receptor, known as frizzled, inactivates the GSK3&#946; kinase through dishevelled, generating a cytosolic pool of &#946;-catenin. &#946;-catenin is associated with members of the Tcf family of transcription factors and modulates the transcription of target genes with Tcf recognition sequences. In some instances, &#946;-catenin increases transcription of target genes by competing for Tcf binding with corepressors, such as Groucho and CREB-binding protein (CBP), to relieve transcriptional repression.</div><div class=\"graphic_reference\">Reproduced with permission from: Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor supressor. J Clin Oncol 2000; 18:1967. Copyright &#169; 2000 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 72022 Version 3.0</div></div></div>"},"72024":{"type":"graphic_figure","displayName":"Hiatus hernia and rereflux","title":"Rereflux with hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rereflux with hiatus hernia</div><div class=\"cntnt\"><img style=\"width:410px; height:251px;\" src=\"images/GAST/72024_Hiatal_hernia_rereflux_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depiction of a radionuclide acid clearance study in a subject with a hiatus hernia. Fifteen seconds after the injection of a 15 mL bolus of 0.1 N HCl labeled with 200&nbsp;microcuries of 99mTc-sulfur colloid, subjects swallowed every 30 seconds. The vertical axis represents the region from the sternal notch to the stomach. The horizontal axis is the time scale. The radioactivity is represented by the black area and no radioactivity is represented by the absence of black color. Soon after injection, the radioactivity appears in the stomach. However, there is reflux of isotope into the esophagus followed by clearance of the isotope during each of the first three swallows.</div><div class=\"graphic_reference\">Reprinted with permission from: Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987; 92:130. Copyright 1987 by American Gastroenterological Association. This material may not be reproduced or distributed in any form or by any means without the proper written permission of the publisher.</div><div id=\"graphicVersion\">Graphic 72024 Version 5.0</div></div></div>"},"72025":{"type":"graphic_table","displayName":"Borderline ovarian CA survival","title":"Borderline carcinoma of the ovary: Five-year survival by stage (1993-95)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Borderline carcinoma of the ovary: Five-year survival by stage (1993-95)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">FIGO Stage</td> <td class=\"subtitle1\" colspan=\"2\">Tumors of low malignant potential</td> </tr> <tr> <td class=\"subtitle2\">Patients, number</td> <td class=\"subtitle2\">Five-year survival, percent</td> </tr> <tr> <td>IA</td> <td>296</td> <td>95.6</td> </tr> <tr> <td>IB</td> <td>28</td> <td>95.9</td> </tr> <tr> <td>IC</td> <td>90</td> <td>96.3</td> </tr> <tr> <td>IIA</td> <td>6</td> <td>100.0</td> </tr> <tr> <td>IIB</td> <td>7</td> <td>85.7</td> </tr> <tr> <td>IIC</td> <td>14</td> <td>59.5</td> </tr> <tr> <td>IIIA</td> <td>14</td> <td>71.4</td> </tr> <tr> <td>IIIB</td> <td>22</td> <td>62.0</td> </tr> <tr> <td>IIIC</td> <td>25</td> <td>45.0</td> </tr> <tr> <td>IV</td> <td>18</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from J Epidemiol Biostat 2001; 6:116.</div><div id=\"graphicVersion\">Graphic 72025 Version 3.0</div></div></div>"},"72026":{"type":"graphic_table","displayName":"Drug pleural eosinophilia","title":"Drug-induced pleural fluid eosinophilia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drug-induced pleural fluid eosinophilia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Frequent</td> </tr> <tr> <td class=\"indent1\">Fenfluramine*</td> </tr> <tr> <td class=\"indent1\">Dexfenfluramine*</td> </tr> <tr> <td class=\"indent1\">Warfarin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Practolol*</td> </tr> <tr> <td class=\"indent1\">Propylthiouracil</td> </tr> <tr> <td class=\"indent1\">Sulfasalazine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infrequent</td> </tr> <tr> <td class=\"indent1\">Acebutolol</td> </tr> <tr> <td class=\"indent1\">Clozapine</td> </tr> <tr> <td class=\"indent1\">Isotretinoin</td> </tr> <tr> <td class=\"indent1\">Mesalamine</td> </tr> <tr> <td class=\"indent1\">Nitrofurantoin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Simvastatin</td> </tr> <tr> <td class=\"indent1\">Trimipramine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rare</td> </tr> <tr> <td class=\"indent1\">Acyclovir</td> </tr> <tr> <td class=\"indent1\">Bromocriptine</td> </tr> <tr> <td class=\"indent1\">Crack cocaine</td> </tr> <tr> <td class=\"indent1\">Dantrolene<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Fluoxetine<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Gliclazide<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Imidapril</td> </tr> <tr> <td class=\"indent1\">Infliximab</td> </tr> <tr> <td class=\"indent1\">Tizanidine</td> </tr> <tr> <td class=\"indent1\">Valproic acid<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Vitamins B5/H</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>Frequent:</strong> 20-100 cases reported.<br /><strong>Infrequent:</strong> up to 10 cases reported.<br /><strong>Rare:</strong> single case report.</div><div class=\"graphic_footnotes\">* Drugs removed from market.<br />Â¶ Drugs associated with combined pleural fluid and&nbsp;peripheral blood&nbsp;eosinophilia.</div><div id=\"graphicVersion\">Graphic 72026 Version 3.0</div></div></div>"},"72027":{"type":"graphic_figure","displayName":"Rotator cuff muscles","title":"Rotator cuff muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rotator cuff muscles</div><div class=\"cntnt\"><img style=\"width:415px; height:531px;\" src=\"images/RHEUM/72027_Rotator_cuff_muscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four rotator cuff muscles pictured&nbsp;above serve important functions related to glenohumeral motion and stability.&nbsp;The picture at the top&nbsp;presents an anterior view and shows the&nbsp;subscapularis muscle&nbsp;inserting on the lesser tuberosity. The remaining muscles, seen best in the posterior view shown in the bottom picture,&nbsp;insert at the greater tuberosity.</div><div id=\"graphicVersion\">Graphic 72027 Version 5.0</div></div></div>"},"72028":{"type":"graphic_diagnosticimage","displayName":"Snowflake calficification on CT in brucellosis","title":"Snowflake calcification in chronic hepatosplenic brucellosis","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Snowflake calcification in chronic hepatosplenic brucellosis</div><div class=\"cntnt\"><img style=\"width:452px; height:345px;\" src=\"images/ID/72028_Snowflake_calc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Noncontrast CT of the liver of patient at the time of admission to the hospital, showing large calcium density without surrounding hypodensity. Serological test results at this time were as follows: rose bengal, negative; agglutination, negative; and Coombs' test, 1/80. Diagnoses of liver abscess and brucellosis were delayed.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Ariza J, Pigrau C, CaÃ±as C, et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis 2001; 32:1024. Copyright Â© 2001 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 72028 Version 4.0</div></div></div>"},"72029":{"type":"graphic_table","displayName":"Groups at high risk for influenza complications","title":"Groups at high risk for influenza complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Groups at high risk for influenza complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Children &#60;5 years, but especially &#60;2 years*</td> </tr> <tr> <td>Adults &#8805;65 years of age</td> </tr> <tr> <td>Persons with medical conditions including: <ul class=\"decimal_heading\"> <li>Asthma </li> <li>Chronic lung disease (eg, chronic obstructive pulmonary disease and cystic fibrosis) </li> <li>Heart disease (except hypertension) </li> <li>Kidney disorders </li> <li>Liver disorders </li> <li>Blood disorders (including sickle cell disease) </li> <li>Endocrine disorders (including diabetes mellitus) </li> <li>Metabolic disorders (including inherited metabolic disorders and mitochondrial disorders) </li> <li>Neurologic and neurodevelopmental conditions (including disorders of the brain, spinal cord, and peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, and spinal cord injury) </li> </ul> </td> </tr> <tr> <td>Immunosuppression due to disease or medications (including HIV, cancer, and chronic glucocorticoids)</td> </tr> <tr> <td>Women who are pregnant or postpartum (within two weeks after delivery)</td> </tr> <tr> <td>Children and adolescents &#60;19 years of age and receiving long-term aspirin therapy</td> </tr> <tr> <td>Native Americans and Alaskan Natives</td> </tr> <tr> <td>Extremely obese (body mass index [BMI] &#8805;40)</td> </tr> <tr> <td>Residents of nursing homes and other long-term care facilities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In young children, rates of hospitalization and mortality are greatest among those &lt;6 months of age.</div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. <A href=\"http://www.cdc.gov/flu/about/disease/high_risk.htm\" target=_blank>www.cdc.gov/flu/about/disease/high_risk.htm</A> (Accessed on August 24, 2017.)</div><div id=\"graphicVersion\">Graphic 72029 Version 17.0</div></div></div>"},"72030":{"type":"graphic_table","displayName":"Overview hip imaging children older than 10 years","title":"Overview of the use of various imaging modalities in the evaluation and management of common hip problems in children older than 10 years*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of the use of various imaging modalities in the evaluation and management of common hip problems in children older than 10 years*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Plain radiograph</td> <td class=\"subtitle1\">Ultrasonography</td> <td class=\"subtitle1\">Computed tomography</td> <td class=\"subtitle1\">Magnetic resonance imaging</td> <td class=\"subtitle1\">Radionuclide bone scan</td> <td class=\"subtitle1\">Arthrography</td> </tr> <tr> <td><strong>Slipped capital femoral epiphysis</strong></td> <td>Diagnosis: <ul> <li>Stable: Widening and irregularity of the capital femoral physis, osteopenia, increased density of metaphysis </li> <li>Unstable: Displacement of the capital femoral epiphysis </li> </ul> </td> <td>NA</td> <td>Treatment planning in advanced disease<sup>&#182;</sup></td> <td> <p>Early diagnosis (demonstrates physeal widening before apparent on plain films)</p> <p>Detection of complications (eg, avascular necrosis)</p> </td> <td>Detection of complications (eg, avascular necrosis)</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Pelvic apophyseal avulsions</strong></td> <td>Displacement of the apophyseal center from its normal position, callus formation, bony reaction</td> <td>NA</td> <td>NA</td> <td> <p>Useful in suspected avulsion injuries with negative radiographs</p> <p>Demonstrates bone marrow edema and soft tissue injuries at the site of avulsion; also may demonstrate physeal widening</p> </td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Iliopsoas tendinosis and bursitis</strong></td> <td>NA</td> <td> <p>Demonstrates enlarged bursa</p> <p>May guide bursal aspiration</p> </td> <td>NA</td> <td>Thickening with increased signal in the iliopsoas tendon with increased synovial fluid or hypertrophy of the bursa</td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Snapping hip syndrome</strong></td> <td>NA</td> <td> <p>Dynamic sonography can confirm the diagnosis</p> <p>In external snapping hip, the posterior iliotibial band or anterior portion of the gluteus maximus muscle catches over the greater trochanter</p> <p>In internal snapping hip, the iliopsoas tendon moves over the lesser trochanter</p> </td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Athletic pubalgia</strong></td> <td>Symmetric sclerosis of the pubic symphysis</td> <td>NA</td> <td>NA</td> <td> <p>Edema of the pubic body</p> <p>Injury to the insertion of the rectus abdominus muscle</p> </td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Stress fractures</strong></td> <td>Chronic stress reaction (may be normal in the early stage)</td> <td>NA</td> <td>NA</td> <td>Early detection (demonstrates bone marrow edema)</td> <td>Early detection (demonstrates increased uptake)</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Acetabular labral tear</strong></td> <td>NA</td> <td>NA</td> <td>NA</td> <td>MR arthrography shows the labral tear</td> <td>NA</td> <td>Demonstrates the labral tear; however, conventional arthrography has been replaced by MR arthrography</td> </tr> <tr class=\"divider_top\"> <td><strong>Femoroacetabular impingement</strong></td> <td> <p>Cam-type: Demonstrates a nonspherical femoral head or lack of femoral head-neck offset</p> <p>Pincer type: Acetabular overcoverage</p> </td> <td>NA</td> <td>NA</td> <td>Facilitates diagnosis of the type (cam or pincer) and demonstrates abnormalities of the femoral head, neck, and acetabulum</td> <td>NA</td> <td>NA</td> </tr> <tr class=\"divider_top\"> <td><strong>Idiopathic chondrolysis of the hip</strong></td> <td>Joint space narrowing and osteopenia, protrusion acetabuli, osteophyte formation, premature physeal fusion</td> <td>NA</td> <td>NA</td> <td>Early detection (shows cartilage loss, geometric abnormal signal in the proximal femoral epiphysis, acetabular bone marrow edema, synovial hypertrophy or enhancement, and minimal joint fluid)</td> <td>NA</td> <td>NA </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable; MR: magnetic resonance.<br />* This age range is approximate; these problems may occur in children outside this age group.<br />Â¶&nbsp;Use of computed tomography is limited because of the risk of radiation exposure.</div><div id=\"graphicVersion\">Graphic 72030 Version 4.0</div></div></div>"},"72031":{"type":"graphic_figure","displayName":"Functional end to end colocolic stapled anastomosis","title":"Functional end to end colocolic stapled anastomosis","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Functional end to end colocolic stapled anastomosis</div><div class=\"cntnt\"><img style=\"width:531px; height:683px;\" src=\"images/SURG/72031_Colocolic-stapled.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The functional end-to-end anastomosis is technically a side-to-side approach of constructing an anastomosis between the proximal and a mobile distal colon. It is not used for colorectal anastomoses.<br> <br> Figure A depicts dividing the proximal colon with a linear stapler. The distal colon is also divided with a linear stapler.<br> Figure B depicts cutting the antimesenteric stapled corners from both the proximal and distal colon.<br> Figure C depicts inserting the linear stapler into both lumens.<br> Figure D depicts the stapled anastomosis between the proximal and distal colon, with&#160;the joined&#160;lumens open.<br> Figure E depicts Allis clamps securing the lumen in preparation for closure.<br> Figure F&#160;depicts a linear stapler placed distal to the Allis clamps and closing the lumen.<br> Figure G depicts the stapled functional end-to-end anastomosis.</div><div id=\"graphicVersion\">Graphic 72031 Version 1.0</div></div></div>"},"72032":{"type":"graphic_picture","displayName":"Chronic HSV ulcer in HIV","title":"Ulcer and vesicle in chronic herpes simplex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ulcer and vesicle in chronic herpes simplex</div><div class=\"cntnt\"><img style=\"width:241px; height:360px;\" src=\"images/ID/72032_Chronic_HSV_ulcer_in_HIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Persistent ulcer of the wrist with surrounding vesicular lesion in an HIV-infected patient.</div><div class=\"graphic_reference\">Courtesy of Lee T Nesbitt Jr, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 72032 Version 3.0</div></div></div>"},"72033":{"type":"graphic_figure","displayName":"Obesity in HIV lipodystrophy","title":"Obesity in HIV lipodystrophy","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Obesity in HIV lipodystrophy</div><div class=\"cntnt\"><img style=\"width:464px; height:226px;\" src=\"images/ID/72033_Obesity_in_HIV_lipodystroph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distinguishing feature of HIV-associated lipodystrophy is that visceral fat deposition is accompanied by normal or decreased (but not increased) amounts of subcutaneous fat. In this situation, waist circumference may not change.</div><div class=\"graphic_reference\">Courtesy of Christine A Wanke, MD.</div><div id=\"graphicVersion\">Graphic 72033 Version 2.0</div></div></div>"},"72036":{"type":"graphic_figure","displayName":"Tidal volume airway pressure","title":"Pressure-volume curve in ARDS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pressure-volume curve in ARDS</div><div class=\"cntnt\"><img style=\"width:390px; height:299px;\" src=\"images/PULM/72036_Tidal_volume_airway_pressur.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure-volume curve in a patient with acute respiratory distress syndrome (ARDS). The slope of the curve is flat at low and high airway pressures (ie, below the inflection point and above the deflection point). In these areas, increases in airway pressure produce minimal increases in lung volume. Compliance is maximized on the straight part of the curve. The deflection point is defined as the level at which the curve begins to divert from a straight line. Above this threshold, the lung is likely to begin to become overdistended. Mechanical ventilation is considered optimal when it takes place on the straight part of the curve between the inflection and deflection points.</div><div class=\"graphic_reference\">Redrawn from Brunet, F, Jeanbourquin, D, Monchi, M, et al, Am J Respir Crit Care Med 1995; 152:524.</div><div id=\"graphicVersion\">Graphic 72036 Version 1.0</div></div></div>"},"72037":{"type":"graphic_picture","displayName":"Retinal artery occlusion in SLE","title":"Central retinal artery occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Central retinal artery occlusion</div><div class=\"cntnt\"><img style=\"width:388px; height:288px;\" src=\"images/RHEUM/72037_Retinal_artery_occlusion_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluorescein angiogram from a patient with systemic lupus erythematosus shows a central retinal artery occlusion.</div><div class=\"graphic_reference\">Courtesy of Michael Tolentino, MD.</div><div id=\"graphicVersion\">Graphic 72037 Version 1.0</div></div></div>"},"72038":{"type":"graphic_picture","displayName":"Sexual maturity rating of breast development in girls","title":"Sexual maturity rating (Tanner staging) of breast development in girls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sexual maturity rating (Tanner staging) of breast development in girls</div><div class=\"cntnt\"><img style=\"width:329px; height:570px;\" src=\"images/PEDS/72038_Breast_development_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stages in breast development in girls.<br />Stage 1: Prepubertal, with no palpable breast tissue.<br />Stage 2: Development of a breast bud, with elevation of the papilla and enlargement of the areolar diameter.<br />Stage 3: Enlargement of the breast, without separation of areolar contour from the breast.<br />Stage 4: The areola and papilla project above the breast, forming a secondary mound.<br />Stage 5: Recession of the areola to match the contour of the breast; the papilla projects beyond the contour of the areola and breast.</div><div class=\"graphic_reference\">Figure from: Roede MJ, van Wieringen JC. Growth diagrams 1980: Netherlands third nation-wide survey. Tijdschr Soc Gezondheids 1985; 63:1. Reproduced with permission from the author.</div><div id=\"graphicVersion\">Graphic 72038 Version 8.0</div></div></div>"},"72039":{"type":"graphic_table","displayName":"Causes and diagnosis of tall R waves in V1","title":"Causes and diagnosis of tall R waves in V1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and diagnosis of tall R waves in V1</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Diagnosis</td>\n\n      <td class=\"subtitle1\">Confirmatory clues</td>\n\n    </tr>\n\n    <tr>\n\n      <td>True posterior infarct</td>\n\n      <td>ST &#8595;, T &#8593; in V1-V2; Q waves and ST\n&#8593; V7-V9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right ventricular hypertrophy</td>\n\n      <td>RAD; RAE; secondary ST-Ts; V7-V9 normal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ventricular septal hypertrophy</td>\n\n      <td>Associated Q waves; LVH; V7-V9 normal or deep narrow Q\nwaves</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Right bundle branch block</td>\n\n      <td>Wide QRS; broad S in V1, V6; R peaks late in V1; V7-V9\nnormal or broad S waves</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Wolff-Parkinson-White syndrome</td>\n\n      <td>Short PR; delta wave; V7-V9 normal or delta wave</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Normal variant</td>\n\n      <td>No other abnormalities</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">LVH: left ventricular hypertrophy; RAD: right-axis deviation; RAE: right atrial enlargement.</div><div id=\"graphicVersion\">Graphic 72039 Version 2.0</div></div></div>"},"72040":{"type":"graphic_picture","displayName":"Edema of hands in Kawasaki disease - acute phase","title":"Indurated edema of the dorsum of the hands as seen in Kawasaki disease (acute phase)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Indurated edema of the dorsum of the hands as seen in Kawasaki disease (acute phase)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/72040_Edema_hands_Kawasaki.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The erythema overlying the metacarpophalangeal and proximal interphalangeal joints is indicative of arthritis of the small joints of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72040 Version 5.0</div></div></div>"},"72041":{"type":"graphic_table","displayName":"Tryptase collection instructions","title":"Instructions for optimal collection and handling of blood samples for measurement of tryptase following suspected anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Instructions for optimal collection and handling of blood samples for measurement of tryptase following suspected anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tryptase (serum or plasma)</td> </tr> <tr> <td class=\"subtitle2_single\">When to collect the sample:</td> </tr> <tr> <td class=\"indent1\">Blood should be collected between 15 minutes and 3 hours after symptom-onset whenever possible. Samples collected &#60;15 minutes or &#62;3 hours after symptom-onset are less likely to be <span style=\"color: black;\">informative due to diminished sensitivity.</span></td> </tr> <tr> <td class=\"subtitle2_single\">How to collect the sample:</td> </tr> <tr> <td class=\"indent1\">Blood can be drawn using standard technique. Collect blood for serum (red top tube) or plasma (tube with heparin, citrate, or EDTA). A minimum of 1 mL is recommended.</td> </tr> <tr> <td class=\"indent1\">For postmortem samples, collect blood from the femoral artery or vein, not the heart.</td> </tr> <tr> <td class=\"subtitle2_single\">How to process the sample:</td> </tr> <tr> <td class=\"indent1\">Serum or plasma should be placed on ice and frozen as soon as possible. Samples should be shipped frozen by overnight courier if the assay cannot be performed on site.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EDTA: ethylenediaminetetraacetic acid.</div><div id=\"graphicVersion\">Graphic 72041 Version 26.0</div></div></div>"},"72042":{"type":"graphic_table","displayName":"Vulvodynia history","title":"Elements of the history in women with vulvodynia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Elements of the history in women with vulvodynia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n\n    <tr>\n\n      <td>Presence of vulvar lesions</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Medical history</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pelvic or vulvovaginal surgery</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pregnancy history</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Injury to or dislocation of hips</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sports injuries</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Back injuries or surgery</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Herniated disk</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Arthritis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spinal stenosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Occupation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leisure activities</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72042 Version 2.0</div></div></div>"},"72045":{"type":"graphic_movie","displayName":"Inferior wall left ventricular aneurysm apical long axis echo","title":"Left ventricular aneurym","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventricular aneurym</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72045_aplailvaconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:240px; height:437px;\" src=\"images/CARD/72045_aplailva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical long axis view from a 2-D echocardiogram shows an aneurysm of the inferior wall of the left ventricle. The left ventricle is diffusely hypokinetic.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 72045 Version 2.0</div></div></div>"},"72046":{"type":"graphic_figure","displayName":"Pubertal events boys","title":"Sequence of puberty in boys","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Sequence of puberty in boys</div><div class=\"cntnt\"><img style=\"width:454px; height:504px;\" src=\"images/PEDS/72046_Pubertal_events_boys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequence of pubertal events in boys with average timing of pubertal development in the United States.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Biro FM et al, Pubertal staging in boys. J Pediatr 1995; 127:100.</li>&#xD;&#xA;    <li>Karpati AM et al, Stature and pubertal stage assessment in American boys: the 1988-1994 Third National Health and Nutrition Examination Survey. J Adolesc Health 2002; 30:205-12.</li>&#xD;&#xA;    <li>Dore E et al. Gender differences in peak muscle performance during growth. Int J Sports Med 2005; 26:274.</li>&#xD;&#xA;    <li>Neu CM et al. Influence of puberty on muscle development at the forearm. Amer J Physiol Endocrin Metab 2002; 283:E103.</li>&#xD;&#xA;    <li>Tanner et al. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72046 Version 3.0</div></div></div>"},"72047":{"type":"graphic_table","displayName":"Charlson risk index","title":"Charlson risk index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Charlson risk index</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Condition</td>\n\n      <td class=\"subtitle1\">Assigned weights for diseases</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myocardial infarct</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart failure</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Peripheral vascular disease</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebrovascular disease</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dementia</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chronic pulmonary disease</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Connective tissue disease</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ulcer disease</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mild liver disease</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diabetes</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemiplegia</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Moderate or severe renal disease</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diabetes with end organ damage</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Any tumor</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leukemia</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lymphoma</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Moderate or severe liver disease</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Metastatic solid tumor</td>\n\n      <td>6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>AIDS</td>\n\n      <td>6</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_left\">Weighted comorbidity classes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Low</td>\n\n      <td>0 points</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Medium</td>\n\n      <td>1 to 2 points</td>\n\n    </tr>\n\n    <tr>\n\n      <td>High</td>\n\n      <td>3 to 4 points</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Very high</td>\n\n      <td>&#8805;5 points</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Charlson ME, Pompei P, Ales KL, et al. J Chron Dis 1987; 40:373.</div><div id=\"graphicVersion\">Graphic 72047 Version 3.0</div></div></div>"},"72049":{"type":"graphic_figure","displayName":"Nasal CPAP in nocturnal asthma","title":"Nasal CPAP improves PEFR in nocturnal asthma","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Nasal CPAP improves PEFR in nocturnal asthma</div><div class=\"cntnt\"><img style=\"width:522px; height:226px;\" src=\"images/PULM/72049_Nasal_CPAP_in_nocturnal_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with nocturnal asthma studied before (blue columns), during (red columns), and after (green columns) nasal continuous positive airway pressure. Nasal CPAP led to a statistically significant increase in peak expiratory flow rate (PEFR) in the morning and evening, and before and after bronchodilators.</div><div class=\"graphic_reference\">Redrawn from Chan CS, Woolcock AJ, Sullivan CE, Am Rev Respir Dis 1988; 137:1502.</div><div id=\"graphicVersion\">Graphic 72049 Version 2.0</div></div></div>"},"72050":{"type":"graphic_figure","displayName":"Transfixion uterosacral ligament","title":"Suture transfixion of the uterosacral ligaments during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suture transfixion of the uterosacral ligaments during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:369px; height:332px;\" src=\"images/OBGYN/72050_Transfixion_uterosacral_lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ligaments are attached to the posterior vaginal mucosa.</div><div id=\"graphicVersion\">Graphic 72050 Version 3.0</div></div></div>"},"72052":{"type":"graphic_table","displayName":"Test quality grades","title":"Grades of the quality of respiratory muscle strength tests are useful indicators of the degree of confidence that a clinician may have in the results","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grades of the quality of respiratory muscle strength tests are useful indicators of the degree of confidence that a clinician may have in the results</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td><strong>A:</strong> Excellent effort with excellent repeatability (&#60;5 cm H<sub>2</sub>O difference among measurements)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><strong>B:</strong> Good effort with good repeatability (5 to 10 cm H<sub>2</sub>O difference among measurements)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><strong>C:</strong> Fair to good effort with fair repeatability (10 to 20 cm H<sub>2</sub>O difference among measurements)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><strong>D:</strong> Only one apparently good maneuver</td>\r\n                </tr>\r\n                <tr>\r\n                    <td><strong>F:</strong> Unable to obtain good maneuvers or very poor repeatability</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div id=\"graphicVersion\">Graphic 72052 Version 2.0</div></div></div>"},"72054":{"type":"graphic_table","displayName":"Types of benign pubertal variants","title":"Types of benign pubertal variants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of benign pubertal variants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Etiology&nbsp;</td> <td class=\"subtitle1\">Clinical Features</td> <td class=\"subtitle1\">Bone Age</td> <td class=\"subtitle1\">Additional Evaluation</td> </tr> <tr> <td> <p><strong>Premature adrenarche</strong></p> (boys or girls)</td> <td> <p>Isolated pubarche. Gonads are prepubertal in size and there is no breast development in girls. Typical age of onset four to eight years.</p> Seen more commonly in African-American and Hispanic girls and in children with obesity and insulin resistance.</td> <td class=\"centered\">&#8593; to &#8593;&#8593;*</td> <td> <p>Further investigations needed only if there is significant progressive virilization, to help exclude peripheral precocity.</p> <p>Mild elevation in DHEAS for chronological age (but appropriate for bone age).</p> Prepubertal concentrations of 17-hydroxyprogesterone and testosterone.</td> </tr> <tr> <td> <p><strong>Premature thelarche</strong></p> (girls)</td> <td> <p>Isolated breast development with normal growth velocity.</p> Most commonly seen in girls less than three years of age.</td> <td class=\"centered\">Normal (prepubertal)</td> <td> <p>No further evaluation needed in most cases, unless evidence of pubertal progression.</p> Basal LH concentrations typically &#60;0.2 to 0.3 mIU/L.<sup>&#182;</sup></td> </tr> <tr> <td> <p><strong>Non-progressive or intermittently progressive precocious puberty</strong></p> (boys or girls)</td> <td>Development of gonadarche (breast or testicular enlargement) with pubarche (pubic and/or axillary hair), with either no progression or intermittent slow progression in clinical pubertal signs.</td> <td class=\"centered\">Normal&nbsp;to &#8593;</td> <td> <p>Basal LH concentrations typically &#60;0.2 to 0.3 mIU/L, although can be in early pubertal range in some children.</p> <p><span style=\"color: black;\">Lower&nbsp;stimulated LH/FSH ratio compared with children with progressive central precocious puberty.<sup>&#916;</sup></span></p> <span style=\"color: black;\">Patients w</span>ith non-progressive precocious puberty do&nbsp;not need treatment with GnRH agonist,&nbsp;because final height untreated is concordant with mid-parental height.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">If further evaluation is needed and performed, patients with benign pubertal variants&nbsp;typically have pre-pubertal basal LH concentrations (&lt;0.2 to 0.3 mIU/L) and/or stimulated LH concentration post GnRHa of &lt;3.3 to 5.0 mIU/L.</div><div class=\"graphic_footnotes\">â: elevated for chronological age;&nbsp;DHEAS: dehydroepiandrosterone sulfate; LH: luteinizing hormone; FSH: follicle-stimulating hormone; GnRH: gonadotropin-releasing hormone.<br />* Up to 30% of children with premature adrenarche can have a bone age more than two years advanced than their chronological age.<SUP>[1]</SUP><br />Â¶ Interpretation of basal LH and stimulated LH concentrations can be difficult in girls younger than two years of age because normal gonadotropin concentrations can be elevated as part of the mini-puberty of infancy.[2]<br /><SPAN style=\"COLOR: black\">Î&nbsp;A peak LH/FSH ratio &lt;0.66 suggests non-progressive&nbsp;precocious&nbsp;puberty, whereas a ratio &gt;0.66 is typically seen with central precocious puberty.<SUP>[3]</SUP> </SPAN></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>DeSalvo, DJ, Mehra R, Vaidyanathan P, Kaplowitz PB. In children with premature adrenarche, bone age advancement by 2 or more years is common and generally benign. J Pediatr Endocrinolo Metab 2013; 26: 215.</LI>&#xD;&#xA;<LI>Bizzarri C, Spadoni G, Bottaro G et al. The response to gonadotropin releasing hormone (GnRH) stimulation test does not predict the progression to true precocious puberty in girls with onset of premature thelarche in the first three years of life. JCEM 2014; 99:433.</LI>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">Oerter KE, Uriarte MM, Rose SR, et al. Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990; 71:1251.</SPAN></LI></OL></div><div id=\"graphicVersion\">Graphic 72054 Version 14.0</div></div></div>"},"72055":{"type":"graphic_picture","displayName":"Erythema multiforme arm","title":"Erythema multiforme","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema multiforme</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/72055_Erythema_multiforme_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous plaques with dusky centers are present on the arms of this patient with erythema multiforme.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72055 Version 4.0</div></div></div>"},"72056":{"type":"graphic_figure","displayName":"Supracondylar fracture neurovascular impingement","title":"Neurovascular impingement supracondylar fractures","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Neurovascular impingement supracondylar fractures</div><div class=\"cntnt\"><img style=\"width:552px; height:332px;\" src=\"images/EM/72056_NVimpingementSCfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neurovascular relations. Right) If the spike of the proximal fracture fragment penetrates medially (posterolateral distal fracture fragment displacement), both the median nerve and brachial artery can be tethered. This type of neurovascular injury is most common. Left) If the proximal fracture fragment spike penetrates the brachialis muscle laterally (posteromedial distal fracture fragment displacement), the radial nerve may be tethered.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright Â© 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72056 Version 13.0</div></div></div>"},"72057":{"type":"graphic_diagnosticimage","displayName":"Indeterminate thyroid nodule scan I","title":"Indeterminate thyroid nodule: Appearance on thyroid scintigraphy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Indeterminate thyroid nodule: Appearance on thyroid scintigraphy</div><div class=\"cntnt\"><img style=\"width:356px; height:272px;\" src=\"images/ENDO/72057_Indeterminatethyroidscan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-I thyroid scan of a 2 cm papillary cancer, which does not appear as a nonfunctioning nodule, because it overlies normal isotope concentration in the uninvolved portion of the right lobe.</div><div class=\"graphic_footnotes\">SSN: suprasternal notch; 123-I: iodine-123.</div><div class=\"graphic_reference\">Courtesy of Douglas Ross, MD.</div><div id=\"graphicVersion\">Graphic 72057 Version 4.0</div></div></div>"},"72059":{"type":"graphic_figure","displayName":"Urinary collections and stones","title":"Increased likelihood of detecting kidney stone risk factors with multiple 24-hour urine collections","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased likelihood of detecting kidney stone risk factors with multiple 24-hour urine collections</div><div class=\"cntnt\"><img style=\"width:440px; height:263px;\" src=\"images/NEPH/72059_Urinary_collections_and_sto.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among calcium renal stones formers, the number of urinary risk factor abnormalities that are identified increases with the number of 24-hour urine collections and with collections obtained at later time points after the occurence of a stone. In this study of 75 recurrent idiopathic calcium renal stone formers, the relative diagnostic utility of one, two, and three urine collections, as well as variations in timing of collections after a clinically evident stone event was evaluated. U1, U2, and U3 were obtained at a mean period of 105, 116, and 163 days after the stone event, respectively. The largest number of abnormalities were observed with the performance of three urinary collections (U1+2+3).</div><div class=\"graphic_footnotes\">++ P: 0.011 versus U1; &#186;&#186; P: 0.011 versus U1+2; &#186;&#186;&#186; P: 0.0001 vs any single urine; *** P: 0.0001 versus any combination of two urines and versus any single urine.</div><div class=\"graphic_reference\">Data from Hess, B, Hasler-Strum U, Ackermann, D, Jaeger, P. Nephrol Dial Transplant 1997; 12:1362.</div><div id=\"graphicVersion\">Graphic 72059 Version 2.0</div></div></div>"},"72060":{"type":"graphic_table","displayName":"Genodermatoses and malignancy","title":"Genodermatoses associated with malignancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genodermatoses associated with malignancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Inheritance/ pathogenesis</td> <td class=\"subtitle1\">Key clinical features</td> </tr> <tr> <td rowspan=\"2\">Basal Cell Nevus Syndrome (Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome)</td> <td>Autosomal dominant</td> <td rowspan=\"2\">Multiple basal cell carcinomas. Other features include odontogenic cysts of the jaw, palmoplantar pits, bifid ribs and other skeletal abnormalities. Common CNS abnormalites include calcification of the falx cerebri and bridging of the sella turcica. Extracutaneous tumors, including medulloblastomas, meningiomas, and ovarian fibrosarcomas, are also associated with the syndrome.</td> </tr> <tr> <td>Mutation of the tumor suppressor gene patched (PTC)</td> </tr> <tr> <td rowspan=\"2\">Gardner Syndrome</td> <td>Autosomal dominant</td> <td rowspan=\"2\">Triad of familial adenomatous polyposis, benign osteomas, and skin and soft tissue tumors. Multiple epidermoid cysts are the most characteristic skin finding. Desmoid tumors may also be seen. Congenital hypertrophy of the retinal pigmented epithelium is a reliable and early marker of disease. Colon cancer develops in all affected individuals requiring prophylactic colectomy.</td> </tr> <tr> <td>Mutation of tumor suppressor gene APC</td> </tr> <tr> <td rowspan=\"2\">Peutz-Jegher Syndrome</td> <td>Autosomal dominant</td> <td rowspan=\"2\">Dark periorificial and acral freckling most markedly on the lips; patients develop hamartomatous polyps of GI tract which may give rise to cancer. Also associated with increased risk of early adenocarcinomas of the breast, cervix, pancreas, uterus and ovaries.</td> </tr> <tr> <td>Mutation of tumor suppressor gene STK11</td> </tr> <tr> <td rowspan=\"2\">Xeroderma Pigmentosa</td> <td>Autosomal recessive</td> <td rowspan=\"2\">Increased photosensitivity, development of cutaneous malignancies in early childhood. Associated ocular and neurologic abnormalities.</td> </tr> <tr> <td>Defective excision repair of UV-induced DNA damage</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Epidermolysis bullosa (EB) syndromes</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Dowling Meara EB simplex</td> <td>Autosomal dominant</td> <td rowspan=\"2\">Presents at birth or in early infancy; bullae occur with mild trauma, but lesions heal without scarring; mild or no mucosal involvement. Increased risk of basal cell carcinoma during mid-adulthood.</td> </tr> <tr> <td>Mutation of keratin 5 or keratin 14 gene</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Herlitz junctional EB</td> <td>Autosomal recessive</td> <td rowspan=\"2\"> <p>Onset at birth with widespread bullae and erosions with nonhealing granulation tissue; absent nails, dysplastic teeth, oral lesions.</p> <p>Increased risk of squamous cell carcinoma beginning in adolescence.</p> </td> </tr> <tr> <td>Mutations in the laminin alpha-3, beta-3, or gamma-2 gene</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hallopeau-Siemens recessive dystrophic EB</td> <td>Autosomal recessive</td> <td rowspan=\"2\"> <p>Onset at birth; generalized bullae that heal with extensive scarring; repeated episodes may lead to contraction flexures at the knees and elbows and fusion of the digits; frequent involvement of the mucous membranes.</p> <p>Increased risk of malignant melanoma beginning in childhood and squamous cell carcinoma beginning in adolescence.</p> </td> </tr> <tr> <td>Mutation in the collagen type VII alpha-1 gene</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72060 Version 4.0</div></div></div>"},"72061":{"type":"graphic_figure","displayName":"Primary neurulation","title":"Schematic representation of primary neurulation","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Schematic representation of primary neurulation</div><div class=\"cntnt\"><img style=\"width:608px; height:446px;\" src=\"images/PEDS/72061_Primary_neurulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central nervous system initially appears as a plate of thickened ectoderm called the neural plate at the beginning of the third week of embryonic life (panel 2). The lateral edges of the neural plate become elevated to form the neural folds, around the neural groove (panel 3). These folds subsequently fuse to form the neural tube (panel 4).</div><div class=\"graphic_reference\">Reproduced with permission from Dr. Martin Ronan, Medical Sciences, Indiana University. Copyright &#169; 2009 Martin Ronan. Accessed (Jan. 27, 2009) at: http://www.indiana.edu/~phys215/lecture/lecnotes/chap8N.html</div><div id=\"graphicVersion\">Graphic 72061 Version 1.0</div></div></div>"},"72062":{"type":"graphic_diagnosticimage","displayName":"Mounier Kuhn syndrome PA","title":"Cystic bibasal bronchiectases in patient with Mounier-Kuhn syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic bibasal bronchiectases in patient with Mounier-Kuhn syndrome</div><div class=\"cntnt\"><img style=\"width:352px; height:347px;\" src=\"images/PULM/72062_Mounier_Kuhn_syndrome_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows bronchial pattern with bibasal cystic bronchiectases, producing ring shadows and gas- liquid levels. Note marked dilatation of the trachea and mainstem bronchi, characteristic of the syndrome.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72062 Version 4.0</div></div></div>"},"72063":{"type":"graphic_diagnosticimage","displayName":"Pulmonary hypertension Lateral","title":"Pulmonary hypertension","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:287px; height:310px;\" src=\"images/PULM/72063_Pulmonary_hypertension_Late.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph in lateral view showing decreased retrosternal space (arrow) due to right ventricular enlargement in pulmonary hypertension.</div><div class=\"graphic_reference\">Courtesy of Sven Paulin, MD.</div><div id=\"graphicVersion\">Graphic 72063 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lateral chest radiograph</div><div class=\"cntnt\"><img style=\"width:252px; height:368px;\" src=\"images/PULM/57909_Normal_chest_film_Lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 57909 Version 1.0</div></div></div>"},"72065":{"type":"graphic_diagnosticimage","displayName":"Intrauterine adhesion hysterosc","title":"Hysteroscopic image of adhesive band bridging from anterior to posterior uterine wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic image of adhesive band bridging from anterior to posterior uterine wall</div><div class=\"cntnt\"><img style=\"width:432px; height:329px;\" src=\"images/OBGYN/72065_Intrauterine_adhesion_hyste.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Marcelle Cedars, MD.</div><div id=\"graphicVersion\">Graphic 72065 Version 2.0</div></div></div>"},"72066":{"type":"graphic_table","displayName":"Sxs adolescent endometriosis","title":"Frequency of presenting symptoms in adolescents with endometriosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of presenting symptoms in adolescents with endometriosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Both acyclic and cyclic pain</td>\n<td>63 percent</td>\n</tr>\n<tr>\n<td>Acyclic pain only</td>\n<td>28 percent</td>\n</tr>\n<tr>\n<td>Cyclic pain only</td>\n<td> 9 percent</td>\n</tr>\n<tr>\n<td>Gastrointestinal pain</td>\n<td>34 percent</td>\n</tr>\n<tr>\n<td>Urinary symptoms</td>\n<td>13 percent</td>\n</tr>\n<tr>\n<td>Irregular menses</td>\n<td> 9 percent</td>\n</tr>\n<tr>\n<td>Vaginal discharge</td>\n<td> 6 percent</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Laufer, MR, Goitein, L, Bush, M, et al. J Pediatr Adolesc Gynecol 1997; 10:199.</div><div id=\"graphicVersion\">Graphic 72066 Version 1.0</div></div></div>"},"72068":{"type":"graphic_figure","displayName":"T3 resin test normal","title":"Normal T3 resin test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal T3 resin test</div><div class=\"cntnt\"><img style=\"width:249px; height:318px;\" src=\"images/ENDO/72068_T3resintestNormal.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiolabeled T3 (*T3) first interacts with available binding sites on binding proteins, and then a resin is added, which binds the remaining tracer.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine.</div><div id=\"graphicVersion\">Graphic 72068 Version 3.0</div></div></div>"},"72070":{"type":"graphic_table","displayName":"Cowden syndrome PHTS testing criteria of the NCCN","title":"Cowden syndrome/PTEN hamartoma tumor syndrome (PHTS) testing criteria from the National Comprehensive Cancer Network (NCCN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cowden syndrome/PTEN hamartoma tumor syndrome (PHTS) testing criteria from the National Comprehensive Cancer Network (NCCN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Individual from a family with a known PTEN mutation</td> </tr> <tr> <td class=\"subtitle1_single\">Individual meeting clinical diagnostic criteria<sup>[1]</sup> for Cowden syndrome/PHTS</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Bannayan-Riley-Ruvalcaba syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Adult Lhermitte-Duclos disease </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Autism spectrum disorder AND macrocephaly </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Two or more biopsy-proven trichilemmomas </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Two or more major criteria (one macrocephaly)<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Three major criteria without macrocephaly<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>One major and three or more minor criteria<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent2\">OR</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Four or more minor criteria<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">At-risk individual:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>With a relative who has a clinical diagnosis of Cowden syndrome, PHTS, or Bannayan-Riley-Ruvalcaba syndrome for whom testing has not been performed </li> </ul> </td> </tr> <tr> <td class=\"indent2\">AND</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Who has any one major criterion or two minor criteria<sup>[1]</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105:1607.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72070 Version 11.0</div></div></div>"},"72071":{"type":"graphic_table","displayName":"Recommended immunizations for kidney transplant recipients","title":"Recommended immunizations for kidney transplant recipients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended immunizations for kidney transplant recipients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Recommended vaccinations</td> <td class=\"subtitle1\">Not recommended</td> </tr> <tr> <td>Influenza types A and B (yearly)</td> <td>Varicella zoster</td> </tr> <tr> <td>Pneumovax (every&nbsp;three to five&nbsp;years)</td> <td>Intranasal influenza</td> </tr> <tr> <td>Diphtheria-pertussis-tetanus</td> <td>BCG</td> </tr> <tr> <td>Haemophilus influenza B</td> <td>Live oral typhoid</td> </tr> <tr> <td>Hepatitis B</td> <td>Measles</td> </tr> <tr> <td>Typhoid Vi</td> <td>Mumps</td> </tr> <tr> <td>Inactivated polio</td> <td>Rubella</td> </tr> <tr> <td>Meningococcus</td> <td>Oral polio</td> </tr> <tr> <td>Hepatitis A</td> <td>Live Japanese B encephalitis vaccine</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td>Yellow fever</td> </tr> <tr> <td>Smallpox</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BCG: Bacillus Calmette-Guerin.</div><div class=\"graphic_reference\">Courtesy of Anil Chandraker, MD.</div><div id=\"graphicVersion\">Graphic 72071 Version 3.0</div></div></div>"},"72072":{"type":"graphic_table","displayName":"Clinical manifestations - Brucellosis","title":"Clinical manifestations - Brucellosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations - Brucellosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Literature reference</td> <td class=\"subtitle1\" colspan=\"7\">Percent of patients reporting condition</td> </tr> <tr> <td class=\"subtitle2\">Fever<br /> (symptom)</td> <td class=\"subtitle2\">Malaise</td> <td class=\"subtitle2\">Night perspiration</td> <td class=\"subtitle2\">Arthralgia</td> <td class=\"subtitle2\">Temperature<br /> (sign)</td> <td class=\"subtitle2\">Hepatomegaly</td> <td class=\"subtitle2\">Splenomegaly</td> </tr> <tr> <td>Aygen, et al. 2002</td> <td>80</td> <td>90</td> <td>84</td> <td>82</td> <td>39</td> <td>21</td> <td>14</td> </tr> <tr> <td>Yinnon, et al. 1993</td> <td>96</td> <td>33</td> <td>ND</td> <td>35</td> <td>ND</td> <td>55</td> <td>69</td> </tr> <tr> <td>Memish, et al. 2000</td> <td>91</td> <td>ND</td> <td>19</td> <td>66</td> <td>84</td> <td>6</td> <td>7</td> </tr> <tr> <td>Andriopoulos, et al. 2007</td> <td>100</td> <td>97</td> <td>96</td> <td>87</td> <td>ND</td> <td>25</td> <td>51</td> </tr> <tr> <td>Shehabi, et al. 1990</td> <td>100</td> <td>ND</td> <td>88</td> <td>60</td> <td>ND</td> <td>54</td> <td>61</td> </tr> <tr> <td>Demiroglu, et al. 2007</td> <td>80</td> <td>86</td> <td>78</td> <td>87</td> <td>ND</td> <td>ND</td> <td>ND</td> </tr> <tr> <td>Tasbakan, et al. 2003</td> <td>94</td> <td>96</td> <td>92</td> <td>82</td> <td>97</td> <td>38</td> <td>60</td> </tr> <tr> <td>Pourbagher, et al. 2006</td> <td>55</td> <td>76</td> <td>53</td> <td>85</td> <td>ND</td> <td>6</td> <td>8</td> </tr> <tr> <td>Trujillo, et al. 1994</td> <td>100</td> <td>77</td> <td>96</td> <td>81</td> <td>ND</td> <td>10</td> <td>12</td> </tr> <tr> <td>Buchanan, et al. 1974</td> <td>ND</td> <td>95</td> <td>93</td> <td>17</td> <td>95</td> <td>ND</td> <td>ND</td> </tr> <tr> <td>Kokoglu, et al. 2006</td> <td>78</td> <td>ND</td> <td>72</td> <td>78</td> <td>41</td> <td>27</td> <td>36</td> </tr> <tr> <td>Bosilkovski, et al. 2010</td> <td>76</td> <td>68</td> <td>72</td> <td>80</td> <td>65</td> <td>50</td> <td>29</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Frequency of clinical characteristics in patients with brucellosis, as reported in the literature and in the CMJ study.</div><div class=\"graphic_footnotes\">ND: not determined.</div><div class=\"graphic_reference\">Reproduced with permission from: Bosilkovski M, Krteva L, Dimova M, et al. Human Brucellosis in Macedonia &ndash; 10 years of Clinical Experience in Endemic Region. Croat Med J 2010; 51:327. Copyright &copy; 2010 Croatian Medical Journal.</div><div id=\"graphicVersion\">Graphic 72072 Version 2.0</div></div></div>"},"72073":{"type":"graphic_picture","displayName":"Candidal intertrigo groin","title":"Candidal intertrigo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Candidal intertrigo</div><div class=\"cntnt\"><img style=\"width:432px; height:314px;\" src=\"images/DERM/72073_Candidal_intertrigo_groin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous plaque with satellite pustules in the groin.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72073 Version 4.0</div></div></div>"},"72076":{"type":"graphic_picture","displayName":"Splinter hemorrhages in infective endocarditis","title":"Splinter hemorrhages in infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Splinter hemorrhages in infective endocarditis</div><div class=\"cntnt\"><img style=\"width:264px; height:360px;\" src=\"images/ID/72076_Splinter_hemorrhages_in_IE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Splinter hemorrhages, linear reddish-brown lesions, are seen in the nail bed of this patient with bacterial endocarditis due to group B <EM>Streptococcus</EM>.</div><div class=\"graphic_reference\">Courtesy of Gene Beyt. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 72076 Version 9.0</div></div></div>"},"72077":{"type":"graphic_figure","displayName":"Pelvimetry 1","title":"Vaginal examination to determine the diagonal conjugate","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Vaginal examination to determine the diagonal conjugate</div><div class=\"cntnt\"><img style=\"width:456px; height:354px;\" src=\"images/OBGYN/72077_Pelvimetry_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">P: sacral promontory; S: symphysis pubis.</div><div class=\"graphic_reference\">Reproduced with permission from: Pritchard JA, MacDonald PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright Â©1980 McGraw Hill. p.280.</div><div id=\"graphicVersion\">Graphic 72077 Version 2.0</div></div></div>"},"72079":{"type":"graphic_table","displayName":"Catch-up immunization schedule for children 7 through 18 years","title":"Catch-up immunization schedule for children and adolescents age 7 through 18 years who start late or who are more than 1 month behind - United States, 2018","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Catch-up immunization schedule for children and adolescents age 7 through 18 years who start late or who are more than 1 month behind - United States, 2018</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Vaccine</td> <td class=\"subtitle1\" rowspan=\"2\">Minimum age for dose 1</td> <td class=\"subtitle1\" colspan=\"3\">Minimum interval between doses</td> </tr> <tr> <td class=\"subtitle2\">Dose 1 to dose 2</td> <td class=\"subtitle2\">Dose 2 to dose 3</td> <td class=\"subtitle2\">Dose 3 to dose 4</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Tetanus, diphtheria; tetanus, diphtheria, and acellular pertussis*</td> <td class=\"divider_bottom\" rowspan=\"2\">7 years*</td> <td class=\"divider_bottom\" rowspan=\"2\">4 weeks</td> <td>4 weeks if first dose of DTaP/DT was administered before the first birthday</td> <td class=\"divider_bottom\" rowspan=\"2\">6 months if first dose of DTaP/DT was administered before the&nbsp;first birthday</td> </tr> <tr class=\"divider_bottom\"> <td>6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the first&nbsp;birthday</td> </tr> <tr class=\"divider_bottom\"> <td>Human papillomavirus<sup>&#182;</sup></td> <td>9 years</td> <td colspan=\"3\">Routine dosing intervals are recommended<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Hepatitis A<sup>&#916;</sup></td> <td>Not applicable</td> <td>6 months</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatitis B<sup>&#9674;</sup></td> <td>Not applicable</td> <td>4 weeks</td> <td>8 weeks <strong>and</strong> at least 16 weeks after first dose</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Inactivated poliovirus<sup>&#167;</sup></td> <td>Not applicable</td> <td>4 weeks</td> <td> <p>6 months<sup>&#167;</sup></p> <p>A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose</p> </td> <td>A fourth dose of IPV is indicated if all previous doses were administered at &#60;4 years or if the third dose was administered &#60;6 months after the second dose</td> </tr> <tr class=\"divider_bottom\"> <td>Serogroups A, C, W, Y meningococcal<sup>&#165;</sup></td> <td>Not applicable</td> <td>8 weeks<sup>&#165;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Measles, mumps, rubella<sup>&#135;</sup></td> <td>Not applicable</td> <td>4 weeks</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Varicella<sup>&#134;</sup></td> <td rowspan=\"2\">Not applicable</td> <td>3 months if younger than age 13 years</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>4 weeks if age 13 years or older</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The above table provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use this table in conjunction with its footnotes and UpToDate content related to the schedule of recommended childhood immunizations for children 7 through 18 years of age in the United States. â<FONT color=black>This table includes recommendations in effect as of January 1, 2018 and is approved by the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists.<br /><br /></FONT>&#xD;&#xA;<UL>&#xD;&#xA;<LI>Consult relevant <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/index.html\" target=_blank>ACIP statements </A>for detailed recommendations. &#xD;&#xA;<LI>For calculating intervals between doses,&nbsp;4 weeks = 28 days. Intervals of â¥4 months are determined by calendar months. &#xD;&#xA;<LI>Vaccine doses administered â¤4 days before the minimum age or interval are considered valid. Doses of any vaccine administered â¥5 days earlier than the minimum interval or minimum age should not be counted as valid and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval.&nbsp;For further details, refer to<EM innerHtml> <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>General Best Practice Guidelines for Immunizati</A></EM><EM><A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>on</A></EM>.&nbsp; &#xD;&#xA;<LI>For information about precautions and contraindications, refer to <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</A>.&#xD;&#xA;<LI>Report clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at <A href=\"http://vaers.hhs.gov/\" target=_blank>vaers.hhs.gov</A> or by telephone, <FONT class=baec5a81-e4d6-4674-97f3-e9220f0136c1>800-822-7967<A title=\"Call: 800-822-7967\" style=\"BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; BORDER-BOTTOM: medium none; MARGIN: 0px; BORDER-LEFT: medium none\" href=\"http://editorial00p/Graphic/Preview.aspx?graphicId=82617&amp;View=Editorial#\"><IMG title=\"Call: 800-822-7967\" style=\"BORDER-TOP: medium none; HEIGHT: 16px; BORDER-RIGHT: medium none; WIDTH: 16px; BORDER-BOTTOM: medium none; MARGIN: 0px; BORDER-LEFT: medium none\" alt=\"\" src=\"data:image/png;base64,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\"></A></FONT>.&nbsp;</LI></UL></div><div class=\"graphic_footnotes\">DTaP: diphtheria, tetanus, and acellular pertussis vaccine; DT: diphtheria, tetanus vaccine; Tdap: tetanus, diphtheria, and acellular pertussis vaccine; Td: tetanus,&nbsp;and diphtheria vaccine;&nbsp;HIV: human immunodeficiency virus; IPV: inactivated poliovirus vaccine.<br />* <STRONG innerHtml>Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine:<br /><FONT color=black><EM></EM></FONT></STRONG><FONT color=black><EM>(Minimum age: 7 years for catch-up vaccination)</EM> </FONT>&#xD;&#xA;<UL>&#xD;&#xA;<LI>Adolescents 13 through 18 years who have not received Tdap: 1 dose followed by a Td booster every 10 years.</LI>&#xD;&#xA;<LI>Persons&nbsp;aged 7 through 18 years not fully immunized with DTaP: 1 dose of Tdap as part of catch-up series (preferably as the first dose). If additional doses are needed, use Td. </LI>&#xD;&#xA;<LI>Children 7 through 10 years who receive Tdap inadvertently or as part of the catch-up series may receive the routine Tdap dose at 11 through 12 years.&nbsp;&nbsp;</LI>&#xD;&#xA;<LI>DTaP given inadvertently after the 7<SUP>th </SUP>birthday<STRONG innerHtml>:&nbsp;</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Child 7 through 10: DTaP may count as part of catch-up series. Routine Tdap dose at 11 through 12 years may be given.</LI>&#xD;&#xA;<LI>Adolescent 11 through 18: Count dose of DTaP as the adolescent Tdap booster.</LI></UL></LI></UL>Â¶ <STRONG>Human papillomavirus (HPV) vaccines:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Routine vaccination for all adolescents at 11 through 12 years (can start at age 9) and through age 18 if not previously adequately vaccinated. Number of doses dependent on age at initial vaccination: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Age 9 through 14 at initiation: 2-dose series at 0 and 6 through 12 months. Minimum interval: 5 months (repeat a dose given too soon at least 12 weeks after the invalid dose and at least 5 months after the&nbsp;first dose).</LI>&#xD;&#xA;<LI>Age 15 years or older at initiation:&nbsp;3-dose series at 0, 1&nbsp;through 2, and 6 months. Minimum intervals: 4 weeks between&nbsp;first and second dose; 12 weeks between second and third dose; 5 months between first and third dose (repeat dose[s] given too soon at or after the minimum interval since the most recent dose).&nbsp;</LI></UL></LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>History&nbsp;of sexual abuse or assault: Begin series at age 9 years.</LI>&#xD;&#xA;<LI>Immunocompromised (including HIV) aged 9 through 26 years: 3 dose series at 0, 1 through 2 months, and 6 months. (Refer to <A href=\"https://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm\" target=_blank>MMWR Morb Mortal Wkly Rep 2016:65:1405</A>.)</LI>&#xD;&#xA;<LI>Pregnancy:&nbsp;Vaccination is not recommended but there is no evidence the vaccine is harmful. No intervention is needed for women who inadvertently received a dose of HPV vaccine while pregnant. Delay remaining doses until after pregnancy. Pregnancy testing not needed before vaccination. </LI></UL></LI></UL>Î <STRONG>Hepatitis A (HepA) vaccine:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Anyone 2 years of age or older may receive HepA vaccine if desired. Minimum interval between doses is 6 months.</LI>&#xD;&#xA;<LI><STRONG>Special populations:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Persons traveling to or working in countries that have high or intermediate endemicity</LI>&#xD;&#xA;<LI>Men who have sex with men</LI>&#xD;&#xA;<LI>Users of injection and noninjection drugs </LI>&#xD;&#xA;<LI>Persons who work with hepatitis A virus (HAV) in a research laboratory or with nonhuman primates</LI>&#xD;&#xA;<LI>Persons with clotting-factor disorders </LI>&#xD;&#xA;<LI>Persons with chronic liver disease</LI>&#xD;&#xA;<LI>Persons who anticipate close, personal contact (eg, household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity (administer the&nbsp;first dose as soon as the adoption is planned--ideally at least 2 weeks before the adoptee's arrival).&nbsp;</LI></UL></LI></UL><FONT class=lozenge>â</FONT> <STRONG>Hepatitis B (HepB) vaccine:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Unvaccinated persons should complete a 3-dose series at 0, 1&nbsp;through 2, and 6 months.</LI>&#xD;&#xA;<LI>Adolescents 11 through 15 years of age may use an alternative 2-dose schedule, with at least 4 months between doses (adult formulation&nbsp;Recombivax HB only).</LI></UL>Â§ <STRONG>Inactivated poliovirus (IPV) vaccine:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>If 4 or more doses were given before the fourth birthday, give 1 more dose at least 6 months after the previous dose. </LI>&#xD;&#xA;<LI>A&nbsp;fourth dose is not necessary if the third dose was given on or after the fourth birthday and at least 6 months after the previous dose. </LI>&#xD;&#xA;<LI>IPV vaccine is not routinely recommended for United States residents 18 years and older. </LI>&#xD;&#xA;<LI><STRONG>Series containing oral polio vaccine (OPV), </STRONG><EM>either mixed OPV-IPV or OPV only series:</EM></LI>&#xD;&#xA;<UL>&#xD;&#xA;<LI><EM>Total number of doses needed to complete the series is the same as that recommended for <FONT color=black>the United States IPV schedule. Refer to <A spellcheck=true href=\"https://www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_cid=mm6601a6_w\" target=_blank>MMWR Morb Mortal Wkly Rep 2017; 66:23</A>.</FONT></EM></LI>&#xD;&#xA;<LI><EM>Only trivalent OPV (tOPV) counts toward the United States vaccination requirements. For guidance to assess doses documented as \"OPV,\" <FONT color=black>refer to <A spellcheck=true href=\"https://www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.htm?s_cid=mm6606a7_w\" target=_blank>MMWR Morb Mortal Wkly Rep 2017; 66:180</A>.</FONT></EM></LI></UL></UL>&#xD;&#xA;<P><FONT color=black>Â¥ <STRONG>Serogroup A, C, W, Y, meningococcal conjugate (MenACWY)&nbsp;vaccines:</STRONG></FONT></P>&#xD;&#xA;<UL>&#xD;&#xA;<LI>Age 13 through 15 years: 1 dose now and booster at age 16 through 18 years. Minimum interval 8 weeks.</LI>&#xD;&#xA;<LI>Age 16 through 18 years: 1 dose. </LI>&#xD;&#xA;<LI>For catch-up guidance for persons with high-risk conditions and other persons at increased risk of disease, refer to UpToDate content related to the routine immunization schedule, meningococcal vaccination, and immunization in the specific high-risk condition, and the <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\" target=_blank>ACIP recommendations</A>.&nbsp;High-risk conditions and conditions that increase the risk&nbsp;of disease include anatomic or functional asplenia, sickle cell disease,&nbsp;HIV infection, persistent&nbsp;complement component deficiency (including eculizumab use), travel to or residence in countries&nbsp;where meningococcal disease is hyperendemic or epidemic (including countries in the African meningitis belt or during the Hajj), or exposure to an outbreak attributable to a vaccine serogroup.</LI></UL>â¡ <STRONG>Measles, mumps, and rubella (MMR) vaccine:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Unvaccinated children and adolescents: 2 doses at least 4 weeks apart.</LI></UL>â  <STRONG>Varicella (VAR) vaccine:</STRONG> &#xD;&#xA;<UL>&#xD;&#xA;<LI>Ensure persons age 7 through 18 years without evidence of immunity (refer to <A href=\"http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf\" target=_blank>MMWR Recomm Rep 2007; 56(RR04):1</A>) have 2 doses of varicella vaccine:</LI>&#xD;&#xA;<LI>Ages 7 through 12: Routine interval 3 months (minimum interval: 4 weeks)</LI>&#xD;&#xA;<LI>Ages 13 and older: Minimum interval 4 weeks.&nbsp;</LI></UL></div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. Immunization schedules. Available at: <A href=\"http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\" target=_blank>www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html</A> (Accessed on February 13, 2018).</div><div id=\"graphicVersion\">Graphic 72079 Version 29.0</div></div></div>"},"72080":{"type":"graphic_table","displayName":"Lab eval hypocalcemia","title":"Laboratory evaluation hypocalcemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation hypocalcemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">PTH </td> <td class=\"subtitle1\">Corrected serum calcium </td> <td class=\"subtitle1\">Phos </td> <td class=\"subtitle1\">Mag </td> <td class=\"subtitle1\">25(OH)D </td> <td class=\"subtitle1\">1,25(OH)2D </td> <td class=\"subtitle1\">Creatinine </td> </tr> <tr> <td>Hypoparathyroidism</td> <td>Low</td> <td>Low</td> <td>Elevated</td> <td>Normal</td> <td>Normal</td> <td>Normal or low</td> <td>Normal</td> </tr> <tr> <td>Activating mutation calcium-sensing receptor</td> <td>Normal or low</td> <td>Low</td> <td>Elevated</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Hypomagnesemia</td> <td>Normal or low</td> <td>Low</td> <td>Normal</td> <td>Low</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>PTH resistance (pseudohypoparathyroidism)</td> <td>Elevated</td> <td>Low</td> <td>Elevated</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Vitamin D deficiency</td> <td>Elevated</td> <td>Low or normal</td> <td>Low or normal</td> <td>Normal</td> <td>Low</td> <td>Normal or high</td> <td>Normal</td> </tr> <tr> <td>Chronic kidney disease</td> <td>Elevated</td> <td>Low</td> <td>Elevated</td> <td>Elevated or normal</td> <td>Normal or low*</td> <td>Low</td> <td>Elevated</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In individuals with concurrent nutritional deficiency.</div><div id=\"graphicVersion\">Graphic 72080 Version 2.0</div></div></div>"},"72081":{"type":"graphic_diagnosticimage","displayName":"Pneumatosis intestinalis plain","title":"Pneumatosis intestinalis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pneumatosis intestinalis</div><div class=\"cntnt\"><img style=\"width:361px; height:126px;\" src=\"images/GAST/72081_Pneumatosis_intestinalis_pl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A is a magnified image of a single fold in the colon demonstrating air within the wall of the colon, which appears as a thin linear lucency on this plain film (arrow). Panel B is a plain film from a 68-year-old male with ischemic bowel, demonstrating numerous linear collections of air within the bowel wall.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 72081 Version 2.0</div></div></div>"},"72082":{"type":"graphic_table","displayName":"ICH and anticoag intensity","title":"Relationship between intracranial hemorrhage and anticoagulation intensity in elderly atrial fibrillation patients: two studies*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relationship between intracranial hemorrhage and anticoagulation intensity in elderly atrial fibrillation patients: two studies*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Longitudinal cohort study</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Absolute rate<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mean age: 71 years</td> </tr> <tr> <td class=\"subtitle3_left\"><em>INR</em></td> <td class=\"subtitle3_left\"> <p><em>Rate</em></p> <em>Per 100 person-years</em></td> </tr> <tr> <td class=\"indent2\">&#60;1.5</td> <td>0.5</td> </tr> <tr> <td class=\"indent2\">1.5-1.9</td> <td>0.3</td> </tr> <tr> <td class=\"indent2\">2-2.5</td> <td>0.3</td> </tr> <tr> <td class=\"indent2\">2.6-3</td> <td>0.5</td> </tr> <tr> <td class=\"indent2\">3.1-3.5</td> <td>0.6</td> </tr> <tr> <td class=\"indent2\">3.6-3.9</td> <td>0.4</td> </tr> <tr> <td class=\"indent2\">4-4.5</td> <td>2.7</td> </tr> <tr> <td class=\"indent2\">&#62;4.5</td> <td>9.4</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Case-control study<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Relative risk</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mean age: cases = 78 years, controls = 75 years</td> </tr> <tr> <td class=\"subtitle3_left\"><em>INR</em></td> <td class=\"subtitle3_left\"><em>Relative risk</em></td> </tr> <tr> <td class=\"indent2\">&#60;1.5</td> <td>1.4</td> </tr> <tr> <td class=\"indent2\">1.5-1.9</td> <td>1.2</td> </tr> <tr> <td class=\"indent2\">2-3</td> <td>1 reference</td> </tr> <tr> <td class=\"indent2\">-</td> <td>-</td> </tr> <tr> <td class=\"indent2\">3.1-3.4</td> <td>1.4</td> </tr> <tr> <td class=\"indent2\">3.5-3.9</td> <td>4.6</td> </tr> <tr> <td class=\"indent2\">&#62;4</td> <td>8.8</td> </tr> <tr> <td class=\"indent2\">-</td> <td>-</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These time-dependent INR-based estimates are not directly applicable to clinical target INR ranges, as the invariable fluctuations in INRs are not considered. Intracranial hemorrhages include both primary intracerebral bleeding and subdural hematomas.<br />Â¶ From Hylek EM, et al. N Engl J Med 2003; 349:1019, a study involving 58 intracranial hemorrhages among 6320 outpatients taking warfarin in a longitudinal cohort study.<br />Î Estimated from Fang et al, involving 170 atrial fibrillation patients with intracranial hemorrhage taking warfarin in a case-control comparison. Fang, MC, Chang, Y, Hylek, EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141:745.</div><div class=\"graphic_reference\">Reproduced with permission from: Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36:1588. Copyright &copy; 2005 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 72082 Version 11.0</div></div></div>"},"72083":{"type":"graphic_table","displayName":"Medical probs breastfeed PI","title":"Medical problems and breastfeeding safety","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical problems and breastfeeding safety</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Breastfeeding is not recommended for women or infants with the following conditions:</td> </tr> <tr> <td>Women who have human immunodeficiency virus (HIV)</td> </tr> <tr> <td>Women with human T-cell lymphotropic virus type I or II (HTLV)</td> </tr> <tr> <td>Women being treated with chemotherapy or radiation therapy</td> </tr> <tr> <td>Women who abuse drugs or alcohol</td> </tr> <tr> <td>Women with herpes simplex lesions on the breasts (ok to breastfeed if one breast has no lesions)</td> </tr> <tr> <td>Infants with classic galactosemia (galactose 1-phosphate uridyltransferase deficiency)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Breastfeeding is encouraged for women or infants with the following conditions:</td> </tr> <tr> <td>Women with hepatitis (A, B, or C)</td> </tr> <tr> <td>Women with past or current cytomegalovirus (CMV) infection</td> </tr> <tr> <td>Infants who develop jaundice</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: American Academy of Pediatrics. Pediatric Nutrition Handbook. 6th edition, 2009.</div><div id=\"graphicVersion\">Graphic 72083 Version 3.0</div></div></div>"},"72085":{"type":"graphic_diagnosticimage","displayName":"Dry tap medial fat pad MRI","title":"Magnetic resonance imaging of medial fat pad in knee explaining dry tap","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of medial fat pad in knee explaining dry tap</div><div class=\"cntnt\"><img style=\"width:342px; height:360px;\" src=\"images/RHEUM/72085_Dry_tap_medial_fat_pad_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Failed arthrocentesis due to focal triangular fat pad. T2 weighted axial image through the mid-pole of the patella shows a prominent triangular fat pad located in the notch of the medial aspect of the patellofemoral joint (white arrow). A 1.5-inch needle (long arrow) could only reach the joint effusion in this relatively thin patient if the needle were placed to the hub.</div><div class=\"graphic_footnotes\">M: medial. L: lateral.</div><div class=\"graphic_reference\">Reproduced with permission from: Roberts WN, Hayes CW, Breitbach SA, et al. Am J Med 1996; 100:461.</div><div id=\"graphicVersion\">Graphic 72085 Version 3.0</div></div></div>"},"72086":{"type":"graphic_picture","displayName":"Flat warts forehead","title":"Flat warts","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Flat warts</div><div class=\"cntnt\"><img style=\"width:590px; height:443px;\" src=\"images/DERM/72086_Flat_warts_forehead.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple flesh-colored, flat-topped papules are present on the forehead.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72086 Version 5.0</div></div></div>"},"72087":{"type":"graphic_waveform","displayName":"Short QT interval tutorial","title":"Short QT interval","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short QT interval</div><div class=\"cntnt\"><img style=\"width:353px; height:107px;\" src=\"images/CARD/72087_Short_QT_interval_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QT interval (not corrected) in this case is approximately 0.24 seconds.</div><div id=\"graphicVersion\">Graphic 72087 Version 2.0</div></div></div>"},"72088":{"type":"graphic_picture","displayName":"Flash burn (welder's keratitis)","title":"Flash burn (welder's keratitis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flash burn (welder's keratitis)</div><div class=\"cntnt\"><img style=\"width:432px; height:276px;\" src=\"images/EM/72088_Welders_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows fluorescein uptake&nbsp;with diffuse punctate lesions of the cornea in a band-like distribution&nbsp;caused by exposure to ultraviolet radiation, in this case from an electric welding arc. Sunlight can also cause such an injury. In this characteristic exposure pattern, the eyelids spare the superior and inferior cornea, which distinguishes this injury from a diffuse infectious process (eg, adenovirus).</div><div class=\"graphic_reference\">Courtesy of Lawrence B Stack, MD.</div><div id=\"graphicVersion\">Graphic 72088 Version 4.0</div></div></div>"},"72091":{"type":"graphic_table","displayName":"Activation classification of tremor","title":"Activation classification of tremor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Activation classification of tremor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tremor type</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Clinical features and provocative maneuvers</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rest tremor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Occurs in a body part that is supported in such a way that skeletal muscle activation is neither necessary nor intended.</td> <td>The patient is recumbent on a bed or seated on a couch with the body part supported. Tremor is often enhanced by the performance of cognitive tasks or motor tasks with other body parts, and it is often suppressed, at least temporarily, by voluntary muscle contraction.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Action tremors</td> </tr> <tr> <td class=\"indent1\">Postural</td> <td>Occurs in an attempt to maintain a specific posture or position against the force of gravity.</td> <td>Extending the upper limbs horizontally, pointing at objects, sitting erect without support for the upper body, standing, protruding the tongue.</td> </tr> <tr> <td class=\"indent1\">Kinetic (including simple kinetic, intention, and isometric tremor)</td> <td>Occurs during any voluntary movement. Intention tremor worsens as the body part approaches its target. Isometric tremor occurs during a muscle contraction against a rigid, stationary object.</td> <td>Finger-to-nose testing, heel-to-shin testing, reaching, writing, drawing, pouring water into a cup, eating with utensils, speaking. With isometric tremor: pushing against a wall, flexing the wrist against a table, making a fist.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000; 54(suppl 4):S2. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72091 Version 15.0</div></div></div>"},"72092":{"type":"graphic_figure","displayName":"Pap test Ayre spatula","title":"Pap test Ayre spatula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pap test Ayre spatula</div><div class=\"cntnt\"><img style=\"width:381px; height:432px;\" src=\"images/OBGYN/72092_Pap_test_Ayre_spatula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Close up view of cross section of upper vagina and cervix with wooden or plastic spatula pressed against cervix, longer end introduced slightly into os. Arrow indicates rotation to obtain ectocervical sample.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART, Nursing. Copyright &#169;2009 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72092 Version 1.0</div></div></div>"},"72094":{"type":"graphic_picture","displayName":"Rash - Henoch Schonlein purpura IgA vasculitis B","title":"Skin manifestations of immunoglobulin A vasculitis (Henoch-SchÃ¶nlein purpura)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin manifestations of immunoglobulin A vasculitis (Henoch-SchÃ¶nlein purpura)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PEDS/72094_RashHSPB.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Susan Kim, MD.</div><div id=\"graphicVersion\">Graphic 72094 Version 5.0</div></div></div>"},"72095":{"type":"graphic_figure","displayName":"47,XXY in Klinefelter syndrome","title":"Chromosome analysis in Klinefelter syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromosome analysis in Klinefelter syndrome</div><div class=\"cntnt\"><img style=\"width:442px; height:321px;\" src=\"images/ENDO/72095_47XXYinKlinefeltersyndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A photograph of the 47 chromosomes of a man with Klinefelter syndrome. This patient has an extra X chromosome (47,XXY) (shaded area).</div><div id=\"graphicVersion\">Graphic 72095 Version 2.0</div></div></div>"},"72096":{"type":"graphic_figure","displayName":"Insulin receptor isoforms","title":"Insulin receptor isoforms","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Insulin receptor isoforms</div><div class=\"cntnt\"><img style=\"width:459px; height:160px;\" src=\"images/ENDO/72096_Insulin_receptor_isoforms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin receptor isoforms due to alternative splicing of the insulin receptor gene. The sequence encoded by exon 11 is either included (exon 11+) or excluded (exon 11-) from the mature mRNA.</div><div id=\"graphicVersion\">Graphic 72096 Version 1.0</div></div></div>"},"72097":{"type":"graphic_figure","displayName":"Linear salpingostomy","title":"Linear salpingostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear salpingostomy</div><div class=\"cntnt\"><img style=\"width:347px; height:653px;\" src=\"images/OBGYN/72097_Linearsalpingostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The tube is stabilized and injected with a dilute solution of vasopressin.<br />(B) An incision is made on the antimesenteric border overlying the ectopic.<br />(C) The products of conception are removed using atraumatic forceps.<br />(D) The implantation site is irrigated and hemostasis obtained.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 72097 Version 4.0</div></div></div>"},"72099":{"type":"graphic_figure","displayName":"Plasma concentrations B","title":"Increase in plasma concentrations of insulin (top) and c-peptide (bottom) for type 2 diabetic patients and healthy subjects after ingestion of a mixed breakfast meal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increase in plasma concentrations of insulin (top) and c-peptide (bottom) for type 2 diabetic patients and healthy subjects after ingestion of a mixed breakfast meal</div><div class=\"cntnt\"><img style=\"width:432px; height:486px;\" src=\"images/PC/72099_Plasma_concentrations_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data are means Â±SE.</div><div class=\"graphic_footnotes\">SE: standard error.<br />* p &lt;0.05 for differences between type 2 diabetic patients and healthy subjects.</div><div class=\"graphic_reference\">Modified with permission from: Vilsboll T, Krarup T, Deacon C, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50:609. Copyright Â© 2001 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 72099 Version 2.0</div></div></div>"},"72101":{"type":"graphic_picture","displayName":"Zanca radiographic view","title":"Zanca radiographic view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Zanca radiographic view</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/EM/72101_Zanca_radiographic_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient in the photograph above is positioned for a Zanca view. Note the upward angle of the x-ray beam.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 72101 Version 2.0</div></div></div>"},"72102":{"type":"graphic_movie","displayName":"Perisplenic free fluid","title":"FAST examination showing perisplenic free fluid","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">FAST examination showing perisplenic free fluid</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/72102_Perisplenfreefluidmovie.mp4\" style=\"width:496px;height:336px\"></div><img style=\"width:504px; height:393px;\" src=\"images/EM/72102_Perisplenfreefluidimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip from a FAST examination shows free fluid (presumably blood) around the spleen.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 72102 Version 1.0</div></div></div>"},"72103":{"type":"graphic_table","displayName":"Pyoderma gangrenosum ddx","title":"Pyoderma gangrenosum: Differential diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum: Differential diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inflammatory papules, pustules, nodules, or plaques (early disease)</td> </tr> <tr> <td class=\"sublist1_start\">Infections</td> </tr> <tr> <td class=\"sublist1\">Folliculitis, furuncles, or carbuncles (bacterial, viral, or fungal)</td> </tr> <tr> <td class=\"sublist1\">Cellulitis or cellulitis-like lesions (bacterial, mycobacterial, or fungal)</td> </tr> <tr> <td>Arthropod bite reaction</td> </tr> <tr> <td>Lymphoma (cutaneous T and B cell)</td> </tr> <tr> <td>Panniculitides (inflammatory, infectious, neoplastic, metabolic)</td> </tr> <tr> <td>Iododerma</td> </tr> <tr> <td>Bromoderma</td> </tr> <tr> <td class=\"subtitle1_single\">Ulcers and vegetative lesions (later disease)</td> </tr> <tr> <td class=\"sublist1_start\">Infections</td> </tr> <tr> <td class=\"sublist1\">Bacterial infections - botryomycosis, streptococcal synergistic gangrene, ecthyma gangrenosum, gummatous treponemal ulcers</td> </tr> <tr> <td class=\"sublist1\">Fungal infections - lesions associated with deep mycosis (blastomycosis, chromomycosis , coccidioidomycosis, paracoccidioidomycosis)</td> </tr> <tr> <td class=\"sublist1\">Mycobacterial infections - atypical and typical mycobacteria</td> </tr> <tr> <td class=\"sublist1\">Parasitic infections - leishmaniasis, amoebiasis, schistosomiasis</td> </tr> <tr> <td class=\"sublist1_start\">Vascular disorders</td> </tr> <tr> <td class=\"sublist1\">Vasculitis - cutaneous polyarteritis nodosa, microscopic polyangiitis, granulomatous vasculitides, autoimmune connective tissue disease, Beh&#231;et's disease</td> </tr> <tr> <td class=\"sublist1\">Ulcers related to:</td> </tr> <tr> <td class=\"sublist2\">Venous hypertension</td> </tr> <tr> <td class=\"sublist2\">Arterial insufficiency</td> </tr> <tr> <td class=\"sublist2\">Hemoglobinopathies</td> </tr> <tr> <td class=\"sublist2\">Non-septic emboli</td> </tr> <tr> <td class=\"sublist2\">Hypercoagulopathic thrombosis</td> </tr> <tr> <td class=\"sublist1_start\">Malignancy</td> </tr> <tr> <td class=\"sublist1\">Nonmelanoma skin cancer (squamous cell or basal cell carcinoma)</td> </tr> <tr> <td class=\"sublist1\">Cutaneous T or B cell lymphoma</td> </tr> <tr> <td class=\"sublist1_start\">Other</td> </tr> <tr> <td class=\"sublist1\">Brown recluse spider bite</td> </tr> <tr> <td class=\"sublist1\">Necrobiosis lipoidica with ulceration</td> </tr> <tr> <td class=\"sublist1\">Blastomycosis-like pyoderma</td> </tr> <tr> <td class=\"sublist1\">Pemphigus vegetans</td> </tr> <tr> <td class=\"sublist1\">Self-induced (factitial) ulcer</td> </tr> <tr> <td class=\"sublist1\">Hydroxyurea-induced ulcer</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Moschella SL, Davis MD. Neutrophilic dermatoses. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Mosby Elsevier, Spain 2008.</div><div id=\"graphicVersion\">Graphic 72103 Version 3.0</div></div></div>"},"72105":{"type":"graphic_waveform","displayName":"Atrial sensing pacer tutorial","title":"Dual chamber atrial sensing pacemaker","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dual chamber atrial sensing pacemaker</div><div class=\"cntnt\"><img style=\"width:295px; height:161px;\" src=\"images/CARD/72105_Atrial_sensing_pacer_tutori.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a normal or intrinsic P wave which, after a preset PR interval, is followed by a pacemaker spike and a paced QRS complex that has a bizarre morphology resembling a left bundle branch block or a ventricular complex.</div><div id=\"graphicVersion\">Graphic 72105 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"72106":{"type":"graphic_picture","displayName":"Hairy leukoplakia in HIV","title":"Hairy leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hairy leukoplakia</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/ID/72106_Hairy_leukoplakia_in_HIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated white plaques are visible on the lateral aspects of the tongue, which cleared with oral acyclovir.</div><div class=\"graphic_reference\">Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 72106 Version 5.0</div></div></div>"},"72108":{"type":"graphic_figure","displayName":"Early surgery flail MV","title":"Early surgery for flail mitral leaflet improves outcome","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Early surgery for flail mitral leaflet improves outcome</div><div class=\"cntnt\"><img style=\"width:547px; height:401px;\" src=\"images/CARD/72108_Early_surgery_flail_MV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early surgery for flail mitral leaflet improves outcomes as compared to conservative therapy. Among 221 with mitral regurgitation due to a flail leaflet who were eligible for surgery, 63 underwent early mitral valve surgery while 158 were treated medically. Compared to medical therapy, early surgery was associated with a higher overall survival (p = 0.028), lower cardiac mortality (p = 0.025), a lower incidence of atrial fibrillation (p = 0.032), and a lower incidence of heart failure (p = 0.046).</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Redrawn from Ling LH, Enriquez-Sarano M, Seward JB, et al. Circulation 1997; 96:1819.</div><div id=\"graphicVersion\">Graphic 72108 Version 2.0</div></div></div>"},"72109":{"type":"graphic_figure","displayName":"Brain anatomy PI","title":"The anatomy of the brain","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">The anatomy of the brain</div><div class=\"cntnt\"><img style=\"width:528px; height:564px;\" src=\"images/PI/72109_Brain_anatomy_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72109 Version 5.0</div></div></div>"},"72111":{"type":"graphic_table","displayName":"Typical lab characteristics of DKA and HHS","title":"Typical laboratory characteristics of DKA and HHS*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical laboratory characteristics of DKA and HHS*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"48%\"></colgroup><colgroup span=\"4\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">DKA</td> <td class=\"subtitle1\" rowspan=\"2\">HHS</td> </tr> <tr> <td class=\"subtitle2\">Mild</td> <td class=\"subtitle2\">Moderate</td> <td class=\"subtitle2\">Severe</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Plasma glucose (mg/dL)</strong></td> <td>&#62;250</td> <td>&#62;250</td> <td>&#62;250</td> <td>&#62;600</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Plasma glucose (mmol/L)</strong></td> <td>&#62;13.9</td> <td>&#62;13.9</td> <td>&#62;13.9</td> <td>&#62;33.3</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Arterial pH</strong></td> <td>7.25 to 7.30</td> <td>7.00 to 7.24</td> <td>&#60;7.00</td> <td>&#62;7.30</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Serum bicarbonate (mEq/L)</strong></td> <td>15 to 18</td> <td>10 to &#60;15</td> <td>&#60;10</td> <td>&#62;18</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Urine ketones</strong><sup>&#182;</sup></td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>Small</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Serum ketones - Nitroprusside reaction</strong></td> <td>Positive</td> <td>Positive</td> <td>Positive</td> <td>&#8804; Small</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Serum ketones - Enzymatic assay of beta hydroxybutyrate (normal range &#60;0.6 mmol/L)</strong><sup>&#916;</sup></td> <td>3 to 4 mmol/L</td> <td>4 to 8 mmol/L</td> <td>&#62;8 mmol/L</td> <td>&#60;0.6 mmol/L</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Effective serum osmolality (mOsm/kg)</strong><sup>&#9674;</sup></td> <td>Variable</td> <td>Variable</td> <td>Variable</td> <td>&#62;320</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Anion gap</strong><sup>&#167;</sup></td> <td>&#62;10</td> <td>&#62;12</td> <td>&#62;12</td> <td>Variable</td> </tr> <tr> <td><strong>Alteration in sensoria or mental obtundation</strong></td> <td>Alert</td> <td>Alert/drowsy</td> <td>Stupor/coma</td> <td>Stupor/coma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; HHS: hyperosmolar hyperglycemic state.<br />* There may be considerable diagnostic overlap between DKA and HHS.<br />&para; Nitroprusside reaction method.<br />&Delta; NOTE: Many assays for beta hydroxybutyrate can only report markedly elevated values as &gt;6.0 mmol/L.<br /><span class=\"lozenge\">&loz;</span> Calculation: 2[measured Na (mEq/L)] + glucose (mg/dL)/18.<br />&sect; Calculation: (Na+) &ndash; (Cl&ndash; + HCO3&ndash;) (mEq/L). See text for details.</div><div class=\"graphic_reference\">Copyright &copy; 2006 American Diabetes Association. From Diabetes Care Vol 29, Issue 12, 2006. Information updated from Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335. Reprinted with permission from the American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 72111 Version 7.0</div></div></div>"},"72112":{"type":"graphic_algorithm","displayName":"CT hepatobiliary disease","title":"Computed tomography of hepatobiliary disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of hepatobiliary disease</div><div class=\"cntnt\"><img style=\"width:349px; height:326px;\" src=\"images/GAST/72112_CT_hepatobiliary_disease.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Heterogeneous enhancement of spleen and kidneys (cortex &gt;&gt; medulla), dense opacification of hepatic artery, minimal enhancement of liver and portal vein, in addition to non-enhancement of hepatic veins may be seen on an optimal vascular phase image.<br>â¢ Dense homogeneous enhancement of the liver, spleen, and kidneys in addition to opacification of all large abdominal blood vessels constitutes an optimal portal phase image.<br>Î Homogeneous enhancement of all abdominal viscera with excretion of contrast-opacified urine by the kidneys constitutes an optimal equilibrium phase image. May be helpful in distinguishing HCC from regenerating nodules and dysplastic nodules as some carcinomas will have a discernible capsule at this stage, whereas regenerating nodules and dysplastic nodules should not.<br>â Tumors with a large component of fibrosis such as cholangiocarcinoma demonstrate prolonged hyperdense enhancement.</div><div id=\"graphicVersion\">Graphic 72112 Version 2.0</div></div></div>"},"72116":{"type":"graphic_table","displayName":"Herbs affecting lipids","title":"Hypolipidemic and hyperlipidemic herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypolipidemic and hyperlipidemic herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Alfalfa</td>\n<td>Hypocholesterolemic, in vivo</td>\n</tr>\n<tr>\n<td>Artichoke</td>\n<td>Hypocholesterolemic, in vivo, human</td>\n</tr>\n<tr>\n<td>Cohosh, black</td>\n<td>Hypocholesterolemic, in vivo</td>\n</tr>\n<tr>\n<td>Fenugreek</td>\n<td>Hypocholesterolemic, in vivo, human</td>\n</tr>\n<tr>\n<td>Garlic</td>\n<td>Hypocholesterolemic, in vivo, human</td>\n</tr>\n<tr>\n<td>Ginger</td>\n<td>Hypocholesterolemic, in vivo</td>\n</tr>\n<tr>\n<td>Hydrocotyle</td>\n<td>Hypercholesterolemic, in vivo</td>\n</tr>\n<tr>\n<td>Plantain</td>\n<td>Hypocholesterolemic, in vivo</td>\n</tr>\n<tr>\n<td>Scullcap</td>\n<td>Hypocholesterolemic, in vivo</td>\n</tr>\n<tr>\n<td>Tansy</td>\n<td>Hypocholesterolemic, in vivo</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.282.</div><div id=\"graphicVersion\">Graphic 72116 Version 2.0</div></div></div>"},"72119":{"type":"graphic_figure","displayName":"TURP scope","title":"Transurethral resection of the prostate (TURP)","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Transurethral resection of the prostate (TURP)</div><div class=\"cntnt\"><img style=\"width:476px; height:586px;\" src=\"images/SURG/72119_TURP_scope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A resectoscope loaded with a diathermy loop is introduced into the bladder. Under direct vision, strips of prostatic adenoma are resected one at a time and dropped into the bladder. After the entire adenoma is resected, the prostate chips are evacuated from the bladder and hemostasis is achieved with electrocautery.</div><div id=\"graphicVersion\">Graphic 72119 Version 1.0</div></div></div>"},"72120":{"type":"graphic_figure","displayName":"Cervical vertebrae anatomy PI","title":"Anatomy of the neck","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the neck</div><div class=\"cntnt\"><img style=\"width:542px; height:543px;\" src=\"images/PI/72120_Cervical_vertebrae_anat_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72120 Version 2.0</div></div></div>"},"72122":{"type":"graphic_waveform","displayName":"ECG strip atrial bigeminy and blocked APB","title":"Single-lead electrocardiogram (ECG) showing atrial bigeminy and blocked atrial premature beats (APBs)","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing atrial bigeminy and blocked atrial premature beats (APBs)</div><div class=\"cntnt\"><img style=\"width:474px; height:89px;\" src=\"images/CARD/72122_Atrial_bigeminy_and_blocked.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The single channel electrocardiographic recording shows a sinus P wave (P) followed by an atrial premature beat (P') in a repeating pattern, termed atrial bigeminy. The P' does not result in ventricular activation since conduction is blocked within the atrioventricular node (blocked atrial premature beat).</div><div id=\"graphicVersion\">Graphic 72122 Version 3.0</div></div></div>"},"72123":{"type":"graphic_table","displayName":"CNS abnormities and Lyme","title":"Relationship of central nervous system abnormities and neuroborreliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relationship of central nervous system abnormities and neuroborreliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manifestation</td> <td class=\"subtitle1\">Caused by neuroborreliosis infection</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td>Meningitis</td> <td>Yes</td> <td>Common</td> </tr> <tr> <td>Benign intracranial hypertension</td> <td>Yes</td> <td>Uncommon; occurs primarily in children</td> </tr> <tr> <td>Encephalomyelitis</td> <td>Yes</td> <td>Rare</td> </tr> <tr> <td>Encephalopathy</td> <td>No</td> <td>Variable</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72123 Version 5.0</div></div></div>"},"72124":{"type":"graphic_figure","displayName":"Annual reported incidence for anaplasmosis in the US for 2010","title":"Annual reported incidence (per million population) for anaplasmosis in the United States for 2010","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Annual reported incidence (per million population) for anaplasmosis in the United States for 2010</div><div class=\"cntnt\"><img style=\"width:564px; height:356px;\" src=\"images/ID/72124_HGA_annual_incidence.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NN: not notifiable.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Statistics and Epidemiology. <a href=\"http://www.cdc.gov/anaplasmosis/stats/index.html\" target=\"_blank\">www.cdc.gov/anaplasmosis/stats/index.html</a> (Accessed on July 21, 2016).</div><div id=\"graphicVersion\">Graphic 72124 Version 2.0</div></div></div>"},"72125":{"type":"graphic_picture","displayName":"Ross River virus small joint arthritis","title":"Small joint arthritis with Ross River virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small joint arthritis with Ross River virus infection</div><div class=\"cntnt\"><img style=\"width:362px; height:237px;\" src=\"images/ID/72125_Small_joint_arthritis_in_RR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The small joints are involved in approximately 40 percent of patients with Ross River virus infection. The proximal interphalangeal joints are a frequent site of involvement and, as in this case, may be accompanied by a rash.</div><div class=\"graphic_reference\">Courtesy of Michael Richards, MB, BS, FRACP.</div><div id=\"graphicVersion\">Graphic 72125 Version 4.0</div></div></div>"},"72126":{"type":"graphic_movie","displayName":"Amplatzer device ASD","title":"Amplatzer device for atrial septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amplatzer device for atrial septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72126_teecamplconv.mp4\" style=\"width:383px;height:276px\"></div><img style=\"width:233px; height:260px;\" src=\"images/CARD/72126_teecampl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram with color flow Doppler shows an Amplatzer device (arrow) which closes an atrial septal defect. With color flow Doppler there is no blood flow across the device, although a small amount of blood flow can be appreciated within the device itself.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 72126 Version 2.0</div></div></div>"},"72127":{"type":"graphic_figure","displayName":"Preterm birth rate in the United States","title":"Preterm birth rate in the United States","html":"<div class=\"graphic\"><div style=\"width: 681px\" class=\"figure\"><div class=\"ttl\">Preterm birth rate in the United States</div><div class=\"cntnt\"><img style=\"width:661px; height:315px;\" src=\"images/PEDS/72127_Prtrm_brth_rt_untd_stts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preterm birth rates in the United States based upon final data for the years 1990 to 2013. NOTE: Rates are the percentage of live births at less than 37 weeks of gestation.</div><div class=\"graphic_reference\">Reproduced from: Martin JA, Hamilton BE, Osterman MK, et al. Births: Final data for 2013. Natl Vital Stat Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 72127 Version 6.0</div></div></div>"},"72131":{"type":"graphic_picture","displayName":"Hepatic adenoma gross","title":"Hepatic adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic adenoma</div><div class=\"cntnt\"><img style=\"width:302px; height:335px;\" src=\"images/GAST/72131_Hepatic_adenoma_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross sectioned pathological specimen of a resected pedunculated hepatic adenoma measuring &gt;6 cm in diameter. The adenoma shows the typically tan fleshy appearance of an adenoma with no capsule. There is no evidence of hemorrhage or necrosis.</div><div class=\"graphic_reference\">Courtesy of Imad Nasser, MD.</div><div id=\"graphicVersion\">Graphic 72131 Version 1.0</div></div></div>"},"72134":{"type":"graphic_figure","displayName":"Human karyotype","title":"Human karyotype","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Human karyotype</div><div class=\"cntnt\"><img style=\"width:400px; height:303px;\" src=\"images/PC/72134_Human_karyotype.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In humans, each cell normally contains 23 pairs of chromosomes, for a total of 46. Twenty-two of these pairs, called autosomes, look the same in both males and females. The 23rd pair, the sex chromosomes, differ between males and females. Females have two copies of the X chromosome, while males have one X and one Y chromosome.<br>The 22 autosomes are numbered by size. The other two chromosomes, X and Y, are the sex chromosomes. This picture of the human chromosomes lined up in pairs is called a karyotype.</div><div class=\"graphic_reference\">Reproduced from US National Library of Medicine.</div><div id=\"graphicVersion\">Graphic 72134 Version 1.0</div></div></div>"},"72135":{"type":"graphic_table","displayName":"Pressure sore status tool","title":"Pressure sore status tool ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pressure sore status tool </div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Clinical features</td>\n\n      <td class=\"subtitle1\">Stage</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Exudate amount</td>\n\n      <td>1 = None&nbsp;&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n      <td>2 = Scant</td>\n    </tr>\n    <tr>\n      <td>3 = Small </td>\n    </tr>\n    <tr>\n      <td>4 = Moderate</td>\n    </tr>\n    <tr>\n      <td>5 = Large</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Skin color surrounding wound</td>\n\n      <td>1 = Pink or normal for ethnic group</td>\n\n    </tr>\n\n    <tr>\n      <td>2 = Bright red and/or blanches to touch</td>\n    </tr>\n    <tr>\n      <td>3 = White or gray pallor or hypopigmented</td>\n    </tr>\n    <tr>\n      <td>4 = Dark red or purple and/or nonblanchable</td>\n    </tr>\n    <tr>\n      <td>5 = Black or hypopigmented</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Peripheral tissue edema</td>\n\n      <td>1 = Minimal swelling around wound</td>\n\n    </tr>\n\n    <tr>\n      <td>2 = Nonpitting edema extends &#60;4 cm around wound</td>\n    </tr>\n    <tr>\n      <td>3 = Nonpitting edema extends &#8805;4 cm around wound</td>\n    </tr>\n    <tr>\n      <td>4 = Pitting edema extends &#60;4 cm around wound</td>\n    </tr>\n    <tr>\n      <td>5 = Crepitus and/or pitting edema extends &#8805;4 cm</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Peripheral tissue induration</td>\n\n      <td>1 = Minimal firmness around wound</td>\n\n    </tr>\n\n    <tr>\n      <td>2 = &#60;2 cm around wound </td>\n    </tr>\n    <tr>\n      <td>3 = 2 to 4 cm extending &#60;50 percent around wound </td>\n    </tr>\n    <tr>\n      <td>4 = 2 to 4 cm extending &#8805;50 percent around wound</td>\n    </tr>\n    <tr>\n      <td>5 = &#62;4 cm in any area</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Granulation tissue</td>\n\n      <td>1 = Skin intact or partial-thickness wound</td>\n\n    </tr>\n\n    <tr>\n      <td>2 = Bright, beefy red; 75 to 100 percent of wound filled and/or tissue overgrowth</td>\n    </tr>\n\n    <tr>\n\n\n      <td>3 = Bright, beefy red; &#60;75 percent and &#62;25 percent of wound filled</td>\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>4 = Pink and/or dull, dusky red and/or fills &#8804;25 percent of wound</td>\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>5 = No granulation tissue present</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Epithilization</td>\n\n      <td>1 = 100 percent of wound covered, surface intact</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td>2 = 75 to 100 percent of wound covered and/or epithelial tissue extends &#62;0.5 cm into wound bed</td>\n\n    </tr>\n\n    <tr>\n\n\n      <td>3 = 50 to 75 percent of wound covered and/or epithelial tissue extends &#60;0.5 cm into wound bed</td>\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>4 = 25 to 50 percent of wound covered</td>\n\n    </tr>\n    <tr>\n      <td>5 = &#60;25 percent of wound covered</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Bates-Jensen, BM, Adv Wound Care 1998; 10:65.</div><div id=\"graphicVersion\">Graphic 72135 Version 2.0</div></div></div>"},"72139":{"type":"graphic_figure","displayName":"Effects of parathyroidectomy","title":"Graph showing the changes in total plasma calcium and phosphate concentrations after parathyroidectomy for secondary hyperparathyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing the changes in total plasma calcium and phosphate concentrations after parathyroidectomy for secondary hyperparathyroidism</div><div class=\"cntnt\"><img style=\"width:210px; height:202px;\" src=\"images/NEPH/72139_Effects_of_parathyroidectom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in total plasma calcium and phosphate levels observed in 11 uremic patients before and following subtotal PTX for severe secondary hyperparathyroidism.</div><div class=\"graphic_footnotes\">PTX: parathyroidectomy.</div><div class=\"graphic_reference\">From Massry SG, Coburn JW, Popovtzer MM, et al. Secondary hyperparathyroidism&nbsp;in chronic renal failure: The clinical spectrum in uremia, during hemodialysis, and after renal transplantation.&nbsp;Arch Intern Med 1969; 124:431. Copyright 1969, American Medical Association.</div><div id=\"graphicVersion\">Graphic 72139 Version 3.0</div></div></div>"},"72140":{"type":"graphic_figure","displayName":"ECG gated MPI and outcomes","title":"Wall motion and left ventricular fraction scores","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Wall motion and left ventricular fraction scores</div><div class=\"cntnt\"><img style=\"width:608px; height:240px;\" src=\"images/CARD/72140_ECG_gated_MPI_and_outcomes.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Travin MI, Heller GV, Johnson LL, et al. The prognostic value of ECG-gated SPECT imaging in patients undergoing stress Tc-99m sestamibi myocardial perfusion imaging. J Nucl Cardiol 2004; 11:253. Copyright &copy; 2004 The American Society of Nuclear Cardiology.</div><div id=\"graphicVersion\">Graphic 72140 Version 4.0</div></div></div>"},"72141":{"type":"graphic_table","displayName":"Phases lung development","title":"Phases of lung development","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phases of lung development</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Gestational age, weeks</td>\n<td class=\"subtitle1\">Stage of lung development</td>\n<td class=\"subtitle1\">Description</td>\n</tr>\n<tr>\n<td>0 to 5</td>\n<td>Embryonic</td>\n<td>Lung bud arises</td>\n</tr>\n<tr>\n<td>6 to 17</td>\n<td>Pseudoglandular</td>\n<td>Nonrespiratory bronchi and bronchioles develop</td>\n</tr>\n<tr>\n<td>17 to 24</td>\n<td>Canalicular</td>\n<td>First gas exchanging acini and pulmonary capillaries are forming</td>\n</tr>\n<tr>\n<td>25 to 37</td>\n<td>Terminal sac</td>\n<td>Subsaccules and alveoli develop with extensive capillary invasion and expansion of the alveolar-blood barrier surface area</td>\n</tr>\n<tr>\n<td>38 to age 3 years</td>\n<td>Alveolar</td>\n<td>Subsaccules become alveoli</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72141 Version 1.0</div></div></div>"},"72142":{"type":"graphic_picture","displayName":"Type 3 breast lobule","title":"Type 3 breast lobule","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Type 3 breast lobule</div><div class=\"cntnt\"><img style=\"width:465px; height:249px;\" src=\"images/SURG/72142_Breast_lobule_type3_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Whole mount preparation of breast tissue of a 35-year-old parous woman showing type 3 breast lobule as viewed by light microscopy.<br />(Left panel) Tissue section stained with toluidine blue x 2.5. (Right panel) Histological section of lobule type 3 stained with hematoxylin and eosin (H&amp;E). Photographs at 10x (left panel) and 40x (right panel) respectively.</div><div class=\"graphic_reference\">Reproduced with permission from: Russo J, Hu Y-F, Silva IDCG, and Russo IH. Cancer risk related to mammary gland structure and development. Microscopy Research and Technique 2001; 52:204. Copyright &copy; 2001 American Cancer Society.</div><div id=\"graphicVersion\">Graphic 72142 Version 4.0</div></div></div>"},"72144":{"type":"graphic_picture","displayName":"Calcaneovalgus feet at rest","title":"Positional calcaneovalgus feet at rest of newborn infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positional calcaneovalgus feet at rest of newborn infant</div><div class=\"cntnt\"><img style=\"width:396px; height:308px;\" src=\"images/PEDS/72144_Calcaneovalgus_feet_at_rest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gerardo Cabrera-Meza, MD, Baylor College of Medicine.</div><div id=\"graphicVersion\">Graphic 72144 Version 4.0</div></div></div>"},"72146":{"type":"graphic_table","displayName":"Doppler diastolic dysfunction","title":"Doppler echocardiographic criteria for classification of diastolic function","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Doppler echocardiographic criteria for classification of diastolic function</div><div class=\"cntnt\"><img style=\"width:606px; height:722px;\" src=\"images/CARD/72146_Dopplerdiastolicdysfunct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Participants with atrial fibrillation with DT &gt;140 ms, other arrhythmia, fusion of E and A, or in whom diastolic parameters were not obtained, who had only&nbsp;one criterion suggesting moderate or severe diastolic dysfunction, or in whom diastolic parameters were borderline and suggestive of but not diagnostic of abnormality were classified as having indeterminate diastolic function.<br />Grade I (mild) diastolic dysfunction is characterized by the impaired relaxation pattern.<br />Grade II (moderate) diastolic dysfunction is charaterized by a pseudonormal pattern.<br />Grades III and IV (severe) diastolic dysfunction are characterized by a (irreversible and fixed) restrictive pattern.</div><div class=\"graphic_footnotes\">E: peak early filling velocity; A: velocity at atrial contraction; DT: deceleration time; Adur: A duration; ARdur: AR duration; S: systolic forward flow; D: diastolic forward flow; AR: pulmonary venous atrial reversal flow; e': velocity of mitral annulus early diastolic motion; a': velocity of mitral annulus motion with atrial systole; DT: mitral E velocity deceleration time.</div><div class=\"graphic_reference\">Reproduced with permission from: Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194. Copyright Â© 2003 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72146 Version 22.0</div></div></div>"},"72147":{"type":"graphic_picture","displayName":"Prurigo of pregnancy","title":"Prurigo of pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prurigo of pregnancy</div><div class=\"cntnt\"><img style=\"width:290px; height:504px;\" src=\"images/OBGYN/72147_Prurigo_of_pregnancy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Miriam Kelt Pomeranz, MD. Department of Dermatology. New York University School of Medicine.</div><div id=\"graphicVersion\">Graphic 72147 Version 1.0</div></div></div>"},"72148":{"type":"graphic_picture","displayName":"Bitot spot caused by vitamin A deficiency","title":"Bitot spot caused by vitamin A deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bitot spot caused by vitamin A deficiency</div><div class=\"cntnt\"><img style=\"width:410px; height:302px;\" src=\"images/PEDS/72148_Bitots_spot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bitot spot (areas of abnormal squamous cell proliferation and keratinization of the conjunctiva), caused by vitamin A deficiency. This picture was taken in Lebanon and used as a clinical standard for examiners in international nutrition surveys.</div><div class=\"graphic_reference\">Reproduced from: Interdepartmental Committee on Nutrition for National Defense (1963). Manual for Nutrition Surveys 2nd ed. Department of Health, Education and Welfare, Public Health Service, NIH, US Government Printing Office, Washington DC 1963.</div><div id=\"graphicVersion\">Graphic 72148 Version 6.0</div></div></div>"},"72152":{"type":"graphic_picture","displayName":"Hulka uterine manipulator","title":"Hulka uterine manipulator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hulka uterine manipulator</div><div class=\"cntnt\"><img style=\"width:437px; height:234px;\" src=\"images/OBGYN/72152_Hulka_uterine_manipulator.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This type of manipulator does not allow injection of dye.</div><div id=\"graphicVersion\">Graphic 72152 Version 1.0</div></div></div>"},"72153":{"type":"graphic_picture","displayName":"Flame cell myeloma","title":"Flame cell in multiple myeloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flame cell in multiple myeloma</div><div class=\"cntnt\"><img style=\"width:401px; height:288px;\" src=\"images/HEME/72153_Flame_cell_myeloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a bone marrow aspirate from a patient with multiple myeloma of the IgA type. Multiple abnormal plasma cells can be seen in this view, including a binucleate form (small arrows). The large cell on the right has an abnormal nucleus and a cytoplasm with a reddish (flame-like) tint, due to the presence of IgA protein (arrow).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD and William C Moloney, MD.</div><div id=\"graphicVersion\">Graphic 72153 Version 2.0</div></div></div>"},"72154":{"type":"graphic_diagnosticimage","displayName":"IVUS tranplanted heart","title":"Early atherosclerosis in a transplanted heart assessed with intracoronary ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early atherosclerosis in a transplanted heart assessed with intracoronary ultrasound</div><div class=\"cntnt\"><img style=\"width:168px; height:305px;\" src=\"images/CARD/72154_IVUS_tranplanted_heart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Athough atherosclerotic changes are not seen on coronary angiography (bottom), extensive atherosclerosis is evident with intracoronary ultrasound (top).</div><div class=\"graphic_reference\">Reproduced with permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.</div><div id=\"graphicVersion\">Graphic 72154 Version 3.0</div></div></div>"},"72155":{"type":"graphic_figure","displayName":"Identification poison ivy","title":"Identification of poison ivy, oak, and sumac","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Identification of poison ivy, oak, and sumac</div><div class=\"cntnt\"><img style=\"width:425px; height:372px;\" src=\"images/PC/72155_Identificationpoisonivy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic features useful for identifying poison ivy, poison oak, and poison sumac. Poison ivy and poison oak are often identified by three leaflets with flowering branches arising from axillary positions on a single stem. Poison sumac more often forms leaflets of five, seven, or more that angle upward toward the top of the stem.</div><div class=\"graphic_reference\">Reproduced with permission from: Bolognia J, Jorizzo JJ, Rapini RP, et al. Dermatology. Elsevier, Boston 2003. Copyright Â© 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 72155 Version 3.0</div></div></div>"},"72157":{"type":"graphic_table","displayName":"Cryofibrinogen associations","title":"Conditions associated with cryofibrinogenemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with cryofibrinogenemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Essential (idiopathic)</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic rheumatic and autoimmune diseases</td> </tr> <tr> <td>ANCA-associated vasculitis</td> </tr> <tr> <td>Ankylosing spondylitis</td> </tr> <tr> <td>Beh&#231;et's disease</td> </tr> <tr> <td>Familial Mediterranean fever</td> </tr> <tr> <td>Giant cell arteritis</td> </tr> <tr> <td>Graves' disease</td> </tr> <tr> <td>Hashimoto's thyroiditis</td> </tr> <tr> <td>Henoch-Sch&#246;nlein purpura&nbsp;(immunoglobulin A vasculitis)</td> </tr> <tr> <td>IgA nephropathy</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Inflammatory muscle disease</td> </tr> <tr> <td>Mixed connective tissue disease</td> </tr> <tr> <td>Osteitis</td> </tr> <tr> <td>Polyarteritis nodosa</td> </tr> <tr> <td>Primary biliary cirrhosis</td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Pyoderma gangrenosum</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Sj&#246;gren's syndrome&nbsp;</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Systemic sclerosis</td> </tr> <tr> <td>Thromboangiitis obliterans (Buerger's disease)</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious diseases</td> </tr> <tr> <td>Chlamydia</td> </tr> <tr> <td>Colitis, infectious</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td>Giardia</td> </tr> <tr> <td>Hepatitis C</td> </tr> <tr> <td>Herpes virus</td> </tr> <tr> <td>HIV</td> </tr> <tr> <td>Post-respiratory infection</td> </tr> <tr> <td><em>Staphylococcus aureus</em>&nbsp;</td> </tr> <tr> <td>Streptococcus</td> </tr> <tr> <td>Trypanosomiasis</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Varicella-Zoster virus</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignancies and neoplastic conditions</td> </tr> <tr> <td>Adenocarcinoma</td> </tr> <tr> <td>Atrial myxoma</td> </tr> <tr> <td>Gallbladder cancer</td> </tr> <tr> <td>Head and neck cancer</td> </tr> <tr> <td>Hepatoma</td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Lung cancer</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Myelodysplastic syndromes</td> </tr> <tr> <td>Myeloproliferative disease&nbsp;</td> </tr> <tr> <td>Ovarian cancer&nbsp;</td> </tr> <tr> <td>Prostate cancer</td> </tr> <tr> <td>Renal cell carcinoma&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Drug-related: Oral contraceptives</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Factor XII deficiency</td> </tr> <tr> <td>Homocystinuria</td> </tr> <tr> <td>Myocardial infarction</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td>Severe athersclerosis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ANCA: antineutrophil cytoplasmic antibody; IgA: immunoglobulin A; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 72157 Version 6.0</div></div></div>"},"72158":{"type":"graphic_diagnosticimage","displayName":"Distal tibia fibula fracture","title":"Transverse fracture of the distal tibia and fibula","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Transverse fracture of the distal tibia and fibula</div><div class=\"cntnt\"><img style=\"width:520px; height:380px;\" src=\"images/EM/72158_Distal_tibia_fibula_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This seven-year-old child sustained distal fractures of the tibia and fibula after being struck by a car while walking. The tibial fracture is comminuted.</div><div class=\"graphic_reference\">Courtesy of Eglal Shalaby-Rana, MD.</div><div id=\"graphicVersion\">Graphic 72158 Version 3.0</div></div></div>"},"72160":{"type":"graphic_figure","displayName":"PSE after TIPS","title":"Portosystemic encephalopathy after TIPS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Portosystemic encephalopathy after TIPS</div><div class=\"cntnt\"><img style=\"width:421px; height:276px;\" src=\"images/GAST/72160_PSE_after_TIPS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in the portosystemic encephalopathy (PSE) index in patients treated with endoscopic sclerotherapy (EST, left) or insertion of a transjugular intrahepatic stent shunt (TIPS, right). There were no significant changes in the PSE index with EST, whereas there was a significant worsening in patients treated with TIPS. The effect was most pronounced at one month; the values returned toward baseline at six months but were still significantly higher than in the EST arm.</div><div class=\"graphic_reference\">Data from Sanyal, AJ, Freedman, AM, Shiffman, ML, et al, Hepatology 1994; 20:46.</div><div id=\"graphicVersion\">Graphic 72160 Version 1.0</div></div></div>"},"72161":{"type":"graphic_waveform","displayName":"EPS tracing AVNRT dual AVN pathways II","title":"Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways</div><div class=\"cntnt\"><img style=\"width:555px; height:410px;\" src=\"images/CARD/72161_AVNRT_dual_AVN_pathways_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tracing shows three surface ECG leads (I, II, V1) and intracardiac recordings from the high right atrium (HRA), bundle of His (HIS), right ventricular apex (RVA), and coronary sinus (CS). During atrial pacing (S1) at a cycle length of 600 ms (100 beats per minute); the AH interval is 120 ms. An atrial premature beat (S2) is added at a coupling cyle of 410 ms; this results in a prolongation of the PR interval and increase in the AH interval to 242 ms, which represents a 60 ms increase compared to the AH when a premature beat was added with a coupling interval of 420 ms. This represents a &quot;jump&quot; due to a shift of AV nodal conduction from the fast to slow AV nodal pathway. Since the fast pathway has time to recover, there is retrograde VA conduction via the fast pathway, resulting in the occurrence of a retrograde His depolarization (HIS &quot;A&quot;) and an atrial echo beat at the CS os area (CS 10-9).</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 72161 Version 3.0</div></div></div>"},"72163":{"type":"graphic_picture","displayName":"TMEP II","title":"Cutaneous mastocytosis: Telangiectasia macularis eruptiva perstans (TMEP) form","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Cutaneous mastocytosis: Telangiectasia macularis eruptiva perstans (TMEP) form</div><div class=\"cntnt\"><img style=\"width:516px; height:254px;\" src=\"images/ALLRG/72163_Clin_pres_masto_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Telangiectasia macularis eruptiva perstans type of maculopapular CM. Lesions are strictly macular (ie, not elevated), reddish-brown, and as shown in the higher magnification; (B) are ill-defined and exhibit fine telangiectasias.</div><div class=\"graphic_footnotes\">CM: cutaneous mastocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolff K, Komar M, Petzelbaur P. Clinical and histopathological aspects of cutaneous mastocytosis. Leukemia Research 2001; 25:519. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72163 Version 3.0</div></div></div>"},"72164":{"type":"graphic_picture","displayName":"Inverted papilloma Light","title":"Inverted (Schneiderian) papilloma","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Inverted (Schneiderian) papilloma</div><div class=\"cntnt\"><img style=\"width:563px; height:266px;\" src=\"images/ONC/72164_Inverted_papilloma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power (left panel) and high power (right panel) photomicrographs of inverted papillomas, which usually arise from the lateral nasal wall or paranasal sinuses. They may be entirely endophytic, or they may also have an exophytic component. These lesions may have, albeit rarely, malignant potential. Cytologically, they are composed of non-keratinized squamous cells that preserve scattered mucin-containing cells of the surface during their inverted growth. These appear as mucin-containing \"microcysts\".</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 72164 Version 4.0</div></div></div>"},"72165":{"type":"graphic_picture","displayName":"Candidal diaper dermatitis B","title":"Candidal diaper dermatitis in an infant","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Candidal diaper dermatitis in an infant</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/PEDS/72165_Candidal_diaper_dermatiti1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic occlusion with wet diapers predisposes to infection, which initially begins in the perianal area with subsequent extension to the perineum and inguinal creases.</div><div class=\"graphic_reference\">Courtesy of Annette Wagner, MD, Children's Memorial Hospital, Chicago, IL.</div><div id=\"graphicVersion\">Graphic 72165 Version 7.0</div></div></div>"},"72166":{"type":"graphic_figure","displayName":"Spermatic cord cross-sectional anatomy","title":"Spermatic cord cross-sectional anatomy","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Spermatic cord cross-sectional anatomy</div><div class=\"cntnt\"><img style=\"width:528px; height:421px;\" src=\"images/PC/72166_Vasectomy_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left spermatic cord.</div><div id=\"graphicVersion\">Graphic 72166 Version 3.0</div></div></div>"},"72167":{"type":"graphic_figure","displayName":"Superior pole thyroid","title":"Superior pole thyroid","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Superior pole thyroid</div><div class=\"cntnt\"><img style=\"width:464px; height:483px;\" src=\"images/SURG/72167_Superiorpolethyroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kelly clamp on superior pole of thyroid with retraction and right-angle dissection, with tips angled in correct direction - anterior and lateral.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72167 Version 11.0</div></div></div>"},"72168":{"type":"graphic_diagnosticimage","displayName":"Middle ear CT axial view","title":"Middle ear CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Middle ear CT scan</div><div class=\"cntnt\"><img style=\"width:350px; height:360px;\" src=\"images/EM/72168_Midd_ear_CT_axial_view_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial cuts of a computed tomography (CT) scan demonstrating traumatic ossicular disruption of the malleo-incudal joint. Note the hypodense space between the malleus and incus that represents a joint separation.</div><div class=\"graphic_reference\">Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.</div><div id=\"graphicVersion\">Graphic 72168 Version 4.0</div></div></div>"},"72169":{"type":"graphic_figure","displayName":"Graves retroorbital fat","title":"Graves' ophthalmopathy: Retroorbital fat and muscle","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Graves' ophthalmopathy: Retroorbital fat and muscle</div><div class=\"cntnt\"><img style=\"width:540px; height:360px;\" src=\"images/ENDO/72169_graves_retro_orbital_fat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both the retroorbital fat and muscles are involved in the development of Graves' opthalmopathy. Cytokine released from fibroblast and pre-adipocytes accentuate the secretion of hyaluronic acid-like molecules, which increase the osmotic pressure in the tissues causing fluid accumulation and, in particular, disruption of the muscle bundles. This figure shows the marked swelling of the retroorbital muscles, often well visualized on MRI or CT scanning in such patients. The consequence of retroorbital swelling is proptosis (exophthalmos), not well illustrated here since this may depend on both the anatomy of the orbit and the degree of swelling.</div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 72169 Version 4.0</div></div></div>"},"72170":{"type":"graphic_figure","displayName":"6-MP metabolism","title":"6-mercaptopurine metabolism","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">6-mercaptopurine metabolism</div><div class=\"cntnt\"><img style=\"width:570px; height:447px;\" src=\"images/GAST/72170_6MPmetabolismedt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial metabolism of 6-mercaptopurine occurs along the competing routes catalyzed by thiopurine methyltransferase (TPMT), xanthine oxidase (XO), and hypoxanthine phosphoribosyltransferase (HPRT). Further metabolism of the thionucleotide is catalyzed by inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase (GMPS). The diphosphates and triphosphates are formed by their respective monophosphate (MPK) and diphosphate (DPK) kinases.</div><div class=\"graphic_reference\">Reproduced with permission from: Cuffari C, et al. Gut 1996; 39:401. Copyright 1996 BMJ Publishing Group.</div><div id=\"graphicVersion\">Graphic 72170 Version 13.0</div></div></div>"},"72171":{"type":"graphic_picture","displayName":"Hyperplast gastric polyp Light","title":"Hyperplastic gastric polyp","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperplastic gastric polyp</div><div class=\"cntnt\"><img style=\"width:288px; height:332px;\" src=\"images/GAST/72171_Hyperplast_gastric_polyp_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a hyperplastic gastric polyp which is composed of elongated, dilated, and architecturally distorted foveolar epithelium within an edematous, congested, and inflamed lamina propria.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 72171 Version 1.0</div></div><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Normal gastric antrum</div><div class=\"cntnt\"><img style=\"width:520px; height:223px;\" src=\"images/GAST/79895_Normal_gastric_antrum_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Normal surface (SE) and foveolar epithelium (FE) and glands (G). Right panel: Higher power view of the glands shows mucous cells (M) and gastrin-secreting endocrine cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 79895 Version 1.0</div></div></div>"},"72172":{"type":"graphic_table","displayName":"ACG guidelines liver disease during pregnancy","title":"American College of Gastroenterology Guidelines: Liver disease in the pregnant patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Gastroenterology Guidelines: Liver disease in the pregnant patient</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Use of gestational age of the pregnancy is the best guide to the differential diagnosis of liver disease in the pregnant woman</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Hyperemesis gravidarum should be considered in the differential diagnosis of abnormal liver tests presenting in the first trimester</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Cholestasis of pregnancy is common, and should be considered in the differential diagnosis of abnormal liver tests presenting initially in the second trimester. Affected pregnancies are at increased risk for prematurity and stillbirth, and early delivery should be considered when possible</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>HELLP (hemolysis, elevated liver tests, low platelets) syndrome and acute fatty liver of pregnancy should be considered in the differential diagnosis of abnormal liver tests in the second half of pregnancy, usually in the third trimester</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Patients with acute fatty liver of pregnancy have true hepatic dysfunction, and may, or may not, have signs of pre-eclampsia and HELLP syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Consider viral or drug-induced hepatitis, gallstone disease, or malignancy in the differential diagnosis of abnormal liver tests in any of the trimesters of pregnancy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chronic hepatitis B or C poses a risk of transmission to the offspring</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Data from: Riely CA. Liver disease in the pregnant patient. Am J Gastroenterol 1999; 94:1728.</div><div id=\"graphicVersion\">Graphic 72172 Version 3.0</div></div></div>"},"72174":{"type":"graphic_table","displayName":"Lead and CKD","title":"Studies evaluating the role of lead in CKD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Studies evaluating the role of lead in CKD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Reference </td> <td class=\"subtitle1\">N </td> <td class=\"subtitle1\">Baseline mean (SD) blood lead (microgram/dL) </td> <td class=\"subtitle1\">Baseline mean (SD) chelatable lead (microgram/72 hours) </td> <td class=\"subtitle1\">Baseline mean (SD) eGFR (mL/min/1.73 m<sup>2</sup>) </td> <td class=\"subtitle1\">Follow-up (years) </td> <td class=\"subtitle1\">Decline in eGFR per 1 SD higher lead dose at baseline per year </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>[1]</td> <td>202</td> <td>5.3 (2.9)</td> <td>104.5 (106.3)</td> <td>41.6 (14.4)</td> <td>two</td> <td>0.16</td> <td>Largest study to date</td> </tr> <tr> <td>[2]</td> <td>121</td> <td>4.2 (2.2)</td> <td>99.1 (83.4)</td> <td>36.0 (9.8)</td> <td>four</td> <td> <p>2.7 (chelatable)</p> <p>2.2 (blood lead)</p> </td> <td>Longest follow-up; 1 microgram/dL higher blood lead, at baseline, associated with 4.0 mL/min/1.73 m<sup>2</sup> reduction in eGFR over&nbsp;four years</td> </tr> <tr> <td>[3]</td> <td>87</td> <td>6.5 (3.4)</td> <td>108.5 (53.8)</td> <td>35.1 (9.0)</td> <td>one</td> <td>3.87</td> <td>Type II diabetics with nephropathy</td> </tr> <tr> <td>[4]</td> <td>108</td> <td>2.9 (1.4)*</td> <td>40.2 (21.2) (all &#60;80)</td> <td>47.6 (9.8)</td> <td>two</td> <td>1.1</td> <td>Lowest lead exposed CKD patients</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">SD: standard deviation; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease.</div><div class=\"graphic_footnotes\">* Notably, mean blood lead level in this study was below that observed in a recent large general population study of 50 to 70 year olds in Baltimore, MD<SUP>[5]</SUP>.</div><div class=\"graphic_reference\">Data from:<BR>1. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348:277.<BR>2. Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol 2004; 15:1016.<BR>3. Lin JL, Lin-Tan DT, Yu CC, et al. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int 2006; 69:2049.<BR>4. Lin JL, Lin-Tan DT, Li YJ, et al. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med 2006; 119:707.<BR>5. Martin D, Glass TA, Bandeen-Roche K, et al. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 2006; 163:467.</div><div id=\"graphicVersion\">Graphic 72174 Version 4.0</div></div></div>"},"72175":{"type":"graphic_picture","displayName":"Optic disc Frisen grade 3","title":"Optic disc FrisÃ©n Grade III","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic disc Fris&#233;n Grade III</div><div class=\"cntnt\"><img style=\"width:450px; height:350px;\" src=\"images/NEURO/72175_Optic_disc_Frisen_grade_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fris&#233;n Grade 3 showing obscuration of a major vessel as it leaves the optic disc (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael Wall, MD.</div><div id=\"graphicVersion\">Graphic 72175 Version 2.0</div></div></div>"},"72176":{"type":"graphic_figure","displayName":"Spinal cord blood supply","title":"Cross section of the spinal cord demonstrating arterial blood supply","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cross section of the spinal cord demonstrating arterial blood supply</div><div class=\"cntnt\"><img style=\"width:418px; height:372px;\" src=\"images/NEURO/72176_SC_blood_supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Craven, J. Spinal Cord. Anaesthesia and intensive care medicine 2004; 5:144. Copyright Â©2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 72176 Version 2.0</div></div></div>"},"72177":{"type":"graphic_table","displayName":"Placental weight","title":"Placental weight standards","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Placental weight standards</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">Gestational age</td>\n<td colspan=\"5\" class=\"subtitle1\">Singleton</td>\n<td colspan=\"5\" class=\"subtitle1\">Twin</td>\n</tr>\n<tr>\n\n<td colspan=\"5\" class=\"subtitle2\">Percentiles</td>\n<td colspan=\"5\" class=\"subtitle2\">Percentiles</td>\n</tr>\n<tr>\n\n<td class=\"subtitle3\">10</td>\n<td class=\"subtitle3\">25</td>\n<td class=\"subtitle3\">50</td>\n<td class=\"subtitle3\">75</td>\n<td class=\"subtitle3\">90</td>\n<td class=\"subtitle3\">10</td>\n<td class=\"subtitle3\">25</td>\n<td class=\"subtitle3\">50</td>\n<td class=\"subtitle3\">75</td>\n<td class=\"subtitle3\">90</td>\n</tr>\n<tr>\n<td>12</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>56</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>14</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>83</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>16</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>110</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>18</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>137.8</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>20</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>145</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>166</td>\n<td>190</td>\n<td>218</td>\n<td>245</td>\n<td>270</td>\n</tr>\n<tr>\n<td>22</td>\n<td>122</td>\n<td>138</td>\n<td>157</td>\n<td>176</td>\n<td>191</td>\n<td>191</td>\n<td>219</td>\n<td>251</td>\n<td>282</td>\n<td>310</td>\n</tr>\n<tr>\n<td>24</td>\n<td>145</td>\n<td>166</td>\n<td>189</td>\n<td>212</td>\n<td>233</td>\n<td>232</td>\n<td>267</td>\n<td>307</td>\n<td>346</td>\n<td>382</td>\n</tr>\n<tr>\n<td>26</td>\n<td>175</td>\n<td>200</td>\n<td>227</td>\n<td>255</td>\n<td>280</td>\n<td>284</td>\n<td>330</td>\n<td>380</td>\n<td>430</td>\n<td>475</td>\n</tr>\n<tr>\n<td>28</td>\n<td>210</td>\n<td>238</td>\n<td>270</td>\n<td>302</td>\n<td>331</td>\n<td>345</td>\n<td>401</td>\n<td>464</td>\n<td>527</td>\n<td>584</td>\n</tr>\n<tr>\n<td>30</td>\n<td>249</td>\n<td>281</td>\n<td>316</td>\n<td>352</td>\n<td>384</td>\n<td>409</td>\n<td>478</td>\n<td>554</td>\n<td>631</td>\n<td>700</td>\n</tr>\n<tr>\n<td>32</td>\n<td>290</td>\n<td>325</td>\n<td>364</td>\n<td>403</td>\n<td>438</td>\n<td>472</td>\n<td>554</td>\n<td>644</td>\n<td>734</td>\n<td>815</td>\n</tr>\n<tr>\n<td>34</td>\n<td>331</td>\n<td>369</td>\n<td>411</td>\n<td>453</td>\n<td>491</td>\n<td>531</td>\n<td>624</td>\n<td>727</td>\n<td>830</td>\n<td>923</td>\n</tr>\n<tr>\n<td>36</td>\n<td>372</td>\n<td>412</td>\n<td>457</td>\n<td>501</td>\n<td>542</td>\n<td>582</td>\n<td>684</td>\n<td>798</td>\n<td>912</td>\n<td>1014</td>\n</tr>\n<tr>\n<td>38</td>\n<td>409</td>\n<td>452</td>\n<td>499</td>\n<td>547</td>\n<td>589</td>\n<td>619</td>\n<td>728</td>\n<td>850</td>\n<td>972</td>\n<td>1082</td>\n</tr>\n<tr>\n<td>40</td>\n<td>442</td>\n<td>487</td>\n<td>537</td>\n<td>587</td>\n<td>632</td>\n<td>638</td>\n<td>753</td>\n<td>879</td>\n<td>1005</td>\n<td>1118</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Pinar, H, Sung, J, Oyer, CE, Singer, DB. Reference values for singleton and twin placental weights. Pediatr Pathol Lab Med 1996; 16:901.</div><div id=\"graphicVersion\">Graphic 72177 Version 1.0</div></div></div>"},"72178":{"type":"graphic_diagnosticimage","displayName":"Nonclassic DWI-PWI mismatch","title":"Nonclassic pattern of DWI-PWI mismatch","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Nonclassic pattern of DWI-PWI mismatch</div><div class=\"cntnt\"><img style=\"width:546px; height:443px;\" src=\"images/NEURO/72178_Nonclassic_DWI_PWI_mismatch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative case with nonclassic pattern of mismatch.<br> (A) Diffusion weighted-image (DWI).<br> (B) DWI abnormal lesion (red) and hypoperfusion lesion (green) superimposed on DWI. Note fragmentation of the pattern.<br> (C) DWI abnormal lesion and hypoperfusion lesion with brain image (DWI) removed.</div><div class=\"graphic_footnotes\">DWI: diffusion-weighted image; PWI: perfusion-weighted image.</div><div class=\"graphic_reference\">Reproduced with permission from: Ogata T, Nagakane Y, Christensen S, et al. A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. Stroke 2011; 42:1596. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72178 Version 4.0</div></div></div>"},"72179":{"type":"graphic_figure","displayName":"Costochondritis PI","title":"Costochrondritis","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Costochrondritis</div><div class=\"cntnt\"><img style=\"width:551px; height:604px;\" src=\"images/PI/72179_Costochondritis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Costochondritis causes pain and tenderness in the costosternal joints.</div><div id=\"graphicVersion\">Graphic 72179 Version 2.0</div></div></div>"},"72180":{"type":"graphic_picture","displayName":"HSTCL bone marrow biopsy","title":"Hepatosplenic T-cell lymphoma with bone marrow involvement","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hepatosplenic T-cell lymphoma with bone marrow involvement</div><div class=\"cntnt\"><img style=\"width:540px; height:346px;\" src=\"images/HEME/72180_HSTCLsinusoidallymphcell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy reveals sinusoidal lymphoma cell infiltration. Hematoxylin and eosin, 40x magnification.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72180 Version 7.0</div></div></div>"},"72182":{"type":"graphic_picture","displayName":"Focal granulation TM","title":"Focal granulation tissue on the surface of the tympanic membrane","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal granulation tissue on the surface of the tympanic membrane</div><div class=\"cntnt\"><img style=\"width:360px; height:365px;\" src=\"images/PEDS/72182_Focal_granulation_TM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focal granulation tissue at the mouth of a deep retraction pocket (arrow) indicating cholesteatoma.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 72182 Version 3.0</div></div></div>"},"72185":{"type":"graphic_figure","displayName":"Shared AAs in DR2 and DR4","title":"Common amino acids in two HLA-DR alleles","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Common amino acids in two HLA-DR alleles</div><div class=\"cntnt\"><img style=\"width:471px; height:404px;\" src=\"images/RHEUM/72185_Shared_AAs_in_DR2_and_DR4.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alpha (green) and beta (blue) chains of the HLA class II molecule join to form an antigen binding pocket or domain. DNA sequencing of the two DR antigens, HLA-DR4 and -DR2, associated with the development of anti-U1 RNP antibodies has revealed that they share a common set of amino acids in the beta chain at positions 26, 28, 30, 31, 32, 70 and 73. As shown, amino acids at these positions form a portion of the antigen binding pocket.</div><div id=\"graphicVersion\">Graphic 72185 Version 1.0</div></div></div>"},"72186":{"type":"graphic_diagnosticimage","displayName":"Echocardiogram of infundibular VSD","title":"Echocardiogram of infundibular VSD","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of infundibular VSD</div><div class=\"cntnt\"><img style=\"width:515px; height:383px;\" src=\"images/CARD/72186_Echocard_infund_VSD_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram showing an infundibular or supracristal defect with and without color flow Doppler in systole and diastole. Aortic valve prolapse is seen in early systole (A). As blood is ejected blood from the left ventricle, the anatomically unsupported coronary cusp and aortic sinus are driven into the right ventricle (RV) by a Venturi effect. Color flow Doppler shows left to right shunt across the VSD (B). In diastole (C), the unsupported cusp does not coapt with the other coronary cusps, resulting in aortic regurgitation (AR).</div><div class=\"graphic_reference\">Reprinted with permission from: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes, CA (Ed). Â© 2009 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 72186 Version 7.0</div></div></div>"},"72187":{"type":"graphic_picture","displayName":"Papular xanthoma","title":"Papular xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papular xanthoma</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/72187_Papular_xanthomas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This healthy 11-year-old boy developed multiple yellow-red papules clustered on and around his nose. He has no mucous membrane lesions, and a lipid profile was normal.</div><div class=\"graphic_reference\">Copyright Â© Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 72187 Version 5.0</div></div></div>"},"72190":{"type":"graphic_figure","displayName":"ASPECTS study form","title":"ASPECTS study form","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">ASPECTS study form</div><div class=\"cntnt\"><img style=\"width:498px; height:319px;\" src=\"images/NEURO/72190_ASPECTS_study_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ASPECTS value is calculated from two standard axial CT cuts: one at the level of the thalamus and basal ganglia (left), and one just rostral to the basal ganglia (right). A: anterior circulation; P: posterior circulation; C: caudate; L: lentiform; IC: internal capsule; I: insular ribbon; MCA: middle cerebral artery; M1: anterior MCA cortex; M2: MCA cortex lateral to insular ribbon; M3: posterior MCA cortex; M4, M5, and M6 are anterior, lateral, and posterior MCA territories immediately superior to M1, M2, and M3, rostral to basal ganglia</div><div class=\"graphic_reference\">Reproduced with permission from: Barber, PA, Demchuk, AM, Zhang, J, Buchan, AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000; 355:1670. Copyright &#169; 2000 The Lancet.</div><div id=\"graphicVersion\">Graphic 72190 Version 1.0</div></div></div>"},"72191":{"type":"graphic_table","displayName":"Anomalies associated with intestinal malrotation","title":"Anomalies associated with intestinal malrotation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anomalies associated with intestinal malrotation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Congenital diaphragmatic hernia*</td> </tr> <tr> <td>Major congenital cardiac anomalies (especially heterotaxia syndromes)*</td> </tr> <tr> <td>Abdominal wall defects (omphalocele, gastroschisis, and prune belly syndrome)*</td> </tr> <tr> <td>Intestinal&nbsp;atresias (duodenal including duodenal web or stenosis, jejunal, and ileal)</td> </tr> <tr> <td>Esophageal atresia (isolated and with tracheoesophageal fistula)</td> </tr> <tr> <td>Biliary atresia&nbsp;</td> </tr> <tr> <td>Meckel diverticulum</td> </tr> <tr> <td>Complex anorectal malformations alone or in combination with VACTERL anomalies</td> </tr> <tr> <td>Cornelia de Lange syndrome</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">VACTERL: vertebral, anal, cardiac, tracheoesophageal, renal, limb. </div><div class=\"graphic_footnotes\">*: Strong association.</div><div id=\"graphicVersion\">Graphic 72191 Version 6.0</div></div></div>"},"72192":{"type":"graphic_table","displayName":"Cultural context DM","title":"Kleinman's explanatory model (adapted for diabetes)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Kleinman's explanatory model (adapted for diabetes)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Provider question</td>\n\t    <td class=\"subtitle1\">Clues to beliefs</td>\n\t  </tr>\n\t  <tr>\n\t    <td>What do you think caused your diabetes?</td>\n\t    <td><p>&#8226; Is the cause biologically, spiritually or emotionally-based?</p>\n\t\t\t<p>&#8226; External or internal source?</p>\n\t\t\t<p>&#8226; Related to God's will, own behavior, environment, imbalance?</p></td>\n\t  </tr>\n\t  <tr>\n\t    <td>Why do you think it started when it did?</td>\n\t    <td>&#8226; Does family believe there was a critical or triggering event?</td>\n\t  </tr>\n\t  <tr>\n\t    <td><p>What do you think your diabetes does to you/your child?</p>\n\t\t\t<p>How does it work?</p></td>\n\t    <td><p>&#8226; Family's explanation of diabetes</p>\n\t\t\t<p>&#8226; What symptoms does family relate to diabetes?</p>\n\t\t\t<p>&#8226; Meaning family attaches to symptoms</p></td>\n\t  </tr>\n\t  <tr>\n\t    <td>How severe is your diabetes?</td>\n\t    <td><p>&#8226; Perception of seriousness</p>\n\t\t\t<p>&#8226; Belief in the diagnosis</p>\n\t\t\t<p>&#8226; Perceptions of duration of diabetes</p></td>\n\t  </tr>\n\t  <tr>\n\t    <td>What kind of treatment do you think you should receive?</td>\n\t    <td><p>&#8226; Types of treatment believed to be effective</p>\n\t\t\t<p>&#8226; Western approaches?</p>\n\t\t\t<p>&#8226; Alternative approaches?</p>\n\t\t\t<p>&#8226; Thoughts about taking insulin</p></td>\n\t  </tr>\n\t  <tr>\n\t    <td>What are the most important results you hope to receive from this treatment?</td>\n\t    <td><p>&#8226; Highlights family priorities</p>\n\t\t\t<p>&#8226; Symptoms and issues of less concern to family</p></td>\n\t  </tr>\n\t  <tr>\n\t    <td>What are the chief problems your diabetes has caused for you?</td>\n\t    <td>&#8226; May provide insight into patient's perceived barriers</td>\n\t  </tr>\n\t  <tr>\n\t    <td>What do you fear most about your diabetes?</td>\n\t    <td><p>&#8226; Quality of life as defined by the family</p>\n\t\t\t<p>&#8226; May uncover feelings of hopelessness and being overwhelmed</p></td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Nwankwo R, Tang T. Tailoring diabetes education and care to minority patients and families. In: Practical psychology for diabetes clinicians, 2nd ed, Anderson B, Rubin R (Eds), American Diabetes Association, Alexandria 2002. p.37.</div><div id=\"graphicVersion\">Graphic 72192 Version 2.0</div></div></div>"},"72193":{"type":"graphic_diagnosticimage","displayName":"MPS I cord compression B","title":"Spinal cord compressions in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal cord compressions in a patient with mucopolysaccharidosis type I (MPS I, Hurler-Scheie syndrome) B</div><div class=\"cntnt\"><img style=\"width:256px; height:403px;\" src=\"images/PEDS/72193_MPS_I_cord_compression_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal T1-weighted&nbsp;magnetic resonance&nbsp;image of the cervical spine in a patient with Hurler-Scheie syndrome showing the grossly abnormal vertebrae and intervertebral discs. Note the abnormal spinus processes of the upper cervical vertebrae and constriction of the cord due to soft tissue thickening and meningeal storage. An enlarged cisterna magna with small cerebellum is also evident.</div><div class=\"graphic_reference\">Courtesy of Emil Kakkis, MD, PhD.</div><div id=\"graphicVersion\">Graphic 72193 Version 4.0</div></div></div>"},"72195":{"type":"graphic_table","displayName":"Rapid overview emergency management severe upper GI bleeding","title":"Rapid overview: Emergency management of severe upper GI bleeding in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergency management of severe upper GI bleeding in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major causes*</td> </tr> <tr> <td>Peptic ulcer, esophagogastric varices, arteriovenous malformation, tumor, esophageal (Mallory-Weiss) tear</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical features</td> </tr> <tr> <td class=\"sublist1_start\">History</td> </tr> <tr> <td class=\"sublist1\">Use of: NSAIDs, aspirin, anticoagulants, antiplatelet agents</td> </tr> <tr> <td class=\"sublist1\">Alcohol abuse; previous GI bleed; liver disease; coagulopathy</td> </tr> <tr> <td class=\"sublist1\">Symptoms and signs: Abdominal pain; hematemesis or \"coffee ground\" emesis; passing melena/tarry stool (stool may be frankly bloody or maroon with massive or brisk upper GI bleeding)</td> </tr> <tr> <td class=\"sublist1_start\">Examination</td> </tr> <tr> <td class=\"sublist1\">Tachycardia, orthostatic blood pressure changes suggest moderate to severe blood loss; hypotension suggests life-threatening blood loss (hypotension may be late finding in healthy younger adult)</td> </tr> <tr> <td class=\"sublist1\">Rectal examination is performed to assess stool color (melena versus hematochezia versus brown)</td> </tr> <tr> <td class=\"sublist1\">Significant abdominal tenderness accompanied by signs of peritoneal irritation (eg, involuntary guarding) suggests perforation</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic testing</td> </tr> <tr> <td>Obtain type and screen (or type and crossmatch for hemodynamic instability, severe bleeding, or high-risk patient)</td> </tr> <tr> <td>Obtain hemoglobin concentration (normal measurement may be inaccurate with acute severe hemorrhage), platelet count, coagulation studies (prothrombin time with INR), liver enzymes (AST, ALT), albumin, BUN and creatinine</td> </tr> <tr> <td>Nasogastric lavage may be helpful if the source of bleeding is unclear (upper or lower GI tract) or to clean the stomach prior to endoscopy</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td>Closely monitor airway, clinical status, vital signs, cardiac rhythm, urine output, nasogastric output (if nasogastric tube in place)</td> </tr> <tr> <td>Do NOT give patient anything by mouth</td> </tr> <tr> <td>Establish two large bore IV lines (16 gauge or larger)</td> </tr> <tr> <td>Provide supplemental oxygen</td> </tr> <tr> <td>Treat hypotension initially with rapid, bolus infusions of isotonic crystalloid</td> </tr> <tr> <td class=\"sublist1_start\">Transfuse for:</td> </tr> <tr> <td class=\"sublist1\">Hemodynamic instability despite crystalloid resuscitation</td> </tr> <tr> <td class=\"sublist1\">Hemoglobin &#60;9 g/dL (90 g/L) in high-risk patients (eg, elderly, coronary artery disease)</td> </tr> <tr> <td class=\"sublist1\">Hemoglobin &#60;7 g/dL (70 g/L) in low-risk patients</td> </tr> <tr> <td class=\"sublist1\">Avoid over-transfusion with possible variceal bleeding</td> </tr> <tr> <td class=\"sublist1\">Give fresh frozen plasma for coagulopathy; give platelets for thrombocytopenia (platelets &#60;50,000) or platelet dysfunction (eg, chronic aspirin therapy)</td> </tr> <tr> <td>Obtain immediate consultation with gastroenterologist; obtain surgical and interventional radiology consultation for any large-scale bleeding&#182;</td> </tr> <tr> <td class=\"sublist1_start\">Pharmacotherapy for all patients with suspected or known severe bleeding:</td> </tr> <tr> <td class=\"sublist1\">Give a proton pump inhibitor (eg, esomeprazole 40 mg IV twice daily&nbsp;or pantoprazole 40 mg IV twice daily)</td> </tr> <tr> <td class=\"sublist1_start\">Pharmacotherapy for known or suspected esophagogastric variceal bleeding and/or cirrhosis:</td> </tr> <tr> <td class=\"sublist1\">Give somatostatin or an analogue (eg, octreotide 50 mcg IV bolus, followed by 50 mcg/hour continuous IV&nbsp;infusion)</td> </tr> <tr> <td class=\"sublist1\">Give an IV antibiotic (eg, ceftriaxone or fluoroquinolone)</td> </tr> <tr> <td>Balloon tamponade may be performed as a temporizing measure for patients with uncontrollable hemorrhage likely due to varices using any of several devices (eg, Sengstaken-Blakemore tube, Minnesota tube); tracheal intubation is necessary if such a device is to be placed; ensure proper device placement prior to inflation to avoid esophageal rupture</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; INR: international normalized ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; IV: intravenous.<br />*An important but uncommon cause of gastrointestinal hemorrhage is vascular-enteric fistula, typically aortoduodenal fistula related to erosion of a prosthetic aortic graft.<br />Â¶Minimally invasive techniques to control bleeding include sclerotherapy,&nbsp;embolization and other vascular occlusion techniques. For patients with massive hemorrhage,&nbsp;resuscitative endovascular balloon occlusion of the aorta&nbsp;(REBOA) can be&nbsp;used to limit blood loss and support perfusion of vital organs until the sites of bleeding can be directly controlled. &nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 72195 Version 8.0</div></div></div>"},"72196":{"type":"graphic_picture","displayName":"NHL rectum Endosc","title":"Non-Hodgkin lymphoma of rectum on endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-Hodgkin lymphoma of rectum on endoscopy</div><div class=\"cntnt\"><img style=\"width:331px; height:310px;\" src=\"images/GAST/72196_NHL_rectum_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the rectum in a 95-year-old patient who presented with weight loss and anemia. The biopsy revealed non Hodgkins lymphoma.</div><div class=\"graphic_reference\">Courtesy of Alfonso Sandoval, MD.</div><div id=\"graphicVersion\">Graphic 72196 Version 3.0</div></div></div>"},"72197":{"type":"graphic_figure","displayName":"Uniparental disomy","title":"Postulated mechanism of uniparental disomy","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Postulated mechanism of uniparental disomy</div><div class=\"cntnt\"><img style=\"width:499px; height:392px;\" src=\"images/OBGYN/72197_Uniparental_disomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chromosomal nondisjunction during meiosis leads, after fertilization, to trisomy. Subsequent loss of one chromosome (rescue) could lead to the formation of cells with a chromosome from each parent or cells in which both chromosomes were from the disomic gamete.</div><div class=\"graphic_reference\">Reprinted from Preece, MA, Moore, GE. Genomic Imprinting, Uniparental Disomy and Fetal Growth. Trends in Endocrinology and Metabolism 2000; 11:270. Copyright 2000, with permission from Elsevier Science.</div><div id=\"graphicVersion\">Graphic 72197 Version 1.0</div></div></div>"},"72199":{"type":"graphic_picture","displayName":"Tracheomalacia bronchoscopy","title":"Tracheomalacia by bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Tracheomalacia by bronchoscopy</div><div class=\"cntnt\"><img style=\"width:518px; height:268px;\" src=\"images/PULM/72199_Tracheomalacia_bronchoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Branchoscopic view of tracheomalacia. A) The normal status during inhalation; B) near total collapse during quiet exhalation.</div><div class=\"graphic_reference\">Courtesy of Dr. P Boiselle.</div><div id=\"graphicVersion\">Graphic 72199 Version 3.0</div></div></div>"},"72201":{"type":"graphic_diagnosticimage","displayName":"Ruptured abdominal aortic aneurysm on computed tomography","title":"Ruptured abdominal aortic aneurysm on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ruptured abdominal aortic aneurysm on computed tomography</div><div class=\"cntnt\"><img style=\"width:504px; height:419px;\" src=\"images/SURG/72201_Ruptured_abd_aort_aneu_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Aortic calcification identifies the intact wall of the aorta. A large heterogenous retroperitoneal hematoma is present adjacent the left kidney at the site of rupture.</div><div id=\"graphicVersion\">Graphic 72201 Version 2.0</div></div></div>"},"72204":{"type":"graphic_figure","displayName":"Survival in HBV cirrhosis","title":"Survival in HBV-related compensated cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in HBV-related compensated cirrhosis</div><div class=\"cntnt\"><img style=\"width:351px; height:219px;\" src=\"images/GAST/72204_Survival_in_HBV_cirrhosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative probability of survival in patients with compensated cirrhosis related to hepatitis B virus (HBV) infection.</div><div class=\"graphic_reference\">Data from: Realdi G, Fattovich G, Hadziyannis S, et al. J Hepatol 1994; 21:656.</div><div id=\"graphicVersion\">Graphic 72204 Version 2.0</div></div></div>"},"72207":{"type":"graphic_figure","displayName":"Processing proteins PD","title":"Cellular processing of proteins involved in the pathogenesis of Parkinson disease","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Cellular processing of proteins involved in the pathogenesis of Parkinson disease</div><div class=\"cntnt\"><img style=\"width:568px; height:464px;\" src=\"images/NEURO/72207_Processing_proteins_PD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Model of dopaminergic cell death and possible sites for therapeutic intervention in PD. Studies on inherited forms of PD have led to the identification of genes that, when mutated, lead to dopaminergic cell loss. These genes are involved in a variety of cellular processes that include protein ubiquitination and degradation via the proteasome, response to oxidative stress, protein phosphorylation, mitochondrial function, and protein folding. Potential points of therapeutic intervention are highlighted: gene silencing therapies to reduce synuclein levels <strong>(i)</strong>; inhibitors of synuclein aggregation and/or processing <strong>(ii)</strong>; interventions to downregulate toxic substrates or upregulate parkin or proteasomal function <strong>(iii)</strong>; interventions to enhance mitochondrial function with factors such as CoQ10, DJ-1, or PINK-1 <strong>(iv)</strong>; free radical scavengers and antioxidants <strong>(v)</strong>; kinase inhibitors to block LRRK2 activity or interventions to increase PINK-1 function <strong>(vi)</strong>; and other therapies using trophic factors such as GDNF, survival genes, or fetal/stem cell replacement that would protect or replace susceptible cells <strong>(vii)</strong>.</div><div class=\"graphic_reference\">Reproduced with permission from: Savitt, J, Dawson, V, Dawson, T. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116:1744. Copyright Â©2006 American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 72207 Version 2.0</div></div></div>"},"72208":{"type":"graphic_table","displayName":"Cairo-Bishop TLS grading","title":"Cairo-Bishop clinical tumor lysis syndrome definition* and grading","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cairo-Bishop clinical tumor lysis syndrome definition* and grading</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Complication </td> <td class=\"subtitle1\" colspan=\"6\">Grade </td> </tr> <tr> <td class=\"subtitle2\">0 </td> <td class=\"subtitle2\">1 </td> <td class=\"subtitle2\">2 </td> <td class=\"subtitle2\">3 </td> <td class=\"subtitle2\">4 </td> <td class=\"subtitle2\">5 </td> </tr> <tr> <td>Creatinine<sup>&#182;&#916;</sup></td> <td>&#8804;1.5 x ULN</td> <td>1.5 x ULN</td> <td>&#62;1.5-3.0 x ULN</td> <td>&#62;3.0-6.0 x ULN</td> <td>&#62;6.0 x ULN</td> <td>Death</td> </tr> <tr> <td>Cardiac arrhythmia<sup>&#182;</sup></td> <td>None</td> <td>Intervention not indicated</td> <td>Nonurgent medical intervention indicated</td> <td>Symptomatic and incompletely controlled medically or controlled with device (eg, defibrillator)</td> <td>Life-threatening (eg, arrhythmia associated with HF, hypotension, syncope, shock)</td> <td>Death</td> </tr> <tr> <td>Seizure<sup>&#182;</sup></td> <td>None</td> <td>-</td> <td>One brief, generalized seizure; seizure(s) well controlled by anticonvulsants or infrequent focal motor seizures not interfering with ADL</td> <td>Seizure in which consciousness is altered; poorly controlled seizure disorder; with breakthrough generalized seizures despite medical intervention</td> <td>Seizure of any kind which are prolonged, repetitive or difficult to control (eg, status epilepticus, intractable epilepsy)</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ULN: upper limit of normal; HF: heart failure; ADL: activities of daily living.<br />* Clinical tumor lysis syndrome defined as laboratory tumor lysis syndrome plus at least one clinical complication.<br />Â¶&nbsp;Not directly or probably attributable to therapeutic agent.<br />Î If no institutional ULN is specified, age/sex ULN creatinine may be defined as follows: &gt;1 to &lt;12 years of age, both male and female, 61.6 mmol/L; â¥12 to &lt;16 years, both male and female, 88 mmol/L; â¥16 years, female 105.6 mmol/L, male 114.4 mmol/L.</div><div class=\"graphic_reference\">Reproduced with permission from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767. Copyright Â© 2008 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72208 Version 3.0</div></div></div>"},"72209":{"type":"graphic_picture","displayName":"HSV cytopathic effect","title":"Herpes simplex virus cytopathic effect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex virus cytopathic effect</div><div class=\"cntnt\"><img style=\"width:444px; height:324px;\" src=\"images/PEDS/72209_HSV_cytopathic_effect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The microscopic appearance of a monolayer of uninfected human fibroblasts grown in cell culture (A) and the same cells after infection with herpes simplex virus (B), demonstrating the cytopathic effect caused by viral replication and concomitant cell lysis.</div><div class=\"graphic_reference\">Reproduced with permission from: Porth CM. Pathophysiology Concepts of Altered Health States, Seventh Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &#169; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72209 Version 2.0</div></div></div>"},"72210":{"type":"graphic_picture","displayName":"Varicella lesion close view","title":"Varicella","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Varicella</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/72210_Varicella_lesion_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A vesicle on an erythematous base is present. Varicella lesions are often described as resembling a \"dew drop on a rose petal.\"</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72210 Version 2.0</div></div></div>"},"72211":{"type":"graphic_table","displayName":"Diagnostic yield of screening for chromosomal anomalies in ID","title":"The yield of testing for genetic anomalies in children with intellectual disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The yield of testing for genetic anomalies in children with intellectual disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Population tested</td> <td class=\"subtitle1\">Diagnostic yield*<br /> (percent of patients with positive results)</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Chromosomal microarray analysis (CMA, also known as comparative genomic hybridization [CGH])</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">GDD/ID</td> <td>15 to 20</td> <td>Recommended as first-line test for most patients with GDD/ID, unless the patient has features suggesting a specific disorder</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Karyotype</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">GDD/ID</td> <td>10 to 15</td> <td>Recommended as first-line test for the following: <ul class=\"decimal_heading\"> <li>Patients with features of Down or other chromosomal syndrome </li> <li>Family history of chromosomal abnormalities </li> <li>Parent with multiple miscarriages </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Subtelomeric fluorescence in situ hybridization (FISH)</td> </tr> <tr> <td class=\"indent1\">GDD/ID or MCA</td> <td>4 to 6</td> <td class=\"divider_bottom\" rowspan=\"2\">Where available,&nbsp;CMA is generally&nbsp;preferred over&nbsp;FISH</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mild GDD/ID</td> <td>1 to 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Whole exome sequencing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Unexplained GDD/ID or MCA</td> <td>16 to 25</td> <td>Where available, based on the cost and institutional resources</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">General metabolic screening<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Unexplained GDD/ID</td> <td>&#60;1 <span style=\"color: black;\">to</span><span style=\"color: black;\"><span style=\"color: black;\">&nbsp;</span>3</span><sup>&#916;</sup></td> <td>Recommended (in addition to CMA) in patients with the following features: <ul class=\"decimal_heading\"> <li>Parental consanguinity </li> <li>Family with other children with similar problems, or unexplained fetal demise </li> <li>Episodic symptoms, including seizures or encephalopathy </li> <li>Multiple organ dysfunction </li> <li>Failure to thrive, dietary selectivity, unusual body odor, hearing loss, hepatomegaly </li> <li>Developmental regression </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Testing the whole X chromosome or testing multiple X-linked genes specifically</td> </tr> <tr> <td class=\"indent1\">Definitely X-linked</td> <td>42</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>Testing the whole X chromosome or multiple X-linked ID genes specifically is recommended in male patients with a family history suggestive of X-linked inheritance of ID </li> <li>Mutations in X-linked genes account for 10 percent of all cases with ID </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Possibly X-linked</td> <td>17</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Specific testing for fragile X (trinucleotide repeat expansion of the <em>FMR1</em> gene)</td> </tr> <tr> <td class=\"indent1\">Males with clinical features of fragile X syndrome</td> <td>15</td> <td class=\"divider_bottom\" rowspan=\"4\">Testing is suggested in children with the following characteristics: <ul class=\"decimal_heading\"> <li>Male or female children with ID and clinical features suggestive of fragile X syndrome, such as macrocephaly, large ears, enlarged testes, perseverative speech, lack of eye contact </li> <li>Male or female children with ID and a family history of ID </li> <li>Children with unexplained ID whose first-line CMA testing is normal (or benign) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Males with unexplained GDD/ID</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Males or females with mild to moderate unexplained GDD/ID</td> <td>2-3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Females with unexplained GDD/ID</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMA: chromosomal microarray analysis (also known as comparative genomic hybridization [CGH]); FISH: fluorescence in situ hybridization; GDD: global developmental delay; ID: intellectual disability; MCA: multiple congenital anomalies.<br />* Represents approximate diagnostic yield, based on a meta-analysis of population studies. Most of the included studies were \"class III,\" defined as a sample of patients studied during the course of a condition, rather than a population-based sample.<br />Â¶ Screening for metabolic disorders varies among institutions. It typically includes urine for amino acids, organic acids, mucopolysaccharides, oligosaccharides, uric acid, sialic acid, purines, and pyrimidines; and plasma for amino acids, acylcarnitines, and sialotransferrins.<br />Î The diagnostic yield of metabolic screening depends on the presence of clinical indicators of metabolic disease and the range of testing performed. Initial metabolic screening does not definitively exclude some diagnoses such as mucopolysaccharidosis and a congenital disorder of glycosylation, and some tests should be repeated if the clinical features are suspicious for one of these disorders.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 2015; 519:223.</li>&#xD;&#xA;    <li>Engbers HM, Berger R, van Hasselt P, et al. Yield of additional metabolic studies in neurodevelopmental disorders. Ann Neurol 2008; 64:212.</li>&#xD;&#xA;    <li>Hagerman RJ, Amiri K, Cronister A. Fragile X chechlist. Am J Med Genet 1991; 38:283.</li>&#xD;&#xA;    <li>Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: Genetic and metabolic testing on children with global developmental delay. Neurology 2011; 77:1629.</li>&#xD;&#xA;    <li>Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86:749.</li>&#xD;&#xA;    <li>van Karnebeek CD, Jansweijer MC, Leenders AG, et al. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet 2005; 13:6.</li>&#xD;&#xA;    <li>Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014; 312:1870.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72211 Version 5.0</div></div></div>"},"72212":{"type":"graphic_picture","displayName":"Short arm cast 2","title":"Completed short arm fiberglass cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Completed short arm fiberglass cast</div><div class=\"cntnt\"><img style=\"width:255px; height:468px;\" src=\"images/EM/72212_Completed_short_arm_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen Titus, MD.</div><div id=\"graphicVersion\">Graphic 72212 Version 1.0</div></div></div>"},"72214":{"type":"graphic_picture","displayName":"ANLL FAB M2","title":"Acute myeloid leukemia (AML FAB M2)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute myeloid leukemia (AML FAB M2)</div><div class=\"cntnt\"><img style=\"width:371px; height:252px;\" src=\"images/HEME/72214_ANLL_FAB_M2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with AML of the M2 variant. The blasts are slightly more mature than M1 blasts. The cytoplasm may contain multiple fine granules (red arrow) and Auer rods (black arrow). (Wright-Giemsa).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 72214 Version 1.0</div></div></div>"},"72215":{"type":"graphic_table","displayName":"Thyroid hormones neonates","title":"Concentrations of free T4, T4, T3, and TSH in preterm and term infants, in cord blood at birth and at 7, 14, and 28 days of age (mean Â± 1 SD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Concentrations of free T4, T4, T3, and TSH in preterm and term infants, in cord blood at birth and at 7, 14, and 28 days of age (mean Â± 1 SD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Gestation (weeks)</td> <td class=\"subtitle1\">Age of infant</td> <td class=\"subtitle1\">Free T4 (ng/dL)</td> <td class=\"subtitle1\">T4 (microgram/dL)</td> <td class=\"subtitle1\">T3 (ng/dL)</td> <td class=\"subtitle1\">TSH (mU/L)</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">23-27 weeks</td> <td>Cord</td> <td>1.28 &#177; 0.4</td> <td>5.4 &#177; 2.0</td> <td>20 &#177; 15</td> <td>6.8 &#177; 2.9</td> </tr> <tr> <td>7 d</td> <td>1.47 &#177; 0.6</td> <td>4.0 &#177; 1.8</td> <td>33 &#177; 20</td> <td>3.5 &#177; 2.6</td> </tr> <tr> <td>14 d</td> <td>1.45 &#177; 0.5</td> <td>4.7 &#177; 2.6</td> <td>41 &#177; 25</td> <td>3.9 &#177; 2.7</td> </tr> <tr> <td>28 d</td> <td>1.50 &#177; 0.4</td> <td>6.1 &#177; 2.3</td> <td>63 &#177; 27</td> <td>3.8 &#177; 4.7</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">28-30 weeks</td> <td>Cord</td> <td>1.45 &#177; 0.4</td> <td>6.3 &#177; 2.0</td> <td>29 &#177; 21</td> <td>7.0 &#177; 3.7</td> </tr> <tr> <td>7 d</td> <td>1.82 &#177; 0.7</td> <td>6.3 &#177; 2.1</td> <td>56 &#177; 24</td> <td>3.6 &#177; 2.5</td> </tr> <tr> <td>14 d</td> <td>1.65 &#177; 0.4</td> <td>6.6 &#177; 2.3</td> <td>72 &#177; 28</td> <td>4.9 &#177; 11.2</td> </tr> <tr> <td>28 d</td> <td>1.71 &#177; 0.4</td> <td>7.5 &#177; 2.3</td> <td>87 &#177; 31</td> <td>3.6 &#177; 2.5</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">31-34 weeks</td> <td>Cord</td> <td>1.49 &#177; 0.3</td> <td>7.6 &#177; 2.3</td> <td>35 &#177; 23</td> <td>7.9 &#177; 5.2</td> </tr> <tr> <td>7 d</td> <td>2.14 &#177; 0.6</td> <td>9.4 &#177; 3.4</td> <td>92 &#177; 36</td> <td>3.6 &#177; 4.8</td> </tr> <tr> <td>14 d</td> <td>1.98 &#177; 0.4</td> <td>9.1 &#177; 3.6</td> <td>110 &#177; 41</td> <td>3.8 &#177; 9.3</td> </tr> <tr> <td>28 d</td> <td>1.88 &#177; 0.5</td> <td>8.9 &#177; 3.0</td> <td>120 &#177; 40</td> <td>3.5 &#177; 3.4</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">&#8805;37 weeks</td> <td>Cord</td> <td>1.41 &#177; 0.3</td> <td>9.2 &#177; 1.9</td> <td>60 &#177; 35</td> <td>6.7 &#177; 4.8</td> </tr> <tr> <td>7 d</td> <td>2.70 &#177; 0.6</td> <td>12.7 &#177; 2.9</td> <td>148 &#177; 50</td> <td>2.6 &#177; 1.8</td> </tr> <tr> <td>14 d</td> <td>2.03 &#177; 0.3</td> <td>10.7 &#177; 1.4</td> <td>167 &#177; 31</td> <td>2.5 &#177; 2.0</td> </tr> <tr> <td>28 d</td> <td>1.65 &#177; 0.3</td> <td>9.7 &#177; 2.2</td> <td>176 &#177; 32</td> <td>1.8 &#177; 0.9</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T4: thyroxine; T3: triiodothyronine; TSH: thyroid stimulating hormone; SD: standard deviation.</div><div class=\"graphic_reference\">Adapted with permission from: Williams FL, Simpson J, Delahunty C, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. J Clin Endocrinol Metab 2004; 89:5314.</div><div id=\"graphicVersion\">Graphic 72215 Version 7.0</div></div></div>"},"72216":{"type":"graphic_table","displayName":"Colorectal CA risk factors","title":"Factors associated with an increased and decreased risk of colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors associated with an increased and decreased risk of colorectal cancer</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Increased risk</td></tr>\n\t\t\t\t\t\t<tr><td>Lack of physical activity</td></tr>\n\t\t\t\t\t\t<tr><td>Consumption of red meat</td></tr>\n\t\t\t\t\t\t<tr><td>Obesity</td></tr>\n\t\t\t\t\t\t<tr><td>Cigarette smoking</td></tr>\n\t\t\t\t\t\t<tr><td>Alcohol use</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Decreased risk</td></tr>\n\t\t\t\t\t\t<tr><td>Multivitamins containing folic acid</td></tr>\n\t\t\t\t\t\t<tr><td>Aspirin and other NSAIDs</td></tr>\n\t\t\t\t\t\t<tr><td>Postmenopausal hormone use</td></tr>\n\t\t\t\t\t\t<tr><td>Calcium supplementation</td></tr>\n\t\t\t\t\t\t<tr><td>Selenium</td></tr>\n\t\t\t\t\t\t<tr><td>Consumption of vegetables, fruits, and fiber</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58005&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Colorectal_CA_risk_factors.htm</title></head></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs.</div><div class=\"graphic_reference\">Harvard Report on Cancer Prevention, Cancer Causes and Control 1999; 10:167.</div><div id=\"graphicVersion\">Graphic 72216 Version 2.0</div></div></div>"},"72217":{"type":"graphic_waveform","displayName":"Right atrial pressure tracings in tricuspid regurgitation","title":"Right atrial pressure tracing in tricuspid regurgitation","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Right atrial pressure tracing in tricuspid regurgitation</div><div class=\"cntnt\"><img style=\"width:474px; height:259px;\" src=\"images/PULM/72217_Swan_Ganz_catheter_tracings.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous electrocardiographic and right atrial pressure tracings from a patient with tricuspid regurgitation. Right atrial pressure tracing shows prominent 'v' waves, caused as blood is regurgitated into the atrium during ventricular systole.</div><div id=\"graphicVersion\">Graphic 72217 Version 3.0</div></div></div>"},"72219":{"type":"graphic_figure","displayName":"Muscles of the anterior abdominal wall","title":"Muscles of the anterior abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Muscles of the anterior abdominal wall</div><div class=\"cntnt\"><img style=\"width:540px; height:691px;\" src=\"images/SURG/72219_Abdominal-wall-musculature-anterior.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72219 Version 2.0</div></div></div>"},"72220":{"type":"graphic_form","displayName":"Hamilton Rating Scale - page 1","title":"Hamilton Rating Scale for Depression, page 1","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Hamilton Rating Scale for Depression, page 1</div><div class=\"cntnt\"><img style=\"width:591px; height:651px;\" src=\"images/PSYCH/72220_Hamilton.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.</div><div id=\"graphicVersion\">Graphic 72220 Version 2.0</div></div></div>"},"72221":{"type":"graphic_picture","displayName":"Brown dog tick","title":"An adult female rhipicephalus sanguineus (brown dog tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female rhipicephalus sanguineus (brown dog tick)</div><div class=\"cntnt\"><img style=\"width:223px; height:225px;\" src=\"images/ID/72221_Brown_dog_tick.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 72221 Version 1.0</div></div></div>"},"72222":{"type":"graphic_table","displayName":"Medical device disinfection and sterilization","title":"Approach to disinfection and sterilization of medical devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to disinfection and sterilization of medical devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12%\"></colgroup><colgroup span=\"2\" width=\"32%\"></colgroup><colgroup width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device classification</td> <td class=\"subtitle1\">Devices (examples)</td> <td class=\"subtitle1\">Spaulding process classification/time</td> <td class=\"subtitle1\">Processes</td> <td class=\"subtitle1\">EPA product classification</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Noncritical</strong> (touches intact skin, not mucous membranes)</td> <td class=\"divider_bottom\" rowspan=\"2\">Stethoscopes, bedpans, blood pressure cuffs, patient furniture</td> <td>Low-level disinfection: Kills most bacteria, some viruses and fungi. Cannot reliably kill resistant microorganisms (eg, tubercle bacilli, bacterial spores).</td> <td class=\"divider_bottom\" rowspan=\"2\">Chemical disinfectants; ethyl or isopropyl alcohol, sodium hypochlorite, iodophor solution, quaternary ammonium germicidal detergent.</td> <td class=\"divider_bottom\" rowspan=\"2\">Hospital disinfectant without label claim for tuberculocidal activity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time:</strong> 10 minutes or less</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Semi-critical</strong> (touches intact mucous membranes [except dental])</td> <td rowspan=\"2\">Flexible endoscopes, laryngoscopes, endotracheal tubes, cervical diaphragms</td> <td>High-level disinfection:&nbsp;Destroys all microorganisms except high numbers of bacterial spores.</td> <td rowspan=\"2\">Wet pasteurization or chemical disinfectants.* Heat sterilization preferred for between patient processing of heat stable instruments. Follow by rinsing with sterile water.</td> <td rowspan=\"2\">Sterilant/disinfectant</td> </tr> <tr> <td><strong>Time:</strong> 20 minutes or more</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Thermometers, hydrotherapy tanks</td> <td>Intermediate-level disinfection: Inactivates tubercle bacilli, vegetative bacteria, most viruses and fungi. Does not necessarily kill bacterial spores.</td> <td class=\"divider_bottom\" rowspan=\"2\">Chemical disinfectants; sodium hypochlorite ethyl or isopropyl alcohol, phenolic and iodophor solutions.</td> <td class=\"divider_bottom\" rowspan=\"2\">Hospital disinfectant with label claim for tuberculocidal activity</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time:</strong> 10 minutes or less</td> </tr> <tr> <td rowspan=\"2\"><strong>Critical</strong> (enters sterile tissue or vascular system)</td> <td rowspan=\"2\">Implants, scalpels, needles, cardiac and urinary catheters</td> <td>Sterilization.</td> <td rowspan=\"2\">Purchase as sterile. Sterilize by steam under pressure. If heat labile, use ethylene oxide gas or chemical sterilants.<sup>&#182;</sup></td> <td rowspan=\"2\">Sterilant/disinfectant</td> </tr> <tr> <td><strong>Time:</strong> prolonged contact (hours)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EPA: Environmental Protection Agency.<br />* 2% glutaraldehyde-based products, 6% stabilized hydrogen peroxide, chlorine, peracetic acid.<br />Â¶ 2% glutaraldehyde-based products, 6% stabilized hydrogen peroxide, peracetic acid.</div><div class=\"graphic_reference\">Modified with permission from: Rutala WA. APIC guideline for selection and use of disinfectants. Am J Infect Control 1996; 24:313. Copyright &copy; 1996 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 72222 Version 5.0</div></div></div>"},"72224":{"type":"graphic_table","displayName":"Echo views and RWMAs","title":"Echocardiographic views and location of regional wall motion abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiographic views and location of regional wall motion abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Parasternal long axis view</td>\n\n      \n\n    </tr>\n\n\n    <tr><td>The parasternal long axis view primarily visualizes the interventricular septum and the posterior left ventricular free wall.</td></tr><tr>\n\n      <td class=\"indent1\">\nThe septum seen in this view is the anterior portion which is almost\nalways perfused by the left anterior descending artery. The basal 1 or\n2 cm of the interventricular septum is usually perfused by the first\nseptal perforator and can be used to determine if the left anterior\ndescending artery obstruction is before or after the first septal\nperforator.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">\nThe posterior left ventricular wall seen in this view is usually\nperfused by the left circumflex coronary artery. It is not generally\ninvolved with an inferior wall infarction that results from right\ncoronary artery or posterior descending artery occlusion.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Short axis view</td>\n\n      \n\n    </tr>\n\n\n    <tr><td>In the short axis view, areas perfused by all three coronary arteries can be seen.</td></tr><tr>\n\n      <td class=\"indent1\">\nThe left anterior descending artery supplies the anterior portion of\nthe left ventricular free wall and the anterior half of the\ninterventricular septum.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">\nThe posterior descending artery supplies the posterior medial portion\nof the left ventricular free wall and the posterior half of the\ninterventricular septum.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">The left circumflex artery usually supplies the posterior lateral portions of the short axis view, although this is variable.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Two chamber apical view</td>\n\n      \n\n    </tr>\n\n\n    <tr><td>The two chamber apical view is comparable to the right anterior oblique view seen on contrast angiography. This view visualizes\nmyocardium supplied almost entirely by the left anterior descending and\nposterior descending arteries.</td></tr><tr>\n\n      <td class=\"indent1\">The basal one-half or two-thirds of the posterior wall is supplied by the posterior descending artery.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">The rest of the left ventricle is perfused by the left anterior descending.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Four chamber view</td>\n\n      \n\n    </tr>\n\n\n    <tr><td>In the four chamber view, the myocardium imaged is supplied by all three&nbsp;coronary arteries.</td></tr><tr>\n\n      <td class=\"indent1\">\nThe apex and distal one-half or two-thirds of the interventricular\nseptum is supplied by the left&nbsp;anterior descending artery.</td>\n\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">The proximal one-third of the septum is usually supplied by the posterior descending artery.&nbsp;</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">The lateral free wall of the left ventricle is usually supplied by branches of the left circumflex&nbsp;artery.</td>\n\n\n    </tr>\n\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72224 Version 1.0</div></div></div>"},"72225":{"type":"graphic_table","displayName":"Diagnostic criteria for anaphylaxis","title":"Diagnostic criteria for anaphylaxis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for anaphylaxis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Anaphylaxis is highly likely when any ONE of the following three criteria&nbsp;is fulfilled:</td> </tr> <tr> <td class=\"subtitle2_single\">1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)</td> </tr> <tr> <td class=\"indent2\"><strong>AND AT LEAST ONE OF THE FOLLOWING:</strong></td> </tr> <tr> <td class=\"indent2\">A. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, hypoxemia)</td> </tr> <tr> <td class=\"indent2\">B. Reduced BP* or associated symptoms of end-organ dysfunction (eg, hypotonia, collapse, syncope, incontinence)</td> </tr> <tr> <td class=\"subtitle2_single\">2. TWO OR MORE OF THE FOLLOWING that occur rapidly <em>after exposure to a LIKELY allergen for that patient</em> (minutes to several hours):</td> </tr> <tr> <td class=\"indent2\">A. Involvement of the skin mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula)</td> </tr> <tr> <td class=\"indent2\">B. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, hypoxemia)</td> </tr> <tr> <td class=\"indent2\">C. Reduced BP* or associated symptoms (eg, hypotonia, collapse, syncope, incontinence)</td> </tr> <tr> <td class=\"indent2\">D. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)</td> </tr> <tr> <td class=\"subtitle2_single\">3. Reduced BP* <em>after exposure to a KNOWN allergen for that patient</em> (minutes to several hours):</td> </tr> <tr> <td class=\"indent2\">A. Infants and children - Low systolic BP (age-specific)* or greater than 30% decrease in systolic BP</td> </tr> <tr> <td class=\"indent2\">B. Adults - Systolic BP of less than 90 mmHg or greater than 30% decrease from that person's baseline</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure.<br />* Low systolic blood pressure for children is defined as:&#xD;&#xA;<UL>&#xD;&#xA;<LI>Less than 70 mmHg from&nbsp;1 month to&nbsp;1 year</LI>&#xD;&#xA;<LI>Less than (70 mmHg + [2 x age]) from 1 to 10 years</LI>&#xD;&#xA;<LI>Less than 90 mmHg from 11 to 17 years</LI></UL></div><div class=\"graphic_reference\">Adapted with permission from: Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391. Copyright &copy; 2006 The American Academy of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 72225 Version 16.0</div></div></div>"},"72226":{"type":"graphic_figure","displayName":"Time of puberty onset","title":"Timing of puberty in Caucasian and African American girls in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Timing of puberty in Caucasian and African American girls in the United States</div><div class=\"cntnt\"><img style=\"width:386px; height:602px;\" src=\"images/ENDO/72226_Time_of_puberty_onset.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this study, the first signs of puberty occurred at a younger age than had been previously reported; the mean age of onset was earlier for African American versus Caucasian girls.</div><div class=\"graphic_reference\">Data from Herman-Giddens, ME, Slora, EJ, Wasserman, RC, et al, Pediatrics 1997; 99:505.</div><div id=\"graphicVersion\">Graphic 72226 Version 2.0</div></div></div>"},"72227":{"type":"graphic_picture","displayName":"DBE NSAID ulcerations","title":"DBE NSAID ulcerations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DBE NSAID ulcerations</div><div class=\"cntnt\"><img style=\"width:396px; height:276px;\" src=\"images/GAST/72227_DBE_NSAID_ulcerations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonsteroidal antiinflammatory drug (NSAID)-induced superficial mid-ileal ulcerations diagnosed by double balloon enteroscopy (DBE).</div><div class=\"graphic_reference\">Courtesy of Louis-Michel Wong Kee Song, MD, FRCP(C).</div><div id=\"graphicVersion\">Graphic 72227 Version 2.0</div></div></div>"},"72229":{"type":"graphic_movie","displayName":"Normal leukocyte movement","title":"Normal leukocyte movement in presence of inflammatory tissue signals","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal leukocyte movement in presence of inflammatory tissue signals</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72229_nlstimconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:303px; height:229px;\" src=\"images/CARD/72229_nlstim.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Amos Etzioni, MD.</div><div id=\"graphicVersion\">Graphic 72229 Version 4.0</div></div></div>"},"72231":{"type":"graphic_figure","displayName":"Two signal model of T cell activation","title":"Schematic representation of two signal model of T cell activation","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Schematic representation of two signal model of T cell activation</div><div class=\"cntnt\"><img style=\"width:468px; height:432px;\" src=\"images/NEPH/72231_Two_signal_model_for_T_cell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T cells require two separate signals before activation occurs. The first signal is antigen-specific and is provided by the interaction of T cell receptor with peptide antigen presented within the antigen binding groove of MHC molecules. The second (costimulatory signal) is provided by the interaction of T cell surface molecules with their ligands on antigen-presenting cells. The provision of signal 1 in the absence of signal 2 may lead to T cell inactivation or anergy, or to failure of a T helper type 1 (Th1) response with promotion of a T helper type 2 (Th2) response.</div><div class=\"graphic_footnotes\">APC: antigen-presenting cell; MHC: major histocompatibility complex.</div><div id=\"graphicVersion\">Graphic 72231 Version 4.0</div></div></div>"},"72232":{"type":"graphic_picture","displayName":"Disc drusen","title":"Disc drusen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disc drusen</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/NEURO/72232_Disc_drusen.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 72232 Version 1.0</div></div></div>"},"72235":{"type":"graphic_figure","displayName":"Myomectomy incision","title":"Abdominal myomectomy","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Abdominal myomectomy</div><div class=\"cntnt\"><img style=\"width:456px; height:380px;\" src=\"images/OBGYN/72235_Myomectomy_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vertical incision into the anterior uterine surface.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 72235 Version 1.0</div></div></div>"},"72237":{"type":"graphic_figure","displayName":"Interdependence sens spec","title":"Depiction of interdependence of sensitivity and specificity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Depiction of interdependence of sensitivity and specificity</div><div class=\"cntnt\"><img style=\"width:442px; height:287px;\" src=\"images/PC/72237_Interdependence_sens_spec.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The curves represent serum aminotransferase levels for populations with and without chronic hepatitis. As the cutoff used for defining an abnormal value (blue line) is moved toward the right, more patients with hepatitis will be missed (loss of sensitivity). As the blue line is moved to the left, more patients without hepatitis will be incorrectly labeled as having hepatitis (loss of specificity).</div><div id=\"graphicVersion\">Graphic 72237 Version 2.0</div></div></div>"},"72238":{"type":"graphic_table","displayName":"Differential diagnosis of arthritis","title":"Differential diagnosis of some systemic causes of arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of some systemic causes of arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Gonococcal arthritis&nbsp;</td> <td class=\"subtitle1\">Reactive arthritis (formerly Reiter's syndrome)</td> <td class=\"subtitle1\">Rheumatoid arthritis</td> <td class=\"subtitle1\">Psoriatic arthritis</td> </tr> <tr> <td>Age</td> <td>Young</td> <td>Young</td> <td>Middle</td> <td>Middle</td> </tr> <tr> <td>Gender</td> <td>Female&#62;male</td> <td>Male&#62;female</td> <td>Female&#62;male</td> <td>No effect</td> </tr> <tr> <td>Onset</td> <td>Abrupt</td> <td>Abrupt</td> <td>Insidious</td> <td>Insidious</td> </tr> <tr> <td>Joint number</td> <td>Monoarthritis or oligoarthritis</td> <td>Oligoarthritis</td> <td>Polyarthritis</td> <td>Oligoarthritis</td> </tr> <tr> <td>Symmetry of arthritis</td> <td>No</td> <td>No</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Sausage digits</td> <td>No&nbsp;</td> <td>Yes</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Back pain</td> <td>No&nbsp;</td> <td>Yes</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Urethritis</td> <td>Yes&nbsp;</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td>Skin lesions</td> <td>Pustular, nodular, or vesicular&nbsp;</td> <td>Palms and soles in 10 percent</td> <td>Subcutaneous nodules</td> <td>Psoriasis</td> </tr> <tr> <td>Gonococcus identified on testing</td> <td>Yes&nbsp;</td> <td>No</td> <td>No</td> <td>No</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72238 Version 3.0</div></div></div>"},"72239":{"type":"graphic_table","displayName":"Molecular classification of colorectal carcinoma","title":"Molecular classification of colorectal carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular classification of colorectal carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Heredity</td> <td class=\"subtitle1\">Chromosomal instability pathway</td> <td class=\"subtitle1\">Mismatch repair pathway</td> <td class=\"subtitle1\" colspan=\"2\">Serrated/CIMP pathway</td> <td class=\"subtitle1\">Hybrid pathway</td> </tr> <tr> <td class=\"subtitle2\">Hereditary and sporadic</td> <td class=\"subtitle2\">Hereditary</td> <td class=\"subtitle2\" colspan=\"2\">Hereditary and sporadic</td> <td class=\"subtitle2\">Sporadic</td> </tr> <tr> <td>CIMP status</td> <td>Negative</td> <td>Negative</td> <td>High</td> <td>High</td> <td>Low</td> </tr> <tr> <td>MSI status</td> <td>MSS</td> <td>MSI-H</td> <td>MSI-H</td> <td>MSI-L</td> <td>MSI-L or MSS</td> </tr> <tr> <td>Chromosomal instability</td> <td>Present</td> <td>Absent</td> <td>Absent</td> <td>Absent</td> <td>Present</td> </tr> <tr> <td><em>KRAS</em> mutation</td> <td>+++</td> <td>+/-</td> <td>---</td> <td>---</td> <td>+++</td> </tr> <tr> <td><em>BRAF</em> mutation</td> <td>---</td> <td>---</td> <td>+++</td> <td>+++</td> <td>---</td> </tr> <tr> <td>MLH1 status</td> <td>Normal</td> <td>Mutation</td> <td>Methylated</td> <td>Partial methylation</td> <td>Normal</td> </tr> <tr> <td>MGMT methylation</td> <td>---</td> <td>---</td> <td>+/-</td> <td>+++</td> <td>+++</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CIMP: CpG island methylator phenotype; MSS: microsatellite stability; MSI: microsatellite instability; MSI-H: high-level microsatellite instability; MSI-L: low-level microsatellite instability; MGMT: O-6-methlyguanine DNA methyltransferase; +++: present; +/-: might or might not be present; ---: absent.</div><div class=\"graphic_reference\">Noffsinger AE. Serrated polyps and colorectal cancer: New pathway to malignancy. Annu Rev Pathol 2009; 4:343. Reprinted, with permission, from the Annual Review of Pathology. Copyright &#169; 2009 Volume 4, 2009 by Annual Reviews. www.annualreviews.org.</div><div id=\"graphicVersion\">Graphic 72239 Version 2.0</div></div></div>"},"72241":{"type":"graphic_movie","displayName":"Wall push-up exercise video","title":"Strength exercise video: Wall push-up","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Strength exercise video: Wall push-up</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PC/72241_Wallpushup.mp4\" style=\"width:480px;height:336px\"></div><img style=\"width:373px; height:306px;\" src=\"images/PC/72241_WallpushupeximgPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These push-ups will strengthen your arms, shoulders, and chest. Try this exercise during a TV commercial break.<br> <ol> <li>Face a wall, standing a little farther than arm's length away, feet shoulder-width apart. </li> <li>Lean your body forward and put your palms flat against the wall at shoulder height and shoulder-width apart. </li> <li>Slowly breathe in as you bend your elbows and lower your upper body toward the wall in a slow, controlled motion. Keep your feet flat on the floor. </li> <li>Hold the position for one second. </li> <li>Breathe out and slowly push yourself back until your arms are straight. </li> <li>Repeat 10 to 15 times. </li> <li>Rest; then repeat 10 to 15 more times. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 72241 Version 1.0</div></div></div>"},"72242":{"type":"graphic_table","displayName":"Chemo nail disorder","title":"Cytotoxic chemotherapy agents causing nail disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy agents causing nail disorders</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pigmentary changes </td> </tr> <tr> <td>Aminoglutethimide</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Busulfan</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Dacarbazine</td> </tr> <tr> <td>Daunorubicin</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Fluorouracil</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Idarubicin</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Melphalan</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Mitomycin</td> </tr> <tr> <td>Mitoxantrone</td> </tr> <tr> <td>Tegafur</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Onycholysis </td> </tr> <tr> <td>Paclitaxel</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Gemcitabine</td> </tr> <tr> <td>Capecitabine</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Doxorubicin</td> </tr> <tr> <td>Etoposide</td> </tr> <tr> <td>Fluorouracil</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Ixabepilone</td> </tr> <tr> <td>Bleomycin/vinblastine combination</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory changes (infectious and noninfectious) </td> </tr> <tr> <td>Capecitabine</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Paclitaxel</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72242 Version 3.0</div></div></div>"},"72243":{"type":"graphic_table","displayName":"Benefits activity PI","title":"Benefits of regular physical activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Benefits of regular physical activity</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td>Reduces the risk of dying prematurely</td>\n  </tr>\n  <tr>\n    <td>Reduces the risk of dying from heart disease</td>\n  </tr>\n  <tr>\n    <td>Reduces the risk of stroke</td>\n  </tr>\n  <tr>\n    <td>Reduces the risk of developing diabetes</td>\n  </tr>\n  <tr>\n    <td>Reduces the risk of developing high blood pressure</td>\n  </tr>\n  <tr>\n    <td>Helps reduce blood pressure in people who already have high blood pressure</td>\n  </tr>\n  <tr>\n    <td>Reduces the risk of developing colon cancer</td>\n  </tr>\n  <tr>\n    <td>Reduces feelings of depression and anxiety</td>\n  </tr>\n  <tr>\n    <td>Helps control weight</td>\n  </tr>\n  <tr>\n    <td>Helps build and maintain healthy bones, muscles and joints</td>\n  </tr>\n  <tr>\n    <td>Helps older adults become stronger and better able to move about without falling</td>\n  </tr>\n  <tr>\n    <td>Promotes psychological well-being</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72243 Version 1.0</div></div></div>"},"72244":{"type":"graphic_figure","displayName":"Diphtheria epidemiology US","title":"Diphtheria cases in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diphtheria cases in the United States</div><div class=\"cntnt\"><img style=\"width:406px; height:670px;\" src=\"images/PEDS/72244_DiphtheriaepidemiologyUS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12<SUP>th</SUP> ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington, DC 2011. Available at: <A href=\"http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf\">www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf</A> (Accessed on September 12, 2012).</div><div id=\"graphicVersion\">Graphic 72244 Version 5.0</div></div></div>"},"72246":{"type":"graphic_table","displayName":"Normal MAC and MAMC females","title":"Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian girls in the US Health and Nutrition Examination Survey I of 1971-1974","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian girls in the US Health and Nutrition Examination Survey I of 1971-1974</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\" rowspan=\"2\">Age, years females</td>\r\n                    <td class=\"subtitle1\" colspan=\"4\">Mid arm circumference (MAC) percentiles</td>\r\n                    <td class=\"subtitle1\" colspan=\"4\">Mid arm muscle circumference (MAMC)&nbsp;percentiles</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2\">5th</td>\r\n                    <td class=\"subtitle2\">50th</td>\r\n                    <td class=\"subtitle2\">90th</td>\r\n                    <td class=\"subtitle2\">95th</td>\r\n                    <td class=\"subtitle2\">5th</td>\r\n                    <td class=\"subtitle2\">50th</td>\r\n                    <td class=\"subtitle2\">90th</td>\r\n                    <td class=\"subtitle2\">95th</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>1-1.9</td>\r\n                    <td>138</td>\r\n                    <td>156</td>\r\n                    <td>172</td>\r\n                    <td>177</td>\r\n                    <td>105</td>\r\n                    <td>124</td>\r\n                    <td>139</td>\r\n                    <td>143</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>2-2.9</td>\r\n                    <td>142</td>\r\n                    <td>160</td>\r\n                    <td>176</td>\r\n                    <td>184</td>\r\n                    <td>111</td>\r\n                    <td>126</td>\r\n                    <td>142</td>\r\n                    <td>14</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>3-3.9</td>\r\n                    <td>143</td>\r\n                    <td>167</td>\r\n                    <td>183</td>\r\n                    <td>189</td>\r\n                    <td>113</td>\r\n                    <td>132</td>\r\n                    <td>146</td>\r\n                    <td>14</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>4-4.9</td>\r\n                    <td>149</td>\r\n                    <td>169</td>\r\n                    <td>184</td>\r\n                    <td>191</td>\r\n                    <td>115</td>\r\n                    <td>136</td>\r\n                    <td>152</td>\r\n                    <td>15</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>5-5.9</td>\r\n                    <td>153</td>\r\n                    <td>175</td>\r\n                    <td>203</td>\r\n                    <td>211</td>\r\n                    <td>125</td>\r\n                    <td>142</td>\r\n                    <td>159</td>\r\n                    <td>16</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>6-6.9</td>\r\n                    <td>156</td>\r\n                    <td>176</td>\r\n                    <td>204</td>\r\n                    <td>211</td>\r\n                    <td>130</td>\r\n                    <td>145</td>\r\n                    <td>166</td>\r\n                    <td>17</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>7-7.9</td>\r\n                    <td>164</td>\r\n                    <td>183</td>\r\n                    <td>216</td>\r\n                    <td>231</td>\r\n                    <td>129</td>\r\n                    <td>151</td>\r\n                    <td>171</td>\r\n                    <td>17</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>8-8.9</td>\r\n                    <td>168</td>\r\n                    <td>195</td>\r\n                    <td>247</td>\r\n                    <td>261</td>\r\n                    <td>138</td>\r\n                    <td>160</td>\r\n                    <td>183</td>\r\n                    <td>19</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>9-9.9</td>\r\n                    <td>178</td>\r\n                    <td>211</td>\r\n                    <td>251</td>\r\n                    <td>260</td>\r\n                    <td>147</td>\r\n                    <td>167</td>\r\n                    <td>194</td>\r\n                    <td>19</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>10-10.9</td>\r\n                    <td>174</td>\r\n                    <td>210</td>\r\n                    <td>251</td>\r\n                    <td>265</td>\r\n                    <td>148</td>\r\n                    <td>170</td>\r\n                    <td>190</td>\r\n                    <td>19</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>11-11.9</td>\r\n                    <td>185</td>\r\n                    <td>224</td>\r\n                    <td>276</td>\r\n                    <td>303</td>\r\n                    <td>150</td>\r\n                    <td>181</td>\r\n                    <td>217</td>\r\n                    <td>22</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>12-12.9</td>\r\n                    <td>194</td>\r\n                    <td>236</td>\r\n                    <td>282</td>\r\n                    <td>294</td>\r\n                    <td>162</td>\r\n                    <td>191</td>\r\n                    <td>214</td>\r\n                    <td>22</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>13-13.9</td>\r\n                    <td>202</td>\r\n                    <td>243</td>\r\n                    <td>301</td>\r\n                    <td>338</td>\r\n                    <td>169</td>\r\n                    <td>198</td>\r\n                    <td>226</td>\r\n                    <td>24</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>14-14.9</td>\r\n                    <td>214</td>\r\n                    <td>252</td>\r\n                    <td>304</td>\r\n                    <td>322</td>\r\n                    <td>174</td>\r\n                    <td>201</td>\r\n                    <td>232</td>\r\n                    <td>24</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>15-15.9</td>\r\n                    <td>208</td>\r\n                    <td>254</td>\r\n                    <td>300</td>\r\n                    <td>322</td>\r\n                    <td>175</td>\r\n                    <td>202</td>\r\n                    <td>228</td>\r\n                    <td>24</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>16-16.9</td>\r\n                    <td>218</td>\r\n                    <td>258</td>\r\n                    <td>318</td>\r\n                    <td>334</td>\r\n                    <td>170</td>\r\n                    <td>202</td>\r\n                    <td>234</td>\r\n                    <td>24</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>17-17.9</td>\r\n                    <td>220</td>\r\n                    <td>264</td>\r\n                    <td>324</td>\r\n                    <td>350</td>\r\n                    <td>175</td>\r\n                    <td>205</td>\r\n                    <td>239</td>\r\n                    <td>25</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>18-18.9</td>\r\n                    <td>222</td>\r\n                    <td>258</td>\r\n                    <td>312</td>\r\n                    <td>325</td>\r\n                    <td>174</td>\r\n                    <td>202</td>\r\n                    <td>237</td>\r\n                    <td>24</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>19-24.9</td>\r\n                    <td>221</td>\r\n                    <td>265</td>\r\n                    <td>319</td>\r\n                    <td>345</td>\r\n                    <td>179</td>\r\n                    <td>207</td>\r\n                    <td>236</td>\r\n                    <td>24</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>25-34.9</td>\r\n                    <td>233</td>\r\n                    <td>277</td>\r\n                    <td>342</td>\r\n                    <td>368</td>\r\n                    <td>183</td>\r\n                    <td>212</td>\r\n                    <td>246</td>\r\n                    <td>26</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>35-44.9</td>\r\n                    <td>241</td>\r\n                    <td>290</td>\r\n                    <td>356</td>\r\n                    <td>378</td>\r\n                    <td>186</td>\r\n                    <td>218</td>\r\n                    <td>257</td>\r\n                    <td>27</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>45-54.9</td>\r\n                    <td>242</td>\r\n                    <td>299</td>\r\n                    <td>362</td>\r\n                    <td>384</td>\r\n                    <td>187</td>\r\n                    <td>220</td>\r\n                    <td>260</td>\r\n                    <td>27</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>55-64.9</td>\r\n                    <td>243</td>\r\n                    <td>303</td>\r\n                    <td>367</td>\r\n                    <td>385</td>\r\n                    <td>187</td>\r\n                    <td>225</td>\r\n                    <td>266</td>\r\n                    <td>28</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>65-74.9</td>\r\n                    <td>240</td>\r\n                    <td>299</td>\r\n                    <td>356</td>\r\n                    <td>373</td>\r\n                    <td>185</td>\r\n                    <td>225</td>\r\n                    <td>264</td>\r\n                    <td>27</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Adapted from: Frisancho AR. Am J Clin Nut 1981; 34:2540.</div><div id=\"graphicVersion\">Graphic 72246 Version 3.0</div></div></div>"},"72247":{"type":"graphic_waveform","displayName":"Intermittent BBB tutorial","title":"Intermittent bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Intermittent bundle branch block</div><div class=\"cntnt\"><img style=\"width:510px; height:164px;\" src=\"images/CARD/72247_Intermittent_BBB_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">QRS complexes with a right bundle branch block morphology are interspersed with normal complexes.</div><div id=\"graphicVersion\">Graphic 72247 Version 2.0</div></div></div>"},"72248":{"type":"graphic_table","displayName":"Causes of erythema multiforme","title":"Causes of erythema multiforme","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of erythema multiforme</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Contact reactions</td> </tr> <tr> <td><em>Tadania ignis</em> (fire sponge)</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Antituberculous agents</td> </tr> <tr> <td>Barbiturates</td> </tr> <tr> <td>Carbamazepine</td> </tr> <tr> <td>Oral hypoglycemic agents</td> </tr> <tr> <td>NSAIDs</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine factors</td> </tr> <tr> <td>Pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td>&#62;50 percent</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Epstein-Barr virus</td> </tr> <tr> <td><em>Francisella tularensis</em></td> </tr> <tr> <td>Hemolytic streptococci</td> </tr> <tr> <td>Herpes simplex 1 and 2</td> </tr> <tr> <td><em>Histoplasma capsulatum</em></td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> </tr> <tr> <td><em>Mycobacterium tuberculosis</em></td> </tr> <tr> <td><em>Proteus</em> spp</td> </tr> <tr> <td><em>Salmonella</em> spp</td> </tr> <tr> <td><em>Staphylococcus</em> spp</td> </tr> <tr> <td><em>Vibrio parahaemolyticus</em></td> </tr> <tr> <td><em>Yersinia</em> spp</td> </tr> <tr> <td class=\"subtitle1_single\">Physical</td> </tr> <tr> <td>Sunlight</td> </tr> <tr> <td>Radiograph therapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal anti-inflammatory drugs.</div><div class=\"graphic_reference\">Adapted with permission from Sanders CV, Diagnosis of the Patient&nbsp;with Fever and Rash. In: The Skin and Infection: A Color Atlas and&nbsp;Text, Sanders CV, Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. Originally modified with permission from Dermatology in General Medicine, Fitzpatrick TB, et al (Eds), McGraw-Hill, New York, 1993.</div><div id=\"graphicVersion\">Graphic 72248 Version 3.0</div></div></div>"},"72250":{"type":"graphic_waveform","displayName":"Basic case 9 with answer","title":"Atrial flutter to sinus rhythm","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Atrial flutter to sinus rhythm</div><div class=\"cntnt\"><img style=\"width:540px; height:80px;\" src=\"images/CARD/72250_Basic_case_9_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spontaneous conversion of atrial flutter (note the regular flutter waves) with variable degrees of atrioventricular block to normal sinus rhythm.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 72250 Version 2.0</div></div></div>"},"72255":{"type":"graphic_table","displayName":"Tyrosine kinase chimeras","title":"Components of tyrosine kinase chimeras","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Components of tyrosine kinase chimeras</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Chimeric gene</td>\n<td class=\"subtitle1\">Origin of promoter and N terminus</td>\n<td class=\"subtitle1\">Origin of C terminus</td>\n</tr>\n<tr>\n<td>RET/PTC1</td>\n<td>H4/D10S170</td>\n<td>RET</td>\n</tr>\n<tr>\n<td>RET/PTC2</td>\n<td>Gene which codes for a portion of the regulatory subunit of RI-alpha cAMP-dependent protein kinase A</td>\n<td>RET</td>\n</tr>\n<tr>\n<td>RET/PTC3</td>\n<td>RFG/ELE1</td>\n<td>RET</td>\n</tr>\n<tr>\n<td>TRK</td>\n<td>Tropomyosin gene</td>\n<td>NTRK1</td>\n</tr>\n<tr>\n<td>TRK1, TRK2</td>\n<td>Translocated promoter region (TPR)</td>\n<td>NTRK1</td>\n</tr>\n<tr>\n<td>TRK3</td>\n<td>TRK-fused gene (TFG) which codes for a cytoplasmic protein with the potential for promoting multimer formation</td>\n<td>NTRK1</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=16493&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Tyrosine_kinase_chimeras.htm</title></head></div><div id=\"graphicVersion\">Graphic 72255 Version 2.0</div></div></div>"},"72258":{"type":"graphic_table","displayName":"IDUS vs EUS for resectability","title":"Rates of detection of biliary obstruction, prediction of resectability, and T-stage by endoscopic ultrasound (EUS) and intraductal ultrasound (IDUS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of detection of biliary obstruction, prediction of resectability, and T-stage by endoscopic ultrasound (EUS) and intraductal ultrasound (IDUS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Determine cause biliary obstruction</td> <td class=\"subtitle1\">Correct prediction of resectability</td> <td class=\"subtitle1\">Correct T-staging</td> </tr> <tr> <td><strong>EUS</strong></td> <td>80 percent</td> <td>76 percent</td> <td>54 percent</td> </tr> <tr> <td><strong>IDUS</strong></td> <td>98 percent</td> <td>82 percent</td> <td>78 percent</td> </tr> <tr> <td><strong>p value</strong></td> <td>&#60;0.001</td> <td>&#60;0.002</td> <td>&#60;0.001</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Menzel J, Poremba C, Dietl KH, Domschke W. Scand J Gastroenterol 2000; 35:77.</div><div id=\"graphicVersion\">Graphic 72258 Version 3.0</div></div></div>"},"72260":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum - ulcer","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72260_Pyod_gangrenosum_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This purulent ulcer with a ragged and violaceous border is consistent with pyoderma gangrenosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72260 Version 3.0</div></div></div>"},"72261":{"type":"graphic_picture","displayName":"Staphylococcal scalded skin syndrome - trunk","title":"Staphylococcal scalded skin syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staphylococcal scalded skin syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/72261_Staphyscaldedskinsynd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythema and desquamation are present in this child with staphylococcal scalded skin syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72261 Version 5.0</div></div></div>"},"72262":{"type":"graphic_figure","displayName":"Pituitary location PI","title":"Pituitary gland","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Pituitary gland</div><div class=\"cntnt\"><img style=\"width:454px; height:346px;\" src=\"images/PI/72262_Pituitary_location_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pituitary gland is a small organ at the base of the brain. It makes substances called &quot;hormones&quot; that control the way certain organs in the body work.</div><div id=\"graphicVersion\">Graphic 72262 Version 1.0</div></div></div>"},"72263":{"type":"graphic_figure","displayName":"Barrx90 ablation catheter","title":"Barrx90 ablation catheter","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Barrx90 ablation catheter</div><div class=\"cntnt\"><img style=\"width:540px; height:335px;\" src=\"images/GAST/72263_HALO90_ablation_catheter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barrx90 ablation catheter.</div><div class=\"graphic_reference\">Reproduced with permission from: BÃRRX Medical Inc. Copyright Â© 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72263 Version 3.0</div></div></div>"},"72265":{"type":"graphic_algorithm","displayName":"ED and hospital Crotalinae snakebite management","title":"Emergency department and hospital management of pit viper* snakebite","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Emergency department and hospital management of pit viper* snakebite</div><div class=\"cntnt\"><img style=\"width:606px; height:918px;\" src=\"images/EM/72265_ED_hosp_crotalin_snakebite.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTES:&#xD;&#xA;<ul>&#xD;&#xA;    <li><strong>Consultation with a medical toxicologist is recommended prior to antivenom administration unless the physician has experience with snake bite treatment. Phone consultation with a medical toxicologist is available through a United States regional poison control center by calling 1-800-222-1222.</strong></li>&#xD;&#xA;    <li><strong>All treatment recommendations in this algorithm refer to Crotalinae polyvalent immune Fab (ovine) (CroFab).</strong></li>&#xD;&#xA;    <li>This worksheet represents general advice from a panel of US snakebite experts convened in May, 2010. No algorithm can anticipate all clinical situations. Other valid approaches exist, and deviations from this worksheet based on individual patient needs, local resources, local treatment guidelines, and patient preferences are expected. <strong>This document is not intended to represent a standard of care.</strong> For more information, please see the accompanying manuscript, available at: <a href=\"http://www.biomedcentral.com/1471-227X/11/2\" target=\"_blank\">http://www.biomedcentral.com/1471-227X/11/2</a>.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* Includes rattlesnakes, copperheads, and cottonmouths (water moccasins).<br />&para; For maintenance antivenom therapy guidance, refer to UpToDate topics on management of pit viper snakebites in the United States and see the related algorithm \"Crotalinae snakebite referral, maintenance, and follow up\".</div><div class=\"graphic_reference\">Reproduced with permission from: Lavonas EJ, Ruha AM, Banner W, et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011; 11:2. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 72265 Version 11.0</div></div></div>"},"72266":{"type":"graphic_picture","displayName":"Cavovarus","title":"Cavovarus deformity in an adolescent patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavovarus deformity in an adolescent patient</div><div class=\"cntnt\"><img style=\"width:312px; height:700px;\" src=\"images/PEDS/72266_Cavovarus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;cavovarus&nbsp;deformity is characterized by an elevated longitudinal arch (cavus). An inverted heel (varus) then results from the muscle imbalance between the posterior tibialis and the peroneal muscles.</div><div class=\"graphic_reference\">Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.</div><div id=\"graphicVersion\">Graphic 72266 Version 3.0</div></div></div>"},"72267":{"type":"graphic_table","displayName":"Genetic terms","title":"Genetic terms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic terms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Term</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Genotype</td> <td>The genetic blueprint</td> </tr> <tr> <td>Phenotype</td> <td>The translation of the genotype into the physical or biochemical manifestation in an individual</td> </tr> <tr> <td>Penetrance</td> <td>The frequency with which the genotype results in any phenotypic changes</td> </tr> <tr> <td>Variable expressivity</td> <td>The range of phenotypic changes (age of onset, severity of disease, different signs and symptoms, etc) that may result from aspecific genotype</td> </tr> <tr> <td>Mutation</td> <td>A change in the sequence of DNA that results in a phenotypic change; a mutation may be beneficial, neutral, or harmful</td> </tr> <tr> <td>Polymorphism</td> <td>A variation in DNA sequence that occurs in greater than 1 percent of the population</td> </tr> <tr> <td>Presymptomatic</td> <td>Term used in predictive genetic testing to identify unaffected persons at increased risk for genetic disease</td> </tr> <tr> <td>Predispositional</td> <td>Term used in predictive genetic testing; refers to detecting a genotype with less than 100 percent penetrance in an asymptomatic individual - ie, the person may or may not develop the condition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Types of chromosomes</td> </tr> <tr> <td class=\"subtitle3_left\">Autosomal chromosomes</td> <td>22 paired sets that are not sex chromosomes</td> </tr> <tr> <td class=\"indent2\">Allele</td> <td>Each of a pair of genes on homologous chromosomes</td> </tr> <tr> <td class=\"indent2\">Homozygous</td> <td>When both of the paired alleles have the mutation</td> </tr> <tr> <td class=\"indent2\">Heterozygous</td> <td>When the mutation occurs on only one of a pair of alleles</td> </tr> <tr> <td class=\"indent2\">Compound heterozygote</td> <td>Genotype formed by each allele having a different mutation</td> </tr> <tr> <td class=\"subtitle3_left\">Sex-linked chromosomes</td> <td>The X and Y chromosomes - XX in females, XY in males</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Modes of inheritance</td> </tr> <tr> <td class=\"subtitle3_left\">Multifactorial</td> <td>A constellation of genetic and environmental factors that interact to produce a specific condition</td> </tr> <tr> <td class=\"subtitle3_left\">Mendelian inheritance</td> <td>Autosomal dominant and recessive inheritance, and X-linked inheritance</td> </tr> <tr> <td class=\"indent2\">Autosomal dominant inheritance</td> <td>When a disorder can result if one of a specific pair of genes has a mutation. Child of an affected individual has a 50 percent chance of inheriting the gene involved.</td> </tr> <tr> <td class=\"indent2\">Autosomal recessive inheritance</td> <td>When a disorder can result only if both genes in a specific pair have a mutation. Child of an affected individual is an obligate carrier; parents of an affected individual have a 25 percent chance of having an affected child in each pregnancy.</td> </tr> <tr> <td class=\"indent2\">X-linked inheritance</td> <td>Mutation exists on X-chromosome: most X-linked conditions are recessive - two copies of a specific gene on the paired X chromosome must be abnormal for a female to be affected.</td> </tr> <tr> <td class=\"subtitle3_left\">Non-Mendelian inheritance</td> <td>Pattern of inheritance that is not autosomal dominant, autosomal recessive, or X-linked</td> </tr> <tr> <td class=\"indent2\">Polygenic</td> <td>When more than one gene is involved in producing a condition</td> </tr> <tr> <td class=\"indent2\">Mitochondrial</td> <td>Condition arising from a mutation in the DNA of the mitochondria, inherited from the mother only</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Types of genetic testing</td> </tr> <tr> <td class=\"indent1\">Diagnostic genetic testing</td> <td>Assessment of DNA sequence or structure for defined genetic risk factors for the purpose of supporting a specific disease diagnosis</td> </tr> <tr> <td class=\"indent1\">Carrier screening</td> <td>Assessment of DNA sequence or structure for specific disease-causing alleles in at-risk populations</td> </tr> <tr> <td class=\"indent1\">Prenatal testing</td> <td>Assessment of fetal DNA sequence or structure for specific disease-causing alleles or karyotypes</td> </tr> <tr> <td class=\"indent1\">Preimplantation testing</td> <td>Assessment of sequence or structure of blastocyst-derived DNA with the purpose of selecting embryos for implantation that are free of pathogenic genotypes</td> </tr> <tr> <td class=\"indent1\">Newborn screening</td> <td>A variety of genetic and metabolic tests performed in the newborn period for the purposes of early (ie, preclinical) identification of children with disease-causing genotypes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72267 Version 4.0</div></div></div>"},"72268":{"type":"graphic_picture","displayName":"Periungual warts","title":"Periungual warts","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Periungual warts</div><div class=\"cntnt\"><img style=\"width:273px; height:288px;\" src=\"images/PC/72268_Periungual_warts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 72268 Version 2.0</div></div></div>"},"72269":{"type":"graphic_table","displayName":"USPSTF grade I statements","title":"Adult screening and prevention statements of USPSTF I statements (balance of benefits and harms uncertain)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult screening and prevention statements of USPSTF I statements (balance of benefits and harms uncertain)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"45%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Service</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Year</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular disease</td> </tr> <tr> <td class=\"indent1\">Aspirin for primary prevention of CVD and colorectal cancer</td> <td>Adults aged &#60;50 years or &#8805;70 years</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Screening for abdominal aortic aneurysm</td> <td>Women aged 65 to 75 years who have ever smoked</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Screening for CHD by resting or exercise ECG</td> <td>Asymptomatic adults at intermediate or high risk of CHD events</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Screening for CHD risk by nontraditional risk factors*</td> <td>Asymptomatic adults with no history of CHD, diabetes, or any CHD risk equivalent<sup>&#182;</sup></td> <td class=\"centered\">2009</td> </tr> <tr> <td class=\"indent1\">Multivitamins; single- or paired-nutrient supplements for the prevention of CVD or cancer<sup>&#916;</sup></td> <td>Healthy adults without special nutritional needs</td> <td class=\"centered\">2014&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for peripheral arterial disease or CVD risk with ABI</td> <td>Asymptomatic adults without PAD, CVD, severe CKD, or diabetes</td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Statin use for primary prevention of CVD</td> <td>Adults aged &#8805;76 years with no CVD history</td> <td class=\"centered\">&nbsp;2016&nbsp;&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cancer</td> </tr> <tr> <td class=\"indent1\">Screening for bladder cancer</td> <td>Asymptomatic adults</td> <td class=\"centered\">2011</td> </tr> <tr> <td class=\"indent1\">Breast cancer screening by mammography</td> <td>Women aged&nbsp;&#8805;75 years</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Breast cancer screening with digital breast tomosynthesis&nbsp;as a primary screening method&nbsp;</td> <td>Women</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Breast cancer adjunctive screening with ultrasound, MRI, digital breast tomosynthesis&nbsp;or other methods </td> <td>Women with dense breasts on an otherwise negative screening mammogram</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"indent1\">Multivitamins; single- or paired-nutrient supplements for the prevention of CVD or cancer<sup>&#916;</sup></td> <td>Healthy adults without special nutritional needs</td> <td class=\"centered\">2014&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for oral cancer</td> <td>Adults</td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Counseling to prevent skin cancer</td> <td>Adults aged &#62;24 years</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Screening for skin cancer with visual&nbsp;skin exam</td> <td>Asymptomatic adults</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Screening for gestational diabetes</td> <td>Asymptomatic pregnant women before 24 weeks gestation</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sexually transmitted infections</td> </tr> <tr> <td class=\"indent1\">Screening for bacterial vaginosis in pregnancy</td> <td>Asymptomatic pregnant women with&nbsp;risk factors&nbsp;for preterm delivery</td> <td class=\"centered\">2008</td> </tr> <tr> <td class=\"indent1\">Screening for chlamydia and gonorrhea</td> <td>Men</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Substance abuse</td> </tr> <tr> <td class=\"indent1\">Screening for illicit drug use</td> <td>Adults and pregnant women </td> <td class=\"centered\">2008</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vision and hearing problems</td> </tr> <tr> <td class=\"indent1\">Screening for glaucoma</td> <td>Adults without vision symptoms, seen in primary care </td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Screening for hearing loss</td> <td>Asymptomatic adults aged &#8805;50 years</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Screening for impaired visual acuity</td> <td>Adults &#8805;65 years without vision problems</td> <td class=\"centered\">2016</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Screening for abuse and neglect</td> <td>Older adults or adults with physical or mental dysfunction</td> <td class=\"centered\">2013&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for celiac disease</td> <td>Asymptomatic adults</td> <td class=\"centered\">&nbsp; 2017&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for CKD</td> <td>Asymptomatic adults</td> <td class=\"centered\">2012</td> </tr> <tr> <td class=\"indent1\">Screening for cognitive impairment</td> <td>Adults age &#62;65 years with no cognitive impairment signs or symptoms</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Screening for vitamin D deficiency</td> <td>Community-dwelling, nonpregnant, asymptomatic adults</td> <td class=\"centered\">2014&nbsp;</td> </tr> <tr> <td class=\"indent1\">Combined vitamin D and calcium supplementation for primary prevention of fractures</td> <td>Men and premenopausal women</td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Daily supplementation &#62;400&nbsp;international units<span style=\"color: #0000ff;\">&nbsp;</span>vitamin D and &#62;1000 mg calcium for primary prevention of fractures</td> <td>Noninstitutionalized postmenopausal women</td> <td class=\"centered\">2013</td> </tr> <tr> <td class=\"indent1\">Screening for gynecologic conditions with pelvic examination</td> <td>Asymptomatic nonpregnant women not at increased risk for a specific gynecologic condition</td> <td class=\"centered\">&nbsp;2017&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for iron deficiency anemia, and giving iron supplementation </td> <td>Asymptomatic pregnant women</td> <td class=\"centered\">2006&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for obstructive sleep apnea </td> <td>Asymptomatic adults</td> <td class=\"centered\">2017&nbsp;</td> </tr> <tr> <td class=\"indent1\">Screening for osteoporosis</td> <td>Men without prior fracture or secondary causes of osteoporosis</td> <td class=\"centered\">2011</td> </tr> <tr> <td class=\"indent1\">Screening for suicide risk</td> <td>Adults and older adults without a psychiatric disorder</td> <td class=\"centered\">2014</td> </tr> <tr> <td class=\"indent1\">Screening for thyroid dysfunction</td> <td>Nonpregnant, asymptomatic adults</td> <td class=\"centered\">2015</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table covers recommendations for adults aged &gt;18 years.</div><div class=\"graphic_footnotes\"><FONT color=black>USPSTF: US Preventive Services Task Force;&nbsp;<FONT color=black>CVD: cardiovascular disease</FONT><FONT color=black>; CHD: coronary heart disease; ECG: electrocardiogram; ABI: ankle-brachial index;&nbsp;PAD: peripheral artery disease; CKD: chronic kidney disease;&nbsp;MRI: magnetic resonance imaging;&nbsp;hs-CRP: high-sensitivity C-reactive protein; EBCT: electron-beam&nbsp;computed tomography&nbsp;for coronary calcification</FONT></FONT><FONT color=black>.<br />* hs-CRP, ABI, carotid artery intima-media thickness, EBCT, homocysteine, lipoprotein(a), leukocyte count, fasting glucose level.<br />Â¶<FONT color=black>&nbsp;Examples of CHD risk equivalents include&nbsp;</FONT><FONT color=black>symptomatic carotid artery disease, peripheral arterial disease, abdominal aortic aneurysm.</FONT><br />Î Except do not use beta-carotene or vitamin E.</FONT></div><div id=\"graphicVersion\">Graphic 72269 Version 25.0</div></div></div>"},"72270":{"type":"graphic_picture","displayName":"Organizing pneumonia low power","title":"Organizing pneumonia histopathology","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Organizing pneumonia histopathology</div><div class=\"cntnt\"><img style=\"width:295px; height:197px;\" src=\"images/PULM/72270_BOOP_low_power_photomicrogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph shows organizing pneumonia with intraluminal plugs of pale staining fibroblastic tissue. The configuration of the intraluminal plugs reflects the dichotomously branching architecture of distal airways and alveolar ducts.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 72270 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"72271":{"type":"graphic_table","displayName":"Effects of cytokines","title":"Biologic effects of proinflammatory cytokines such as TNF and IL-1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Biologic effects of proinflammatory cytokines such as TNF and IL-1</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Fever</td>\n</tr>\n<tr>\n<td>Hypotension</td>\n</tr>\n<tr>\n<td>Acute phase protein response</td>\n</tr>\n<tr>\n<td>Induction of IL-6 and IL-8</td>\n</tr>\n<tr>\n<td>Coagulation activation</td>\n</tr>\n<tr>\n<td>Fibrinolytic activation</td>\n</tr>\n<tr>\n<td>Leukocytosis</td>\n</tr>\n<tr>\n<td>Neutrophil degranulation and augmented antigen expression (TNF)</td>\n</tr>\n<tr>\n<td>Increased endothelial permeability (TNF)</td>\n</tr>\n<tr>\n<td>Stress hormone response</td>\n</tr>\n<tr>\n<td>Enhanced gluconeogenesis (TNF)</td>\n</tr>\n<tr>\n<td>Enhanced lipolysis (TNF)</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72271 Version 1.0</div></div></div>"},"72275":{"type":"graphic_figure","displayName":"Incidence rates of primary brain tumors","title":"Incidence rates of primary brain tumors by major neuroepithelial tissue and meningeal histologic types and age group","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Incidence rates of primary brain tumors by major neuroepithelial tissue and meningeal histologic types and age group</div><div class=\"cntnt\"><img style=\"width:483px; height:362px;\" src=\"images/ONC/72275_Incidence_primary_brain_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The category \"All brain tumors\" includes some specific types not individually shown (tumors of cranial and spinal nerves, hemangioblastomas, primary lymphomas, germ cell tumors, and tumors of the sellar region). The \"Astrocytoma\" category includes diffuse astrocytomas, anaplastic astrocytomas, unique astrocytoma variants, and astrocytomas not otherwise specified.</div><div class=\"graphic_footnotes\">PNET: primitive neuroectodermal tumor.</div><div class=\"graphic_reference\">Reproduced with permission from: Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro-Oncology 2002; 4:278. Copyright Â© 2002 Margaret Wrensch, MD.</div><div id=\"graphicVersion\">Graphic 72275 Version 6.0</div></div></div>"},"72276":{"type":"graphic_picture","displayName":"Rotationplasty reconstruction","title":"Rotationplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rotationplasty</div><div class=\"cntnt\"><img style=\"width:443px; height:288px;\" src=\"images/ONC/72276_Rotationplasty_reconstr_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 15-year-old male presented with a very large osteosarcoma of the distal femur (left panel) with major posteriorly placed soft tissue mass. The patient was treated by a turnabout procedure (rotationplasty) where the distal half of the femur was resected, and replaced by the tibia but &quot;turned around&quot; so that the foot was pointing backwards (right panel). Using this system, the ankle joint now served as a knee joint, and the patient uses a special prosthesis to use the new knee joint (formerly the ankle) to flex and extend.</div><div class=\"graphic_reference\">Courtesy of Dr. Henry Mankin.</div><div id=\"graphicVersion\">Graphic 72276 Version 3.0</div></div></div>"},"72280":{"type":"graphic_diagnosticimage","displayName":"MRI Spinal cord infarct","title":"MRI findings in spinal cord ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI findings in spinal cord ischemia</div><div class=\"cntnt\"><img style=\"width:430px; height:246px;\" src=\"images/NEURO/72280_MRI_SC_infarct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance images (MRI) of the thoracolumbar spine demonstrating spinal cord infarction in a patient with paraplegia after thoracoabdominal aneurysm repair. T2 weighted sagittal imaging through the center of the spinal cord (left panel) showed central infarction extending from the high thoracic level into the lumbar segments. T2 weighted axial images of the spinal cord at the thoracic level demonstrated central infraction (right panel).</div><div class=\"graphic_reference\">Courtesy of Michael L McGarvy, MD and Michael Mullen, MD.</div><div id=\"graphicVersion\">Graphic 72280 Version 4.0</div></div></div>"},"72281":{"type":"graphic_diagnosticimage","displayName":"Normal cervix on ultrasound","title":"Normal cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal cervix</div><div class=\"cntnt\"><img style=\"width:334px; height:288px;\" src=\"images/OBGYN/72281_Normal_cervix_on_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of normal cervix with equal thickness of anterior and posterior cervical lips. X marks the internal cervical os; + marks the external cervical os; the echodense line connecting the two points is the endocervical canal.</div><div class=\"graphic_footnotes\">AF: amniotic fluid; VTX: fetal head.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Johnson, MD.</div><div id=\"graphicVersion\">Graphic 72281 Version 2.0</div></div></div>"},"72282":{"type":"graphic_picture","displayName":"Congenital esotropia","title":"Congenital esotropia in a three-month-old infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital esotropia in a three-month-old infant</div><div class=\"cntnt\"><img style=\"width:327px; height:520px;\" src=\"images/PEDS/72282_Congenital_esotropia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The right eye is being used for fixation. B) The left eye is being used for fixation. The infant is spontaneously alternating fixation, indicating equal vision in each eye.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72282 Version 1.0</div></div></div>"},"72285":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:360px; height:291px;\" src=\"images/GAST/72285_Pyoderma_gangrenosum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peristomal pyoderma gangrenosum is caused by an inflammatory process that produces severe and painful skin ulcerations.</div><div class=\"graphic_reference\">Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.</div><div id=\"graphicVersion\">Graphic 72285 Version 2.0</div></div></div>"},"72286":{"type":"graphic_figure","displayName":"Origins ovarian tumors","title":"Origins of ovarian tumors","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Origins of ovarian tumors</div><div class=\"cntnt\"><img style=\"width:462px; height:342px;\" src=\"images/OBGYN/72286_Origins_ovarian_tumors_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some epithelial ovarian carcinomas may originate in the fallopian tube epithelium.</div><div id=\"graphicVersion\">Graphic 72286 Version 6.0</div></div></div>"},"72289":{"type":"graphic_diagnosticimage","displayName":"Fracture of thumb metacarpal base Bennetts","title":"Fracture of thumb metacarpal base: Type I (Bennett's)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fracture of thumb metacarpal base: Type I (Bennett's)</div><div class=\"cntnt\"><img style=\"width:442px; height:329px;\" src=\"images/EM/72289_FirstmetacarpfxtypIedt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each of these anteroposterior radiographs shows an intra-articular fracture of the thumb metacarpal (arrows). The Type I or \"Bennett's\" fracture of the proximal first metacarpal illustrated here is characterized by its articular involvement and the persistent attachment of the volar fragment to the trapezium.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 72289 Version 10.0</div></div></div>"},"72290":{"type":"graphic_table","displayName":"Equipment for emergency pericardiocentesis","title":"Equipment for emergency pericardiocentesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment for emergency pericardiocentesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Sterile gown, gloves, and mask</td> </tr> <tr> <td>Sterile barrier drapes</td> </tr> <tr> <td>Chlorhexidine-based skin preparation solution</td> </tr> <tr> <td>20 to 25-gauge needle for local anesthetic infiltration</td> </tr> <tr> <td>Syringes (10 and 60 mL)</td> </tr> <tr> <td>Three-way stopcock</td> </tr> <tr> <td>Plastic drainage tubing</td> </tr> <tr> <td>18-gauge 7 cm large bore introducer needle</td> </tr> <tr> <td>Flexible or curved-tip (J) guidewire</td> </tr> <tr> <td> <p>6 to 8 French drainage catheter (pigtail, sheath, or central venous catheter)</p> <p>(Supplies in a standard 7 French central venous catheter set are good immediate substitutes)</p> </td> </tr> <tr> <td>Echocardiographic system with 2-5 MHz transducer</td> </tr> <tr> <td>Ultrasound needle guide</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The list above includes all equipment that may be necessary to perform emergency pericardiocentesis. Time to obtain all materials may not be available in life-threatening circumstances.</div><div id=\"graphicVersion\">Graphic 72290 Version 4.0</div></div></div>"},"72292":{"type":"graphic_picture","displayName":"Mixed-cellularity Hodgkin lymphoma","title":"Mixed-cellularity Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Mixed-cellularity Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:502px; height:756px;\" src=\"images/HEME/72292_MixcellHodgkinlymph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is an absence of fibrous bands in mixed-cellularity Hodgkin lymphoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al. Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72292 Version 7.0</div></div></div>"},"72293":{"type":"graphic_table","displayName":"Host factors and meningitis","title":"Host immune defects predisposing to meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Host immune defects predisposing to meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Host problem</td> <td class=\"subtitle1\">Organism favored</td> <td class=\"subtitle1\">Frequency of defect actually leading to infection</td> </tr> <tr> <td rowspan=\"2\">Absence of opsonizing antibody</td> <td><em>Streptococcus pneumoniae</em></td> <td>Common in all age groups</td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> <td>Common in very young children</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Asplenia: surgical or functional</td> <td><em>S. pneumoniae</em></td> <td>Rare</td> </tr> <tr> <td><em>Neisseria meningitidis</em></td> <td>Very rare</td> </tr> <tr class=\"divider_top\"> <td>Complement deficiency</td> <td><em>N. meningitidis</em></td> <td>Very rare</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Glucocorticoid excess</td> <td><em>Listeria monocytogenes</em></td> <td>Rare</td> </tr> <tr> <td><em>Cryptococcus neoformans</em></td> <td>Rare</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">HIV infection</td> <td><em>C. neoformans</em></td> <td>About 5 percent eventually get cryptococcal meningitis</td> </tr> <tr> <td><em>S. pneumoniae</em></td> <td>Common presenting illness</td> </tr> <tr> <td><em>L. monocytogenes</em></td> <td>Rare</td> </tr> <tr class=\"divider_top\"> <td>Bacteremia/endocarditis</td> <td><em>Staphylococcus aureus</em>; various gram-negative rods</td> <td>Rare</td> </tr> <tr class=\"divider_top\"> <td>Basilar skull fracture</td> <td><em>S. pneumoniae</em>; other upper respiratory tract flora</td> <td>Very rare</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">8</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=30990&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 72293 Version 8.0</div></div></div>"},"72294":{"type":"graphic_form","displayName":"TB risk assessment in children","title":"Questionnaire for assessing risk of latent tuberculosis infection in children","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Questionnaire for assessing risk of latent tuberculosis infection in children</div><div class=\"cntnt\"><img style=\"width:590px; height:584px;\" src=\"images/ID/72294_TB_risk_assessment.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Any affirmative response on the questionnaire constitutes a positive screen and should prompt testing for latent tuberculosis.</div><div class=\"graphic_reference\">Reference:&nbsp;<br /><UL>&#xD;&#xA;<LI>âPediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004; 114:1175.</LI></UL></div><div id=\"graphicVersion\">Graphic 72294 Version 4.0</div></div></div>"},"72296":{"type":"graphic_diagnosticimage","displayName":"Brain MRI age 4 months infantile Alexander disease","title":"Early brain MRI study at the age of four months in a patient with autopsy-proved infantile Alexander disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early brain MRI study at the age of four months in a patient with autopsy-proved infantile Alexander disease</div><div class=\"cntnt\"><img style=\"width:432px; height:553px;\" src=\"images/NEURO/72296_MRI_infantile_4mo_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-D: T2-weighted images show abnormally high signal in the medulla (A), the hilus of the dentate nucleus (arrows, A), the entire midbrain except for the red nuclei (B), the basal ganglia, and the thalamus (C). The frontal white matter has a slightly higher signal intensity than the occipital white matter (C). The head of the caudate nucleus is swollen (arrowheads, C). Around the ventricles, there is a rim of low signal intensity (arrows, B-D). <br />E-G: T1-weighted images show high signal intensity of the periventricular rim (arrows, E). After contrast administration, the T1-weighted images show enhancement of areas in the midbrain (F), ventricular lining (arrows, F), and periventricular rim (arrows, G).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 72296 Version 4.0</div></div></div>"},"72297":{"type":"graphic_picture","displayName":"Cornea vit A defic","title":"Xerosis of the cornea in vitamin A deficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xerosis of the cornea in vitamin A deficiency</div><div class=\"cntnt\"><img style=\"width:376px; height:541px;\" src=\"images/PEDS/72297_Cornea_vit_A_defic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corneal clouding from vitamin A deficiency in an unsupplemented child recovering from Kwashiorkor, taken at Instituto de Nutricion de Centroamerica y Panama (INCAP), Guatemala.</div><div class=\"graphic_reference\">Reproduced from: Interdepartmental Committee on Nutrition for National Defense (1963). Manual for Nutrition Surveys 2nd ed. Department of Health, Education and Welfare, Public Health Service, NIH, US Government Printing Office, Washington DC 1963.</div><div id=\"graphicVersion\">Graphic 72297 Version 2.0</div></div></div>"},"72298":{"type":"graphic_picture","displayName":"Lumbosacral hemangioma","title":"Lumbosacral hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbosacral hemangioma</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/PEDS/72298_Lumbosacral_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemangiomas located over the lumbosacral spine may be associated with spinal dysraphism or other underlying congenital anomalies. Segmental lesions, like the one depicted above, that span the midline and are flat or telangiectatic in appearance are of greatest concern.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD</div><div id=\"graphicVersion\">Graphic 72298 Version 1.0</div></div></div>"},"72299":{"type":"graphic_table","displayName":"Lab findings metabolic causes acidosis coma","title":"Laboratory evaluation of metabolic causes of acidosis and coma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation of metabolic causes of acidosis and coma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"11\" width=\"9%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Starvation or high fat intake</td> <td class=\"subtitle1\">DKA</td> <td class=\"subtitle1\">Lactic acidosis</td> <td class=\"subtitle1\">Uremic acidosis</td> <td class=\"subtitle1\">Alcoholic ketosis (starvation)</td> <td class=\"subtitle1\">Salicylate intoxication</td> <td class=\"subtitle1\">Methanol or ethylene glycol intoxication</td> <td class=\"subtitle1\">Hyperosmolar coma</td> <td class=\"subtitle1\">Hypoglycemic coma</td> <td class=\"subtitle1\">Rhabdomyolysis</td> </tr> <tr> <td><strong>pH</strong></td> <td>Normal</td> <td>&#8595;</td> <td>&#8595;</td> <td>Mild &#8595;</td> <td>&#8595;&#8593;</td> <td>&#8595;&#8593;*</td> <td>&#8595;</td> <td>Normal</td> <td>Normal</td> <td>Mild &#8595; may be &#8595;&#8595;</td> </tr> <tr> <td><strong>Plasma glucose</strong></td> <td>Normal</td> <td>&#8593;</td> <td>Normal</td> <td>Normal</td> <td>&#8595; or normal</td> <td>Normal or &#8595;</td> <td>Normal</td> <td> <p>&#8593;&#8593;</p> &#62;500mg/dL</td> <td> <p>&#8595;&#8595;</p> &#60;30 mg/dL</td> <td>Normal</td> </tr> <tr> <td><strong>Glycosuria </strong></td> <td>Negative</td> <td>++</td> <td>Negative</td> <td>Negative</td> <td>Negative</td> <td>Negative<sup>&#182;</sup></td> <td>Negative</td> <td>++</td> <td>Negative</td> <td>Negative</td> </tr> <tr> <td><strong>Total plasma ketones<sup>&#916;</sup></strong></td> <td>Slight &#8593;</td> <td>&#8593;&#8593;</td> <td>Normal</td> <td>Normal </td> <td>Slight to moderate &#8593; </td> <td>Normal</td> <td>Normal</td> <td>Normal or slight &#8593;</td> <td>Normal or slight &#8593;</td> <td>Normal</td> </tr> <tr> <td><strong>Anion gap</strong></td> <td>Slight &#8593;</td> <td>&#8593;</td> <td>&#8593;</td> <td>Slight &#8593;</td> <td>&#8593;</td> <td>&#8593;</td> <td>&#8593;</td> <td>Normal</td> <td>Normal or slight &#8593;</td> <td>&#8593;&#8593;</td> </tr> <tr> <td><strong>Osmolality</strong></td> <td>Normal</td> <td>&#8593;</td> <td>Normal</td> <td>&#8593;</td> <td>Normal</td> <td>Normal</td> <td>&#8593;&#8593;</td> <td> <p>&#8593;&#8593;</p> &#62;330 mOsm/kg</td> <td>Normal</td> <td>Normal or slight &#8593;</td> </tr> <tr> <td><strong>Uric acid</strong></td> <td>Mild (starvation)</td> <td>&#8593;</td> <td>Normal</td> <td>Normal</td> <td>&#8593;</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>&#8593;</td> </tr> <tr> <td><strong>Miscellaneous</strong></td> <td>&nbsp;</td> <td>May give false-positive for ethylene glycol<sup>&#9674;</sup></td> <td>Serum lactate &#62;7 mmol/l</td> <td>BUN &#62;200 mg/dL</td> <td>&nbsp;</td> <td>Serum salicylate positive</td> <td>Serum levels positive</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Myoglobinuria hemoglobinuria</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; +: positive; BUN: blood urea nitrogen.<br />* Acetest and Ketostix measure acetoacetic acid only: thus, misleading low values may be obtained because the majority of \"ketone bodies\" are beta-hydroxybutyrate.<br />&para; Respiratory alkalosis/metabolic acidosis.<br />&Delta; May get false-positive or false-negative urinary glucose caused by the presence of salicylate or its metabolites.</div><div class=\"graphic_reference\">Reproduced with permission from: Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of Hyperglycemic Crises in Patients with Diabetes. Diabetes Care 2001; 24:131. Copyright &copy; 2006 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 72299 Version 5.0</div></div></div>"},"72300":{"type":"graphic_picture","displayName":"Duodenal carcinoid Endosc","title":"Carcinoid tumor in the duodenum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid tumor in the duodenum</div><div class=\"cntnt\"><img style=\"width:312px; height:327px;\" src=\"images/GAST/72300_Duodenal_carcinoid_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a duodenal carcinoid (arrow). Carcinoids can appear as small, round sessile or polypoid lesions. They usually have normal overlying mucosa and rarely ulcerate.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 72300 Version 2.0</div></div></div>"},"72301":{"type":"graphic_figure","displayName":"RVOT nine site mapping","title":"Nine site mapping schema for RVOT tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nine site mapping schema for RVOT tachycardia</div><div class=\"cntnt\"><img style=\"width:394px; height:351px;\" src=\"images/CARD/72301_RVOTninesitemapping.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The septal aspect of the right ventricular outflow tract (RVOT) is depicted as seen in the 30Â° RAO view, divided into posterior (1, 4, and 7), intermediate (2, 5, and 8), and anterior (3, 6, and 9) sites. Pacing from posterior sites (1 and 7) results in a dominant R wave in lead I, and frequently in a small R wave before a dominant S wave in lead aVL. Pacing from anterior sites (3 and 9) always produces an initial Q wave (QS, Qr, or qR) in lead I, and a QS complex in a VL. Early precordial R wave transition (R/S &gt;1 in V1, V2, or V3) is observed during pacing from posterior and superior sites. Moving diagonally from superior-posterior to inferior-anterior results in progressive delay in the precordial R wave transition.</div><div class=\"graphic_reference\">Redrawn with permission from: Callans DJ. J Cardiovasc Electrophysiol 1994; 5:880. Futura Publishing Company.</div><div id=\"graphicVersion\">Graphic 72301 Version 3.0</div></div></div>"},"72302":{"type":"graphic_figure","displayName":"Reconstruction with Lat flap PI","title":"Reconstruction with Lat flap","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Reconstruction with Lat flap</div><div class=\"cntnt\"><img style=\"width:503px; height:529px;\" src=\"images/PI/72302_Reconst_Lat_flap_ed2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Women who have reconstruction with a Lat flap have a flap of muscle and skin freed from their back. (The back muscle that is used is called the &quot;latissimus dorsi&quot; muscle.) After freeing the flap, surgeons tunnel it under the skin, around the armpit, and over to the chest. Then they attach the flap to the chest so that it becomes the new breast. Usually, they also put an implant under the muscle layer, so that the new breast can match the other one in size. Later, surgeons can also reconstruct a nipple.</div><div class=\"graphic_reference\">Courtesy of Jorge de la Pedraja, MD.</div><div id=\"graphicVersion\">Graphic 72302 Version 3.0</div></div></div>"},"72303":{"type":"graphic_diagnosticimage","displayName":"MRI well differentiated pancreatic neuroendocrine tumor","title":"T2-weighted MRI image of a neuroendocrine tumor of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T2-weighted MRI image of a neuroendocrine tumor of the pancreas</div><div class=\"cntnt\"><img style=\"width:358px; height:512px;\" src=\"images/ONC/72303_T2_MRI_islet_cell_tum_pancr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic neuroendocrine tumor.<br />(A) Fat-suppressed T2-weighted image shows small high-signal intensity mass (arrow) involving tail of pancreas.<br />(B) Arterial phase fat-suppressed gradient echo image from dynamic examination reveals mass (arrow) to be hypervascular.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Leyendecker JR, Brown JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72303 Version 5.0</div></div></div>"},"72304":{"type":"graphic_table","displayName":"Genetic basis of SQTS","title":"Genetic basis of SQTS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic basis of SQTS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">QTc (msec)</td> <td class=\"subtitle1\">Gene (cardiac ion channel)</td> </tr> <tr> <td><strong>SQT1<sup></sup></strong><sup>[1]</sup></td> <td>286&#177;6</td> <td><em>KCNH2</em> (I<sub>Kr</sub>) &#8593;</td> </tr> <tr> <td><strong>SQT2<sup></sup></strong><sup>[2]</sup></td> <td>302</td> <td><em>KCNQ1</em> (I<sub>Ks</sub>) &#8593;</td> </tr> <tr> <td><strong>SQT3<sup></sup></strong><sup>[3]</sup></td> <td>315-330</td> <td><em>KCNJ2</em> (I<sub>K1</sub>) &#8593;</td> </tr> <tr> <td><strong>SQT4<sup></sup></strong><sup>[4]</sup></td> <td>331-370</td> <td><em>CACNB2b</em> (I<sub>Ca</sub>) &#8595;</td> </tr> <tr> <td><strong>SQT5<sup></sup></strong><sup>[4]</sup></td> <td>346-360</td> <td><em>CACNA1C</em> (I<sub>Ca</sub>) &#8595;</td> </tr> <tr> <td><strong>SQT6<sup></sup></strong><sup>[5]</sup></td> <td>330</td> <td><em>CACNA2D1</em> (I<sub>Ca</sub>) &#8595;</td> </tr> <tr> <td><strong>SQT7<sup></sup></strong><sup>[6]</sup></td> <td>282-340</td> <td>SLC22A5 (&#8595; carnitine - &#8593; I<sub>Kr</sub>)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109:30. </LI>&#xD;&#xA;<LI>Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109:2394.</LI>&#xD;&#xA;<LI>Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005; 96:800. </LI>&#xD;&#xA;<LI>Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442. </LI>&#xD;&#xA;<LI>Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011; 32:1077. </LI>&#xD;&#xA;<LI>Roussel J, Labarthe F, Thireau J, et al. Carnitine deficiency induces a short QT syndrome. Heart Rhythm 2016; 13:165.</LI></OL></div><div id=\"graphicVersion\">Graphic 72304 Version 4.0</div></div></div>"},"72306":{"type":"graphic_picture","displayName":"Central line wire","title":"Placement of a guidewire for a central venous catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placement of a guidewire for a central venous catheter</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/72306_Central_line_wire.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 72306 Version 2.0</div></div></div>"},"72307":{"type":"graphic_table","displayName":"Syndromic hereditary neurop I","title":"Clinical features of hereditary peripheral neuropathies associated with other disorders-I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of hereditary peripheral neuropathies associated with other disorders-I</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Inheritance</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr class=\"divider_bottom\"> <td>Friedreich ataxia</td> <td>AR</td> <td>FXN</td> <td>Usual onset before age 25 years, progressive ataxia of all limbs, optic atrophy, pyramidal signs, early loss of position and vibration sense, bladder dysfunction, distal muscle atrophy, kyphoscoliosis, cardiomyopathy, diabetes mellitus</td> </tr> <tr class=\"divider_bottom\"> <td>Infantile neuroaxonal dystrophy (PLA2G6-associated neurodegeneration)</td> <td>AR</td> <td>PLA2G6</td> <td>Usual onset at age 1 to 3 years, motor and cognitive regression, spasticity, muscle atrophy, hypotonia, cerebellar ataxia, dystonia, optic atrophy, distal sensory loss</td> </tr> <tr class=\"divider_bottom\"> <td>Tangier disease</td> <td>AC</td> <td>ABCA1</td> <td>Orange tonsils, hepatosplenomegaly, premature coronary disease, neuropathy, absent (homozygotes) or 50 percent normal (heterozygotes) HDL cholesterol</td> </tr> <tr class=\"divider_bottom\"> <td>Abetalipoproteinemia</td> <td>AR</td> <td>MTP</td> <td>Acanthocytes, fat malabsorption, retinitis pigmentosa, peripheral neuropathy, ataxia, sensory motor neuropathy, absent tendon reflexes, low serum cholesterol and VLDL, absent serum beta lipoprotein</td> </tr> <tr class=\"divider_bottom\"> <td>Classic Refsum disease</td> <td>AR</td> <td>PHYH</td> <td>Retinitis pigmentosa, peripheral polyneuropathy, cerebellar ataxia, elevated CSF protein, sensorineural deafness, ichthyosis, anosmia, abnormal accumulation of phytanic acid</td> </tr> <tr class=\"divider_bottom\"> <td>Infantile Refsum disease</td> <td>AR</td> <td> <p>PEX1</p> PEX6</td> <td>Abnormal accumulation of phytanic acid</td> </tr> <tr> <td>Chediak-Higashi syndrome</td> <td>AR</td> <td>LYST</td> <td>Recurrent infections, partial albinism, hepatosplenomegaly, increased risk of lymphoreticular malignancy, nystagmus, seizures, mental retardation, generalized weakness, spinocerebellar degeneration, and parkinsonism</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AR: autosomal recessive; AC: autosomal codominant.</div><div id=\"graphicVersion\">Graphic 72307 Version 6.0</div></div></div>"},"72309":{"type":"graphic_picture","displayName":"Pterygium 1","title":"Pterygium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pterygium</div><div class=\"cntnt\"><img style=\"width:402px; height:255px;\" src=\"images/PC/72309_Pterygium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the typical wedge-shaped appearance of a pterygium extending onto the cornea.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 72309 Version 2.0</div></div></div>"},"72311":{"type":"graphic_figure","displayName":"Transjugular intrahepatic portosystemic shunt","title":"Transjugular intrahepatic portosystemic shunt","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Transjugular intrahepatic portosystemic shunt</div><div class=\"cntnt\"><img style=\"width:527px; height:664px;\" src=\"images/GAST/72311_Transjugular-intrahepatic-portosystemic-shunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transjugular intrahepatic portosystemic shunt (TIPS) is created by passing a needle catheter via the transjugular route into the hepatic vein and wedging it there. The needle is then extruded and advanced through the liver parenchyma to the intrahepatic portion of the portal vein and a stent is placed between the portal and hepatic veins. A TIPS functions like side-to-side surgical portacaval shunt, but does not require general anesthesia or major surgery for placement. (A) Passage of a guidewire between the hepatic vein and the portal vein. (B) Inflation of a balloon catheter within the liver to dilate the tract between the hepatic vein and the portal vein. (C) Deployment of the stent. (D) Stent in its final position.</div><div id=\"graphicVersion\">Graphic 72311 Version 2.0</div></div></div>"},"72312":{"type":"graphic_waveform","displayName":"Atrial flutter and AV block","title":"Atrial flutter and AV block","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Atrial flutter and AV block</div><div class=\"cntnt\"><img style=\"width:453px; height:307px;\" src=\"images/PEDS/72312_Atrial_flutter_AV_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraatrial reentry tachycardia in an 18 year-old man following Mustard operation for d-transposition of the great arteries. There is 2:1 atrioventricular conduction and low amplitude &quot;flutter&quot; waves (f waves), making the diagnosis difficult to recognize. The administration of adenosine results in the obvious appearance of f waves. The sweep speed is 50 mm/sec.</div><div id=\"graphicVersion\">Graphic 72312 Version 3.0</div></div></div>"},"72313":{"type":"graphic_table","displayName":"Disorders with coll gn","title":"Disorders associated with collapsing glomerulopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with collapsing glomerulopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Infection</td> <td>HIV, cytomegalovirus, parvovirus B1, pulmonary TB, leishmaniasis</td> </tr> <tr> <td>Autoimmune</td> <td>Adult Still's disease, lupus-like syndrome, mixed connective tissue disorder, cerebral arteritis</td> </tr> <tr> <td>Malignancy</td> <td>Multiple myeloma, acute monoblastic leukemia, hemophagocytic syndrome</td> </tr> <tr> <td>Genetic</td> <td>Action myoclonus-renal failure syndrome, mitochondrial cytopathy, familial, sickle cell disease, MYH9 and APOL1 gene polymorphisms</td> </tr> <tr> <td>Drug exposure</td> <td>Interferon-alpha, beta, or gamma; anabolic steroids, pamidronate</td> </tr> <tr> <td>Post transplanation</td> <td>De novo, recurrent, arteriopathy, acute vascular rejection, thrombotic microangiopathy</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Albaqumi M, Soos TJ, Barisoni L, Nelson PJ. Collapsing glomerulopathy. J Am Soc Nephrol 2006; 17:2854.</div><div id=\"graphicVersion\">Graphic 72313 Version 4.0</div></div></div>"},"72314":{"type":"graphic_diagnosticimage","displayName":"Retromembranous bleed 1","title":"Retromembranous bleed 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retromembranous bleed 1</div><div class=\"cntnt\"><img style=\"width:360px; height:271px;\" src=\"images/OBGYN/72314_Retromemembranous_bleed_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large retromembranous bleed is present posteriorly.</div><div class=\"graphic_reference\">Courtesy of Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 72314 Version 2.0</div></div></div>"},"72316":{"type":"graphic_diagnosticimage","displayName":"Conglomerate shadows PA","title":"Large opacities in pneumoconiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large opacities in pneumoconiosis</div><div class=\"cntnt\"><img style=\"width:365px; height:350px;\" src=\"images/PULM/72316_Conglomerate_shadows_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard ILO film for large B opacities in patient with silicosis or coal worker's pneumoconiosis. Conglomerate masses of silicosis or progressive massive fibrosis of coal worker's pneumoconiosis can produce the so-called angel wings.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72316 Version 3.0</div></div></div>"},"72317":{"type":"graphic_diagnosticimage","displayName":"Med bronchogenic cyst MRI","title":"Paratracheal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratracheal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:256px;\" src=\"images/PULM/72317_Med_bronchogenic_cyst_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial T2-weighted spin echo MR scan shows high signal in the right paratracheal mass.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72317 Version 3.0</div></div></div>"},"72319":{"type":"graphic_form","displayName":"The 3 incontinence questions","title":"The 3 incontinence questionnaire (3IQ)","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">The 3 incontinence questionnaire (3IQ)</div><div class=\"cntnt\"><img style=\"width:572px; height:670px;\" src=\"images/PC/72319_Threeincontinencequestion.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Brown JS, Bradley CS, Subak LL, et al. The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med 2006; 144:715. Copyright &copy; 2006 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 72319 Version 14.0</div></div></div>"},"72320":{"type":"graphic_diagnosticimage","displayName":"Pelvic AP compression fracture type II","title":"Pelvic AP compression fracture: Type II","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Pelvic AP compression fracture: Type II</div><div class=\"cntnt\"><img style=\"width:526px; height:420px;\" src=\"images/EM/72320_Pelvicantpostfx22.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three images of a Type II AP compression fracture: (A) schematic; (B) AP radiograph; (C) CT scan.</div><div class=\"graphic_footnotes\">AP: anterior posterior; CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 72320 Version 13.0</div></div></div>"},"72321":{"type":"graphic_diagnosticimage","displayName":"T2 esophageal cancer EUS","title":"T2 esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">T2 esophageal cancer</div><div class=\"cntnt\"><img style=\"width:468px; height:463px;\" src=\"images/GAST/72321_T2_esophageal_cancer_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image showing stage T2 esophageal cancer.</div><div class=\"graphic_reference\">Courtesy of John R Saltzman, MD.</div><div id=\"graphicVersion\">Graphic 72321 Version 2.0</div></div></div>"},"72322":{"type":"graphic_picture","displayName":"T pallidum darkfield microscopy","title":"<em>Treponema pallidum</em> spirochetes depicted with darkfield microscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Treponema pallidum</em> spirochetes depicted with darkfield microscopy</div><div class=\"cntnt\"><img style=\"width:432px; height:342px;\" src=\"images/PEDS/72322_T-pallidium-darkfield.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using a darkfield microscopy technique, this photomicrograph revealed the presence of <em>Treponema pallidum</em> spirochetes, which are the bacterial agents that cause syphilis.</div><div class=\"graphic_reference\">Courtesy of the Centers for Disease Control and Prevention/Schwartz WF.</div><div id=\"graphicVersion\">Graphic 72322 Version 5.0</div></div></div>"},"72323":{"type":"graphic_figure","displayName":"HPLC normal hemoglobins","title":"Cation exchange HPLC for normal adult hemoglobins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cation exchange HPLC for normal adult hemoglobins</div><div class=\"cntnt\"><img style=\"width:404px; height:376px;\" src=\"images/HEME/72323_HPLC_normal_hemoglobins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cation exchange HPLC pattern from a normal subject (Hb A). Note the separation of minor (post-translationally modified) Hbs, A1c, A1d, etc.</div><div class=\"graphic_footnotes\">HPLC: high performance liquid chromatography; %: percent.</div><div id=\"graphicVersion\">Graphic 72323 Version 1.0</div></div></div>"},"72326":{"type":"graphic_diagnosticimage","displayName":"Estimation of LV volumes","title":"2D echocardiographic estimation of left ventricular volumes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">2D echocardiographic estimation of left ventricular volumes</div><div class=\"cntnt\"><img style=\"width:276px; height:512px;\" src=\"images/CARD/72326_CalculationLVvolume.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The endocardium of the apical two- and four-chamber echocardiographic views in systole and diastole is traced manually. The digitized tracings are automatically calibrated and can be analyzed according to a number of algorithms. In this case, the computer has analyzed the orthogonal tracings according to the method of discs algorithm by dividing each image into twenty equal slices. Each slice is matched to its counterpart in the orthogonal view and each pair is extrapolated into a circular disc. This disc is stacked with the others forming a stack of coins, the volume of each contributing to a sum that closely approximates the volume of the chamber.</div><div id=\"graphicVersion\">Graphic 72326 Version 4.0</div></div></div>"},"72328":{"type":"graphic_diagnosticimage","displayName":"CT angiogram of infrarenal AAA","title":"CT angiogram of infrarenal abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT angiogram of infrarenal abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:277px; height:389px;\" src=\"images/SURG/72328_CT_angiogram_abdominal_aneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The appearance of a small infrarenal abdominal aortic aneurysm (AAA) by computed tomography (CT). This imaging technique can be used to determine if the patient is a candidate for endovascular aneurysm repair.</div><div id=\"graphicVersion\">Graphic 72328 Version 6.0</div></div></div>"},"72330":{"type":"graphic_picture","displayName":"Polyp colonoscopy PI","title":"Colonic polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic polyp</div><div class=\"cntnt\"><img style=\"width:194px; height:287px;\" src=\"images/PI/72330_Polyp_colonoscopy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Virtual colonoscopy shows a small polyp (arrow) in the transverse colon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 72330 Version 1.0</div></div></div>"},"72331":{"type":"graphic_figure","displayName":"TMLR improvement angina","title":"Improvement in angina is greater with transmyocardial laser revascularization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Improvement in angina is greater with transmyocardial laser revascularization</div><div class=\"cntnt\"><img style=\"width:436px; height:261px;\" src=\"images/CARD/72331_TMLR_improvement_angina.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 275 patients with NYHA class IV refractory angina who were randomized to transmyocardial laser revascularization (TMLR) or medical therapy (MT), improvement in angina at 3, 6, and 12 months was better with TMLR than MT (p &lt;0.001 for the comparison between TMLR and MT at all three points in time). Patients initially assigned to receive MT who met the criteria for treatment failure and subsequently underwent TMLR (crossover) also had a significant improvement in angina.</div><div class=\"graphic_reference\">Data from Allen KB, Dowling RD, Fudge TL, et al. N Engl J Med 1999; 341:1029.</div><div id=\"graphicVersion\">Graphic 72331 Version 2.0</div></div></div>"},"72334":{"type":"graphic_figure","displayName":"Exam for gynecomastia","title":"Examination for gynecomastia","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Examination for gynecomastia</div><div class=\"cntnt\"><img style=\"width:543px; height:539px;\" src=\"images/ENDO/72334_Exam_for_gynecomastia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physical examination method to distinguish gynecomastia, due to enlargement of the glandular tissue, from pseudogynecomastia, due to excessive adipose tissue. The thumb and forefinger are placed on opposite sides of the breast and slowly brought together towards the areolar-nipple complex. Gynecomastia is appreciated as a concentric, rubbery-to-firm disk of tissue, often mobile, located directly beneath the areolar area. Pseudogynecomastia presents no discrete mass, and other masses due to disorders such as cancer tend to be eccentrically positioned (insert).</div><div class=\"graphic_reference\">Adapted from: Braunstein GD. Gynecomastia. N Engl J Med 2007; 357:1229.</div><div id=\"graphicVersion\">Graphic 72334 Version 3.0</div></div></div>"},"72336":{"type":"graphic_picture","displayName":"Splenic marginal zone NHL","title":"Splenic marginal zone lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Splenic marginal zone lymphoma</div><div class=\"cntnt\"><img style=\"width:368px; height:287px;\" src=\"images/HEME/72336_Splenic_marginal_zone_NHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of the spleen shows follicles with expanded mantle and marginal zones, with areas of coalescence (arrows).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 72336 Version 1.0</div></div></div>"},"72339":{"type":"graphic_diagnosticimage","displayName":"Flock workers lung CT - Honeycombing","title":"Flock worker's lung CT - Honeycombing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flock worker's lung CT - Honeycombing</div><div class=\"cntnt\"><img style=\"width:221px; height:274px;\" src=\"images/PULM/72339_Flock_workers_lung_CT_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Supine CT of the chest reveals honeycombing, a feature characteristic of advanced fibrotic lung disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of David Kern, MD and Robert Crausman, MD.</div><div id=\"graphicVersion\">Graphic 72339 Version 5.0</div></div></div>"},"72340":{"type":"graphic_table","displayName":"Polygenic risk in JIA","title":"Polygenic risk in early-onsetÂ oligoarticular juvenile idiopathic arthritis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polygenic risk in early-onset&nbsp;oligoarticular juvenile idiopathic arthritis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Number</td> <td class=\"subtitle1\">Percent</td> <td class=\"subtitle1\">x<sup>2</sup></td> <td class=\"subtitle1\">p-value</td> <td class=\"subtitle1\">Cumulative odds ratio<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">DRB1*0801 study (n = 98)</td> </tr> <tr> <td class=\"indent1\">Female sex</td> <td>89</td> <td>90.8</td> <td>14.12</td> <td>&#60;0.001</td> <td>4.51</td> </tr> <tr> <td class=\"indent1\">Female + HLA-A2</td> <td>67</td> <td>68.4</td> <td>29.71</td> <td>&#60;0.001</td> <td>8.74</td> </tr> <tr> <td class=\"indent1\">Female + HLA-A2, DRB1*0801</td> <td>21</td> <td>21.4</td> <td>17.21</td> <td>&#60;0.001</td> <td>63.00</td> </tr> <tr> <td class=\"indent1\">Female + HLA-A2, DRB1*0801, DPB1*0201</td> <td>10</td> <td>10.2</td> <td>8.96</td> <td>&#60;0.010</td> <td>119.00</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">DRB1*1301 study (n = 102)</td> </tr> <tr> <td class=\"indent1\">Female sex</td> <td>93</td> <td>91.2</td> <td>14.44</td> <td>&#60;0.001</td> <td>4.55</td> </tr> <tr> <td class=\"indent1\">Female + HLA-A2</td> <td>74</td> <td>72.5</td> <td>7.28</td> <td>&#60;0.010</td> <td>5.55</td> </tr> <tr> <td class=\"indent1\">Female + HLA-A2, DRB1*1301</td> <td>21</td> <td>20.6</td> <td>9.78</td> <td>&#60;0.010</td> <td>10.50</td> </tr> <tr> <td class=\"indent1\">Female + HLA-A2, DRB1*1301, DPB1*0201</td> <td>13</td> <td>12.7</td> <td>13.21</td> <td>&#60;0.001</td> <td>52.00</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on homogenous population of 98 patients studied for DRB1*0801 and of 102 patients studied for DRB1*1301, from Cincinnati/Indianapolis area.<br />Â¶&nbsp;Calculated based on risk of 1.00 for individuals negative for all risk factors.<br />HLA: human leukocyte antigen, also called major histocompatibility complex (MHC); HLA-A: one of three major types of MHC class I cell surface receptors; HLA-DR and -DP: two types of MHC class II cell surface receptors; B1: beta-1.</div><div id=\"graphicVersion\">Graphic 72340 Version 8.0</div></div></div>"},"72341":{"type":"graphic_table","displayName":"Distribution of coronary artery for D-TGA","title":"Frequency distribution of the coronary patterns in transposition of the great arteries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency distribution of the coronary patterns in transposition of the great arteries</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Coronary pattern</td> <td class=\"subtitle1\">Percent of cases</td> </tr> <tr> <td>Usual</td> <td>66.9</td> </tr> <tr> <td>Circumflex from RCA</td> <td>16.1</td> </tr> <tr> <td>Single RCA</td> <td>3.9</td> </tr> <tr> <td>Single LCA</td> <td>1.7</td> </tr> <tr> <td>Inverted</td> <td>2.4</td> </tr> <tr> <td>Inverted circumflex/RCA</td> <td>4.2</td> </tr> <tr> <td>Intramural LCA</td> <td>2.1</td> </tr> <tr> <td>Intramural LAD</td> <td>0.1</td> </tr> <tr> <td>Intramural RCA</td> <td>1.0</td> </tr> <tr> <td>Other</td> <td>1.6</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=95993&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Distribution_of_coronary_artery_for_D-TGA.htm</title></head></div><div class=\"graphic_footnotes\">RCA: right coronary artery; LCA: left coronary artery; LAD: left anterior descending.</div><div class=\"graphic_reference\">Reproduced with permission from: Wernovsky G. Transposition of the great arteries. In: Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult, 7th ed, Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72341 Version 8.0</div></div></div>"},"72342":{"type":"graphic_picture","displayName":"Erythroderma in Sezary syndrome","title":"Erythroderma in SÃ©zary syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythroderma in SÃ©zary syndrome</div><div class=\"cntnt\"><img style=\"width:278px; height:600px;\" src=\"images/HEME/72342_ErythrodermaSezary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythroderma, defined as erythema covering at least 80 percent of body surface area, is present in all patients with SÃ©zary syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright Â© 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72342 Version 8.0</div></div></div>"},"72343":{"type":"graphic_table","displayName":"PCP risk factors","title":"Risk factors for <EM>Pneumocystis</EM> pneumonia in patients without HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for <EM>Pneumocystis</EM> pneumonia in patients without HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Glucocorticoid use in patients with another cause of immunocompromise</td> </tr> <tr> <td class=\"sublist1_start\">Other immunosuppressive drugs such as:</td> </tr> <tr> <td class=\"sublist1\">Antirejection medications</td> </tr> <tr> <td class=\"sublist1\">Purine analogs (eg, fludarabine)</td> </tr> <tr> <td class=\"sublist1\">Tumor necrosis factor-alpha inhibitors (eg, infliximab)</td> </tr> <tr> <td class=\"sublist1\">Temozolomide (especially when used in combination with radiation)</td> </tr> <tr> <td class=\"sublist1\">Alemtuzumab</td> </tr> <tr> <td class=\"sublist1\">Ibrutinib</td> </tr> <tr> <td class=\"sublist1\">Idelalisib</td> </tr> <tr> <td>Defects in cell-mediated immunity</td> </tr> <tr> <td>Cancer (particularly hematologic malignancy)</td> </tr> <tr> <td>Hematopoietic cell transplantation (HCT; especially allogeneic HCT)</td> </tr> <tr> <td>Solid organ transplantation</td> </tr> <tr> <td>Treatment for rejection</td> </tr> <tr> <td>Treatment for inflammatory conditions (eg, granulomatosis with polyangiitis [Wegener's])</td> </tr> <tr> <td>Severe malnutrition (especially protein malnutrition)</td> </tr> <tr> <td>Primary immunodeficiencies (particularly severe combined immunodeficiency)</td> </tr> <tr> <td>Prematurity</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72343 Version 6.0</div></div></div>"},"72344":{"type":"graphic_figure","displayName":"Brachial fem artery","title":"Brachial and femoral artery recordings from an adult with coarctation of aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brachial and femoral artery recordings from an adult with coarctation of aorta</div><div class=\"cntnt\"><img style=\"width:288px; height:298px;\" src=\"images/CARD/72344_Brachial_fem_artery.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracings of the pulse pressure of the brachial and femoral arteries demonstrate the delay in the peak systolic pressure of the femoral artery compared with the peak pulse pressure in the brachial artery.</div><div class=\"graphic_reference\">Crawford MH. Inspection and palpation of venous and arterial pulses. In: Examination of the Heart. Part 2. American Heart Association; New York 1990. Reprinted with permission. Copyright Â© 1990 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 72344 Version 13.0</div></div></div>"},"72345":{"type":"graphic_diagnosticimage","displayName":"CT rupt corpus luteum cyst","title":"Adnexal mass","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Adnexal mass</div><div class=\"cntnt\"><img style=\"width:504px; height:361px;\" src=\"images/OBGYN/72345_CT_rupt_corpus_luteum_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography. Arrow indicates poorly defined adnexal mass, which at exploration was ruptured corpus luteum cyst and clot.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 72345 Version 2.0</div></div></div>"},"72347":{"type":"graphic_picture","displayName":"P6 acupressure point PI","title":"P6 acupressure point","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">P6 acupressure point</div><div class=\"cntnt\"><img style=\"width:504px; height:376px;\" src=\"images/PI/72347_P6_acupressure_point_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure or massage at the P6 acupressure point might help relieve motion sickness. The point is found three finger-widths away from the wrist, roughly in the middle of the forearm. The spot is shown in this picture by the tip of the pen.</div><div class=\"graphic_reference\">Courtesy of Judith A Smith, Pharm D, BCOP, FCCP, FISOPP.</div><div id=\"graphicVersion\">Graphic 72347 Version 2.0</div></div></div>"},"72349":{"type":"graphic_figure","displayName":"Intest transplant adult","title":"Indication for intestinal transplantation in adults","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Indication for intestinal transplantation in adults</div><div class=\"cntnt\"><img style=\"width:550px; height:326px;\" src=\"images/GAST/72349_Intest_transplant_adult.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Data from: the Intestinal Transplant Registry, Final Summary 2003. Reproduced with permission from David Grant, MD. http://www.intestinaltransplant.org.</div><div id=\"graphicVersion\">Graphic 72349 Version 1.0</div></div></div>"},"72350":{"type":"graphic_figure","displayName":"Dose response PEG rHuMGDF B","title":"Response to thrombopoietin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Response to thrombopoietin</div><div class=\"cntnt\"><img style=\"width:370px; height:370px;\" src=\"images/HEME/72350_DoseresponsePEGrHuMGDFB.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fold increase in platelet count on day 14 is shown here versus the logarithm of the administered dose of thrombopoietin. The platelet counts returned to baseline values upon discontinuation of therapy.</div><div class=\"graphic_reference\">Data from Harker, LA, Marzec, UM, Hunt, P, et al, Blood 1996; 88:511.</div><div id=\"graphicVersion\">Graphic 72350 Version 2.0</div></div></div>"},"72351":{"type":"graphic_figure","displayName":"Seasonal variation VTE","title":"Seasonal variation in venous thromboembolism","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">Seasonal variation in venous thromboembolism</div><div class=\"cntnt\"><img style=\"width:559px; height:433px;\" src=\"images/HEME/72351_Seasonal_variation_VTE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depicted are the monthly percentage variations in French hospital admissions for deep vein thrombosis and pulmonary embolism. Hospital admissions for venous thromboembolism were most frequent in the winter and least frequent in the summer.</div><div class=\"graphic_reference\">Reproduced with permission from: Boulay, F, Berthier, F, Schoukroun, G, et al. Seasonal variations in hospital admission for deep venous thrombosis and pulmonary embolism: analysis of discharge data. BMJ 2001; 323:601. Copyright &#169; 2001, BMJ.</div><div id=\"graphicVersion\">Graphic 72351 Version 1.0</div></div></div>"},"72353":{"type":"graphic_picture","displayName":"Skin biopsy Stills dermis","title":"Skin biopsy of adult Still's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin biopsy of adult Still's disease</div><div class=\"cntnt\"><img style=\"width:367px; height:245px;\" src=\"images/RHEUM/72353_Skin_biopsy_Stills_dermis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this micrograph of a biopsy specimen from the involved skin from a patient with adult Still's disease, perivascular infiltration of inflammatory cells and edema separating collagen bundles in the dermis is apparent.</div><div class=\"graphic_reference\">Courtesy of Lisa Mandl, MD.</div><div id=\"graphicVersion\">Graphic 72353 Version 1.0</div></div></div>"},"72354":{"type":"graphic_table","displayName":"PARP inhibitors clinical development","title":"A summary of representative PARP inhibitors in clinical development by route of administration and current clinical status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A summary of representative PARP inhibitors in clinical development by route of administration and current clinical status</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Company</td> <td class=\"subtitle1\">Route of administration</td> <td class=\"subtitle1\">Clinical status</td> </tr> <tr> <td>Olaparib (AZD2281)</td> <td>AstraZeneca/KuDOS</td> <td>Oral</td> <td>Phase I, II, and III</td> </tr> <tr> <td>Veliparib (ABT-888)</td> <td>Abbott</td> <td>Oral</td> <td>Phase I, II, and III</td> </tr> <tr> <td>Rucaparib (AG014699)</td> <td>Clovis</td> <td>Oral</td> <td>Phase II</td> </tr> <tr> <td>Niraparib (MK4827)</td> <td>Tesaro</td> <td>Oral</td> <td>Phase III</td> </tr> <tr> <td>INO-1001</td> <td>Inotek</td> <td>IV</td> <td>Phase I</td> </tr> <tr> <td>Talazoparib (BMN 673)</td> <td>BioMarin Pharmaceutical</td> <td>Oral</td> <td>Phase III</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; PARP: Poly(ADP-ribose) polymerase.</div><div class=\"graphic_reference\">Adapted from: Anders C, Winer E, Ford J, et al. Poly(ADP-Ribose) Polymerase Inhibition: \"Targeted\" Therapy for Triple-Negative Breast Cancer. Clin Cancer Res 2010; 16:4702.</div><div id=\"graphicVersion\">Graphic 72354 Version 4.0</div></div></div>"},"72355":{"type":"graphic_figure","displayName":"Wound healing time line","title":"Wound healing time line","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Wound healing time line</div><div class=\"cntnt\"><img style=\"width:598px; height:332px;\" src=\"images/SURG/72355_Wound_healing_time_line_PR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wound healing time line with dominant cell types and major physiologic events.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery Scientific Principles and Practice, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72355 Version 3.0</div></div></div>"},"72358":{"type":"graphic_figure","displayName":"Peritonsillar space anatomy","title":"Anatomy of the palatine tonsil","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Anatomy of the palatine tonsil</div><div class=\"cntnt\"><img style=\"width:520px; height:601px;\" src=\"images/EM/72358_Peritonsil_space_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tonsils are positioned laterally in the pharyngeal wall between the palatoglossal arch and palatopharyngeal arch (the anterior and posterior tonsillar pillars), which merge superiorly to become the soft palate. Figure A shows a sagitattal section through the oropharynx. Figure B shows a coronal section through the tonsillar region from medial (palatoglossus muscle) to lateral (palatopharyngeus muscle).</div><div id=\"graphicVersion\">Graphic 72358 Version 5.0</div></div></div>"},"72359":{"type":"graphic_table","displayName":"Laxative herbal ingredients","title":"Laxative herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laxative herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Drug</td>\n\n      <td class=\"subtitle1\">Effect</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aloes</td>\n\n      <td>Anthraquinone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cascara</td>\n\n      <td>Anthraquinone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Eyebright</td>\n\n      <td>Iridoids, in vivo</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Frangula</td>\n\n      <td>Anthraquinone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Horehound, white</td>\n\n      <td>Large doses</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ispaghula</td>\n\n      <td>Bulk laxative</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Plantain</td>\n\n      <td>Iridoid, in vivo (much less than senna)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rhubarb</td>\n\n      <td>Anthraquinone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Senna</td>\n\n      <td>Anthraquinone constituents</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Yellow dock</td>\n\n      <td>Anthraquinone constituents</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. The Pharmaceutical Press 1996, p. 277.</div><div id=\"graphicVersion\">Graphic 72359 Version 2.0</div></div></div>"},"72361":{"type":"graphic_picture","displayName":"Full mask ventilation","title":"Full mask ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Full mask ventilation</div><div class=\"cntnt\"><img style=\"width:316px; height:158px;\" src=\"images/PULM/72361_Full_mask_ventilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A full mask (covering the nose and mouth) as used to deliver nocturnal assisted ventilation.</div><div class=\"graphic_reference\">Courtesy of Peter C Gay, MD.</div><div id=\"graphicVersion\">Graphic 72361 Version 2.0</div></div></div>"},"72362":{"type":"graphic_table","displayName":"Metered dose inhaler technique without spacer or chamber PI","title":"Technique for use of a metered dose inhaler (MDI) without a spacer or chamber","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of a metered dose inhaler (MDI) without a spacer or chamber</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Remove the cover of the mouthpiece</td> </tr> <tr> <td>Prime your inhaler if this is the first time you are using it, if you have not used it for several days, or if you have dropped it. Priming a metered dose inhaler usually involves shaking it and spraying it into the air (away from your face) up to 4 times. See the information that came with your inhaler for exact instructions.</td> </tr> <tr> <td>Shake MDI canister vigorously for 5 seconds.</td> </tr> <tr> <td>Hold the MDI upright with your index finger on the top of the canister and your thumb supporting the bottom of the inhaler.</td> </tr> <tr> <td>Breathe out normally.</td> </tr> <tr> <td>Put the mouthpiece between your teeth and close your lips around mouthpiece or position mouthpiece about 4 cm (about the width of 2 fingers) from your mouth.</td> </tr> <tr> <td>Keep your tongue away from the opening of the mouthpiece.</td> </tr> <tr> <td>Press down the top of the canister with the index finger to release the medicine.</td> </tr> <tr> <td>At the same time as the canister is pressed, breathe in deeply and slowly through your mouth until your lungs are completely full. This should take 4 to 6 seconds.</td> </tr> <tr> <td>Hold the medicine in your lungs for as long as comfortable (about 5 to 10 seconds) before breathing out.</td> </tr> <tr> <td>If you need a second puff, wait about 15 to 30 seconds between puffs. Shake the canister again before the next puff.</td> </tr> <tr> <td>When finished, put the mouthpiece cover back on.</td> </tr> <tr> <td>If your inhaler contains a steroid medicine (sometimes called a \"glucocorticoid\" or \"corticosteroid\"), rinse your mouth and gargle with water after you use it. Then spit out the water. Do not swallow it.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These instructions do&nbsp;<STRONG>not</STRONG> apply to dry powder or soft mist inhalers. Cleaning instructions are provided separately.<br />More detailed information about individual medicines can be found at <A href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A>.</div><div class=\"graphic_footnotes\">MDI: metered dose inhaler.</div><div id=\"graphicVersion\">Graphic 72362 Version 11.0</div></div></div>"},"72363":{"type":"graphic_table","displayName":"Causes of a dry tap","title":"Differential diagnosis of a dry tap","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of a dry tap</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Cause</td>\n<td class=\"subtitle1\">Setting</td>\n</tr>\n<tr>\n<td>Obesity</td>\n<td>Particularly likely when leg is large and suspected effusion is small</td>\n</tr>\n<tr>\n<td>Thick medial trianglular fat or medial plica</td>\n<td>Likely when lateral approach is successful after medial approach fails</td>\n</tr>\n<tr>\n<td>Lipoma arborescens or gelatinous \"pseudoeffusion\"</td>\n<td>Likely in particularly large and chronic inflammatory effusions</td>\n</tr>\n<tr>\n<td>Obstruction of needle lumen by particular matter</td>\n<td>Likely in rheumatoid effusion</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72363 Version 1.0</div></div></div>"},"72366":{"type":"graphic_figure","displayName":"Diagram cervical effacement","title":"Diagram of cervical effacement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of cervical effacement</div><div class=\"cntnt\"><img style=\"width:364px; height:278px;\" src=\"images/OBGYN/72366_Diagram_cervical_effacement.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Progression of cervical effacement at the internal cervical os from completely uneffaced (T) to completely effaced (U).</div><div class=\"graphic_reference\">Adapted from: Zilianti M, Azuaga A, Calderon F, et al. Monitoring the effacement of the uterine cervix by transperineal sonography: a new perspective. J Ultrasound Med 1995; 14:719.</div><div id=\"graphicVersion\">Graphic 72366 Version 3.0</div></div></div>"},"72367":{"type":"graphic_picture","displayName":"Sinonasal undiff CA Light","title":"Sinonasal undifferentiated carcinoma (SNUC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinonasal undifferentiated carcinoma (SNUC)</div><div class=\"cntnt\"><img style=\"width:395px; height:258px;\" src=\"images/ONC/72367_Sinonasal_undiff_CA_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph demonstrating sheets of large pleomorphic tumor cells with a high mitotic rate and extensive necrosis.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 72367 Version 1.0</div></div></div>"},"72368":{"type":"graphic_figure","displayName":"Teen births US","title":"Birth rates for teenagers aged 15 to 19 years, by age: United States, 1960 to 2012","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Birth rates for teenagers aged 15 to 19 years, by age: United States, 1960 to 2012</div><div class=\"cntnt\"><img style=\"width:558px; height:426px;\" src=\"images/PEDS/72368_Teen_births_US_2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Martin JA, Hamilton BE, Osterman MJ, et al. Births: Final data for 2012. Natl Vital Stat Rep 2013; 62:1. Available at: <a href=\"http://www.cdc.gov/nchs/data/nvsr/nvsr62/nvsr62_09.pdf\" target=\"_blank\">www.cdc.gov/nchs/data/nvsr/nvsr62/nvsr62_09.pdf</a> (Accessed on February 12, 2014).</div><div id=\"graphicVersion\">Graphic 72368 Version 6.0</div></div></div>"},"72369":{"type":"graphic_picture","displayName":"Vitiligo segmental","title":"Segmental vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Segmental vitiligo</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PC/72369_Vitiligosegmental.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental vitiligo: patches of depigmentation on the anterior trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright Â©2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72369 Version 3.0</div></div></div>"},"72372":{"type":"graphic_table","displayName":"Soy alternatives","title":"Nutrients to be replaced on a soy avoidance diet and alternative dietary sources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutrients to be replaced on a soy avoidance diet and alternative dietary sources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nutrients in soy </td> <td class=\"subtitle1\">Alternative dietary sources </td> </tr> <tr> <td>Protein</td> <td>Meat, fish, poultry, egg, milk, peanut, other legumes, tree nuts, seeds</td> </tr> <tr> <td>Thiamine</td> <td>Liver, pork, other meats, sunflower seeds, enriched and whole grain products, nuts and other legumes</td> </tr> <tr> <td>Riboflavin</td> <td>Milk, dark green leafy vegetables, enriched and whole grains</td> </tr> <tr> <td>Pyridoxine (vitamin B6)</td> <td>Whole grains, seeds, meat, vegetables</td> </tr> <tr> <td>Folic acid</td> <td>Enriched and whole grain products, beef liver, green leafy vegetables, other legumes, seeds, orange juice</td> </tr> <tr> <td>Calcium</td> <td>Milk and milk products, calcium-fortified juice and calcium-enriched alternative \"milk\" beverages (rice, oat, potato, hemp, almond)</td> </tr> <tr> <td>Phosphorus</td> <td>Milk, meat, fish, poultry</td> </tr> <tr> <td>Magnesium</td> <td>Nuts, fruits, vegetables, whole grains</td> </tr> <tr> <td>Iron</td> <td> <p>Heme iron - Meat, fish, shellfish, poultry</p> <p>Non-heme irons -&nbsp;Iron-fortified enriched and whole grain products, other legumes, and dried fruits</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72372 Version 4.0</div></div></div>"},"72373":{"type":"graphic_table","displayName":"Symptoms of diabetic neuropathy","title":"Clinical features of diabetic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of diabetic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Characteristic</td>\n\n      <td class=\"subtitle1\">Favors neuropathy</td>\n\n      <td class=\"subtitle1\">Favors vascular disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Site of pain</td>\n\n      <td>Feet more than calves</td>\n\n      <td>Calves, thighs, and buttocks more than feet</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Quality of pain</td>\n\n      <td>Sharp, superficial, burning, tingling</td>\n\n      <td>Deep ache</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Present at rest</td>\n\n      <td>Common</td>\n\n      <td>Rare</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Effect of walking</td>\n\n      <td>Pain improves</td>\n\n      <td>Pain made worse</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pain worse in bed</td>\n\n      <td>Yes</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Preceded by recent change in glycemic control</td>\n\n      <td>Sometimes</td>\n\n      <td>No</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Clinical features to help distinguish the pain in diabetic neuropathy from that with peripheral vascular disease and intermittent claudication.</div><div id=\"graphicVersion\">Graphic 72373 Version 1.0</div></div></div>"},"72376":{"type":"graphic_picture","displayName":"Juvenile colonic polyp Light","title":"Juvenile colonic polyp","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Juvenile colonic polyp</div><div class=\"cntnt\"><img style=\"width:259px; height:405px;\" src=\"images/GAST/72376_Juvenile_colonic_polyp_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a juvenile colonic polyp shows dilated cystic crypts and abundant, mildly inflamed lamina propria.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 72376 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"72380":{"type":"graphic_figure","displayName":"Positive SAECG following myocardial infarction","title":"Late potentials on the signal-averaged ECG suggesting possible substrate for reentrant ventricular arrhythmias","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Late potentials on the signal-averaged ECG suggesting possible substrate for reentrant ventricular arrhythmias</div><div class=\"cntnt\"><img style=\"width:471px; height:316px;\" src=\"images/CARD/72380_Positive_SAECG_in_CHD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Signal-averaged electrocardiogram (SAECG) showing a QRS complex after a first and second myocardial infarction (MI) in the same patient. Left panel: After a first MI, no late potentials are present on the SAECG. Right panel: After a second MI, late potentials are seen as low amplitude signals at the end of the QRS complex (arrow). The filtered QRS duration is increased to &gt;120 msec.</div><div id=\"graphicVersion\">Graphic 72380 Version 2.0</div></div></div>"},"72381":{"type":"graphic_figure","displayName":"Anatomy of hand fractures - Phalanges and metacarpals","title":"Anatomy of hand fractures - Phalanges and metacarpals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of hand fractures - Phalanges and metacarpals</div><div class=\"cntnt\"><img style=\"width:441px; height:526px;\" src=\"images/SURG/72381_Anat_hand_fx_phalanges.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A precise anatomical description of the exact location of a fracture aids in localizing the fracture. The anatomical sites for phalanges and metacarpals include head, neck, shaft, and base. Tuft fractures refer specifically to fractures involving the head of the distal phalanx and intra-articular fractures refer to fractures involving the joint.</div><div id=\"graphicVersion\">Graphic 72381 Version 2.0</div></div></div>"},"72383":{"type":"graphic_picture","displayName":"Choi laryngoscope","title":"Choi (double angle) laryngoscope blade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choi (double angle) laryngoscope blade</div><div class=\"cntnt\"><img style=\"width:396px; height:282px;\" src=\"images/EM/72383_Choilaryngoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72383 Version 10.0</div></div></div>"},"72385":{"type":"graphic_picture","displayName":"Fusarium macroconidia","title":"<EM>Fusarium</EM> macroconidia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\"><EM>Fusarium</EM> macroconidia</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/ID/72385_Fusarium_conidia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Fusarium oxysporum</EM>. Macroconidia with distinct foot cells. Phase contrast microscopy, 630X.</div><div class=\"graphic_reference\">Courtesy of www.doctorfungus.org Â© 2006. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 72385 Version 6.0</div></div></div>"},"72386":{"type":"graphic_picture","displayName":"Mycobacterium fortuitum skin infection","title":"<EM>Mycobacterium fortuitum</EM> skin infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Mycobacterium fortuitum</EM> skin infection</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/ID/72386_M_fortuitum_skin_infection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ulceration and surrounding cellulitis of the neck caused by <EM>M. fortuitum</EM>.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Lippincott Williams &amp; Wilkins, Baltimore 1995. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72386 Version 11.0</div></div></div>"},"72389":{"type":"graphic_table","displayName":"Vaginal lubricants","title":"Vaginal moisturizers and lubricants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vaginal moisturizers and lubricants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Product (manufacturer)</td> <td class=\"subtitle1\">Ingredients</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Moisturizers</td> </tr> <tr> <td class=\"indent1\">Replens&#174;</td> <td>Water, carbomer, polycarbophil, paraffin, hydrogenated palm oil, glyceride, sorbic acid, and sodium hydroxide</td> <td>Should be used 3 times weekly</td> </tr> <tr> <td class=\"indent1\">Me Again&#8482;</td> <td>Water, carbomer, aloe, citric acid, chlorhexidine deglutinate, sodium benzoate, potassium sorbate, diazolidinyl urea, and sorbic acid</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Vagisil&#174; Feminine Moisturizer</td> <td>Water, glycerin, propylene glycol, poloxamer 407, methylparaben, polyquaternium-32, propylparaben, chamomile, and aloe</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Feminease&#174;</td> <td>Water, mineral oil, glycerin, yerba santa, cetyl alcohol, and methyl paraben</td> <td>Yerba santa (Eriodictyon spp), a plant native to the Pacific Northwest, is used as a moisturizer in place of aloe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">K-Y&#174; SILK-E&#174;</td> <td>Water, propylene glycol, sorbitol, polysorbate 60, hydroxyethylcellulose, benzoic acid, methylparaben, tocopherol, and aloe</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lubricants</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Water-based</td> </tr> <tr> <td class=\"indent2\">Slippery Stuff&#174;</td> <td>Water, polyoxyethylene, methylparaben, propylene glycol, isopropynol</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Astroglide&#174;</td> <td>Water, glycerin, methylparaben, propylparaben, polypropylene glycol, polyquaternium, hydroxyethylcellulose, and sodium benzoate</td> <td>Also sold in a glycerin-free and paraben-free formulation</td> </tr> <tr> <td class=\"indent2\">K-Y&#174; Jelly</td> <td>Water, glycerin, hydroxyethylcellulose, parabens, and chlorhexidine</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Pre-Seed&#174;</td> <td>Water, hydroxyethylcellulose, arabinogalactan, paraben, and Pluronic copolymers</td> <td>Promoted to women and their partners who are trying to conceive</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Silicone-based</td> </tr> <tr> <td class=\"indent2\">ID&#174; Millennium</td> <td>Cyclomethicone, dimethicone, and dimethiconol</td> <td>Less drying than other lubricants</td> </tr> <tr> <td class=\"indent2\">Pjur&#174; Eros</td> <td>Cyclopentasiloxane, dimethicone, and dimethiconol</td> <td>Compatible with a condom</td> </tr> <tr> <td class=\"indent2\">Pink&#8482;</td> <td>Dimethicone, vitamin E, aloe vera, dimethiconol, and cyclomethicone</td> <td>Compatible with a condom</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Oil-based</td> </tr> <tr> <td class=\"indent2\">El&#233;gance Women's Lubricant</td> <td>Natural oils</td> <td>Does not contain alcohol, glycerin, or parabens; is <strong>not</strong> compatible with a condom</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Marshall DD, Iglesia C. A guide to lotions and potions for treating vaginal atrophy. OBG Management 2009; 21:29. Copyright &copy; 2009 Dowden Health Media.</div><div id=\"graphicVersion\">Graphic 72389 Version 18.0</div></div></div>"},"72393":{"type":"graphic_figure","displayName":"Pap test smear","title":"Conventional Pap smear","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Conventional Pap smear</div><div class=\"cntnt\"><img style=\"width:460px; height:248px;\" src=\"images/OBGYN/72393_Pap_test_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Obtaining endocervical portion of Pap smear. B) Smearing specimen on slide.</div><div class=\"graphic_reference\">Reproduced with permission from: Beckmann CRB, Ling FW, Laube DW, et al. Obstetrics and Gynecology, 4th Edition. Baltimore: Lippincott Williams &amp; Wilkins, 2002. Copyright Â©2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72393 Version 2.0</div></div></div>"},"72394":{"type":"graphic_table","displayName":"Causes of hemolysis","title":"Common causes of intravascular and extravascular hemolysis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of intravascular and extravascular hemolysis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Extravascular destruction of red blood cells</td> </tr> <tr> <td class=\"subtitle2_single\">Intrinsic red blood cell defects</td> </tr> <tr> <td class=\"indent1\">Enzyme deficiencies (eg, deficiencies of&nbsp;G6PD, pyruvate kinase, glucose-phosphate isomerase, 5' nucleotidase)</td> </tr> <tr> <td class=\"indent1\">Hemoglobinopathies (eg, sickle cell disease, thalassemias, unstable hemoglobins)</td> </tr> <tr> <td class=\"indent1\">Membrane defects (eg, hereditary spherocytosis, elliptocytosis)</td> </tr> <tr> <td class=\"subtitle2_single\">Extrinsic red blood cell defects</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Hypersplenism</td> </tr> <tr> <td class=\"indent1\">Infections (eg, <em>Bartonella</em>, <em>Babesia</em>, malaria)</td> </tr> <tr> <td class=\"indent1\">Oxidant agents (eg, dapsone, nitrites, aniline dyes)</td> </tr> <tr> <td class=\"indent1\">Other agents (eg, lead, copper, snake and spider bites)</td> </tr> <tr> <td class=\"indent1\">Large granular lymphocyte leukemia</td> </tr> <tr> <td class=\"indent1\">Autoimmune hemolytic anemia (warm- or cold-reacting, drugs)</td> </tr> <tr> <td class=\"indent1\">Intravenous immune globulin infusion</td> </tr> <tr> <td class=\"subtitle1_single\">Intravascular destruction of red blood cells</td> </tr> <tr> <td class=\"indent1\">Microangiopathic hemolytic anemia (eg, TTP, HUS, aortic stenosis, prosthetic valve leak)</td> </tr> <tr> <td class=\"indent1\">Transfusion reactions (eg, ABO incompatibility)</td> </tr> <tr> <td class=\"indent1\">Infection (eg, clostridial sepsis, severe malaria)</td> </tr> <tr> <td class=\"indent1\">Paroxysmal cold hemoglobinuria; cold agglutinin disease (on occasion)</td> </tr> <tr> <td class=\"indent1\">Paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"indent1\">Following intravenous infusion of Rho(D) immune globulin</td> </tr> <tr> <td class=\"indent1\">Following intravenous infusion with hypotonic solutions</td> </tr> <tr> <td class=\"indent1\">Snake bites</td> </tr> <tr> <td class=\"indent1\">Exposure to compounds with high oxidant potential (eg, copper poisoning, Wilson disease)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate dehydrogenase; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome.</div><div id=\"graphicVersion\">Graphic 72394 Version 14.0</div></div></div>"},"72396":{"type":"graphic_picture","displayName":"Tinea versicolor back","title":"Tinea versicolor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea versicolor</div><div class=\"cntnt\"><img style=\"width:396px; height:397px;\" src=\"images/PC/72396_Tinea_versicolor_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tinea versicolor. Hypopigmented macules and patches are present on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72396 Version 2.0</div></div></div>"},"72398":{"type":"graphic_waveform","displayName":"EP study tracings preablation mapping WPW","title":"Intracardiac and surface electrocardiogram (ECG) recordings during electrophysiologic (EP) study in Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface electrocardiogram (ECG) recordings during electrophysiologic (EP) study in Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><img style=\"width:589px; height:419px;\" src=\"images/CARD/72398_PreablationmappingWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are five surface ECG leads (I, aVF, V1, V3, V6) and intracardiac recordings from the high right atrium (HRA), lateral mitral annulus (HBE1-2 and HBE3-4), coronary sinus (proximal to distal, CS9-10, CS7-8, CS5-6, CS3-4, and CS1-2), and the right ventricular apex (RVA3-4). During the diagnostic electrophysiology study, orthodromic atrioventricular reentrant tachycardia was induced. Recordings from the CS demonstrated that the earliest site of ventricular activation was at CS7-8, indicating a left lateral location of the accessory pathway (arrow). The mapping catheter (HBE1-2,3-4) was advanced through a patent foramen ovale to the lateral mitral annulus. Activation mapping was used to select the ablation site; during sinus rhythm, the ablation catheter was maneuvered to the site along the mitral annulus, which recorded earliest ventricular activity (HBE1-2) (ie, the atrial [A] and ventricular [V] electrograms recorded from the ablation catheter tip were continuous and the local ventricular activity preceded the onset of the delta wave on the surface ECG).</div><div id=\"graphicVersion\">Graphic 72398 Version 5.0</div></div></div>"},"72399":{"type":"graphic_table","displayName":"Treatable infectious causes of myocarditis","title":"Treatable infectious causes of myocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatable infectious causes of myocarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cytomegalovirus infection</td> </tr> <tr> <td>Lyme carditis (Borrelia)</td> </tr> <tr> <td>Mycoplasma infection</td> </tr> <tr> <td>Psittacosis</td> </tr> <tr> <td>Legionnaire's disease</td> </tr> <tr> <td>Salmonella/Shigella infection</td> </tr> <tr> <td>Brucellosis</td> </tr> <tr> <td>Leptospirosis</td> </tr> <tr> <td>Rickettsial infection</td> </tr> <tr> <td>Candidiasis</td> </tr> <tr> <td>Coccidioidomycosis</td> </tr> <tr> <td>Cryptococcosis</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Trichinosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72399 Version 3.0</div></div></div>"},"72401":{"type":"graphic_table","displayName":"Grading system SVC synd","title":"Proposed grading system for superior vena cava syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed grading system for superior vena cava syndrome</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Grade\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Category\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Estimated incidence, percent\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Definition*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>0</td>\r\n  \r\n   <td>Asymptomatic</td>\r\n  \r\n   <td>10</td>\r\n  \r\n   <td>Radiographic superior vena cava obstruction in the absence of symptoms</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>1</td>\r\n  \r\n   <td>Mild</td>\r\n  \r\n   <td>25</td>\r\n  \r\n   <td>Edema in head or neck (vascular distention), cyanosis, plethora</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>2</td>\r\n  \r\n   <td>Moderate</td>\r\n  \r\n   <td>50</td>\r\n  \r\n   <td>Edema in head or neck with functional impairment (mild dysphagia, cough, mild or moderate impairment of head, jaw or eyelid movements, visual disturbances caused by ocular edema)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>3</td>\r\n  \r\n   <td>Severe</td>\r\n  \r\n   <td>10</td>\r\n  \r\n   <td>Mild or moderate cerebral edema (headache, dizziness) or mild/moderate laryngeal edema or diminished cardiac reserve (syncope after bending)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>4</td>\r\n  \r\n   <td>Life-threatening</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>Significant cerebral edema (confusion, obtundation) or significant laryngeal edema (stridor) or significant hemodynamic compromise (syncope without precipitating factors, hypotension, renal insufficiency)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>5</td>\r\n  \r\n   <td>Fatal</td>\r\n  \r\n   <td>&#60;1</td>\r\n  \r\n   <td>Death</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">8/27/2008--Requested permission (JD). 9/15/2008--Permission granted; figure to Terrence, invoice to Susan (JD). 9/11/2009--Renewal granted via Rightslink (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46325&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Grading_system_SVC_synd.htm</title></head></div><div class=\"graphic_footnotes\">* Each sign or symptom must be thought due to superior vena cava obstruction and the effects of cerebral or laryngeal edema or effects on cardiac function. Symptoms caused by other factors (eg, vocal cord paralysis, compromise of the tracheobronchial tree, or heart as a result of mass effect) should not be considered as they are due to mass effect on other organs and not superior vena cava obstruction.</div><div class=\"graphic_reference\">Reproduced with permission from: Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome-a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3:811. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72401 Version 7.0</div></div></div>"},"72402":{"type":"graphic_picture","displayName":"Proton gantry system","title":"The proton gantry system at the MGH northeast proton therapy center (MGH-NPTC)","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">The proton gantry system at the MGH northeast proton therapy center (MGH-NPTC)</div><div class=\"cntnt\"><img style=\"width:468px; height:338px;\" src=\"images/ONC/72402_Proton_gantry_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An isocentric gantry with a mobile proton beam source is used in conjunction with a robotic patient positioning treatment couch. The robotic unit has six degrees of freedom, three linear and three rotational. The patient is positioned to place the target lesion at the center of beam isocenter.</div><div class=\"graphic_reference\">Courtesy of Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 72402 Version 2.0</div></div></div>"},"72404":{"type":"graphic_picture","displayName":"Immunohistology skin Alport","title":"Immunohistological analysis of the distribution of the Î±5(IV) collagen chain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunohistological analysis of the distribution of the Î±5(IV) collagen chain</div><div class=\"cntnt\"><img style=\"width:446px; height:300px;\" src=\"images/PEDS/72404_Immunohistology_skin_Alport.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The analysis was carried out in the skin of (<strong>A</strong>) controls, (<strong>B</strong>) male and (<strong>C</strong>) female patients with X-linked Alport syndrome, and (<strong>D</strong>) patients with autosomal recessive Alport syndrome. The Î±5(IV) chain is (<strong>A</strong>) present in the epidermal basement membrane (arrow) of the skin of controls, but is (<strong>B</strong>) absent from the skin basement membrane (arrow) of the male patient with X-linked Alport syndrome. (<strong>C</strong>) Segmental labeling (single arrow) is seen in the X-linked female patient. Nonspecific labeling of the keratin layer is indicated by a double arrow. (<strong>D</strong>) Normal staining patterns of the epidermal basement membrane (single arrow) are observed in autosomal recessive Alport syndrome. Nonspecific labeling of the keratin layer is indicated by a double arrow.</div><div class=\"graphic_reference\">Reprinted with permission from: Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008; 1:24. Copyright Â©2008 Macmillan Publishers Ltd.</div><div id=\"graphicVersion\">Graphic 72404 Version 3.0</div></div></div>"},"72405":{"type":"graphic_table","displayName":"Oral and systemic health","title":"Controversial associations between oral and systemic health","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Controversial associations between oral and systemic health</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Association </td> <td class=\"subtitle1\">Background </td> <td class=\"subtitle1\">Current status/advice for patients </td> </tr> <tr> <td>Dental amalgam (mercury) and systemic disorders</td> <td>Anecdotes have implicated the mercury in dental amalgam in many systemic illnesses. No data support other than an occasional allergy. Environmental disposal of scrap amalgam is the main issue in trying to reduce its use.</td> <td>Dental amalgam is safe. Removal of mercury-containing fillings should not be done routinely.</td> </tr> <tr> <td>Systemic fluoride and systemic disorder</td> <td>Antifluoridationists contend fluoride causes cancer and other ailments. No data support this contention, but voluminous irrefutable data confirm its anticaries benefit.</td> <td>Fluoride remains the single most important anticaries tool available. Today, overuse of fluoride is possible, causing fluorosis, so prescribing needs to follow guidelines.</td> </tr> <tr> <td>Toxicity of resins and hormonal interaction</td> <td>Composite resins are used for sealants and tooth-colored fillings. Some chemical components have been suggested as toxic or hormonal analogues. No human or animal studies support these claims, and only trace amounts leak from resins.</td> <td>Resin restorations and dental sealants remain safe for children. Bisphenol-A (BPA)-free sealants are available.</td> </tr> <tr> <td>Orthodontic problems and mouth breathing</td> <td>This longstanding controversy holds that certain malocclusions arise from excessive tonsil/adenoid tissue, forcing mouth breathing. T&#38;A procedures can help some children, but not all.</td> <td>Orthodontic malocclusion should not be rationale alone for T&#38;A procedures.</td> </tr> <tr> <td>Maternal periodontal disease and prematurity <span style=\"color: black;\">and low-birthweight</span> of offspring</td> <td><span style=\"color: black;\">Case-control studies have linked maternal periodontal disease with premature and low-birthweight infants. However, randomized trials have not proven that periodontal treatment reduces preterm birth.</span></td> <td>Encourage pregnant women<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #ff0000;\"> </span>to establish and maintain personal oral health.</td> </tr> <tr> <td>Periodontal status and coronary heart disease risk</td> <td>Several independent reports have shown an association between periodontal disease and cardiac disease. Research is looking at circulating proteins. Causality is not established.</td> <td>This does not relate to children.</td> </tr> <tr> <td>Dental caries and lead exposure</td> <td>Recent investigations show a relationship between dental caries and exposure to lead (pica), primarily in poor children.</td> <td>Poverty brings with it health problems, and at this time, this may be simply a covariable associated with being poor.</td> </tr> <tr> <td>Cone beam computerized tomography (CBCT) scans and dental diagnosis</td> <td>The use of CBCT is increasing in dentistry, with few data to support its benefit over lower-radiation imaging. In some cases, such as orthognathic surgery, CBCT may offer better diagnostic images.</td> <td>Question dentists on radiation dose and need for CBCT for routine dental treatment.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T&amp;A: tonsillectomy with adenoidectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Casamassimo PS. Pediatr Clin North Am 2000; 47:1149. Copyright Â© 2000 W.B. Saunders Co.</div><div id=\"graphicVersion\">Graphic 72405 Version 4.0</div></div></div>"},"72407":{"type":"graphic_waveform","displayName":"Basic case 12 with answer","title":"Pericarditis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Pericarditis</div><div class=\"cntnt\"><img style=\"width:538px; height:322px;\" src=\"images/CARD/72407_Basic_case_12_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in acute pericarditis showing diffuse upsloping ST segment elevations seen best here in leads II, III, aVF, and V3 to V6. There is also subtle PR segment deviation (positive in aVR, negative in most other leads). ST segment elevation is due to a ventricular current of injury associated with epicardial inflammation; similarly, the PR segment changes are due to an atrial current of injury which, in pericarditis, typically displaces the PR segment upward in lead aVR and downward in most other leads.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 72407 Version 2.0</div></div></div>"},"72408":{"type":"graphic_picture","displayName":"Micrograph showing calcification","title":"Micrograph showing arterial calcification in a patient with calciphylaxis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph showing arterial calcification in a patient with calciphylaxis</div><div class=\"cntnt\"><img style=\"width:436px; height:188px;\" src=\"images/NEPH/72408_Calciphylaxis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low- and high-power view of characteristic arterial calcifications in the absence of vasculitic change from a patient with calciphylaxis.</div><div id=\"graphicVersion\">Graphic 72408 Version 3.0</div></div></div>"},"72410":{"type":"graphic_picture","displayName":"Crossed radioimmunoelectrophoresis of cat allergen extract","title":"Crossed radioimmunoelectrophoresis (CRIE) of cat allergen extract","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Crossed radioimmunoelectrophoresis (CRIE) of cat allergen extract</div><div class=\"cntnt\"><img style=\"width:507px; height:243px;\" src=\"images/ALLRG/72410_CRIE_cat_allgn_extr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A) Crossed immunoelectrophoresis (CIE) showing blue-stained, bell-shaped antigen-antibody precipitates. Each precipitate represents one antigen. <br />Panels B and C) Crossed radioimmunoelectrophoresis (CRIE) showing&nbsp;radiograph chromatograms of radio-staining of immunoglobulin E (IgE) from individual patients. Each stained precipitate represents reactivity with an allergen that can be identified by comparison with panel A.</div><div class=\"graphic_reference\">Courtesy of JÃ¸rgen Nedergaard Larsen, PhD and Henning LÃ¸wenstein, PhD, DSc.</div><div id=\"graphicVersion\">Graphic 72410 Version 6.0</div></div></div>"},"72411":{"type":"graphic_figure","displayName":"Laryngeal anatomy sagittal","title":"Diagrammatic representation of laryngeal anatomy in the sagittal plane","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Diagrammatic representation of laryngeal anatomy in the sagittal plane</div><div class=\"cntnt\"><img style=\"width:560px; height:461px;\" src=\"images/ONC/72411_Laryngeal_anatomy_sagittal.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72411 Version 1.0</div></div></div>"},"72413":{"type":"graphic_picture","displayName":"Onchochorioretinitis","title":"Onchochorioretinitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Onchochorioretinitis</div><div class=\"cntnt\"><img style=\"width:504px; height:501px;\" src=\"images/ID/72413_Onchochorioretinitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Onchocercal chorioretinits with optic disc pallor.</div><div class=\"graphic_reference\">Reproduced with permission from: Murdoch ME, Murdoch IE. Onchocerciasis. In: Principles of Medicine in Africa, 3rd Ed, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press 2004. Copyright &copy; 2004 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 72413 Version 1.0</div></div></div>"},"72414":{"type":"graphic_diagnosticimage","displayName":"Monteggia fracture","title":"Monteggia fracture/dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Monteggia fracture/dislocation</div><div class=\"cntnt\"><img style=\"width:154px; height:432px;\" src=\"images/EM/72414_Monteggiafracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 4-year-old boy fell off his bike. The ulna is fractured and angulated, and a line through the radius clearly does not pass through the center of the capitellum. (Courtesy of Dr. Andrew Capraro.)</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin M. Trauma: Extremeties. In: Atlas of pediatric emergency medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72414 Version 13.0</div></div></div>"},"72415":{"type":"graphic_figure","displayName":"Hormones and menses","title":"Hormonal changes during normal menstrual cycle","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Hormonal changes during normal menstrual cycle</div><div class=\"cntnt\"><img style=\"width:570px; height:234px;\" src=\"images/ENDO/72415_Hormonesandmenses.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential changes in the serum concentrations of the hormones released from the pituitary (FSH and LH; left panel) and from the ovaries (estrogen and progesterone; right panel) during the normal menstrual cycle. By convention, the first day of menses is day 1 of the cycle (shown here as day -14). The cycle is then divided into two phases: the follicular phase is from the onset of menses until ovulation, and the luteal phase is from ovulation until the next menses. To convert serum estradiol values to pmol/L, multiply by 3.67, and to convert serum progesterone values to nmol/L, multiply by 3.18.</div><div class=\"graphic_footnotes\">LH: luteinizing hormone; IU: international units; FSH: follicle-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 72415 Version 4.0</div></div></div>"},"72417":{"type":"graphic_figure","displayName":"Reciprocal translocation CML","title":"Reciprocal translocation in CML","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reciprocal translocation in CML</div><div class=\"cntnt\"><img style=\"width:408px; height:460px;\" src=\"images/HEME/72417_Reciprocal_translocation_CM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of the reciprocal translocation t(9;22), which is a characteristic finding in chronic myelogenous leukemia (CML). A small, distal piece of chromosome 9 (indicated by the arrow in the left upper chromosome) is broken off and translocated to the distal chromosome 22, as illustrated by the derivative chromosome der (22)-. The chromosomal segment that was originally present in the normal chromosome 22 (below the arrow in the left lower chromosome) is translocated to the shortened chromosome 9 to form a derivative, large chromosome der (9)+.</div><div id=\"graphicVersion\">Graphic 72417 Version 1.0</div></div></div>"},"72418":{"type":"graphic_figure","displayName":"Causes of downbeat nystagmus","title":"Causes of downbeat nystagmus in 287 patients","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Causes of downbeat nystagmus in 287 patients</div><div class=\"cntnt\"><img style=\"width:521px; height:297px;\" src=\"images/PC/72418_Causes_of_downbeat_nystagmu.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">The numbers in parentheses associated with the pie graph represent the percent of patients with each cause.</div><div id=\"graphicVersion\">Graphic 72418 Version 1.0</div></div></div>"},"72419":{"type":"graphic_picture","displayName":"Pemphigus foliaceus chest","title":"Pemphigus foliaceus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceus</div><div class=\"cntnt\"><img style=\"width:428px; height:300px;\" src=\"images/DERM/72419_Pemphigus_foliaceus_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pemphigus foliaceus is characterized by erythema, scaling, and crusting that first appears on the face and scalp, and later involves the chest and back.</div><div class=\"graphic_reference\">Reproduced with permission from: Bystryn J, Ruldolph J. Pemphigus. Lancet 2005; 266:61. Copyright Â© 2005 Nicholas Soter, MD. Reproduced in Lancet with permission from: the New York University Department of Dermatology.</div><div id=\"graphicVersion\">Graphic 72419 Version 4.0</div></div></div>"},"72421":{"type":"graphic_picture","displayName":"Squamous CA keratin Light","title":"Keratinization in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratinization in lung cancer</div><div class=\"cntnt\"><img style=\"width:398px; height:255px;\" src=\"images/PULM/72421_Squamous_CA_keratin_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratin (arrow) appears as waxy, darkly staining eosinophilic cytoplasm in this high powered photomicrograph of&nbsp;a <SPAN style=\"COLOR: black\">keratinizing </SPAN>squamous cell carcinoma of the lung.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 72421 Version 2.0</div></div></div>"},"72423":{"type":"graphic_diagnosticimage","displayName":"Radiofrequency ablation of cord of acardiac twin","title":"Radiofrequency ablation of cord of acardiac twin","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Radiofrequency ablation of cord of acardiac twin</div><div class=\"cntnt\"><img style=\"width:485px; height:428px;\" src=\"images/OBGYN/72423_Radiofrequency_ablation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image from a radiofrequency ablation of an acardiac twin. The probe (arrow) enters into the fetal anterior abdominal wall with the tines at the cord insertion site. The high signal around the tines (arrowhead) is due to gas formation during the procedure.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 72423 Version 3.0</div></div></div>"},"72424":{"type":"graphic_diagnosticimage","displayName":"Pott's disease in an adult","title":"Pott's disease in an adult","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pott's disease in an adult</div><div class=\"cntnt\"><img style=\"width:374px; height:289px;\" src=\"images/ID/72424_Potts_disease_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterioanterior thoracic spine film from a patient with Pott's disease shows the contours of a tuberculous paraspinal mass (arrows) with destruction of the T7-8 disc space and adjacent vertebral bodies.</div><div class=\"graphic_reference\">Courtesy of Charles E Putnam, MD.</div><div id=\"graphicVersion\">Graphic 72424 Version 5.0</div></div></div>"},"72426":{"type":"graphic_table","displayName":"Pregnancy outcome after assault","title":"Outcome in women assaulted during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcome in women assaulted during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Untraumatized controls, percent</td> <td class=\"subtitle1\">Delivery during hospitalization for assault, percent<sup>&#182;</sup> (n = 269)</td> <td class=\"subtitle1\">Delivery subsequent to hospitalization for assault, percent (n = 1801)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Maternal outcome</td> </tr> <tr> <td class=\"indent1\">Preterm labor</td> <td>5.4</td> <td>16.4<sup>&#916;</sup></td> <td>10.5<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Abruption</td> <td>0.9</td> <td>5.4<sup>&#916;</sup></td> <td>2.1<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Death</td> <td>0.01</td> <td>0.7<sup>&#916;</sup></td> <td>0.17</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Uterine rupture*</td> <td>0.01 to 0.07</td> <td>0.7<sup>&#916;</sup></td> <td>0.11</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infant outcome</td> </tr> <tr> <td class=\"indent1\">Preterm delivery</td> <td>9.7</td> <td>23.9<sup>&#916;</sup></td> <td>15.2<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Low birth weight</td> <td>5.8</td> <td>27.1<sup>&#916;</sup></td> <td>13.4<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Asphyxia</td> <td>0.5</td> <td>1.4<sup>&#916;</sup></td> <td>0.6</td> </tr> <tr> <td class=\"indent1\">Fetal death</td> <td>0.5</td> <td>9.3<sup>&#916;</sup></td> <td>0.9</td> </tr> <tr> <td class=\"indent1\">Neonatal death</td> <td>0.7</td> <td>7.5<sup>&#916;</sup></td> <td>1.3</td> </tr> <tr> <td class=\"indent1\">Infant death</td> <td>0.9</td> <td>8.2<sup>&#916;</sup></td> <td>2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PROM: premature rupture of membranes; RDS: respiratory distress syndrome.<br />* Range indicates before labor and during labor.<br />&para; All values significantly different from controls.<br />&Delta; Values significantly different from controls.</div><div class=\"graphic_reference\">Adapted from: El Kady D, Gilbert WM, Xing G, Smith LH. Obstet Gynecol 2005; 105:357.</div><div id=\"graphicVersion\">Graphic 72426 Version 3.0</div></div></div>"},"72427":{"type":"graphic_table","displayName":"Survival postsurgery PMP","title":"Survival after surgery for pseudomyxoma peritonei (PMP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival after surgery for pseudomyxoma peritonei (PMP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Institution</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Median survival (years)</td> <td class=\"subtitle1\">Five-year survival (percent)</td> <td class=\"subtitle1\">10-year survival (percent)</td> </tr> <tr> <td>Mayo Clinic<sup>[1]</sup></td> <td class=\"centered\">56</td> <td class=\"centered\">5.9</td> <td class=\"centered\">53</td> <td class=\"centered\">32</td> </tr> <tr> <td>Sloan-Kettering<sup>[2]</sup></td> <td class=\"centered\">17</td> <td class=\"centered\">6.25</td> <td class=\"centered\">75</td> <td class=\"centered\">10</td> </tr> <tr> <td>MD Anderson<sup>[3]</sup></td> <td class=\"centered\">38</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">54</td> <td class=\"centered\">18</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PMP: pseudomyxoma peritonei.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gough DB, et al. Ann Surg 1994; 219:112.</li>&#xD;&#xA;    <li>Smith JW, et al. Cancer 1992; 70:396.</li>&#xD;&#xA;    <li>Fernandez RN, et al. Arch Surg 1980; 115:409.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72427 Version 5.0</div></div></div>"},"72429":{"type":"graphic_figure","displayName":"Potential PCV coverage","title":"Potential serotype coverage of PCV7, PCV10, and PCV13 of serotypes causing IPD, AOM, AC, and those carried by healthy Israeli children","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Potential serotype coverage of PCV7, PCV10, and PCV13 of serotypes causing IPD, AOM, AC, and those carried by healthy Israeli children</div><div class=\"cntnt\"><img style=\"width:583px; height:354px;\" src=\"images/PEDS/72429_Potential_PCV_coverage_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AC: acute conjunctivitis; AOM: acute otitis media; IPD: invasive pneumococcal disease; NP: nasopharyngeal carriage.</div><div class=\"graphic_reference\">Reproduced with permission from: Shouval DS, Greenberg D, Givon-Lavi N, et al. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J 2009; 28:277. Copyright Â© 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72429 Version 12.0</div></div></div>"},"72432":{"type":"graphic_picture","displayName":"Small bowel leiomyoma Light","title":"Small intestinal leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Small intestinal leiomyoma</div><div class=\"cntnt\"><img style=\"width:535px; height:202px;\" src=\"images/GAST/72432_Small_bowel_leiomyoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left panel demonstrates the submucosal location of leiomyomas that arise in the small bowel. In the right panel, high power magnification reveals bland appearing spindle shaped cells and an absence of mitotic figures.</div><div class=\"graphic_reference\">Courtesy of Dr. Saint Aufranc.</div><div id=\"graphicVersion\">Graphic 72432 Version 1.0</div></div></div>"},"72433":{"type":"graphic_picture","displayName":"Giant platelets","title":"Giant platelets in hereditary macrothrombocytopenia","html":"<div class=\"graphic normal\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Giant platelets in hereditary macrothrombocytopenia</div><div class=\"cntnt\"><img style=\"width:504px; height:349px;\" src=\"images/HEME/72433_Giant_platelet_2_1_12.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows many giant platelets (arrows) in a young&nbsp;woman with congenital thrombocytopenia. The patient has persistent severe thrombocytopenia and high-frequency sensorineural hearing loss, a constellation of findings consistent with one of the congenital macrothrombocytopenias. The patient had been erroneously&nbsp;diagnosed as having immune thrombocytopenia (ITP) during childhood&nbsp;and had been treated with&nbsp;glucocorticoids and splenectomy with no response.</div><div class=\"graphic_footnotes\">1000X</div><div class=\"graphic_reference\">Courtesy of German A Pihan, MD, Beth Israel Deaconess Medical Center, Department of Pathology, and Jeffrey Zwicker, MD, Beth Israel Deaconess Medical Center, Department of Medicine.</div><div id=\"graphicVersion\">Graphic 72433 Version 8.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"72434":{"type":"graphic_picture","displayName":"Perforating folliculitis - close view","title":"Perforating folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perforating folliculitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72434_Perfor_folliculitis_close.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules with central hyperkeratosis were present on the extremities of this woman with perforating folliculitis and renal failure. Perforating folliculitis most often occurs in the setting of renal failure or diabetes.</div><div class=\"graphic_reference\">Copyright Â© Patrick Keehan, D.O. and Greg Hosler, MD, PhD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 72434 Version 5.0</div></div></div>"},"72435":{"type":"graphic_diagnosticimage","displayName":"Axial MRI showing perianal fistulas in Crohn disease","title":"Perianal fistulas in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal fistulas in Crohn disease</div><div class=\"cntnt\"><img style=\"width:360px; height:333px;\" src=\"images/GAST/72435_Axial_MRI_perianal_fistulas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted axial magnetic resonance imaging (MRI) study showing perianal fistulas (arrows) in a patient with Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 72435 Version 5.0</div></div></div>"},"72436":{"type":"graphic_table","displayName":"Systemic antibiotics for Acinetobacter infection in adults","title":"Systemic antibiotics for treatment of <EM>Acinetobacter </EM>infection in adults with normal renal function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic antibiotics for treatment of <EM>Acinetobacter </EM>infection in adults with normal renal function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td>Ceftazidime</td> <td>2 g intravenously every 8 hours</td> </tr> <tr> <td>Cefepime</td> <td>2 g intravenously every 8 hours</td> </tr> <tr> <td>Ampicillin-sulbactam*</td> <td>3 g intravenously every 6 hours</td> </tr> <tr> <td>Imipenem-cilastatin</td> <td>0.5 to 1 g intravenously every 6 hours to 1 g every 8 hours</td> </tr> <tr> <td>Meropenem</td> <td>1 to 2 g intravenously every 8 hours</td> </tr> <tr> <td>Doripenem</td> <td>0.5 g intravenously every 8 hours</td> </tr> <tr> <td>Gentamicin<sup>&#182;</sup></td> <td>1 to 2.5 mg/kg intravenously every 8 to 12 hours or 7 mg/kg every 24 to 48 hours depending on creatinine clearance</td> </tr> <tr> <td>Tobramycin<sup>&#182;</sup></td> <td>1 to 2.5 mg/kg intravenously every 8 to 12 hours or 7 mg/kg every 24 to 48 hours depending on creatinine clearance</td> </tr> <tr> <td>Amikacin<sup>&#182;</sup></td> <td>5 to 7.5 mg/kg intravenously every 8 hours or 15 mg/kg every 24 to 48 hours depending on creatinine clearance</td> </tr> <tr> <td>Ciprofloxacin<sup>&#182;</sup></td> <td>400 mg intravenously every 8 hours</td> </tr> <tr> <td>Colistin<sup>&#916;</sup></td> <td>2.5 to 5 mg/kg/day as <strong>colistin base</strong><sup>&#916;</sup> intravenously in two to four divided doses</td> </tr> <tr> <td>Polymyxin B&nbsp;</td> <td>25,000 units/kg (2.5 mg/kg) loading dose followed by 12,500 units/kg (2.5 mg/kg) intravenously every 12 hours</td> </tr> <tr> <td>Minocycline</td> <td>200 mg single dose, followed by 100 mg intravenously every 12 hours</td> </tr> <tr> <td>Tigecycline<sup>&#9674;</sup></td> <td>100 mg single dose, followed by 50 mg intravenously every 12 hours; 100 mg every 12 hours in serious infections</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists typical doses for use in <EM>Acinetobacter </EM>infection among patients with normal renal function. Antimicrobial susceptibility should be confirmed for clinical isolates. Higher doses may be warranted for infections of the central nervous system.</div><div class=\"graphic_footnotes\">* Sulbactam is the active component. Dose is expressed as sum of ampicillin and sulbactam.<br />Â¶ Aminoglycosides and fluoroquinolones are generally used in combination with another agent.<br />Î Dose is expressed as colistin base activity as in United States licensed product information. 1 mg colistin base activity â 30,000 international units colistimethate sodium. In the setting of critical illness, a loading dose may be administered (depending on clinical circumstances including renal function) of 5 to 7.5 mg/kg as colistin base (single dose)<SUP>[1]</SUP>. One study reported good outcomes with an approximate&nbsp;300 mg loading dose followed by&nbsp;150 mg every 12 hours for treatment of sepsis due to multidrug resistant Acinetobacter infection<SUP>[2]</SUP>.<br /><FONT class=lozenge>â</FONT> Tigecycline may not reach adequate levels in the serum, urinary tract, or central nervous system to successfully treat infections in these compartments.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430. </li>&#xD;&#xA;    <li>Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Inf Dis 2012; 54:1720.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72436 Version 14.0</div></div></div>"},"72437":{"type":"graphic_diagnosticimage","displayName":"Adrenal myelolipoma","title":"Adrenal myelolipoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adrenal myelolipoma</div><div class=\"cntnt\"><img style=\"width:396px; height:577px;\" src=\"images/ENDO/72437_Adrenal_myelolipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial image from abdominal CT scan shows an 11 x 15 cm mixed signal intensity right adrenal mass (arrow) with large amounts of macroscopic fat consistent with adrenal myelolipoma.<br />(B) Gross pathology cut section showing a 19 x 12 x 9.5 1030 gm adrenal myelolipoma.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 72437 Version 3.0</div></div></div>"},"72438":{"type":"graphic_picture","displayName":"BL bone marrow aspirate smear","title":"Burkitt lymphoma cells in bone marrow aspirate smear","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Burkitt lymphoma cells in bone marrow aspirate smear</div><div class=\"cntnt\"><img style=\"width:540px; height:367px;\" src=\"images/HEME/72438_BLbonemarraspiratesmear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cells have basophilic cytoplasm, round nuclei with coarse chromatin, multiple nucleoli, and numerous cytoplasmic vacuoles. Wright-Giemsa stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Burkitt lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright Â© 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72438 Version 6.0</div></div></div>"},"72441":{"type":"graphic_picture","displayName":"Inflamed pinguecula","title":"Inflamed pinguecula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflamed pinguecula</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PC/72441_Inflamed_pinguecula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pinguecula arises from and remains confined to the conjunctiva. There is usually space between the pinguecula and the edge of the cornea.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellog Eye Center, University of Michigan. Copyright &#169; Jonathan D Trobe, MD.</div><div id=\"graphicVersion\">Graphic 72441 Version 4.0</div></div></div>"},"72444":{"type":"graphic_table","displayName":"Initiation of volume-cycled NPPV in NM disease","title":"Protocol for initiation of noninvasive positive pressure ventilation using volume-cycled ventilator","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protocol for initiation of noninvasive positive pressure ventilation using volume-cycled ventilator</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Choose appropriately monitored location.</td> </tr> <tr> <td>2. Obtain baseline vital signs, arterial blood gas, and oximetry, as clinically indicated.</td> </tr> <tr> <td>3. Direct patient to sit in bed or chair at &#62;30 angle. Ensure patient comfort.</td> </tr> <tr> <td>4. Select and fit interface (nasal or oronasal mask).</td> </tr> <tr> <td>5. Apply headgear; avoid excessive strap tension (one&nbsp;to two fingers should fit under strap).</td> </tr> <tr> <td>6. Select ventilator.</td> </tr> <tr> <td>7. Connect interface to ventilator tubing and turn on ventilator.</td> </tr> <tr> <td>8. For volume-cycled ventilator, start with synchronized mandatory ventilation mode, tidal volume 6 to 10 mL/kg, and PEEP&nbsp;4 to 5 cm H<sub>2</sub>O. Set&nbsp;a back up rate of&nbsp;two breaths per minute below the patient's spontaneous nocturnal rate.</td> </tr> <tr> <td>9. Gradually increase tidal volume by 25 to 50 mL increments, as tolerated, to achieve alleviation of dyspnea, decreased respiratory rate, increased tidal volume (if being monitored), and good patient-ventilator synchrony.</td> </tr> <tr> <td>10. Check for air leaks, readjust straps as needed. Add chin strap if oral air leak noted.</td> </tr> <tr> <td>11. Add heated humidification, as indicated.</td> </tr> <tr> <td>12. Provide encouragement, reassurance, and frequent checks and adjustments as needed.</td> </tr> <tr> <td>13. Monitor vital signs and oximetry during trial; obtain occasional blood gases as needed.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72444 Version 4.0</div></div></div>"},"72445":{"type":"graphic_figure","displayName":"Decreased survival in RA","title":"Decreased survival in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Decreased survival in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:467px; height:328px;\" src=\"images/RHEUM/72445_Decreased_survival_in_RA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival curves for 905 patients with RA in Saskatoon, Canada compared with data from the general Canadian population. The death rate is increased throughout the course of RA with a tendency to accelerate after 15 years of follow-up.</div><div class=\"graphic_reference\">Data from Wolfe, F, Mitchell, DM, Sibley, JT, et al, Arthritis Rheum 1994; 37:481.</div><div id=\"graphicVersion\">Graphic 72445 Version 1.0</div></div></div>"},"72446":{"type":"graphic_table","displayName":"Classification of jerk nystagmus","title":"Classification of jerk nystagmus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of jerk nystagmus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary position</td> </tr> <tr> <td class=\"sublist2_start\">Pure directions</td> </tr> <tr> <td class=\"sublist2\">Upbeat</td> </tr> <tr> <td class=\"sublist2\">Downbeat</td> </tr> <tr> <td class=\"sublist2\">Torsional</td> </tr> <tr> <td class=\"sublist2\">Horizontal</td> </tr> <tr> <td class=\"sublist3\">Peripheral vestibular</td> </tr> <tr> <td class=\"sublist3\">Congenital</td> </tr> <tr> <td class=\"sublist3\">Periodic alternating</td> </tr> <tr> <td class=\"sublist3\">Latent</td> </tr> <tr> <td class=\"sublist3\">Epileptic</td> </tr> <tr> <td class=\"sublist2_start\">Mixed directions (peripheral vestibular)</td> </tr> <tr> <td class=\"sublist2\">Horizontal/torsional</td> </tr> <tr> <td class=\"sublist2\">Vertical/torsional</td> </tr> <tr> <td class=\"subtitle1_single\">Gaze-evoked</td> </tr> <tr> <td class=\"indent1\">Gaze holding</td> </tr> <tr> <td class=\"indent1\">Rebound</td> </tr> <tr> <td class=\"indent1\">Peripheral vestibular</td> </tr> <tr> <td class=\"indent1\">Brun's</td> </tr> <tr> <td class=\"subtitle1_single\">Positional</td> </tr> <tr> <td class=\"sublist2_start\">Paroxysmal positional</td> </tr> <tr> <td class=\"sublist2\">Posterior canalithiasis</td> </tr> <tr> <td class=\"sublist2\">Anterior canalithiasis</td> </tr> <tr> <td class=\"sublist2\">Horizontal canalithiasis</td> </tr> <tr> <td class=\"indent1\">Static positional</td> </tr> <tr> <td class=\"subtitle1_single\">Dissociated</td> </tr> <tr> <td class=\"indent1\">Internuclear ophthalmoplegia</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Convergence-retraction nystagmus</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72446 Version 3.0</div></div></div>"},"72447":{"type":"graphic_figure","displayName":"Syndromes of sensory loss","title":"Syndromes of sensory loss","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Syndromes of sensory loss</div><div class=\"cntnt\"><img style=\"width:540px; height:437px;\" src=\"images/PC/72447_Sensory_syndromes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In these figures, the blue shading indicates hypalgesia (loss of pain and temperature sensation) and the arrows indicate limbs with significant accompanying weakness. In the Brown-Sequard syndrome (hemisection of the cord, top row, right) there is often diminished tactile sensation on the side of weakness and opposite the side with hypalgesia.</div><div class=\"graphic_reference\">Reproduced with permission from McGee, S, Evidence-based Physical Diagnosis, WB Saunders, Philadelphia, 2001. Copyright Â© 2001 Elsevier.</div><div id=\"graphicVersion\">Graphic 72447 Version 2.0</div></div></div>"},"72449":{"type":"graphic_picture","displayName":"Telangiectasia in scleroderma","title":"Telangiectasias in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Telangiectasias in scleroderma</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/RHEUM/72449_Telangiectasia_in_scleroder.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Telangiectasias in a patient with limited cutaneous systemic sclerosis.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 72449 Version 1.0</div></div></div>"},"72450":{"type":"graphic_picture","displayName":"Villous maturational arrest","title":"Villous maturational arrest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Villous maturational arrest</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/OBGYN/72450_Dist_villous_hypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A term placenta from a recently delivered fetal demise showing large villi without vasculosyncytial membranes (arrows), hemorrhagic endovasculitis (arrowhead) and a paucity of small villi, syncytiotrophoblastic knots, and vasculosyncytial membranes.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 72450 Version 3.0</div></div></div>"},"72451":{"type":"graphic_picture","displayName":"Hymenolepis diminuta eggs","title":"<EM>Hymenolepis diminuta</EM>Â eggs","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\"><EM>Hymenolepis diminuta</EM>&nbsp;eggs</div><div class=\"cntnt\"><img style=\"width:581px; height:293px;\" src=\"images/ID/72451_Hymenolepiasis_diminuta_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Eggs of <em>Hymenolepis diminuta</em>. These eggs are round or slightly oval, size 70 to 85 micrometers by 60 to 80 micrometers, with a striated outer membrane and a thin inner membrane. The space between the membranes is smooth or faintly granular. The oncosphere has six hooks. There are no polar filaments extending into the space between the oncosphere and the outer shell.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hymenolepiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/hymenolepiasis/index.html\">http://www.cdc.gov/dpdx/hymenolepiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 72451 Version 7.0</div></div></div>"},"72452":{"type":"graphic_picture","displayName":"Candida images","title":"<em>Candida</em> images","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\"><em>Candida</em> images</div><div class=\"cntnt\"><img style=\"width:514px; height:379px;\" src=\"images/ID/72452_Candida_images.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cytology figure shows pseudohyphae and a few budding yeast of <EM>Candida</EM> on Papanicolaou stain.<br />(B) Grocott's methenamine silver stain showing <EM>Candida</EM> pseudohyphae. <br />(C) <EM>Candida </EM>as seen on a wet mount. This is characteristic of <EM>Candida albicans</EM>.</div><div class=\"graphic_reference\">(A) and (B) Reproduced with permission from: Cagle PT, MD. Color Atlas and Text of Pulmonary Pathology. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.<br />(C) Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005 Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72452 Version 4.0</div></div></div>"},"72453":{"type":"graphic_picture","displayName":"Light microscopy of acute tubular necrosis I","title":"Light microscopy of acute tubular necrosis I","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light microscopy of acute tubular necrosis I</div><div class=\"cntnt\"><img style=\"width:378px; height:255px;\" src=\"images/NEPH/72453_Acute_tubular_necrosis_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in acute tubular necrosis showing focal loss of tubular epithelial cells (arrows) and partial occlusion of tubular lumens by cellular debris (D).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 72453 Version 2.0</div></div></div>"},"72454":{"type":"graphic_table","displayName":"Limb signs symptoms ALS","title":"Limb signs and symptoms associated with amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Limb signs and symptoms associated with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n      <td class=\"container\">\n      \n      <table cellspacing=\"0\">\n\n        <tbody>\n\n          <tr>\n\t\t<td></td>\n            </tr>\n          <tr>\n            <td class=\"subtitle1_single\">Upper motor neuron signs</td>\n          </tr>\n\n            <tr>\n            <td>Spasticity</td>\n          </tr>\n\n            <tr>\n            <td>Slowed rapid alternating movements</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1_start\">Increased reflexes</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">\"Preserved\" reflexes in weak/atrophic muscles</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Distal spread of arm reflexes</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Hoffman's sign</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Crossed adduction</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Upgoing toe</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Triple flexion</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1_start\">Gait disorder</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Spastic</td>\n          </tr>\n\n            <tr>\n            <td class=\"subtitle1_single\">Lower motor neuron signs</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1_start\">Weakness</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Intrinsic hand weakness</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Foot drop</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Proximal arm and leg weakness</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Poor heel and or toe walking</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Poor rise from chair</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Poor squat</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1_start\">Gait disorder</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Steppage</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Waddling</td>\n          </tr>\n\n            <tr>\n            <td>Reduced reflexes</td>\n          </tr>\n\n            <tr>\n            <td>Muscle atrophy and fasciculations</td>\n          </tr>\n\n          \n        \n        </tbody>\n      \n      </table>\n\n      </td>\n\n\t\n\t<td class=\"container\">\n      \n      <table cellspacing=\"0\">\n\n        <tbody>\n\n          <tr>\n\t\t<td></td>\n            </tr>\n          <tr>\n            <td class=\"subtitle1_single\">Upper motor neuron symptoms</td>\n          </tr>\n\n            <tr>\n            <td>Stiffness, slowness and incoordination of movement</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Hand and / or arm</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Difficulty performing activities of daily living</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Difficulty manipulating small objects or writing</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Leg and / or foot</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Gait dysfunction</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist3\">Slow stiff gait, difficulty turning</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist3\">Legs \"heavy\"</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist3\">Poor balance and falling</td>\n          </tr>\n\n            <tr>\n            <td>Spontaneous clonus</td>\n          </tr>\n\n            <tr>\n            <td>Spontaneous flexor spasms</td>\n          </tr>\n\n            <tr>\n            <td class=\"subtitle1_single\">Lower motor neuron symptoms</td>\n          </tr>\n\n            <tr>\n            <td>Weakness and atrophy</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Arm and / or hand</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Difficulty performing activities of daily living</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Difficulty manipulating small objects or writing</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist1\">Leg and / or foot</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Difficulty arising from chairs or from floor</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Difficulty climbing stairs</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Foot drop</td>\n          </tr>\n\n            <tr>\n            <td class=\"sublist2\">Tripping, falling</td>\n          </tr>\n\n            <tr>\n            <td>Fasciculations</td>\n          </tr>\n\n            <tr>\n            <td>Cramps</td>\n          </tr>\n\n          \n        \n        </tbody>\n      \n      </table>\n\n      </td>\n\n  </tr>\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72454 Version 1.0</div></div></div>"},"72455":{"type":"graphic_diagnosticimage","displayName":"Hypertrophic pulmonary osteo bonescan","title":"Hypertrophic pulmonary osteoarthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic pulmonary osteoarthropathy</div><div class=\"cntnt\"><img style=\"width:192px; height:532px;\" src=\"images/ONC/72455_Hypr_pl_ost_bnscn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image from a 69-year-old male with non-small cell lung cancer (NSCLC) and bilateral lower extremity pain. Whole body bone of shows patchy uptake in the periosteal aspects of the long bones typical of hypertrophic pulmonary osteoarthropathy. No clear evidence of skeletal metastases.</div><div class=\"graphic_reference\">Courtesy of Robert C. Murphy, MD, PhD.</div><div id=\"graphicVersion\">Graphic 72455 Version 4.0</div></div></div>"},"72459":{"type":"graphic_figure","displayName":"Heart failure action plan - page 1","title":"Heart failure action plan - page 1","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Heart failure action plan - page 1</div><div class=\"cntnt\"><img style=\"width:574px; height:725px;\" src=\"images/CARD/72459_Heart_failure_chart_1.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72459 Version 3.0</div></div></div>"},"72460":{"type":"graphic_movie","displayName":"Parasternal short axis view tetralogy of Fallot","title":"Parasternal short axis view in tetralogy of Fallot (TOF)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal short axis view in tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/72460_Parasternshortaxisview.mp4\" style=\"width:432px;height:400px\"></div><img style=\"width:452px; height:371px;\" src=\"images/PEDS/72460_Parasternalshortaxisview.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from the accompanying echocardiographic video clip of the parasternal short axis view of a patient with tetralogy of Fallot (TOF) demonstrates the dynamic obstruction in the right ventricular outflow tract (RVOT) and the hypoplastic pulmonary annulus. The main and branch pulmonary arteries are also imaged.</div><div class=\"graphic_footnotes\">Ao: aorta; RPA: right pulmonary artery; LPA: left pulmonary artery; MPA: main pulmonary artery; LA: left atrium; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 72460 Version 1.0</div></div></div>"},"72461":{"type":"graphic_table","displayName":"Docetaxel cisplatin and FU plus RT HNC ver2","title":"Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by radiotherapy for locally advanced, squamous cell carcinoma of the head and neck (TAX323)<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by radiotherapy for locally advanced, squamous cell carcinoma of the head and neck (TAX323)<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\"><strong>Cycle length:</strong> Every 21 days for four cycles. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\" colspan=\"2\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Docetaxel</td> <td>75 mg/m<sup>2</sup> IV</td> <td colspan=\"2\">Dilute in 250 mL normal saline (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.</td> <td>Day 1</td> </tr> <tr> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td colspan=\"2\">Dilute in 250 mL NS and administer over 60 minutes. Do not administer with aluminum needles or IV sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Fluorouracil (FU)</td> <td>750 mg/m<sup>2</sup>/day IV</td> <td colspan=\"2\">Dilute in 500 to 1000 mL 5% dextrose in water or NS and administer as a continuous infusion over 24 hours.</td> <td>Days 1 through 5</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"4\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. Additional hydration of 1 to 2 liters of NS on day 2 to prevent nephrotoxicity. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"4\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"4\"> <ul> <li>Premedicate with dexamethasone prior to docetaxel administration. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"4\"> <ul> <li>In the original protocol, prophylactic therapy with a fluoroquinolone antibiotic was used on days 5 to 15 of each cycle because of the high frequency of grade 3 or 4 neutropenia.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"4\"> <ul> <li>Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"4\"> <ul> <li>Docetaxel should not be given if bilirubin is &#62;ULN, or if AST and/or ALT &#62;1.5 times the ULN with AP &#62;2.5 times the ULN.<sup>[2]</sup> Dose adjustments for FU may be needed for patients with hepatic impairment.<sup>[2]</sup> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for known drug interactions</strong></td> <td colspan=\"4\"> <ul> <li>Caution is needed when administering docetaxel with strong CYP3A4 inhibitors. Although specific dose recommendations are not available, the United States Prescribing Information suggests close monitoring for toxicity and consideration of docetaxel dose reduction if coadministration with a strong CYP3A4 inhibitor cannot be avoided.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>CBC, differential, and platelet count on day 1 on each cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Creatinine and electrolytes on day 5 or 6 of each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Basic metabolic panel, including creatinine and electrolytes, and liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Monitor for neurotoxicity, diarrhea, and palmar-plantar erythrodysesthesias prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"5\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"5\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"7\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"4\"> <ul> <li>Doses of docetaxel and FU should be reduced for grade 3 or 4 diarrhea or mucositis:<sup>[2]</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle3\" colspan=\"2\">Toxicity</td> <td class=\"subtitle3\" colspan=\"2\">Dose adjustment</td> </tr> <tr> <td colspan=\"2\">Diarrhea grade 3</td> <td colspan=\"2\">First episode: Reduce FU dose by 20%.<br /> Second episode: Reduce docetaxel dose by 20%.</td> </tr> <tr> <td colspan=\"2\">Diarrhea grade 4</td> <td colspan=\"2\">First episode: Reduce docetaxel and FU doses by 20%.<br /> Second episode: Discontinue treatment.</td> </tr> <tr> <td colspan=\"2\">Stomatitis/mucositis grade 3</td> <td colspan=\"2\">First episode: Reduce FU dose by 20%.<br /> Second episode: Stop FU only at all subsequent cycles.<br /> Third episode: Reduce docetaxel dose by 20%.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Stomatitis/mucositis grade 4</td> <td colspan=\"2\">First episode: Stop FU only at all subsequent cycles.<br /> Second episode: Reduce docetaxel dose by 20%.</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"4\"> <ul> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression or severe, prolonged neutropenia and/or thrombocytopenia after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"4\"> <ul> <li>Docetaxel should not be given if bilirubin is &#62;ULN, or if AST and/or ALT &#62;1.5 times the ULN with AP &#62;2.5 times the ULN.<sup>[2]</sup> For intracycle increases of AST/ALT &#62;2.5 to &#8804;5 times the ULN and AP &#8804;2.5 times the ULN, <strong>OR</strong> AST/ALT &#62;1.5 to &#8804;5 times the ULN <strong>AND</strong> AP &#62;2.5 to &#8804;5 times the ULN, docetaxel should be reduced by 20%. In case of AST/ALT &#62;5 times the ULN <strong>AND/OR</strong> AP &#62;5 times the ULN, docetaxel should be stopped.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"4\"> <ul> <li>Patients should not be retreated with docetaxel until the neutrophil count is &#62;1500 cells/microL.<sup>[2]</sup> In the original protocol, G-CSF was allowed during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than seven days. If an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection occurs, the United States Prescribing Information suggests reduction of docetaxel dose from 75 to 60 mg/m<sup>2</sup>. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced further from 60 mg/m<sup>2</sup> to 45 mg/m<sup>2</sup>. In case of grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"4\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"4\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Reduce cisplatin dose 20% for grade 2 peripheral neuropathy and discontinue for grade 3 neuropathy or grade 3 ototoxicity.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"4\"> <ul> <li>Hold FU for grade 2 or greater palmar-plantar erythrodysesthesia, and reduce subsequent dose by 20%.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"4\"> <ul> <li>For other grade 3 or worse toxicity except for alopecia and anemia, delay chemotherapy (maximum of two weeks) until resolution to &#60;grade 1, then restart if medically appropriate. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"5\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; AP: alkaline phosphatase; G-CSF: granulocyte colony-stimulating factors.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Vermorken JB, et al. N Eng J Med 2007; 357:1695.</LI>&#xD;&#xA;<LI>Docetaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 72461 Version 15.0</div></div></div>"},"72462":{"type":"graphic_figure","displayName":"Lateral ankle ligaments","title":"Lateral ankle ligaments","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Lateral ankle ligaments</div><div class=\"cntnt\"><img style=\"width:549px; height:305px;\" src=\"images/EM/72462_Ltrl_ankl_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ATFL: anterior talofibular ligament; PTFL: posterior talofibular ligament; CFL: calcaneofibular ligament.</div><div id=\"graphicVersion\">Graphic 72462 Version 6.0</div></div></div>"},"72463":{"type":"graphic_table","displayName":"Diagnosis simple cysts","title":"Clinical manifestations and imaging findings suggesting a hepatic cystic lesion is more than a simple cyst","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations and imaging findings suggesting a hepatic cystic lesion is more than a simple cyst</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Manifestation/imaging finding</td>\n<td class=\"subtitle1\">Differential diagnosis</td>\n</tr>\n<tr>\n<td>Progressive symptoms</td>\n<td>Cystadenoma, cystadenocarcinoma, metastasis</td>\n</tr>\n<tr>\n<td>Abnormal hepatic biochemical tests</td>\n<td>Cystadenocarcinoma, metastasis</td>\n</tr>\n<tr>\n<td>Rapid growth on periodic follow-up</td>\n<td>Cystadenoma, cystadenocarcinoma, metastasis</td>\n</tr>\n<tr>\n<td>Calcifications or daughter cysts</td>\n<td>Echinococcal cyst</td>\n</tr>\n<tr>\n<td>Thick or irregular cyst wall</td>\n<td>Cystadenoma, cystadenocarcinoma, metastasis, echinococcal cyst</td>\n</tr>\n<tr>\n<td>Nonhomogeneous cyst content</td>\n<td>Cystadenoma, cystadenocarcinoma, echinococcal cyst, bleeding into a simple cyst</td>\n</tr>\n<tr>\n<td>Sepations or multilocular cyst space</td>\n<td>Cystadenoma, cystadenocarcinoma, echinococcal cyst, bleeding into a simple cyst</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72463 Version 2.0</div></div></div>"},"72467":{"type":"graphic_table","displayName":"Doses beta agonist preparations","title":"Dosages of beta agonists used in the routine treatment of asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosages of beta agonists used in the routine treatment of asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug and US trade name(s)</td> <td class=\"subtitle1\">Age range approved in US prescribing information</td> <td class=\"subtitle1\">Preparation(s)*</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Short-acting, inhaled beta-2 agonists</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Albuterol (salbutamol)</td> </tr> <tr> <td class=\"indent2\">Proventil HFA, Ventolin HFA, or ProAir HFA metered dose inhaler</td> <td>&#8805;4 years old</td> <td>MDI: 90 mcg/puff</td> <td>2 puffs every 4 to 6 hours as needed</td> <td>2 puffs every 4 to 6 hours as needed</td> </tr> <tr> <td class=\"indent2\">AccuNeb or generic solution for nebulization</td> <td>&#8805;2 years old</td> <td> <p>Nebulizer solutions:</p> <p>0.021 percent (0.63 mg/3 mL)</p> <p>0.042 percent (1.25 mg/3 mL)</p> <p>0.083 percent (2.5 mg/3 mL)</p> 0.5 percent (2.5 mg/0.5 mL) concentrate</td> <td>2.5 mg every 4 to 6 hours as needed</td> <td>0.1 to 0.15 mg/kg every 4 to 6 hours as needed</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Levalbuterol (levosalbutamol)</td> </tr> <tr> <td class=\"indent2\">Xopenex HFA metered dose inhaler</td> <td>&#8805;4 years old</td> <td>45 mcg/puff</td> <td>2 puffs every 4 to 6 hours as needed</td> <td>1 to 2 puffs every 4 to 6 hours as needed</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Xopenex solution for nebulization or generic solution for nebulization</td> <td>&#8805;6 years old</td> <td> <p>Nebulizer solution:</p> <p>0.31/3 mL</p> <p>0.63/3 mL</p> <p>1.25 mg/3 mL</p> 1.25 mg/0.5 mL concentrate</td> <td>0.63 to 1.25 mg, 2 to 4 times daily, as needed</td> <td>0.31 mg, 2 to 4 times daily, as needed</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Long-acting, beta-2 agonists<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Salmeterol<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Serevent Diskus dry powder inhaler</td> <td>&#8805;4 years old</td> <td>DPI: 50 mcg/inhalation</td> <td>1 inhalation every 12 hours</td> <td>1 inhalation every 12 hours</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"5\">Formoterol<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent2\">Foradil Aerolizer dry powder inhaler</td> <td>&#8805;5 years old</td> <td>DPI: 12 mcg/inhalation</td> <td>1 inhalation every 12 hours</td> <td>1 inhalation every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Weight based pediatric dose should not exceed the usual adult dose shown.</div><div class=\"graphic_footnotes\">HFA: hydrofluoroalkane; MDI: metered-dose inhaler; DPI: dry-powder inhaler.<br />* Product strengths shown are according to United States (US) official prescribing information. For non US products, consult local prescribing information for product detail.<br />Â¶ These medications are NEVER used for monotherapy in asthma.<br />Î Salmeterol is also available in combination with fluticasone (Advair).<br /><FONT class=lozenge>â</FONT> Formoterol is also available in combination with budesonide (Symbicort) or mometasone (Dulera).</div><div id=\"graphicVersion\">Graphic 72467 Version 15.0</div></div></div>"},"72468":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM CXR I","title":"Arteriovenous malformation in right lower lobe in patient who developed a stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation in right lower lobe in patient who developed a stroke</div><div class=\"cntnt\"><img style=\"width:360px; height:311px;\" src=\"images/PULM/72468_Pulm_AVM_CXR_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a feeding artery and draining vein in the right lower lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72468 Version 2.0</div></div></div>"},"72469":{"type":"graphic_figure","displayName":"Severity obstructive dz","title":"Interpretation of office spirometry: Obstructive pattern","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Interpretation of office spirometry: Obstructive pattern</div><div class=\"cntnt\"><img style=\"width:536px; height:303px;\" src=\"images/PULM/72469_Severity_obstructive_dz.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If the FEV<SUB>1</SUB>/FVC ratio is normal AND the FEV<SUB>1</SUB> is greater than 80 percent of predicted, then the spirometry is normal. <BR>If the FEV<SUB>1</SUB>/FVC is reduced and the FEV<SUB>1</SUB> is &gt;80 percent predicted, spirometry may be normal; this finding may be due to a prolonged exhalation phase leading to overestimation of the FVC.<BR>If the FEV<SUB>1</SUB>/FVC ratio is normal, but the FVC is mildly reduced (70 to 80 percent of predicted), the cause may be abdominal obesity or poor technique.<BR>If the FEV<SUB>1</SUB>/FVC ratio is normal, but the FVC is below 80 percent of predicted, consider referring the patient to a pulmonary function laboratory for measurement of lung volumes and diffusing capacity (DLCO) to assess for a possible restrictive ventilatory defect (eg, interstitial lung disease or respiratory muscle weakness).</div><div class=\"graphic_footnotes\">FEV<SUB>1</SUB>: forced expiratory volume in one second; FVC: forced vital capacity.<BR>* The FEV<SUB>1</SUB> decreases with age, so the lower limit of normal (LLN) should be used to detect airway obstruction rather than the absolute value of FEV<SUB>1</SUB>/FVC.</div><div class=\"graphic_reference\">Adapted from: Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948.</div><div id=\"graphicVersion\">Graphic 72469 Version 2.0</div></div></div>"},"72470":{"type":"graphic_diagnosticimage","displayName":"Monteggia fracture in a child","title":"Monteggia fracture in a child","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Monteggia fracture in a child</div><div class=\"cntnt\"><img style=\"width:514px; height:329px;\" src=\"images/EM/72470_Monteggia_frac_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral (Panel A) and anteroposterior (Panel B) plain radiographs showing proximal ulnar fracture with dislocation of the radial head (indicated by lack of alignment of the radial head with the capitellum).</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 72470 Version 3.0</div></div></div>"},"72475":{"type":"graphic_figure","displayName":"Survival with ICD in dialysis","title":"Estimated unadjusted survival of dialysis patients with and without an implantable cardioverter-defibrillator (ICD)","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Estimated unadjusted survival of dialysis patients with and without an implantable cardioverter-defibrillator (ICD)</div><div class=\"cntnt\"><img style=\"width:470px; height:416px;\" src=\"images/NEPH/72475_Survival_with_ICD_in_dialys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure showing probability of survival over time among dialysis patients with a history of sudden cardiac death. At every time point, a higher unadjusted survival is observed in patients with an ICD (blue line) compared with those without an ICD (black line).</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator.</div><div class=\"graphic_reference\">Data from: Herzog CA, Li S, Weinhandl ED, et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68:818.</div><div id=\"graphicVersion\">Graphic 72475 Version 2.0</div></div></div>"},"72476":{"type":"graphic_diagnosticimage","displayName":"CT perimesencephalic nonaneurysmal SAH","title":"Perimesencephalic subarachnoid hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perimesencephalic subarachnoid hemorrhage</div><div class=\"cntnt\"><img style=\"width:341px; height:325px;\" src=\"images/NEURO/72476_Perimesencephalic_SAH_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan demonstrates the typical findings of a nonaneurysmal perimesencephalic subarachnoid hemorrhage. Note the predominance of hemorrhage in the interpeduncular fossa (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 72476 Version 4.0</div></div></div>"},"72477":{"type":"graphic_table","displayName":"Stage of pelvic organ prolapse","title":"Pelvic organ prolapse staging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pelvic organ prolapse staging</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1_left\">Stage 0<br />\n      </td>\n\n      <td>No prolapse</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Aa, Ba, Ap, Bp are -3 cm and C or D&#8804; -(tvl - 2) cm</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Stage 1</td>\n\n      <td>Most distal portion of the prolapse -1 cm (above the level of hymen)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Stage 2</td>\n\n      <td>Most distal portion of the prolapse &#8805; -1 cm but &#8804; +1 cm (&#8804;1 cm above or below the hymen)</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Stage 3</td>\n\n      <td>Most\ndistal portion of the prolapse &#62; +1 cm but &#60; +(tvl - 2) cm\n(beyond the hymen; protrudes no farther than 2 cm less than\nthe total vaginal length)</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\">Stage 4</td>\n\n      <td>Complete eversion; most distal portion of the prolapse &#8805; + (tvl - 2) cm</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Aa: Point A of anterior wall; Ba: point B of anterior wall; Ap: point A of posterior wall; Bp: point B of posterior wall; -: above the hymen; +: beyond the hymen; tvl: total vaginal length.</div><div class=\"graphic_reference\">Reproduced with permission from Harvey, M-A, Versi, E. Urogynecology and pelvic floor dysfunction. In: Kistner's Gynecology and Women's Health, 7th ed, Ryan, KJ, Berkowitz, RS, Barbieri, RL, Dunaif, A (Eds), St. Louis, Mosby 1999. Copyright &#169; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 72477 Version 1.0</div></div></div>"},"72478":{"type":"graphic_figure","displayName":"Construction of a loop colostomy - exteriorization","title":"Construction of a loop colostomy - exteriorization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Construction of a loop colostomy - exteriorization</div><div class=\"cntnt\"><img style=\"width:434px; height:538px;\" src=\"images/SURG/72478_Loop-colostomy-ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts exteriorizing a loop of colon by gently pulling the limb through the abdominal wall trephine. A penrose drain around the bowel facilitates this maneuver.</div><div id=\"graphicVersion\">Graphic 72478 Version 1.0</div></div></div>"},"72479":{"type":"graphic_figure","displayName":"Rapid cricothyrotomy step two","title":"Rapid four-step cricothyrotomy technique: Step 2","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Rapid four-step cricothyrotomy technique: Step 2</div><div class=\"cntnt\"><img style=\"width:461px; height:444px;\" src=\"images/EM/72479_Cric_rapid_step_two.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Make a horizontal stab incision through both skin and cricothyroid membrane with the scalpel.</div><div id=\"graphicVersion\">Graphic 72479 Version 3.0</div></div></div>"},"72480":{"type":"graphic_table","displayName":"Infection rates of open fractures","title":"Classification system for open fracture and related infection rates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification system for open fracture and related infection rates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Fracture type</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Historical infection rates (percentage)</td> </tr> <tr> <td>I</td> <td>Wound &#60;1 cm; minimal contamination, comminution and soft-tissue damage</td> <td>0-2</td> </tr> <tr> <td>II</td> <td>Wound &#62;1 cm; moderate soft-tissue damage, minimal periosteal stripping</td> <td>2-5</td> </tr> <tr> <td>III</td> <td>Severe soft-tissue damage and substantial contamination; coverage adequate</td> <td>5-10</td> </tr> <tr> <td>IV</td> <td>Severe soft-tissue damage and substantial contamination; coverage inadequate</td> <td>10-50</td> </tr> <tr> <td>V</td> <td>Arterial injury requiring repair</td> <td>25-50</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Okike K, Bhattacharyya T. Trends in the management of open fractures. A critical analysis. J Bone Joint Surg Am 2006; 88:2739. Copyright Â© 2006 Journal of Bone and Joint Surgery, Inc.</div><div id=\"graphicVersion\">Graphic 72480 Version 4.0</div></div></div>"},"72481":{"type":"graphic_diagnosticimage","displayName":"Ampullary carcinoma EUS","title":"Ampullary carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ampullary carcinoma</div><div class=\"cntnt\"><img style=\"width:312px; height:329px;\" src=\"images/GAST/72481_Ampullary_carcinoma_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic image obtained during endoscopic ultrasound showing invasion of an ampullary lesion into the pancreatic head (T3). The tumor clearly penetrates the muscularis propria.</div><div class=\"graphic_reference\">Courtesy of A James Moser, MD.</div><div id=\"graphicVersion\">Graphic 72481 Version 3.0</div></div></div>"},"72482":{"type":"graphic_picture","displayName":"Endosc double pigtail stent","title":"Pancreatic pseudocyst drainage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic pseudocyst drainage</div><div class=\"cntnt\"><img style=\"width:432px; height:299px;\" src=\"images/GAST/72482_Endosc_double_pigtail_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of double pigtail stents protruding from fistulous tract into the pseudocyst.</div><div class=\"graphic_reference\">Courtesy of Kenneth E Fasanella, MD, and Michael K Sanders, MD.</div><div id=\"graphicVersion\">Graphic 72482 Version 1.0</div></div></div>"},"72483":{"type":"graphic_table","displayName":"Frequency malignant OGCNs","title":"Incidence of histologic types among malignant ovarian germ cell neoplasms: United States Surveillance Epidemiology and End Results national cancer database (1262 tumors; 1973 to 2002)<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of histologic types among malignant ovarian germ cell neoplasms: United States Surveillance Epidemiology and End Results national cancer database (1262 tumors; 1973 to 2002)<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td>Dysgerminomas</td> <td>32.8</td> </tr> <tr> <td>Immature teratomas</td> <td>35.6</td> </tr> <tr> <td>Mature teratomas with malignant degeneration</td> <td>2.9</td> </tr> <tr> <td>Yolk sac tumor (endodermal sinus tumor)</td> <td>14.5</td> </tr> <tr> <td>Embryonal</td> <td>4.1</td> </tr> <tr> <td>Choriocarcinoma</td> <td>2.1</td> </tr> <tr> <td>Mixed germ cell tumors</td> <td>5.3</td> </tr> <tr> <td>Teratocarcinoma</td> <td>2.6</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Smith HO. Obstet Gynecol 2006; 107:1075. </li> </ol></div><div id=\"graphicVersion\">Graphic 72483 Version 6.0</div></div></div>"},"72484":{"type":"graphic_diagnosticimage","displayName":"Superior sulcus PET","title":"Superior sulcus tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior sulcus tumor</div><div class=\"cntnt\"><img style=\"width:342px; height:235px;\" src=\"images/PULM/72484_Superior_sulcus_PET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal PET scan shows the glucose avid right apical tumor as well as a lower rib metastasis (arrow).</div><div class=\"graphic_footnotes\">PET: positron emission tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72484 Version 3.0</div></div></div>"},"72486":{"type":"graphic_picture","displayName":"Slit lamp focusing rod","title":"Slit lamp focusing rod","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slit lamp focusing rod</div><div class=\"cntnt\"><img style=\"width:240px; height:320px;\" src=\"images/EM/72486_Slit_lamp_focusing_rod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The focusing rod enables the clinician to obtain consistent focusing from one slit lamp examination to the next.</div><div class=\"graphic_reference\">Courtesy of Kevin J Knoop, MD.</div><div id=\"graphicVersion\">Graphic 72486 Version 1.0</div></div></div>"},"72487":{"type":"graphic_picture","displayName":"Mucorales hyphae","title":"Mucorales hyphae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucorales hyphae</div><div class=\"cntnt\"><img style=\"width:275px; height:232px;\" src=\"images/ID/72487_Mucorales_hyphae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspiration of right lower lobe of lung showing aseptate hyphae (Papanicolaou stain, x400).</div><div class=\"graphic_reference\">Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright Â© 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72487 Version 5.0</div></div></div>"},"72488":{"type":"graphic_diagnosticimage","displayName":"Aortoiliac aneurysm on arteriography","title":"Aortoiliac aneurysm on arteriography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortoiliac aneurysm on arteriography</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/SURG/72488_Aortoiliac_aneu_arteriograp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arteriography demonstrating an abdominal aortic aneurysm and bilateral iliac artery aneurysms. An endograft has been partially deployed (main body only).</div><div id=\"graphicVersion\">Graphic 72488 Version 2.0</div></div></div>"},"72489":{"type":"graphic_picture","displayName":"Chair dip exercise","title":"Strength exercise: Chair dip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Chair dip</div><div class=\"cntnt\"><img style=\"width:374px; height:306px;\" src=\"images/PC/72489_Chair_dip_exercise_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This pushing motion will strengthen your arm muscles even if you are not able to lift yourself up off the chair. <ol> <li>Sit in a sturdy chair with armrests with your feet flat on the floor, shoulder-width apart. </li> <li>Lean slightly forward; keep your back and shoulders straight. </li> <li>Grasp arms of chair with your hands next to you. Breathe in slowly. </li> <li>Breathe out and use your arms to push your body slowly off the chair. </li> <li>Hold position for one second. </li> <li>Breathe in as you slowly lower yourself back down. </li> <li>Repeat 10 to 15 times. </li> <li>Rest; then repeat 10 to 15 more times. </li> </ol></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 72489 Version 2.0</div></div></div>"},"72496":{"type":"graphic_figure","displayName":"Character photons a","title":"Depth dose curve for an unmodulated proton beam, 10 MeV photon radiation, and spread-out Bragg Peak (SOBP) proton radiation","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Depth dose curve for an unmodulated proton beam, 10 MeV photon radiation, and spread-out Bragg Peak (SOBP) proton radiation</div><div class=\"cntnt\"><img style=\"width:567px; height:399px;\" src=\"images/ONC/72496_Character_photons_a.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dose distribution of an unmodulated proton beam consists of a slowly rising dose, a rapid rise to a maximum (also known as the Bragg Peak), followed by a fall to near zero. As a result, a significant portion of the beam energy is deposited in a small volume. In contrast, the energy deposition of photon irradiation is dictated by the laws of exponential decay and is distributed over a larger volume. Because of the sharpness of the Bragg Peak, a single monoenergetic proton beam will only irradiate an area approximately the size of a pituitary gland. Irradiation of larger targets is achieved by superimposing proton beams of different energies. The end result of this superposition is known as the spread-out Bragg Peak (SOBP).</div><div class=\"graphic_reference\">Courtesy of Massachusetts General Hospital.</div><div id=\"graphicVersion\">Graphic 72496 Version 2.0</div></div></div>"},"72500":{"type":"graphic_table","displayName":"Factors water maintenance needs","title":"Factors affecting water maintenance needs in children and infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors affecting water maintenance needs in children and infants</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Source </td>\n\n      <td colspan=\"1\" class=\"subtitle1\">Increased water needs</td>\n\n\n      <td class=\"subtitle1\">Decreased water needs</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Skin</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Burns<br />Fever<br />Phototherapy<br />Prematurity<br />Radiant heater<br />Sweat</td>\n\n\n      <td>Enclosed incubator<br />Mist tent</td>\n\n    </tr>\n\n    \n    \n    \n    \n    \n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Lungs</td>\n\n      <td>Tachypnea<br />Tracheostomy</td>\n\n\n      <td>Humidified air</td>\n\n    </tr>\n\n    \n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Gastrointestinal tract</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Diarrhea<br />Emesis<br />Ileostomy<br />Nasogastric suction</td>\n\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    \n    \n    \n    <tr>\n\n      <td>Renal</td>\n\n      <td>Polyuria</td>\n\n\n      <td>Oliguria/anuria</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"1\">Miscellaneous</td>\n\n      <td rowspan=\"1\" colspan=\"1\">Surgical drain<br />Increased activity</td>\n\n      <td colspan=\"1\" rowspan=\"1\">Sedation<br />Hypothyroidism</td>\n\n    </tr>\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72500 Version 2.0</div></div></div>"},"72501":{"type":"graphic_table","displayName":"Toilet training guidance","title":"Anticipatory guidance for toilet training","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticipatory guidance for toilet training</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Visit </td> <td class=\"subtitle1\">Action </td> </tr> <tr> <td rowspan=\"2\">12-month </td> <td>Discourage active toilet training until after 18-month visit</td> </tr> <tr> <td>Evaluate parental expectations</td> </tr> <tr> <td>15-month</td> <td>Discuss the criteria for readiness</td> </tr> <tr> <td rowspan=\"2\">18-month </td> <td>Review the criteria for readiness</td> </tr> <tr> <td>Provide written information on the toilet-training process</td> </tr> <tr> <td rowspan=\"4\">24-month </td> <td>Evaluate the child's readiness</td> </tr> <tr> <td>Provide feedback on progress and plan if training has begun</td> </tr> <tr> <td>Discuss nighttime enuresis if the child has daytime control</td> </tr> <tr> <td>Congratulate the child and parents if the child is toileting independently</td> </tr> <tr> <td rowspan=\"5\">36-month </td> <td>Provide feedback on progress and plan</td> </tr> <tr> <td>Discuss toileting refusal issues</td> </tr> <tr> <td>Discuss nighttime enuresis</td> </tr> <tr> <td>Discuss reasons for follow-up before 48-month visit</td> </tr> <tr> <td>Congratulate the child and parents if the child is toileting independently</td> </tr> <tr> <td rowspan=\"3\">48-month </td> <td>Discuss nighttime enuresis</td> </tr> <tr> <td>Revisit any medical causes that may be interfering with completion of toilet training (eg, constipation)</td> </tr> <tr> <td>Refer to behavior specialist if child refuses daytime training</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Michel RS. Pediatrics in Review 1999; 20:240.</div><div id=\"graphicVersion\">Graphic 72501 Version 2.0</div></div></div>"},"72502":{"type":"graphic_picture","displayName":"Multiple verrucae OLT","title":"Multiple verrucae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple verrucae</div><div class=\"cntnt\"><img style=\"width:393px; height:260px;\" src=\"images/GAST/72502_Multiple_verrucae_OLT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple verrucae of the hands and digits in a patient who has undergone liver transplantation.</div><div class=\"graphic_reference\">Courtesy of Jean-Fran&#231;ois Dufour, MD.</div><div id=\"graphicVersion\">Graphic 72502 Version 1.0</div></div></div>"},"72503":{"type":"graphic_picture","displayName":"Group B Streptococcus in CSF","title":"Group B <EM>Streptococcus </EM>in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Group B <EM>Streptococcus </EM>in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:372px; height:240px;\" src=\"images/ID/72503_GramstainCSF4withanswe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and gram-positive coccobacilli. <EM>Streptococcus agalactiae</EM> (group B <EM>Streptococcus</EM>) grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 72503 Version 4.0</div></div></div>"},"72505":{"type":"graphic_picture","displayName":"Glomerular capillary wall","title":"Normal glomerular capillary wall","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal glomerular capillary wall</div><div class=\"cntnt\"><img style=\"width:378px; height:204px;\" src=\"images/NEPH/72505_Glomerular_capillary_wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power electron micrograph shows the three layers of the normal glomerular capillary wall: the fenestrated endothelium (Endo); the glomerular basement membrane (GBM); and the epithelial cell with its foot processes (FP). The foot processes are separate by slit pores which are closed by a thin membrane, the slit diaphragm (arrow). In terms of permeability to macromolecules, the GBM and the slit diaphragms are the major sites of size-selectivity, while the endothelium and GBM are the major sites of charge-selectivity.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 72505 Version 1.0</div></div></div>"},"72507":{"type":"graphic_diagnosticimage","displayName":"Clubfoot3","title":"Sonogram of fetal clubfoot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of fetal clubfoot</div><div class=\"cntnt\"><img style=\"width:383px; height:266px;\" src=\"images/OBGYN/72507_Clubfoot3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plantar surface of the entire fetal right foot can be seen in the same plane as the fibula and tibia. This fetus is one of a twin pair; the other twin did not have any abnormalities.</div><div class=\"graphic_reference\">Courtesy of Urania Magriples, MD.</div><div id=\"graphicVersion\">Graphic 72507 Version 2.0</div></div></div>"},"72508":{"type":"graphic_table","displayName":"Selection of patients for venom immunotherapy","title":"Selection of patients for venom immunotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of patients for venom immunotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reaction to sting </td> <td class=\"subtitle1\">Result of skin test or venom-specific IgE test</td> <td class=\"subtitle1\">Venom immunotherapy indicated?</td> </tr> <tr> <td class=\"indent1\">Non-life-threatening, widespread, cutaneous reaction: Generalized urticaria, angioedema, erythema, pruritus</td> <td>Positive</td> <td>No*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Systemic, life-threatening reaction: Possible cutaneous symptoms but also respiratory symptoms (laryngeal edema or bronchospasm) or cardiovascular symptoms (hypotension, shock)</td> <td>Positive</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Systemic reaction</td> <td>Negative</td> <td>No<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Large local reaction (&#62;4 inches or 10 cm in diameter, &#62;24-hour duration)</td> <td>Positive or negative</td> <td>No*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Normal reaction (&#8804;4 inches or 10 cm in diameter, &#60;24-hour duration)</td> <td>Positive or negative</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.<br />* Exceptions occasionally made.<br />Â¶ It is unknown whether this applies to imported fire ant hypersensitivity.<br />âÎ Patients with a convincing history of a systemic sting reaction but negative tests for venom-specific IgE may be at risk for a future systemic reaction due to unclear mechanisms. This diagnostic dilemma is discussed in the UpToDate topic on diagnosis of Hymenoptera venom allergy.</div><div class=\"graphic_reference\">Original figure modified for this publication. Graft DF. Insect sting allergy. Med Clin N Am 2006; 90:211. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72508 Version 6.0</div></div></div>"},"72511":{"type":"graphic_table","displayName":"R-CODOX-M IVAC regimen","title":"R-CODOX-M/IVAC (Magrath) regimen for Burkitt lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">R-CODOX-M/IVAC (Magrath) regimen for Burkitt lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>The R-CODOX-M/IVAC regimen is composed of four cycles, each cycle lasting until the absolute neutrophil count returns to &#62;1000/microL and the platelet count &#62;100,000/microL. Cycles 1 and 3 are R-CODOX-M and cycles 2 and 4 are R-IVAC. Three cycles of R-CODOX-M are sufficient for patients with low-risk disease (ie, a single focus of disease &#60;10 cm in diameter and a normal serum lactate dehydrogenase level).</td> </tr> <tr> <td class=\"subtitle1_single\">R-CODOX-M (cycles one and three):<sup>[1-4]</sup></td> </tr> <tr> <td class=\"indent1\">Rituximab 375 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide 800 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide 200 mg/m<sup>2</sup> IV on days 2 through 5</td> </tr> <tr> <td class=\"indent1\">Doxorubicin 40 mg/m<sup>2</sup> slow IV push on day 1</td> </tr> <tr> <td class=\"indent1\">Vincristine 1.5 mg/m<sup>2</sup> (maximum 2 mg) IV on days 1 and 8 (cycle 1) and days 1 and&nbsp;8 (cycle 3)</td> </tr> <tr> <td class=\"sublist2_start\">Methotrexate</td> </tr> <tr> <td class=\"sublist2\">Age 65 years or younger: 300 mg/m<sup>2</sup> IV loading dose over one hour on day 10, followed by 2700 mg/m<sup>2</sup> IV infusion administered over the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion</td> </tr> <tr> <td class=\"sublist2\">Age &#62;65 years: 100 mg/m<sup>2</sup> IV loading dose over one hour on day 10, followed by 900 mg/m<sup>2</sup> IV infusion administered over the next 23 hours; leucovorin rescue begins 36 hours from the start of the methotrexate infusion</td> </tr> <tr> <td class=\"indent1\">Granulocyte colony-stimulating factor begins 24 hours after leucovorin rescue is started and continues until the absolute neutrophil count is &#62;1000/microL</td> </tr> <tr> <td class=\"sublist2_start\">Intrathecal medications</td> </tr> <tr> <td class=\"sublist2\">Intrathecal cytarabine 70 mg (if &#62;3 years of age) on days 1 and 3</td> </tr> <tr> <td class=\"sublist2\">Intrathecal methotrexate 12 mg (if &#62;3 years of age) on day 15</td> </tr> <tr> <td class=\"sublist2\">Oral leucovorin 15 mg/dose on day 16, 24 hours after intrathecal methotrexate</td> </tr> <tr> <td class=\"sublist2\">Enhanced CNS directed therapy for patients with CNS disease at presentation: cytarabine 70 mg/dose (if &#62;3 years of age) intrathecal (or 15 mg if via Ommaya reservoir) on day 5 and methotrexate 12 mg (if &#62;3 years of age) intrathecal (or 2 mg if via Ommaya reservoir) on day 17 in cycle 1<sup>[2]</sup></td> </tr> <tr> <td class=\"subtitle1_single\">R-IVAC (cycles two and four):<sup>[1-4]</sup></td> </tr> <tr> <td class=\"indent1\">Rituximab 375 mg/m<sup>2</sup> IV on day 1</td> </tr> <tr> <td class=\"sublist2_start\">Ifosfamide</td> </tr> <tr> <td class=\"sublist2\">Age 65 years or younger: 1500 mg/m<sup>2</sup> IV on days 1 through 5 with mesna uroprotection</td> </tr> <tr> <td class=\"sublist2\">Age &#62;65 years: 1000 mg/m<sup>2</sup> IV on days 1 through 5 with mesna uroprotection</td> </tr> <tr> <td class=\"indent1\">Etoposide 60 mg/m<sup>2</sup> IV on days 1 through 5</td> </tr> <tr> <td class=\"sublist2_start\">Cytarabine</td> </tr> <tr> <td class=\"sublist2\">Age 65 years or younger: 2 g/m<sup>2</sup> IV every 12 hours on days 1 and 2 (four doses)</td> </tr> <tr> <td class=\"sublist2\">Age &#62;65 years: 1 g/m<sup>2</sup> IV every 12 hours on days 1 and 2 (four doses)</td> </tr> <tr> <td class=\"indent1\">Granulocyte colony-stimulating factor begins 24 hours after the completion of IV chemotherapy and continues until the absolute neutrophil count is &#62;1000/microL</td> </tr> <tr> <td class=\"sublist2_start\">Intrathecal medications</td> </tr> <tr> <td class=\"sublist2\">Intrathecal methotrexate 12 mg (if &#62;3 years of age) on day 5</td> </tr> <tr> <td class=\"sublist2\">Oral leucovorin 15 mg on day 6, 24 hours after intrathecal methotrexate</td> </tr> <tr> <td class=\"sublist2\">Enhanced CNS directed therapy for patients with CNS disease at presentation: cytarabine 70 mg (if &#62;3 years of age) intrathecal (or 15 mg if via Ommaya reservoir) on days 7 and 9 in cycle 2<sup>[2]</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table illustrates the R-CODOX-M/IVAC (Magrath) regimen used for aggressive lymphomas. The version used in the earliest clinical trial included a cycle 3 day 15 dose of vincristine, which has been eliminated from most subsequent trials investigating this regimen. </div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14:925. </li>&#xD;&#xA;    <li>Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 Study. Ann Oncol 2002; 13:1264. </li>&#xD;&#xA;    <li>Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 Trial). Blood 2008; 112:2248. </li>&#xD;&#xA;    <li>Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45:761.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72511 Version 7.0</div></div></div>"},"72513":{"type":"graphic_picture","displayName":"Macular stain - neck","title":"Macular stain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macular stain</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/72513_Macular_stain_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous patch is present on the posterior scalp and neck of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72513 Version 3.0</div></div></div>"},"72516":{"type":"graphic_picture","displayName":"Two rescuer bag-mask ventilation pediatric","title":"Two rescuer bag-mask ventilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two rescuer bag-mask ventilation</div><div class=\"cntnt\"><img style=\"width:360px; height:307px;\" src=\"images/EM/72516_Two_rescuer_bag_pediatric.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two rescuers may be necessary to provide ventilation. One rescuer may need both hands to open the airway and make the seal between the child's face and the mask. The second rescuer is then needed to provide positive pressure ventilation.</div><div id=\"graphicVersion\">Graphic 72516 Version 5.0</div></div></div>"},"72517":{"type":"graphic_figure","displayName":"Treatment of severe retinopathy","title":"Photocoagulation slows progression of severe diabetic retinopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photocoagulation slows progression of severe diabetic retinopathy</div><div class=\"cntnt\"><img style=\"width:448px; height:248px;\" src=\"images/ENDO/72517_Treatment_of_severe_retinop.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative rates of developing severe visual loss in untreated eyes with advanced retinopathy and those treated with argon laser or xenon arc photocoagulation. Photocoagulation slowed the rate of progressive disease by more than 50 percent.</div><div class=\"graphic_reference\">Data from: The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.&nbsp;Ophthalmology 1981; 88:583.</div><div id=\"graphicVersion\">Graphic 72517 Version 2.0</div></div></div>"},"72518":{"type":"graphic_table","displayName":"Frequency adverse effects","title":"Frequency of adverse drug events by type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of adverse drug events by type</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\"> <p>Total adverse drug events (n = 815)</p> <p>N (percent)</p> </td> <td class=\"subtitle1\"> <p>Preventable adverse drug events (n = 338)</p> <p>N (percent)</p> </td> </tr> <tr> <td>Neuropsychiatric</td> <td>199 (24)</td> <td>97 (29)</td> </tr> <tr> <td>Hemorrhagic</td> <td>159 (20)</td> <td>53 (16)</td> </tr> <tr> <td>Gastrointestinal</td> <td>140 (17)</td> <td>55 (16)</td> </tr> <tr> <td>Renal/electrolytes</td> <td>80 (10)</td> <td>40 (12)</td> </tr> <tr> <td>Metabolic/endocrine</td> <td>64 (8)</td> <td>35 (10)</td> </tr> <tr> <td>Cardiovascular</td> <td>36 (4)</td> <td>15 (4)</td> </tr> <tr> <td>Dermatologic</td> <td>36 (4)</td> <td>4 (1)</td> </tr> <tr> <td>Extrapyramidal symptoms</td> <td>30 (4)</td> <td>7 (2)</td> </tr> <tr> <td>Fall with injury</td> <td>21 (3)</td> <td>17 (5)</td> </tr> <tr> <td>Fall without injury</td> <td>21 (3)</td> <td>11 (3)</td> </tr> <tr> <td>Infection</td> <td>19 (2)</td> <td>1 (&#60;1)</td> </tr> <tr> <td>Syncope/dizziness</td> <td>16 (2)</td> <td>8 (2)</td> </tr> <tr> <td>Anticholinergic</td> <td>9 (1)</td> <td>3 (1)</td> </tr> <tr> <td>Ataxia/difficulty with gait</td> <td>9 (1)</td> <td>5 (2)</td> </tr> <tr> <td>Hematologic</td> <td>8 (1)</td> <td>3 (1)</td> </tr> <tr> <td>Respiratory</td> <td>6 (1)</td> <td>4 (1)</td> </tr> <tr> <td>Anorexia</td> <td>3 (&#60;1)</td> <td>2 (&#60;1)</td> </tr> <tr> <td>Functional decline</td> <td>3 (&#60;1)</td> <td>2 (&#60;1)</td> </tr> <tr> <td>Hepatic</td> <td>1 (&#60;1)</td> <td>1 (&#60;1)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adverse drug events could manifest as more than one type. Neuropsychiatric events include oversedation, confusion, hallucinations, and delirium. Anticholinergic effects include dry mouth, dry eyes, urinary retention, and constipation.</div><div class=\"graphic_reference\">Reproduced with permission from: Gurwitz, MD, Field, T, Judge, J, Rochon, P, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118:251. Copyright &#169; 2005 Excerpta Media.</div><div id=\"graphicVersion\">Graphic 72518 Version 3.0</div></div></div>"},"72519":{"type":"graphic_picture","displayName":"Urticaria 1","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:252px; height:384px;\" src=\"images/PC/72519_Urticaria_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticaria is characterized by circumscribed, raised, erythematous, and extremely pruritic lesions. They typically appear in one area, resolve over the course of several hours, and then reappear elsewhere. Individual lesions may enlarge and develop central pallor before fading.</div><div class=\"graphic_reference\">Courtesy of Andrew Samel, MD.</div><div id=\"graphicVersion\">Graphic 72519 Version 1.0</div></div></div>"},"72520":{"type":"graphic_diagnosticimage","displayName":"Early postpneumonectomy PA","title":"Expected chest radiographic changes in the early postpneumonectomy period","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Expected chest radiographic changes in the early postpneumonectomy period</div><div class=\"cntnt\"><img style=\"width:360px; height:255px;\" src=\"images/PULM/72520_Early_postpneumonectomy_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immediately after surgery, a chest tube is in place, the postpneumonectomy space (arrow) is empty, and the ipsilateral hemidiaphragm is slightly elevated.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 72520 Version 3.0</div></div></div>"},"72523":{"type":"graphic_figure","displayName":"Nerves of the lower extremity","title":"Nerves of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nerves of the lower extremity</div><div class=\"cntnt\"><img style=\"width:446px; height:659px;\" src=\"images/SURG/72523_Nerves_of_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 72523 Version 4.0</div></div></div>"},"72525":{"type":"graphic_waveform","displayName":"ECG in electrical alternans","title":"Electrical alternans","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrical alternans</div><div class=\"cntnt\"><img style=\"width:408px; height:360px;\" src=\"images/CARD/72525_Electrical_alternans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus tachycardia with electrical alternans which is characterized by beat-to-beat alternation in the QRS appearance (best seen in leads V2 to V4). These findings are strongly suggestive of pericardial effusion, usually with cardiac tamponade. The alternating ECG pattern is related to back-and-forth swinging motion of the heart in the pericardial fluid.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 72525 Version 4.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"72526":{"type":"graphic_table","displayName":"Results Roche trial NO16966","title":"Results of Roche trial NO 16966","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of Roche trial NO 16966</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Treatment group\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   FOLFOX + placebo\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   XELOX + placebo\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   FOLFOX + bevacizumab\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   XELOX + bevacizumab\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   N\r\n  \r\n   </td>\r\n  \r\n   <td>351</td>\r\n  \r\n   <td>350</td>\r\n  \r\n   <td>349</td>\r\n  \r\n   <td>350</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2\" colspan=\"2\">\r\n  \r\n   Both placebo groups\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle2\" colspan=\"2\">\r\n  \r\n   Both bevacizumab groups\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>PFS, median (months)</td>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   8.0\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   9.4 (p = .0023)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>OS, median (months)</td>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   19.9\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   21.3\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Response rate, percent</td>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   38 (49)*\r\n  \r\n   </td>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   38 (47)*\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">PFS: progression free survival; FOLFOX: oxaliplatin, 5FU, leucovorin; XELOX: capecitabine + oxaliplatin; OS: overall survival.<br>* Objective response rates according to independent review committee, followed by investigator-reported rates, in parentheses.</div><div class=\"graphic_reference\">Data from: Saltz, LB, et al. J Clin Oncol 2008; 26:2013.</div><div id=\"graphicVersion\">Graphic 72526 Version 1.0</div></div></div>"},"72528":{"type":"graphic_figure","displayName":"Interincisal distance","title":"Measurement of interincisal distance","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Measurement of interincisal distance</div><div class=\"cntnt\"><img style=\"width:491px; height:577px;\" src=\"images/PEDS/72528_Interincisal_distance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tongue is placed at the posterior edge of the upper teeth, and the mouth is opened as widely as possible. Measurement (in millimeters) is taken between the teeth, as illustrated above.</div><div id=\"graphicVersion\">Graphic 72528 Version 1.0</div></div></div>"},"72529":{"type":"graphic_figure","displayName":"Stirrup splint","title":"Stirrup splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stirrup splint</div><div class=\"cntnt\"><img style=\"width:360px; height:443px;\" src=\"images/PEDS/72529_Stirrup_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ankle stirrup splint is applied to prevent inversion or eversion of the ankle, and provides better immobilization for fractures near the ankle than the posterior leg splint. Plaster is applied from below the knee and wrapped around the ankle.</div><div id=\"graphicVersion\">Graphic 72529 Version 2.0</div></div></div>"},"72531":{"type":"graphic_figure","displayName":"Digoxin in HF","title":"Digoxin withdrawal worsens HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digoxin withdrawal worsens HF</div><div class=\"cntnt\"><img style=\"width:408px; height:254px;\" src=\"images/CARD/72531_Digoxin_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probability of worsening heart failure in stable patients treated with digoxin, diuretics, and angiotensin converting enzyme inhibitors in patients switched to placebo (upper line) or continued on digoxin (lower line). Patients withdrawn from digoxin fared much worse, with the difference increasing with time (p</div><div class=\"graphic_reference\">Data from: Packer, M, Gheorghiade, M, Young, JB, et al, N Engl J Med 1993; 329:1.</div><div id=\"graphicVersion\">Graphic 72531 Version 1.0</div></div></div>"},"72532":{"type":"graphic_waveform","displayName":"Intermediate case 19","title":"Intermediate case 19","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intermediate case 19</div><div class=\"cntnt\"><img style=\"width:540px; height:112px;\" src=\"images/CARD/72532_Intermediate_case_19.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72532 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"72533":{"type":"graphic_figure","displayName":"Pathophysiology ASD","title":"Pathophysiology of atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of atrial septal defect</div><div class=\"cntnt\"><img style=\"width:499px; height:446px;\" src=\"images/CARD/72533_Pathophysiology_ASD.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72533 Version 2.0</div></div></div>"},"72534":{"type":"graphic_diagnosticimage","displayName":"TEE right pulmonary veins","title":"Pulmonary veins on transesophageal echocardiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary veins on transesophageal echocardiogram</div><div class=\"cntnt\"><img style=\"width:317px; height:226px;\" src=\"images/CARD/72534_TEE_right_pulmonary_veins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior rotation of the probe and transducer rotation to 54Âº demonstrates the three right pulmonary veins: right upper (RUPV); right middle (RMPV); and right lower pulmonary vein (RLPV).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 72534 Version 2.0</div></div></div>"},"72535":{"type":"graphic_diagnosticimage","displayName":"Oblique fracture 4th metacarpal shaft","title":"Oblique fracture of the 4th metacarpal shaft","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Oblique fracture of the 4th metacarpal shaft</div><div class=\"cntnt\"><img style=\"width:480px; height:348px;\" src=\"images/EM/72535_4th_MC_oblique_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique fractures of the metacarpal shaft (arrows) are more likely to shorten and rotate.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 72535 Version 3.0</div></div></div>"},"72536":{"type":"graphic_picture","displayName":"Groin abscess","title":"Groin abscess","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Groin abscess</div><div class=\"cntnt\"><img style=\"width:518px; height:196px;\" src=\"images/EM/72536_Groinabscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A large abscess formed in the groin of the child, directly over the femoral vessels and nerve. <br />(B) A superficial incision produced an immediate return of pus.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR. Selected Procedures. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72536 Version 11.0</div></div></div>"},"72537":{"type":"graphic_table","displayName":"Sting provocation test after stopping VIT of at least 3 years ","title":"Sting provocation test after stopping venom immunotherapy of at least three years' duration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sting provocation test after stopping venom immunotherapy of at least three years' duration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients</td> <td class=\"subtitle1\" rowspan=\"2\">Insect</td> <td class=\"subtitle1\" colspan=\"2\">Sting challenge</td> </tr> <tr> <td class=\"subtitle2\">Years since stopping VIT</td> <td class=\"subtitle2\">Number with SAR (percentage)</td> </tr> <tr> <td rowspan=\"2\">Urbanek<sup>[1]</sup></td> <td>29</td> <td rowspan=\"2\">Honey bee</td> <td>1</td> <td>1 (3)</td> </tr> <tr> <td>14</td> <td>2</td> <td>2 (14)</td> </tr> <tr> <td rowspan=\"2\">Golden<sup>[2]</sup></td> <td>29</td> <td>Mostly vespid</td> <td>1</td> <td>0</td> </tr> <tr> <td>74</td> <td>Mostly vespid</td> <td>2 to 5</td> <td>7 (9.5)</td> </tr> <tr> <td>M&#252;ller<sup>[3]</sup></td> <td>86</td> <td>Honey bee</td> <td>1</td> <td>15 (17)</td> </tr> <tr> <td>Haugaard<sup>[4]</sup></td> <td>25</td> <td>Vespid</td> <td>2</td> <td>0</td> </tr> <tr> <td>Keating<sup>[5]</sup></td> <td>51</td> <td>Mostly vespid</td> <td>1</td> <td>2 (4)</td> </tr> <tr> <td>van Halteren<sup>[6]</sup></td> <td>75</td> <td>Vespid</td> <td>1 to 3</td> <td>6 (8)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VIT: venom immunotherapy; SAR: systemic allergic reaction.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Urbanek R, Forster J, Kuhn W, Ziupa J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatrics 1985; 107:367. </li>&#xD;&#xA;    <li>Golden DBK, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: Outcome after five years. J Allergy Clin Immunol 1996; 97:587. </li>&#xD;&#xA;    <li>M&uuml;ller U, Berchtold E, Helbling A. Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702. </li>&#xD;&#xA;    <li>Haugaard L, N&ouml;rregaard OF, Dahl R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87:699. </li>&#xD;&#xA;    <li>Keating MU, Kagey-Sobotka A, Hamilton RG, Yunginger JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339. </li>&#xD;&#xA;    <li>van Halteren HK, van der Linden PW, Burgers JA, Bartelink AK. Discontinuation of yellow jacket venom immunotherapy: Follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997; 100:767. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72537 Version 10.0</div></div></div>"},"72538":{"type":"graphic_diagnosticimage","displayName":"Anterior shoulder dislocation scapular Y view","title":"Anterior shoulder dislocation on a scapular Y view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior shoulder dislocation on a scapular Y view</div><div class=\"cntnt\"><img style=\"width:360px; height:373px;\" src=\"images/EM/72538_Shoulder_ant_DL_scap_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"Y\" of this view is formed by the scapula's body, spine, and coracoid process. The glenoid normally falls in the center of the \"Y\" and is obscured by the humeral head. In this x-ray an anterior dislocation is present, and the humeral head appears&nbsp;anterior to the \"Y\".</div><div id=\"graphicVersion\">Graphic 72538 Version 2.0</div></div></div>"},"72539":{"type":"graphic_figure","displayName":"Dopamine agonists in prolactinoma","title":"Dopamine agonist drugs lower serum prolactin concentrations in lactotroph adenoma (prolactinoma)","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Dopamine agonist drugs lower serum prolactin concentrations in lactotroph adenoma (prolactinoma)</div><div class=\"cntnt\"><img style=\"width:460px; height:264px;\" src=\"images/ENDO/72539_Dopamine_agonists_in_PLoma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum prolactin concentrations in women with hyperprolactinemic amenorrhea treated with bromocriptine and cabergoline. Both drugs lowered serum prolactin concentrations into the normal range (upper limit of normal equals 20 mcg/L).</div><div class=\"graphic_reference\">Data from: Webster J, Piscitelli MD, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331:904.</div><div id=\"graphicVersion\">Graphic 72539 Version 4.0</div></div></div>"},"72540":{"type":"graphic_figure","displayName":"Serum prolactin by dx","title":"Ranges of serum prolactin concentrations in several causes of hyperprolactinemia","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Ranges of serum prolactin concentrations in several causes of hyperprolactinemia</div><div class=\"cntnt\"><img style=\"width:514px; height:424px;\" src=\"images/ENDO/72540_Serum_prolactin_by_dx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The serum prolactin concentration is much higher in most patients who have lactotroph macroadenoma than in patients with any other cause of hyperprolactinemia. The prolactin concentrations among other causes overlap with each other.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.</LI>&#xD;&#xA;<LI>Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors.&nbsp;N Engl J Med 1977; 296:589.</LI>&#xD;&#xA;<LI>David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085. </LI>&#xD;&#xA;<LI>Rivera JL, Lal S, Ettigi P, et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 1976; 5:273.</LI>&#xD;&#xA;<LI>McCallum RW, Sowers JR, Hershman JM, Sturdevant RA. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab 1976; 42:1148.</LI>&#xD;&#xA;<LI>Mancini AM, Guitelman A, Vargas CA, et al. Effect of sulpiride on serum prolactin levels in humans.&nbsp;J Clin Endocrinol Metab 1976; 42:181. </LI>&#xD;&#xA;<LI>Sowers JR, Sharp B, McCallum RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab 1982; 54:869.</LI>&#xD;&#xA;<LI>Steiner J, Cassar J, Mashiter K, et al. Effects of methyldopa on prolactin and growth hormone.&nbsp;Br Med J 1976; 1:1186.</LI>&#xD;&#xA;<LI>Lee PA, Kelly MR, Wallin JD. Increased prolactin levels during reserpine treatment of hypertensive patients.&nbsp;JAMA 1976; 235:2316. </LI>&#xD;&#xA;<LI>Fearrington EL, Rand CH Jr, Rose JD. Hyperprolactinemia-galactorrhea induced by verapamil. Am J Cardiol 1983; 51:1466.</LI>&#xD;&#xA;<LI>Veldhuis JD, Borges JL, Drake CR, et al. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man.&nbsp;J Clin Endocrinol Metab 1985; 60:144.</LI></OL></div><div id=\"graphicVersion\">Graphic 72540 Version 2.0</div></div></div>"},"72544":{"type":"graphic_table","displayName":"HCG levels in GTD","title":"USA hCG Reference Service experience, concentration of hCG and hCG-H in serum samples in gestational trophoblastic diseases and non-gestational malignancies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">USA hCG Reference Service experience, concentration of hCG and hCG-H in serum samples in gestational trophoblastic diseases and non-gestational malignancies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Source</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\">Total hCG, mIU/ml</td> <td class=\"subtitle1\">hCG-H, mIU/ml equivalents*</td> </tr> <tr> <td class=\"subtitle2\">Median (range)</td> <td class=\"subtitle2\">Percent of total hCG &#177; SD</td> </tr> <tr> <td>Complete hydatidiform mole (prior to evacuation)</td> <td>30</td> <td>192,995 (24,160-3,704,084)</td> <td>4.9 &#177; 2.1 percent</td> </tr> <tr> <td>Partial hydatidiform mole (prior to evacuation)</td> <td>21</td> <td>48,900 (11,600-220,114)</td> <td>3.6 &#177; 1.7 percent</td> </tr> <tr> <td>Invasive mole, recurrent mole (at commencement of therapy)</td> <td>72</td> <td>869 (24-30,255)</td> <td>30 &#177; 35 percent</td> </tr> <tr> <td>Choriocarcinoma/GTN (at time of diagnosis)</td> <td>102</td> <td>16,298 (5.2-597,000)</td> <td>61 &#177; 41 percent</td> </tr> <tr> <td>Quiescent GTD (at time of diagnosis)<sup>&#182;</sup></td> <td>101</td> <td>22 (1-212)</td> <td>0.31 percent &#177; 2.16 percent</td> </tr> <tr> <td>PSTT (at time of diagnosis)<sup>&#182;</sup></td> <td>21</td> <td>30 (1-231)</td> <td>7.1 &#177; 13 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; hCG-H: hyperglycosylated hCG; PSTT: Placental site trophoblastic tumor; GTD: Gestational trophoblastic disease; GTN: Gestational trophoblastic neoplasia; SD: standard deviation.<br />* Values are measured as equivalents of regular hCG, assuming that 1 ng/ml hCG is 11.1 mIU/ml (using WHO 4th international standard).<br />Â¶ As measured by USA hCG Reference Service, indicated diagnosis confirmed at biopsy by referring center.</div><div id=\"graphicVersion\">Graphic 72544 Version 2.0</div></div></div>"},"72545":{"type":"graphic_picture","displayName":"Caudal regression syndrome","title":"Caudal regression syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Caudal regression syndrome</div><div class=\"cntnt\"><img style=\"width:371px; height:490px;\" src=\"images/PEDS/72545_Caudal_regression_synd_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Infant of a diabetic mother with caudal regression syndrome. Top panel shows decreased growth of the left leg. In the bottom panel, a plain radiograph reveals absence of the sacrum.</div><div class=\"graphic_reference\">Courtesy of G Cabrera-Mesa, MD.</div><div id=\"graphicVersion\">Graphic 72545 Version 4.0</div></div></div>"},"72547":{"type":"graphic_waveform","displayName":"ECG ventricular bigeminy","title":"Single-lead electrocardiogram (ECG) showing sinus rhythm with ventricular bigeminy","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing sinus rhythm with ventricular bigeminy</div><div class=\"cntnt\"><img style=\"width:520px; height:142px;\" src=\"images/CARD/72547_Ventricular_bigeminy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm with ventricular bigeminy. Each sinus beat is followed by a uniform premature complex with prolonged duration and no apparent P wave; these findings are indicative of ventricular ectopic beats.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 72547 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"72548":{"type":"graphic_figure","displayName":"NADPH oxidase system","title":"NADPH oxidase activation","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">NADPH oxidase activation</div><div class=\"cntnt\"><img style=\"width:497px; height:533px;\" src=\"images/ALLRG/72548_NADPH_oxidase_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glucose-6-phosphate dehydrogenase is required for the production of NADPH, an essential component of the NADPH oxidase system (1). The phagocyte NADPH oxidase system generates O<SUP>-</SUP> <SUB>2</SUB> by transferring e<SUP>-</SUP> from NADPH to O<SUB>2</SUB> (2). Superoxide is metabolized to H<SUB>2</SUB>O<SUB>2</SUB> by superoxide dismutase (3). Hydrogen peroxide can follow different metabolic pathways inside the cell. Myeloperoxidase can convert it into HOCl (4), which is involved in the oxygen-dependent killing of microorganisms in combination with other reactive oxygen species&nbsp;(5). Alternatively, hydrogen peroxide can be degraded to H<SUB>2</SUB>O and O<SUB>2</SUB>, thereby avoiding deleterious effect on the cell (6). Hydrogen peroxide can also diffuse outside the cell and can augment other defective cells (7).</div><div class=\"graphic_footnotes\">NADPH: reduced form of nicotinamide adenine dinucleotide phosphate; <FONT color=black>NADP<SUP>+</SUP>:</FONT> nicotinamide adenine dinucleotide phosphate; p47 phox: 47 kilodalton (KD) phagocyte oxidase; p67 phox: 67 kilodalton (KD) phagocyte oxidase; p40 phox: 40 kilodalton (KD) phagocyte oxidase; p22 phox: 22 kilodalton (KD) phagocyte oxidase; gp91 phox: 91 kilodalton (KD) glycoprotein oxidase; GTP: guanosine triphosphate;<FONT color=black> rap1: a small GTP hydrolase (GTPase); rac: GTPase</FONT>-activating protein; H<SUB>2</SUB>O<SUB>2</SUB>: hydrogen peroxide; O<SUB>2</SUB>: molecular oxygen; e<SUP>-</SUP>: electron; O<SUP>-</SUP> 2: superoxide anion; HOCl: hypocholorous acid.</div><div id=\"graphicVersion\">Graphic 72548 Version 5.0</div></div></div>"},"72550":{"type":"graphic_picture","displayName":"Polypectomy APC Endosc","title":"Argon plasma coagulation following colonic polypectomy","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Argon plasma coagulation following colonic polypectomy</div><div class=\"cntnt\"><img style=\"width:554px; height:183px;\" src=\"images/GAST/72550_Polypectomy_APC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: A large sessile polyp is seen in the sigmoid colon. Middle panel: Following snare excision, the base is oozing blood, and residual adenomatous tissue is vissible at the inferior margin (arrow). Right panel: The argon plasma coagulator has been used to fulgurate the base and remaining adenomatous tissue.</div><div class=\"graphic_reference\">Courtesy of Jonathan Cohen, MD.</div><div id=\"graphicVersion\">Graphic 72550 Version 2.0</div></div></div>"},"72551":{"type":"graphic_diagnosticimage","displayName":"Medial directed cecum","title":"Contrast enema demonstrating a medially directed cecum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast enema demonstrating a medially directed cecum</div><div class=\"cntnt\"><img style=\"width:379px; height:498px;\" src=\"images/PEDS/72551_Medial_directed_cecum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This contrast enema illustrates the high, medially directed cecum (see arrow) that can be seen in malrotation.</div><div class=\"graphic_reference\">Reproduced with permission from Carlo Buonomo, MD, Children's Hospital-Boston. Copyright Â© Carlo Buonomo, MD.</div><div id=\"graphicVersion\">Graphic 72551 Version 2.0</div></div></div>"},"72553":{"type":"graphic_algorithm","displayName":"Evaluation of suspected PH","title":"Algorithm for investigation of suspected pulmonary hypertension","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Algorithm for investigation of suspected pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:505px; height:577px;\" src=\"images/PULM/72553_Evaluation_of_suspected_PH.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; ANA: antinuclear antibody; RF: rheumatoid factor; ANCA: antineutrophil cytoplasmic antibody.</div><div id=\"graphicVersion\">Graphic 72553 Version 2.0</div></div></div>"},"72554":{"type":"graphic_diagnosticimage","displayName":"Trapezoid edema T2 coronal MRI","title":"Trapezoid edema on T2 coronal MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trapezoid edema on T2 coronal MRI</div><div class=\"cntnt\"><img style=\"width:324px; height:346px;\" src=\"images/EM/72554_Trapezoid_edema_MRI_T2_coro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This T2-weighted, coronal magnetic resonance image of the wrist shows increased signal in the trapezoid, when compared to the adjacent trapezium (T) and capitate (C). This appearance is consistent with edema due to microtrabecular injury to the trapezoid.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 72554 Version 4.0</div></div></div>"},"72555":{"type":"graphic_table","displayName":"Example of schedule for moderately sensitive patients","title":"Aeroallergen subcutaneous immunotherapy (SCIT) - Example of schedule for moderately sensitive patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeroallergen subcutaneous immunotherapy (SCIT) - Example of schedule for moderately sensitive patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Concentration: 1:100 v/v dilution of maintenance vial</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.05 mL</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.20 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"indent1\">0.70 mL</td> </tr> <tr> <td class=\"subtitle1_single\">Concentration: 1:10 v/v</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.20 mL</td> </tr> <tr> <td class=\"indent1\">0.30 mL</td> </tr> <tr> <td class=\"indent1\">0.50 mL</td> </tr> <tr> <td class=\"indent1\">0.70 mL</td> </tr> <tr> <td class=\"subtitle1_single\">Maintenance concentration: 1:1 v/v</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.15 mL</td> </tr> <tr> <td class=\"indent1\">0.20 mL</td> </tr> <tr> <td class=\"indent1\">0.30 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"indent1\">0.50 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"indent1\">0.50 mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">v/v: volume/volume.</div><div id=\"graphicVersion\">Graphic 72555 Version 9.0</div></div></div>"},"72556":{"type":"graphic_diagnosticimage","displayName":"Coronal CT met well-differentiated NET with mesenteric mass","title":"Coronal CT of metastatic well-differentiated neuroendocrine tumor with a mesenteric mass","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Coronal CT of metastatic well-differentiated neuroendocrine tumor with a mesenteric mass</div><div class=\"cntnt\"><img style=\"width:457px; height:468px;\" src=\"images/ONC/72556_Coron_CT_metast_carcin_PR2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">&nbsp;Metastatic neuroendocrine tumor with mesenteric mass indicating a presumptive small bowel primary. Coronal reformat from a CT scan in equilibrium phase showing a lobulated enhancing mass in the mesentery with a small coarse calcification (thin arrow) and a subcapsular hepatic lesion in segment VII (arrowheads) that is well circumscribed and hypoenhancing at this phase. There is a clip from a prior cholecystectomy (thick arrow) and oral contrast opacification of juejunal and some ileal loops.</div><div class=\"graphic_reference\">Courtesy of Martin Smith, MD.</div><div id=\"graphicVersion\">Graphic 72556 Version 3.0</div></div></div>"},"72557":{"type":"graphic_table","displayName":"Skin tumors after OLT","title":"Skin tumors after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Skin tumors after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Squamous cell and basal cell carcinomas</td> <td>Squamous cell carcinomas are more frequent than basal cell carcinomas, in contrast to the non-transplantation context where basal cell carcinomas are five times more frequent than squamous cell carcinomas. The risk increases with the length of the immunosuppression. After 15 years, they can be found in more than 50 percent of the recipients of a liver transplantation, particularly in regions exposed to sunlight. Regular use of sunscreens may prevent the development of squamous cell carcinoma and to a lesser degree basal cell carcinoma<sup>[1]</sup>. The use of topical diclofenac 3 percent gel may improve post-liver transplantation actinic keratosis and decrease the risk of squamous cell carcinoma<sup>[2]</sup>. These cancers are also frequent in the anogenital region, where they may indicate the presence of another pathogen, human papilloma virus. They are often multiple and aggressive with rapid recurrence after excision, early metastases, or coexistence with a sarcomatous component.</td> </tr> <tr class=\"divider_bottom\"> <td>Cutaneous lymphomas</td> <td>Primary lymphomas of the skin are rare after liver transplantation. When present, they appear as nodules and tumors that are necrotic or ulcerative, more often on the face. They typically occur about three years after transplantation and are a sign of an infection with Epstein-Barr virus and/or strong immunosuppression. T-cell lymphoma/S&#233;zary syndrome is rare after liver transplantation<sup>[3]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Melanomas</td> <td>Melanomas are 2.5 to 4 times more frequent after liver transplantation than in a non-transplanted population<sup>[4]</sup>. A history of a melanoma before the transplantation is a risk factor for a subsequent melanoma. Melanomas can appear de novo after transplantation (after a mean time of five years), be a recurrence or, rarely, be transferred by the graft. Remission has been described in the setting of kidney transplantation after removal of the graft.</td> </tr> <tr class=\"divider_bottom\"> <td>Kaposi's sarcoma</td> <td>The risk of developing a Kaposi's sarcoma after liver transplantation increases 400 to 500 times. The lesions can appear in the first six months following the transplantation. Late presentations are also possible (more than 10 years after transplantation). Infection with herpes virus 8 and immunosuppression have a pathogenic role. The lesions are limited to the skin in 50 percent of the cases. They appear as violaceous plaques or nodules accompanied by lymphedema. They are most frequently seen on the inferior extremities but can occur anywhere. They may display Koebner's phenomenon (occur in areas of trauma). The evolution is usually indolent, but fulminant forms have been reported.</td> </tr> <tr> <td>Merkel's cell tumors</td> <td>The incidence of these tumors, which have been associated with the Merkel cell polyoma virus, is increased after liver transplantation. The clinical presentation is usually a firm and inflammatory nodule. These tumors can be aggressive with local diffusion, metastasis, and rapid recurrence after excision.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Ulrich C, Jurgensen JS, Degan A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 Suppl 3:78.</li>&#xD;&#xA;    <li>Ulrich C, Johannsen A, Rowert-Huber J, et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010; 20:482.</li>&#xD;&#xA;    <li>Al Ajroush N, Rafique Sheikh K, Kadry R, et al. T-cell lymphoma/S&eacute;zary syndrome in a liver transplant recipient. J Cutan Med Surg 2012; 16:68.</li>&#xD;&#xA;    <li>Otley CC, Pittelkow MR. Skin cancer in liver transplant recipients. Liver Transpl 2000; 6:253.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72557 Version 7.0</div></div></div>"},"72560":{"type":"graphic_diagnosticimage","displayName":"IMRT prostate cancer target vol","title":"Planning target volume (PTV) for intensity modulated radiation therapy (IMRT) of prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Planning target volume (PTV) for intensity modulated radiation therapy (IMRT) of prostate cancer</div><div class=\"cntnt\"><img style=\"width:596px; height:127px;\" src=\"images/ONC/72560_IMRT_prostate_cancer_target.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two intraprostatic lesions were initially identified on magnetic resonance scanning, then registered onto treatment planning CT images. (A): Coronal image of the PTV contoured in red, with the dominant intraprostatic lesion at left base of the prostate (DIL1) contoured in pink (arrow), and the dominant intraprostatic lesion at right apex of the prostate (DIL2) contoured in orange (arrowhead); (B) Axial image, demonstrating the PTV and the DIL2 with the rectum in purple; (C) Axial image of the PTV and the DIL1 with the bladder in blue (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Xia P, et al. Int J Radiat Oncol Biol Phys 2001; 51:244. Copyright &copy; 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 72560 Version 6.0</div></div></div>"},"72561":{"type":"graphic_diagnosticimage","displayName":"Calcified intraorbital mass","title":"Calcified intraorbital mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcified intraorbital mass</div><div class=\"cntnt\"><img style=\"width:371px; height:439px;\" src=\"images/PEDS/72561_Calcified_intraorbital_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT scan demonstrates a calcified intraorbital mass. The calcification makes retinoblastoma the most likely diagnosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from Jeanne Chow, MD. Children's Hospital-Boston, Copyright &copy; Jeanne Chow, MD.</div><div id=\"graphicVersion\">Graphic 72561 Version 3.0</div></div></div>"},"72564":{"type":"graphic_table","displayName":"Categories of occupational rhinitis","title":"Categories of occupational rhinitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of occupational rhinitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification</td> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Exposure</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Annoyance</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td>Detergents</td> <td>Supermarket</td> </tr> <tr> <td>Perfumes</td> <td>Department store</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Irritant-induced</td> </tr> <tr> <td rowspan=\"5\">&nbsp;</td> <td>Air pollutants</td> <td>Outdoor, inner city worker</td> </tr> <tr> <td>Cigarette smoke</td> <td>Any workplace</td> </tr> <tr> <td>Cold air</td> <td>Meat packer</td> </tr> <tr> <td>Hairspray</td> <td>Department store</td> </tr> <tr> <td>Talc</td> <td>Cosmetics industry</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Allergic/immunologic</td> </tr> <tr> <td rowspan=\"9\">&nbsp;</td> <td class=\"sublist1_start\" colspan=\"2\">Natural</td> </tr> <tr> <td class=\"sublist1\">Guar gum</td> <td class=\"sublist_other\">Carpet worker</td> </tr> <tr> <td class=\"sublist1\">Latex</td> <td class=\"sublist_other\">Nurse</td> </tr> <tr> <td class=\"sublist1\">Psyllium</td> <td class=\"sublist_other\">Nursing home</td> </tr> <tr> <td class=\"sublist1\">Rats</td> <td class=\"sublist_other\">Laboratory researcher</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Synthetic</td> </tr> <tr> <td class=\"sublist1\">Acid anhydride</td> <td class=\"sublist_other\">Epoxy worker</td> </tr> <tr> <td class=\"sublist1\">Platinum</td> <td class=\"sublist_other\">Jeweler</td> </tr> <tr> <td class=\"sublist1\">Toluene diisocyanate</td> <td class=\"sublist_other\">Spray painter</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Corrosive</td> </tr> <tr> <td>&nbsp;</td> <td>Ammonia</td> <td>Chemical plant</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72564 Version 5.0</div></div></div>"},"72565":{"type":"graphic_table","displayName":"PPI cytochrome metabolism","title":"Principal cytochrome P450Â enzymes involved in hepatic metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principal cytochrome P450&#160;enzymes involved in hepatic metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">PPI</td>\n\n      <td class=\"subtitle1\">Primary pathway</td>\n\n      <td class=\"subtitle1\">Secondary pathway</td>\n\n      <td class=\"subtitle1\">Sulfotransferase</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Omeprazole</td>\n\n      <td>CYP2C19</td>\n\n      <td>CYP3A4</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lansoprazole</td>\n\n      <td>CYP3A4</td>\n\n      <td>CYP2C19</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rabeprazole</td>\n\n      <td>CYP2C19</td>\n\n      <td>CYP3A4</td>\n\n      <td>No</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pantoprazole</td>\n\n      <td>CYP2C19</td>\n\n      <td>CYP3A4</td>\n\n      <td>Yes</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Esomeprazole</td>\n\n      <td>CYP2C19</td>\n\n      <td>CYP3A4</td>\n\n      <td>No</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor.</div><div class=\"graphic_reference\">Adapted from: Gugler R, Jensen JC, Gastroenterology 1985; 89:1235; Diaz D, Fabre I, Daujat M, et al, Gastroenterology 1990; 99:737; Meyer UA, Eur J Gastroenterol Hepatol 1996; 8 Suppl 1:S21; Parsons ME, Eur J Gastroenterol Hepatol 1996; 8 Suppl 1:S15; Lew EA, Aliment Pharmacol Ther 1999; 13 Suppl 5:11.</div><div id=\"graphicVersion\">Graphic 72565 Version 2.0</div></div></div>"},"72566":{"type":"graphic_picture","displayName":"Sutured groin incisions","title":"Bilateral sentinel node identification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bilateral sentinel node identification</div><div class=\"cntnt\"><img style=\"width:432px; height:274px;\" src=\"images/OBGYN/72566_Sutured_groin_incisions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sutured incisions on both sides of the groin.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 72566 Version 3.0</div></div></div>"},"72568":{"type":"graphic_figure","displayName":"External PEEP with auto PEEP","title":"External positive end-expiratory pressure (PEEP) with auto-PEEP","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">External positive end-expiratory pressure (PEEP) with auto-PEEP</div><div class=\"cntnt\"><img style=\"width:542px; height:325px;\" src=\"images/PULM/72568_External_PEEP_with_auto_PEE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The use of external positive end-expiratory pressure (PEEP) in the setting of auto-PEEP may be conceptualized by the \"waterfall over a dam\" analogy. In this analogy, the presence of dynamic hyperinflation and 10 cm H<SUB>2</SUB>O of auto-PEEP is represented in the top panel by the reservoir of water trickling over the dam represented by the solid block. In the middle panel, as long as the external PEEP is less than or equal to the amount of auto-PEEP, the amount of water in the upstream reservoir, representing dynamic hyperinflation, does not increase. However, once the amount of water in the reservoir does increase (bottom panel), dynamic hyperinflation worsens. Additional experimental studies done by others suggest that this effect occurs once the external PEEP is greater than approximately 85 percent of the amount of auto-PEEP.</div><div class=\"graphic_reference\">Redrawn from Tobin MJ, Lodato RF, Chest 1989; 96:449.</div><div id=\"graphicVersion\">Graphic 72568 Version 2.0</div></div></div>"},"72569":{"type":"graphic_diagnosticimage","displayName":"HRCT reticular pattern in scleroderma","title":"Interstitial lung disease with honeycombing in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interstitial lung disease with honeycombing in scleroderma</div><div class=\"cntnt\"><img style=\"width:327px; height:262px;\" src=\"images/PULM/72569_Reticulonodular_change_in_S.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT in a patient with scleroderma and interstital lung disease showing a reticular pattern, honeycombing, and traction bronchiectasis in both lung fields. This pattern correlates with fibrotic changes on lung biopsy and is consistent with usual interstitial pneumonia.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Carol Black, MD.</div><div id=\"graphicVersion\">Graphic 72569 Version 8.0</div></div></div>"},"72570":{"type":"graphic_table","displayName":"Specimens from bronchoscopy","title":"Suggested studies for specimens obtained at bronchoscopy when evaluating lung transplant rejection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested studies for specimens obtained at bronchoscopy when evaluating lung transplant rejection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bronchoalveolar lavage </td> </tr> <tr> <td>Cytology</td> </tr> <tr> <td>Bacterial culture</td> </tr> <tr> <td>Viral cultures - CMV, herpes</td> </tr> <tr> <td>Pneumocystis jirovecii (Pneumocystis carnii)</td> </tr> <tr> <td>Legionella*</td> </tr> <tr> <td>Nocardia*</td> </tr> <tr> <td>Respiratory viruses (respiratory syncytial virus, parainfluenza, adenovirus, rhinovirus)*</td> </tr> <tr> <td>AFB culture*</td> </tr> <tr> <td class=\"subtitle1_single\">Transbronchial biopsies (5 or more) </td> </tr> <tr> <td>Pathology</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Denotes when clinically indicated.</div><div id=\"graphicVersion\">Graphic 72570 Version 2.0</div></div></div>"},"72571":{"type":"graphic_diagnosticimage","displayName":"Thoracic aortic aneurysm in giant cell arteritis","title":"Thoracic aortic aneurysm in giant cell arteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic aneurysm in giant cell arteritis</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/RHEUM/72571_Thoracic_aortic_aneurysm_GC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan in a patient with giant cell arteritis who developed an aortic aneurysm with dissection six years after the original diagnosis of arteritis by temporal artery biopsy. The aneurysm extended from the enlarged thoracic aorta (arrow) into the abdomen.</div><div class=\"graphic_reference\">Courtesy of Gene G Hunder, MD.</div><div id=\"graphicVersion\">Graphic 72571 Version 4.0</div></div></div>"},"72572":{"type":"graphic_figure","displayName":"Diphyllobothriasis life cycle","title":"Diphyllobothriasis life cycle","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Diphyllobothriasis life cycle</div><div class=\"cntnt\"><img style=\"width:589px; height:470px;\" src=\"images/ID/72572_Diphyllobothr_life_cycle_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immature eggs are passed in feces <STRONG>(1)</STRONG>. Under appropriate conditions, the eggs mature (approximately 18 to 20 days) <STRONG>(2)</STRONG> and yield oncospheres, which develop into a coracidia <STRONG>(3)</STRONG>. After ingestion by a suitable freshwater crustacean (the copepod's first intermediate host), the coracidia develop into procercoid larvae <STRONG>(4)</STRONG>. Following ingestion of the copepod by a suitable second intermediate host, typically minnows and other small freshwater fish, the procercoid larvae are released from the crustacean and migrate into the fish flesh where they develop into a plerocercoid larvae (sparganum) <STRONG>(5)</STRONG>. The plerocercoid larvae are the infective stage for humans. Because humans do not generally eat undercooked minnows and similar small freshwater fish, these do not represent an important source of infection. Nevertheless, these small second intermediate hosts can be eaten by larger predator species (eg, trout, perch, walleyed pike) <STRONG>(6)</STRONG>. In this case, the sparganum can migrate to the musculature of the larger predator fish and humans can acquire the disease by eating these later intermediate infected host fish raw or undercooked <STRONG>(7)</STRONG>. After ingestion of the infected fish, the plerocercoid develop into immature adults and then into mature adult tapeworms, which will reside in the small intestine. The adults of <EM>D. latum</EM> attach to the intestinal mucosa by means of the two bilateral groves (bothria) of their scolex <STRONG>(8)</STRONG>. The adults can reach more than 10 m in length, with more than 3000 proglottids. Immature eggs are discharged from the proglottids (up to 1,000,000 eggs per day per worm) <STRONG>(9)</STRONG> and are passed in the feces <STRONG>(1)</STRONG>. Eggs appear in the feces five to six weeks after infection. In addition to humans, many other mammals can also serve as definitive hosts for <EM>D. latum</EM>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Diphyllobothriasis. Available at: <A href=\"http://www.cdc.gov/dpdx/diphyllobothriasis/index.html\">http://www.cdc.gov/dpdx/diphyllobothriasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 72572 Version 5.0</div></div></div>"},"72574":{"type":"graphic_picture","displayName":"Chronic rejection Light I","title":"Light micrograph showing chronic renal transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing chronic renal transplant rejection</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/72574_Chronic_rejection_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of an intermediate stage of chronic vascular rejection in an interlobular artery. The arterial lumen is narrowed by marked subintimal thickening with loose connective tissue (arrow).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 72574 Version 3.0</div></div></div>"},"72575":{"type":"graphic_table","displayName":"Infections associated with nonimmune hydrops","title":"Infections associated with nonimmune hydrops","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections associated with nonimmune hydrops</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Pathogen</td>\n<td class=\"subtitle1\">Screening</td>\n<td class=\"subtitle1\">Therapy</td>\n</tr>\n<tr>\n<td>Cytomegalovirus</td>\n<td>Virus antigen in amniotic fluid</td>\n<td>None approved</td>\n</tr>\n<tr>\n<td>Herpes simplex</td>\n<td>Cultureamniotic fluid or fetal tissue</td>\n<td>Acyclovir for maternal indications</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"2\">Parvovirus B19</td>\n<td>Maternal IgM, IgG</td>\n<td>Close observation</td>\n</tr>\n<tr>\n\n<td>PCR amniotic fluid, fetal blood</td>\n<td>In-utero transfusion</td>\n</tr>\n<tr>\n<td>Rubella virus</td>\n<td>Fetal body fluid IgM</td>\n<td>None</td>\n</tr>\n<tr>\n<td>Coxsackievirus</td>\n<td>None</td>\n<td>None</td>\n</tr>\n<tr>\n<td>Varicella Zoster</td>\n<td>Maternal IgM</td>\n<td>Acyclovir for maternal indications</td>\n</tr>\n<tr>\n<td>Syphilis</td>\n<td>Non-treponemal and treponemal serology</td>\n<td>Penicillin</td>\n</tr>\n<tr>\n<td>Toxoplasmodium gondii</td>\n<td>Maternal or placental IgM, IgG; amniotic fluid PCR</td>\n<td>Spiramycin with sulfadiazine</td>\n</tr>\n<tr>\n<td>Tryponosoma cruzii (Chagas disease) </td>\n<td>Maternal serology for T. cruzii</td>\n<td>Benznidazole</td>\n</tr>\n<tr>\n<td>Adenovirus</td>\n<td>Maternal IgM, IgG, PCR and serology</td>\n<td>None</td>\n</tr>\n<tr>\n<td>Coxsackievirus</td>\n<td>Maternal serology</td>\n<td>None</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=43214&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Infections_causes_of_hydrop.htm</title></head></div><div id=\"graphicVersion\">Graphic 72575 Version 2.0</div></div></div>"},"72577":{"type":"graphic_table","displayName":"Modern ALL protocols","title":"Methotrexate dose, duration of infusion, and leucovorin rescue for several modern ALL protocols","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methotrexate dose, duration of infusion, and leucovorin rescue for several modern ALL protocols</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Dose of methotrexate (MTX)</td> <td class=\"subtitle1\">Duration of methotrexate (MTX) infusion</td> <td class=\"subtitle1\">Leucovorin rescue dose</td> <td class=\"subtitle1\">Start of leucovorin*</td> </tr> <tr> <td> <p>DCLSG ALL VI</p> Veerman, A; 1996</td> <td>2g/m<sup>2</sup></td> <td>24 hours</td> <td>25-75 mg q 6 hours</td> <td>36 hours</td> </tr> <tr> <td> <p>BFM/DCLSG/ALL 8</p> Kamps, W; 2002</td> <td> <p>2 gm/m<sup>2</sup> for SRG<sup>&#182;</sup></p> 5 gm/m<sup>2</sup> for MRG<sup>&#182;</sup></td> <td>24 hours</td> <td>15 mg/m<sup>2</sup> q 6 hours</td> <td>36-48 hours</td> </tr> <tr> <td> <p>JALSG-ALL 93</p> Takeuchi, J; 2002</td> <td>100 mg/m<sup>2</sup> bolus then 500 mg/m<sup>2</sup></td> <td>4 hours</td> <td>15 mg q 6 hours x 8 doses</td> <td>28 hours</td> </tr> <tr> <td> <p>UCSF 8707</p> Linker, C; 2002</td> <td>220 mg/m<sup>2</sup> bolus then 60 mg/m<sup>2</sup> per hour x 36 hours</td> <td>36 hours</td> <td>50 mg q 6 hours</td> <td>36 hours</td> </tr> <tr> <td> <p>MRC UKALL XI</p> Hill, F; 2004</td> <td> <p>6 gm/m<sup>2</sup> (age &#60;4)</p> 8 gm/m<sup>2</sup> (age &#62;4)</td> <td>10 percent bolus, rest over 23 hours</td> <td>15 mg/m<sup>2</sup> q 3 hours, then every 6 hours when serum MTX &#60;2 x 10<sup>6</sup> microM</td> <td>36 hours</td> </tr> <tr> <td> <p>MDACC</p> Kantarjian, H; 2004 </td> <td>1 gm/m<sup>2</sup></td> <td>24 hours</td> <td>15 mg q 6 hours</td> <td>36 hours</td> </tr> <tr> <td> <p>St Jude XIIIB</p> Pui, C; 2004</td> <td>2 gm/m<sup>2</sup></td> <td>2 hours</td> <td>10 mg/m<sup>2</sup> q 6 hours</td> <td>44 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALL: Acute lymphoblastic leukemia.<br />* After start of methotrexate (MTX).<br />Â¶ SRG: standard risk group; MRG: medium risk group.</div><div id=\"graphicVersion\">Graphic 72577 Version 3.0</div></div></div>"},"72579":{"type":"graphic_figure","displayName":"Peripheral blood analysis by flow cytometry I","title":"Peripheral blood analysis by flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood analysis by flow cytometry</div><div class=\"cntnt\"><img style=\"width:358px; height:340px;\" src=\"images/ALLRG/72579_Periph_blood_anal_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of peripheral blood analysis examining size (FSC) and granularity (SSC) demonstrating three predominant cell populations.</div><div class=\"graphic_footnotes\">SSC: side scatter; FSC: forward scatter.</div><div id=\"graphicVersion\">Graphic 72579 Version 4.0</div></div></div>"},"72580":{"type":"graphic_table","displayName":"Sulfonylurea kinetics","title":"Pharmacokinetics of the sulfonylureas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics of the sulfonylureas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generation</td> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Trade name<br /> (United States)</td> <td class=\"subtitle1\">Time to peak,<br /> hours</td> <td class=\"subtitle1\">Half-life,<br /> hours</td> <td class=\"subtitle1\">Duration of action,<br /> hours</td> <td class=\"subtitle1\">Metabolism and clearance</td> <td class=\"subtitle1\">Active metabolites</td> </tr> <tr class=\"divider_bottom\"> <td>First</td> <td>Chlorpropamide</td> <td>Diabinase</td> <td>2-7</td> <td>36*</td> <td>24-72</td> <td>Hepatically by CYP2C9; renally as active metabolite (55%) and unchanged drug (20%)</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>First</td> <td>Tolbutamide</td> <td>Orinase</td> <td>3-4</td> <td>4.5-6.5*<br /> (range 3-28)</td> <td>6-12<br /> (up to 24 after repeated dosing)</td> <td>Hepatically by CYP2C9; renally as active metabolite (30%)<sup>&#182;</sup></td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>First</td> <td>Tolazamide</td> <td>Tolinase</td> <td>3-4</td> <td>4-8*</td> <td>12-24</td> <td>Hepatically; renally as active metabolite (35%) and unchanged drug (7%)</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Second</td> <td>Gliclazide<br /> (not available in United States)</td> <td>Diamicron<br /> (Canada and elsewhere)</td> <td>2-4</td> <td>8-12</td> <td>12-24</td> <td>Hepatically by CYP2C9</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Second</td> <td>Glipizide</td> <td>Glucatrol</td> <td>1-3</td> <td>2-5</td> <td>16-24</td> <td>Hepatically by CYP2C9; renally as unchanged drug (&#60;10%)</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Second</td> <td>Glipizide</td> <td>Glucatrol XL</td> <td>6-12</td> <td>7</td> <td>24</td> <td>Hepatically by CYP2C9; renally as unchanged drug (&#60;10%)</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td>Second</td> <td>Glyburide<br /> (glibenclamide)</td> <td> <p>Micronase</p> <p>DiaBeta</p> Glynase</td> <td>2-6</td> <td>10*</td> <td>&#60;24</td> <td>Hepatically by CYP2C9; renally as active metabolites (36%)</td> <td>Yes</td> </tr> <tr> <td>Third</td> <td>Glimepiride</td> <td>Amaryl</td> <td>2-3</td> <td>5-9*</td> <td>16-24</td> <td>Hepatically by CYP2C9; renally as active metabolite (63%)<sup>&#916;</sup></td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Time to peak and duration of effect are as reported in product labeling and small pharmacokinetic studies; these values may be increased in overdose.</div><div class=\"graphic_footnotes\">* Half-life prolonged in older adults or renal impairment; duration of action may be prolonged.<br />&para; Active metabolite (hydroxytolbutamide) has less hypoglycemic effect than parent drug.<br />&Delta; Active metabolite (cyclohexylhydroxymethyl derivative) has less hypoglycemic effect than parent drug.</div><div id=\"graphicVersion\">Graphic 72580 Version 2.0</div></div></div>"},"72581":{"type":"graphic_figure","displayName":"Ig heavy chain gene rearrangement","title":"Immunoglobulin heavy chain gene rearrangement","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin heavy chain gene rearrangement</div><div class=\"cntnt\"><img style=\"width:553px; height:327px;\" src=\"images/ALLRG/72581_V_D_J_joining_Ig_heavy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">L: light chain gene segment; V<SUB>H</SUB>: variable region of heavy chain; D: diversity; J<SUB>H</SUB>: joining segment of heavy chain; CÂµ: constant region of immunoglobulin M (IgM) heavy chain.</div><div class=\"graphic_reference\">Reproduced with permission from: Bona C, Bonilla FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright Â© 1996 Overseas Publishers Association, NV. Permission granted by Gordon and Breach Publishers.</div><div id=\"graphicVersion\">Graphic 72581 Version 3.0</div></div></div>"},"72582":{"type":"graphic_figure","displayName":"Anatomy sliding hiatus hernia","title":"Anatomic features of sliding hiatus hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomic features of sliding hiatus hernia</div><div class=\"cntnt\"><img style=\"width:333px; height:348px;\" src=\"images/GAST/72582_Anat_slid_hiatus_hern_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of the anatomic features of a sliding hiatus hernia viewed radiographically during swallowing. The &quot;A&quot; ring is a muscular ring visible during swallowing which demarcates the superior margin of the lower esophageal sphincter. The &quot;B&quot; ring at the squamocolumnar junction is present in only about 15 percent of individuals; it permits accurate division of the phrenic ampulla into the esophageal vestibule (A ring to B ring) and the sliding hiatus hernia (B ring to the subdiaphragmatic stomach). Rugal folds traversing the hiatus support the conviction that a portion of the stomach is supradiaphragmatic.</div><div class=\"graphic_reference\">Reproduced with permission from: Kahrilas PJ. Hiatus hernia causes reflux: Fact or fiction? Gullet 1993; 3(Suppl):21.</div><div id=\"graphicVersion\">Graphic 72582 Version 4.0</div></div></div>"},"72583":{"type":"graphic_figure","displayName":"Breastfeeding anatomy PI","title":"The breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The breast</div><div class=\"cntnt\"><img style=\"width:433px; height:386px;\" src=\"images/PI/72583_Breastfeeding_anat_PI_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72583 Version 5.0</div></div></div>"},"72584":{"type":"graphic_figure","displayName":"IMA versus vein graft patency after CABG","title":"Graft patency after CABG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graft patency after CABG</div><div class=\"cntnt\"><img style=\"width:388px; height:250px;\" src=\"images/CARD/72584_Graft_patency_after_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patency of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery. The 10-year patency rate was significantly higher with the arterial grafts. There was a variable number of patients studied at each interval, accounting for the irregular shape of the curves.</div><div class=\"graphic_reference\">Data from: Loop FD, Lytle BW, Cosgrove DM, et al, N Engl J Med 1986; 314:1.</div><div id=\"graphicVersion\">Graphic 72584 Version 3.0</div></div></div>"},"72586":{"type":"graphic_picture","displayName":"Staphylococcal folliculitis","title":"Staphylococcal folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Staphylococcal folliculitis</div><div class=\"cntnt\"><img style=\"width:330px; height:492px;\" src=\"images/PC/72586_Staphylococcal_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pustules and papules can be seen on this woman's thigh.<br />(B) This is a close-up view of Panel A.</div><div class=\"graphic_reference\">Reproduced with permission: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72586 Version 3.0</div></div></div>"},"72587":{"type":"graphic_algorithm","displayName":"CDC algorithm for screening for GBS in preterm labor ","title":"CDC algorithm for screening for GBS in preterm labor before 37 weeks","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">CDC algorithm for screening for GBS in preterm labor before 37 weeks</div><div class=\"cntnt\"><img style=\"width:457px; height:372px;\" src=\"images/OBGYN/72587_Algo_screen_GBS_pre_lab_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention; GBS: Group B streptococcus.<br> * If patient has undergone vaginal-rectal GBS culture within the preceding 5 weeks, the results of that culture should guide management. GBS-colonized women should receive intrapartum antibiotic prophylaxis. No antibiotics are indicated for GBS prophylaxis if a vaginal-rectal screen within 5 weeks was negative.<br> <span class=bullet>â¢</span> Patient should be regularly assessed for progression to true labor; if the patient is considered not to be in true labor, discontinue GBS prophylaxis.<br> Î If GBS culture results become available prior to delivery and are negative, then discontinue GBS prophylaxis.<br> <span class=lozenge>â</span> Unless subsequent GBS culture prior to delivery is positive.<br> Â§ A negative GBS screen is considered valid for 5 weeks. If a patient with a history of PTL is re-admitted with signs and symptoms of preterm labor and had a negative GBS screen &gt;5 weeks prior, she should be rescreened and managed according to this algorithm at that time.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010. MMWR 2010; 59:No. RR-10.</div><div id=\"graphicVersion\">Graphic 72587 Version 7.0</div></div></div>"},"72588":{"type":"graphic_picture","displayName":"Discoid lupus scalp","title":"Discoid lupus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Discoid lupus erythematosus</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/72588_Discoid_lupus_scal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular plugging is evident in this patient with discoid lupus erythematosus involving the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: Messenger A. Varieties of scarring alopecia. Dermatology In Practice 2003; 11:20. Copyright Â© Hayward Medical Communications.</div><div id=\"graphicVersion\">Graphic 72588 Version 4.0</div></div></div>"},"72592":{"type":"graphic_picture","displayName":"IPMN gastric","title":"Histologic appearance of intraductal papillary mucinous neoplasm, gastric fovelolar type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of intraductal papillary mucinous neoplasm, gastric fovelolar type</div><div class=\"cntnt\"><img style=\"width:432px; height:292px;\" src=\"images/ONC/72592_IPMN_gastric.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraductal papillary mucinous neoplasm (IPMN) of the gastric foveolar type. The apical cytoplasm is clear reflecting the high mucin content. Hematoxylin and eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 72592 Version 3.0</div></div></div>"},"72593":{"type":"graphic_table","displayName":"Meningioma subtypes","title":"Meningioma subtypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Meningioma subtypes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"90%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">WHO grade</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Meningiomas with low risk of recurrence or aggressive growth:</td> </tr> <tr> <td class=\"indent1\">Meningothelial</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Fibrous (fibroblastic)</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Transitional (mixed)</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Psammomatous</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Angiomatous</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Microcystic</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Secretory</td> <td>I</td> </tr> <tr> <td class=\"indent1\">Lymphoplasmacyte-rich</td> <td>I</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Metaplastic</td> <td>I</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Meningiomas with greater likelihood of recurrence and/or aggressive behavior:</td> </tr> <tr> <td class=\"indent1\">Atypical<sup>*</sup></td> <td>II</td> </tr> <tr> <td class=\"indent1\">Clear cell (intracranial)</td> <td>II</td> </tr> <tr> <td class=\"indent1\">Chordoid</td> <td>II</td> </tr> <tr> <td class=\"indent1\">Rhabdoid</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Papillary</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Anaplastic (malignant)</td> <td>III</td> </tr> <tr> <td class=\"indent1\">Meningiomas of any subtype or grade with high proliferation index</td> <td>&nbsp;I, II, III</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* As of the 2016 edition of the&nbsp;WHO Classification of Tumours of the Central Nervous System [1], atypical meningioma is defined as a&nbsp;tumor with increased mitotic activity (â¥4 mitoses per ten high powered fields), brain invasion, or three or more of the following features: increased cellularity, small cells with a high nuclear:cytoplasmic ratio, prominent nucleoli, uninterrupted patternless or sheet-like growth, or foci of spontaneous or geographic necrosis.</div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced with permission from: Perry A, Louis DN, Scheithauer BW, et al. Meningiomas. In: WHO Classification of Tumours of the Central Nervous System, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC Press, Lyon 2007.<br /><br /><EM>[1] WHO Classification of Tumours of the Central Nervous System, Fourth Edition, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</EM></div><div id=\"graphicVersion\">Graphic 72593 Version 5.0</div></div></div>"},"72595":{"type":"graphic_table","displayName":"Prevention of indoor fire ant infestation","title":"Prevention of indoor fire ant infestation at health care facilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of indoor fire ant infestation at health care facilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Determine if facility's pest service contract covers fire ants</td> </tr> <tr> <td>Vigilance to identify fire ant infestation should be increased during weather extremes</td> </tr> <tr> <td>Do not allow beds or linens to touch the wall or floor</td> </tr> <tr> <td>Limit food in the bed as much as possible</td> </tr> <tr> <td>Check mattresses for food accumulation</td> </tr> <tr> <td>Place food left in the room in a well-sealed (air tight) container</td> </tr> <tr> <td>Keep the outside of intravenous inserts as dry as possible</td> </tr> <tr> <td>Make sure that catheters are properly functioning</td> </tr> <tr> <td>Avoid accumulation of water or food particles under base plates during floor sweeping or mopping</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Goddard J, Jarratt J, deShazo RD. Recommendations for prevention and management of fire ant infestation of health care facilities. South Med J 2002; 95:627. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72595 Version 13.0</div></div></div>"},"72596":{"type":"graphic_figure","displayName":"Type I drug reaction","title":"Type I (IgE-mediated) immediate drug hypersensitivity","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Type I (IgE-mediated) immediate drug hypersensitivity</div><div class=\"cntnt\"><img style=\"width:529px; height:466px;\" src=\"images/ALLRG/72596_Type_1_drug_rxn.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Ig: immunoglobulin.</div><div class=\"graphic_reference\">Reproduced with permission from: Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. p. 1205-1226. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72596 Version 3.0</div></div></div>"},"72597":{"type":"graphic_picture","displayName":"APC probe","title":"Argon plasma coagulator probe","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Argon plasma coagulator probe</div><div class=\"cntnt\"><img style=\"width:320px; height:317px;\" src=\"images/GAST/72597_APC_probe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The disposable probes are available in 1.5 mm, 2.3 mm (the most commonly used size), and 3.2 mm. The standard probes are 220 cm long.</div><div id=\"graphicVersion\">Graphic 72597 Version 1.0</div></div></div>"},"72598":{"type":"graphic_table","displayName":"Pharmacokinetic properties of PPIs","title":"Pharmacokinetic properties of proton pump inhibitors in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetic properties of proton pump inhibitors in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Regimen tested</td> <td class=\"subtitle1\">Oral bioavailability</td> <td class=\"subtitle1\">Time to peak<br /> (hours)</td> <td class=\"subtitle1\">Cmax<br /> (micrograms/mL)</td> <td class=\"subtitle1\">AUC<sub>0-24</sub><br /> (mg&#8226;h/L)</td> <td class=\"subtitle1\">Metabolism and clearance</td> <td class=\"subtitle1\">Half-life<br /> (hours)*</td> <td class=\"subtitle1\">pKa<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Dexlansoprazole</td> <td>30 mg once daily</td> <td>Absorbed to a similar extent under fasting and fed conditions</td> <td> <p>1-2 (peak 1)</p> 4-5 (peak 2)</td> <td>0.7</td> <td>3.3</td> <td>Hepatically by CYP2C19<sup>&#916;</sup> and 3A4; inactive metabolites are excreted in urine and feces</td> <td>1-2</td> <td>Not available</td> </tr> <tr class=\"divider_bottom\"> <td>Esomeprazole</td> <td>20 mg once daily</td> <td> <p>64% (single dose);</p> 90% (after multiple doses if taken on an empty stomach; bioavailability is reduced by ~50% if taken with food)</td> <td>1-1.6</td> <td>2.1 (micromol/L)</td> <td>4.2 (micromol&#8226;h/L)</td> <td>Hepatically by CYP2C19<sup>&#916;</sup> and 3A4; inactive metabolites are excreted in urine and feces</td> <td>1.2-2.5</td> <td>4.0</td> </tr> <tr class=\"divider_bottom\"> <td>Lansoprazole</td> <td>30 mg once daily</td> <td>85% (taken on an empty stomach; absorption is reduced by ~50% if taken with food)</td> <td>1.5-3</td> <td>0.5-1.0</td> <td>3.2</td> <td>Hepatically by CYP2C19<sup>&#916;</sup> and 3A4; inactive metabolites are excreted in feces via bile and in urine</td> <td>0.9-1.5</td> <td>4.0</td> </tr> <tr class=\"divider_bottom\"> <td>Omeprazole</td> <td>20 mg once daily (delayed release capsule)</td> <td> <p>45% (single dose)</p> Varies by formulation; absorption is significantly increased after multiple doses</td> <td>0.5-3.5</td> <td>0.7</td> <td>3.3</td> <td>Hepatically by CYP2C19<sup>&#916;</sup> and 3A4; inactive metabolites are excreted in urine and bile</td> <td>0.5-3</td> <td>4.0</td> </tr> <tr class=\"divider_bottom\"> <td>Pantoprazole</td> <td>40 mg once daily</td> <td>77%</td> <td>2-2.5</td> <td>2.5</td> <td>5.0</td> <td>Hepatically by CYP2C19<sup>&#916;</sup> and 3A4; inactive metabolites are excreted in urine and feces via bile</td> <td>1 (increased to 3.5-10 hours in CYP2C19 poor-metabolizers)</td> <td>3.9</td> </tr> <tr> <td>Rabeprazole</td> <td>20 mg once daily</td> <td>52%</td> <td>2-5</td> <td>0.4-0.48</td> <td>0.9</td> <td>Hepatically by CYP2C19<sup>&#916;</sup> and 3A4; inactive metabolites are excreted in urine and feces via bile</td> <td>1-2</td> <td>5.0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AUC<sub>0-24</sub>: cumulative systemic drug exposure as measured by the area under the plasma concentration versus time curve over 24 hours; Cmax: maximum plasma concentration; pKa: acid dissociation constant transformed by negative log; PPI: proton pump inhibitor.<br />* Duration of antisecretory effect of PPIs exceeds that predicted by drug half-life due to irreversible binding at site of action (ie, parietal proton pumps).<br />&para; PPIs are converted to their active form (ie, protonated) when pH of parietal cell is lower than pKa of the individual PPI (ie, in presence of gastric acidity). For detail, refer to accompanying text.<br />&Delta; Drug metabolism via hepatic CYP2C19 enzymes is polymorphic; thus, PPI systemic exposure (AUC<sub>0-24</sub>) can be increased several (ie, 2 to 12) times in patients who are intermediate or poor-metabolizers compared with those who are extensive-metabolizers (ie, most patients). 15-20% of persons of Asian descent are CYP2C19 poor-metabolizer phenotypes.</div><div class=\"graphic_reference\">Prepared with data from: United States prescribing information available at US National Library of Medicine DailyMed website (<a href=\"http://dailymed.nlm.nih.gov/dailymed/index.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/index.cfm</a>).</div><div id=\"graphicVersion\">Graphic 72598 Version 5.0</div></div></div>"},"72600":{"type":"graphic_waveform","displayName":"Fusion beats tutorial","title":"Fusion beats","html":"<div class=\"graphic normal\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Fusion beats</div><div class=\"cntnt\"><img style=\"width:495px; height:124px;\" src=\"images/CARD/72600_Fusion_beats_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rhythm strip in a patient with sustained ventricular tachycardia shows a fusion beat and a capture beat. The fusion beat occurs when a supraventricular impulse (following the first P wave) causes ventricular activation, which fuses with the complex originating in the ventricle, producing a hybrid complex. The complex following the second P wave has the appearance of a normal QRS complex and is known as a capture beat.</div><div id=\"graphicVersion\">Graphic 72600 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"72601":{"type":"graphic_table","displayName":"Classification arrhythmias","title":"Classification of cardiac arrhythmias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of cardiac arrhythmias</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Supraventricular</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Atrial origin</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Atrial fibrillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Atrial flutter</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Atrial tachycardia</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Ectopic focus (enhanced automaticity) </td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Intraatrial or sinoatrial reentry</td>\n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Atrial extrasystoles (atrial premature beats)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">AV junction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Atrioventricular nodal reentrant tachycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Atrioventricular reentrant tachycardia</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">AV junctional rhythms (enhanced automaticity)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">AV junctional extrasystoles</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Ventricular</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2_start\">Ventricular tachycardia</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist2\">Sustained </td>\n    </tr>\n    <tr>\n      <td class=\"sublist2\">Nonsustained</td>\n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Ventricular fibrillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ventricular extrasystoles (ventricular premature beats)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72601 Version 1.0</div></div></div>"},"72603":{"type":"graphic_table","displayName":"Costimulatory molecules in T cell activation and regulation","title":"Costimulatory molecules in T cell activation and regulation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Costimulatory molecules in T cell activation and regulation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">T cell molecule </td> <td class=\"subtitle1\">Ligand </td> <td class=\"subtitle1\">Functions </td> </tr> <tr> <td>CD2</td> <td>CD58 (LFA-3)</td> <td>Adhesion, activation</td> </tr> <tr> <td>CD4</td> <td>MHC class II</td> <td>Adhesion, activation (associates with Lck tyrosine kinase)</td> </tr> <tr> <td>CD5</td> <td>CD72</td> <td>Adhesion, activation</td> </tr> <tr> <td>CD8</td> <td>MHC class I</td> <td>Adhesion, activation (associates with Lck tyrosine kinase)</td> </tr> <tr> <td>CD11a/CD18 (LFA-1)</td> <td>CD54 (ICAM-1)</td> <td>Adhesion, activation</td> </tr> <tr> <td>CD27</td> <td>CD70</td> <td>Adhesion, activation</td> </tr> <tr> <td>CD28</td> <td>CD8O, CD86 (B7-1, B7-2)</td> <td>Adhesion, major costimulatory pathway</td> </tr> <tr> <td>CD69</td> <td>?</td> <td>C type lectin, early T cell activation marker, triggers calcium-mediated activation</td> </tr> <tr> <td>CD134 (OX40)</td> <td>OX40 ligand</td> <td>Adhesion, activation</td> </tr> <tr> <td>CDw137 (4-1BB)</td> <td>4-1BB ligand</td> <td>Adhesion, activation</td> </tr> <tr> <td>CD154 (CD40L)</td> <td>CD40</td> <td>Expressed on activated T cells, important stimulator of&nbsp;antigen-presenting cell&nbsp;function and B cell&nbsp;immunoglobulin class-switching</td> </tr> <tr> <td>CTLA-4</td> <td>CD80, CD86 (B7-1, B7-2)</td> <td>Downregulates T cell activation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD: cluster of differentiation; LFA: leukocyte-function antigen; MHC: major histocompatibility complex; ICAM: intercellular adhesion molecule;<SPAN style=\"COLOR: black\"> B7: B-lymphocyte activation antigen; OX40: also called tumor necrosis factor receptor superfamily, member 4 (TNFRSF4) or CD134; CDw137: also called tumor necrosis factor receptor superfamily, member 9 (TNFRSF9) or 4-1BB; CTLA: cytotoxic T lymphocyte-associated.</SPAN></div><div id=\"graphicVersion\">Graphic 72603 Version 2.0</div></div></div>"},"72604":{"type":"graphic_picture","displayName":"Acromioclavicular joint injection","title":"Acromioclavicular joint injection","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular joint injection</div><div class=\"cntnt\"><img style=\"width:504px; height:342px;\" src=\"images/EM/72604_AC_joint_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The clinician pictured above is using a radiograph of the patient's acromioclavicular joint to help identify landmarks and guide the injection.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 72604 Version 2.0</div></div></div>"},"72605":{"type":"graphic_diagnosticimage","displayName":"Intrahepatic PSC ERCP","title":"Primary sclerosing cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis</div><div class=\"cntnt\"><img style=\"width:291px; height:360px;\" src=\"images/GAST/72605_Intrahepatic_PSC_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image obtained during endoscopic retrograde cholangiopancreatography in a patient with primary sclerosing cholangitis demonstrates stenotic intrahepatic bile ducts (arrows) with several intraductal stones (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 72605 Version 2.0</div></div></div>"},"72607":{"type":"graphic_table","displayName":"LCIS risk factor recurrence","title":"LCIS as a risk factor for local recurrence in women treated with breast conserving therapy for early breast cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">LCIS as a risk factor for local recurrence in women treated with breast conserving therapy for early breast cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study, year</td> <td class=\"subtitle1\" rowspan=\"2\">Number of patients with LCIS within the specimen</td> <td class=\"subtitle1\" rowspan=\"2\">Number of control patients</td> <td class=\"subtitle1\" rowspan=\"2\">Median follow-up (months)</td> <td class=\"subtitle1\" colspan=\"2\">Risk of local failure, percent</td> </tr> <tr> <td class=\"subtitle2\">+LCIS</td> <td class=\"subtitle2\">-LCIS</td> </tr> <tr> <td rowspan=\"4\">Sasson AR; 2001</td> <td rowspan=\"4\">65</td> <td rowspan=\"4\">1209</td> <td rowspan=\"4\">76</td> <td>5</td> <td>3</td> </tr> <tr> <td colspan=\"2\">(5 years, NSS)</td> </tr> <tr> <td>29</td> <td>6</td> </tr> <tr> <td colspan=\"2\">(10 years, p = .003)</td> </tr> <tr> <td rowspan=\"2\">Jolly S; 2006</td> <td rowspan=\"2\">56</td> <td rowspan=\"2\">551</td> <td rowspan=\"2\">104</td> <td>14</td> <td>7</td> </tr> <tr> <td colspan=\"2\">(10 years, p = 0.04)</td> </tr> <tr> <td rowspan=\"2\">Moran M; 1998</td> <td rowspan=\"2\">51</td> <td rowspan=\"2\">1045</td> <td rowspan=\"2\">127</td> <td>23</td> <td>16</td> </tr> <tr> <td colspan=\"2\">(NSS)</td> </tr> <tr> <td rowspan=\"2\">Abner AL; 2000</td> <td rowspan=\"2\">137</td> <td rowspan=\"2\">1062</td> <td rowspan=\"2\">161</td> <td>13</td> <td>12</td> </tr> <tr> <td colspan=\"2\">(NSS)</td> </tr> <tr> <td rowspan=\"2\">Ben-David M; 2006</td> <td rowspan=\"2\">64</td> <td rowspan=\"2\">121*</td> <td rowspan=\"2\">45</td> <td>1.7</td> <td>1.6</td> </tr> <tr> <td colspan=\"2\">(NSS)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LCIS: lobular carcinoma in situ; NSS: not statistically significant.<br />* Matched for histology, stage, age, and date of diagnosis.</div><div id=\"graphicVersion\">Graphic 72607 Version 2.0</div></div></div>"},"72608":{"type":"graphic_table","displayName":"Assessment of severity of diabetic ketoacidosis in children","title":"Assessment of severity of diabetic ketoacidosis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of severity of diabetic ketoacidosis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Mild</td> <td class=\"subtitle1\">Moderate</td> <td class=\"subtitle1\">Severe</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Defining features</td> </tr> <tr> <td class=\"indent1\">Venous pH</td> <td>7.2-7.3</td> <td>7.1-7.2</td> <td>&#60;7.1</td> </tr> <tr> <td class=\"indent1\">Serum bicarbonate (mEq/L)</td> <td>10-15</td> <td>5-10</td> <td>&#60;5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.</div><div id=\"graphicVersion\">Graphic 72608 Version 4.0</div></div></div>"},"72609":{"type":"graphic_figure","displayName":"Nissen fundoplication PI","title":"Nissen fundoplication","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Nissen fundoplication</div><div class=\"cntnt\"><img style=\"width:516px; height:251px;\" src=\"images/PI/72609_Nissen_fundoplication_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original artwork by JP Gray, 2007.</div><div id=\"graphicVersion\">Graphic 72609 Version 2.0</div></div></div>"},"72614":{"type":"graphic_figure","displayName":"Vulvar anatomy","title":"Anatomy of the vulva","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Anatomy of the vulva</div><div class=\"cntnt\"><img style=\"width:505px; height:499px;\" src=\"images/OBGYN/72614_Vulvar_anatomy_edt4.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72614 Version 10.0</div></div></div>"},"72615":{"type":"graphic_table","displayName":"Causes of acute persistent visual loss by presentation","title":"Causes of acute persistent visual loss by presentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acute persistent visual loss by presentation</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Presentation\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Differential diagnosis\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td rowspan=\"7\">\r\n \r\n Unilateral painless\r\n \r\n </td>\r\n \r\n <td>Lens dislocation</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Vitreous hemorrhage</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Acute maculopathy</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Retinal detachment</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Retinal artery occlusion</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Retinal vein occlusion</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Ischemic optic neuropathy</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td rowspan=\"7\">\r\n \r\n Unilateral painful\r\n \r\n </td>\r\n \r\n <td>Corneal abrasion</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Keratitis</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Acute glaucoma</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Hyphema</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Endophthalmitis</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Anterior uveitis</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Optic neuritis</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td rowspan=\"3\">\r\n \r\n Bilateral painless\r\n \r\n </td>\r\n \r\n <td>Pseudotumor cerebri (variable symptoms)</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Metabolic or toxic (hyperglycemia, methanol toxicity)</td>\r\n \r\n </tr>\r\n\r\n <tr>\r\n\t\r\n <td>Homonymous field loss (chiasmal or retrochiasmal etiology)</td>\r\n\r\n </tr>\r\n \r\n <tr>\r\n \r\n <td rowspan=\"3\">\r\n \r\n Bilateral painful\r\n \r\n </td>\r\n \r\n <td>Keratitis from bilateral exposure (eg, contact lens, UV light, chemical, etc)</td>\r\n \r\n </tr>\r\n \r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57785&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Causes_of_APVL_symptoms.htm</title></head></div><div class=\"graphic_lgnd\">UV: ultraviolet.</div><div class=\"graphic_reference\">Adapted from Guluma, K. An Evidence-Based Approach to Abnormal Vision. Emergency Medicine Practice 2007; 9:1.</div><div id=\"graphicVersion\">Graphic 72615 Version 2.0</div></div></div>"},"72616":{"type":"graphic_picture","displayName":"Scabies infant scalp","title":"Scabies, infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies, infant</div><div class=\"cntnt\"><img style=\"width:396px; height:264px;\" src=\"images/PC/72616_Scabies_infant_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of scabies may be more diffuse in infants, spreading to the trunk and scalp in addition to the extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright Â©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72616 Version 3.0</div></div></div>"},"72617":{"type":"graphic_figure","displayName":"Carotid plaques PI","title":"Carotid artery disease","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Carotid artery disease</div><div class=\"cntnt\"><img style=\"width:515px; height:674px;\" src=\"images/PI/72617_Carotid-plaques-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In people with carotid artery disease, fatty deposits called plaques build up inside the artery walls. These plaques can break open and cause blood clots to form, and that can lead to stroke.</div><div id=\"graphicVersion\">Graphic 72617 Version 2.0</div></div></div>"},"72618":{"type":"graphic_figure","displayName":"Plaque features responsible for acute thrombosis","title":"Plaque features responsible for acute thrombosis","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Plaque features responsible for acute thrombosis</div><div class=\"cntnt\"><img style=\"width:599px; height:348px;\" src=\"images/CARD/72618_Plaque_resp4_acute_throm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronary plaque features responsible for acute thrombosis, which comprise three different morphologies: rupture, erosion, and calcified nodules. Ruptured plaques are thin fibrous cap atheromas with luminal thrombi (Th). These lesions usually have an extensive necrotic core (NC) containing large numbers of cholesterol crystals and a thin fibrous cap (&lt;65 Âµm) infiltrated by foamy macrophages and T lymphocytes. The fibrous cap is thinnest at the site of rupture and consists of a few collagen bundles and rare smooth muscle cells. The luminal thrombus is in communication with the lipid-rich necrotic core. Erosions occur over lesions rich in smooth muscle cells and proteoglycans. Luminal thrombi overlie areas lacking surface endothelium. The deep intima of the eroded plaque often shows extracellular lipid pools, but necrotic cores are uncommon; when present, the necrotic core does not communicate with the luminal thrombus. Inflammatory infiltrate is usually absent, but if present, is sparse and consists of macrophages and lymphocytes. Calcified nodules are plaques with luminal thrombi showing calcific nodules protruding into the lumen through a disrupted thin fibrous cap. There is absence of an endothelium at the site of the thrombus, and inflammatory cells (macrophages, T lymphocytes) are absent.</div><div class=\"graphic_reference\">Reproduced with permission from: Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262. Copyright Â© 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72618 Version 9.0</div></div></div>"},"72619":{"type":"graphic_figure","displayName":"Variability in presentation of rapid cycling bipolar disorder","title":"Variability in presentation of rapid cycling bipolar disorder","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Variability in presentation of rapid cycling bipolar disorder</div><div class=\"cntnt\"><img style=\"width:515px; height:406px;\" src=\"images/PSYCH/72619_Var_pres_rapid_cycl_bipolar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12-month prospective follow-up of three bipolar patients with rapid cycling bipolar disorder at increasing frequencies compared to a non-rapid cycling patient with a single biphasic episode.<br> Excursion above each horizontal line represents hypomania or mania; excursion below the line represents depression. Amplitude indicates severity of symptoms.</div><div class=\"graphic_reference\">Data from: the Stanley Foundation Bipolar Network: Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162:1273.</div><div id=\"graphicVersion\">Graphic 72619 Version 1.0</div></div></div>"},"72620":{"type":"graphic_diagnosticimage","displayName":"CT image of cancellous bone","title":"CT image of cancellous bone","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">CT image of cancellous bone</div><div class=\"cntnt\"><img style=\"width:584px; height:207px;\" src=\"images/ENDO/72620_CT_image_cancellous_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional CT images of cancellous bone from a normal individual (left panel) and a patient with osteoporosis (right panel). Please note the trabeculae in the osteoporotic patient are thinner, disconnected, and further apart.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Dr. David Dempster, Helen Hayes Hospital, Columbia University.</div><div id=\"graphicVersion\">Graphic 72620 Version 3.0</div></div></div>"},"72621":{"type":"graphic_diagnosticimage","displayName":"Low grade cystic duct leak","title":"Low grade cystic duct stump leak after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low grade cystic duct stump leak after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:323px;\" src=\"images/GAST/72621_Low_grade_cystic_duct_leak.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) shows extravasation from the cystic duct stump. It was necessary to fill the intrahepatic biliary tree to demonstrate the leak.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 72621 Version 4.0</div></div></div>"},"72624":{"type":"graphic_table","displayName":"Language literacy milestones","title":"Normal developmental milestones of language and literacy acquisition in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal developmental milestones of language and literacy acquisition in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Language milestones</td> <td class=\"subtitle1\">Literacy milestones</td> </tr> <tr> <td>6 months</td> <td> <p>Turns to voice (4 months)</p> <p>Orients to bell horizontally</p> <p>Imitates speech sounds</p> <p>Does raspberries</p> <p>Babbles&nbsp;&ndash; Consonant-vowel combinations</p> </td> <td> <p>Reaches for book</p> <p>Brings book to mouth</p> <p>Looks at pictures</p> <p>Vocalizes or pats at pictures</p> <p>Prefers pictures of faces</p> </td> </tr> <tr> <td>12 months</td> <td> <p>Orients to bell diagonally (10 months)</p> <p>Understands \"no\"</p> <p>Follows simple gestured commands</p> <p>Uses \"dada\"/\"mama\" appropriately</p> <p>Additional one or more words</p> <p>Immature jargoning</p> <p>Begins to point for desired objects</p> </td> <td> <p>Holds book with help</p> <p>Turns board book pages with assistance</p> <p>Points to pictures with one finger, nonspecific</p> <p>May begin to label pictures with \"words\"</p> <p>Prefers pictures of familiar objects</p> </td> </tr> <tr> <td>18 months</td> <td> <p>Identifies familiar objects</p> <p>Follows simple ungestured commands</p> <p>Points to two to four body parts</p> <p>Vocabulary of 10 to 25 words</p> <p>Giant words (\"Thank you\")</p> <p>Mature jargoning</p> </td> <td> <p>Brings book to parent</p> <p>Turns board book pages easily</p> <p>Points to familiar pictures, specific</p> <p>Scribbles spontaneously</p> </td> </tr> <tr> <td>24 months</td> <td> <p>Follows novel two-step commands</p> <p>Vocabulary of &#62;50 words</p> <p>Creates two- to three-word sentences</p> <p>Begins to use \"I,\" \"me,\" or \"you\"</p> <p>Telegraphic speech, no jargon</p> <p>50% intelligible to strangers</p> </td> <td> <p>Learning to handle paper pages</p> <p>Looks \"through\" book for favorite pictures</p> <p>May fill in words or complete rhymes from familiar books</p> <p>Imitates vertical stroke</p> </td> </tr> <tr> <td>30 months</td> <td> <p>Follows two prepositional commands</p> <p>Understands concept of \"just one\"</p> <p>Names all body parts</p> <p>Names four pictures, one color</p> <p>Knows two actions</p> <p>Echolalia ceases</p> </td> <td> <p>\"Reads\" as part of creative play</p> <p>May complete sentences from familiar books</p> <p>Recites parts of well-known stories</p> <p>Imitates circular motion with crayon</p> </td> </tr> <tr> <td>3 years</td> <td> <p>Follows three element commands</p> <p>Three- to four-word sentences, &#62;500 words</p> <p>75% intelligible to strangers</p> <p>Uses pronouns, plurals correctly</p> <p>Counts to three, names &#62;1 color</p> <p>Disfluency is common</p> </td> <td> <p>Turns pages easily</p> <p>Recites whole phrases, sometimes whole stories</p> <p>Begins to coordinate text with pictures</p> <p>Corrects mistakes made by the reader</p> <p>Copies a circle</p> </td> </tr> <tr> <td>4 years</td> <td> <p>Understands four prepositions</p> <p>Creates four- to five-word sentences</p> <p>100% intelligible to strangers</p> <p>Uses past tense</p> <p>Counts to four, names four colors</p> <p>Retells familiar stories</p> </td> <td> <p>Developing awareness of print</p> <p>Recognizes some letters of the alphabet</p> <p>Beginning writing skills</p> <p>Picks longer line</p> <p>Copies a cross</p> </td> </tr> <tr> <td>5 years</td> <td> <p>Understands opposites</p> <p>Creates complete (&#62;5-word) sentences</p> <p>Uses future tense, irregular verbs</p> <p>Disfluencies uncommon</p> <p>Counts to 10 or more</p> </td> <td> <p>Understands print carries the message</p> <p>May move finger along the text</p> <p>Recognizes most letters of the alphabet, writes some</p> <p>\"Writes\" name</p> <p>Copies a square</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72624 Version 4.0</div></div></div>"},"72626":{"type":"graphic_figure","displayName":"AUDIT questionnaire","title":"The alcohol use disorders identification test: Self-report version","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">The alcohol use disorders identification test: Self-report version</div><div class=\"cntnt\"><img style=\"width:597px; height:750px;\" src=\"images/PC/72626_AUDIT_questionnaire_edit.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorder Identification Test: Guidelines for Use in Primary Care, Second Edition. World Health Organization, 2001. Available at: http://whqlibdoc.who.int/hq/2001/who_msd_msb_ 01.6a.pdf.</div><div id=\"graphicVersion\">Graphic 72626 Version 2.0</div></div></div>"},"72627":{"type":"graphic_algorithm","displayName":"Hyperglycemia treatment for hospitalized patients on normal diet","title":"Hyperglycemia treatment for hospitalized patients eating a normal diet","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Hyperglycemia treatment for hospitalized patients eating a normal diet</div><div class=\"cntnt\"><img style=\"width:458px; height:660px;\" src=\"images/ENDO/72627_Hypergly_tx_pat_norm_diet.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Proposed algorithm for management of diabetes and hyperglycemia in the noncritical care setting.</div><div class=\"graphic_footnotes\">DM: diabetes mellitus; GLP-1: glucagon-like peptide-1; BG: blood glucose; D/C: discontinue.</div><div class=\"graphic_reference\">Reproduced with permission from: Inzucchi SE. Diabetes facts and guidelines. Yale Diabetes Center, 2011. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 72627 Version 5.0</div></div></div>"},"72628":{"type":"graphic_figure","displayName":"Sulfonamide metabolic pathways","title":"Sulfonamide metabolic pathways","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Sulfonamide metabolic pathways</div><div class=\"cntnt\"><img style=\"width:587px; height:322px;\" src=\"images/ALLRG/72628_Sulfonamide_metabolic_pathw.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sulfonamide antimicrobial drugs are metabolized by oxidation of the arylamine group (shown in blue). Nontoxic metabolites are then excreted. Factors that slow metabolism, such as slow acetylator status or depletion of glutathione stores (in HIV infection), can affect the steps shown in bold red. This may lead to prolonged exposure to reactive metabolites and increased rate of hypersensitivity reactions.</div><div class=\"graphic_reference\">Modified with permission from: Solensky R. Drug desensitization. Immunol Allergy Clin North Am 2004; 24:425. Copyright &copy; 2004 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 72628 Version 3.0</div></div></div>"},"72629":{"type":"graphic_table","displayName":"Causes of toxic megacolon","title":"Causes of toxic megacolon","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of toxic megacolon</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Inflammatory</td>\n</tr>\n<tr>\n<td>Ulcerative colitis</td>\n</tr>\n<tr>\n<td>Crohn's colitis</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Infectious</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Bacterial</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Clostridium difficile pseudomembranous colitis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Salmonella - typhoid and non-typhoid</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Shigella</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Campylobacter</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Yersinia</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Parasitic</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Entameba histolytica</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Cryptosporidium</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Viral</td>\n</tr>\n<tr>\n<td class=\"sublist1\">CMV colitis</td>\n</tr>\n<tr>\n<td>Self-limited colitis (culture negative)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Other</td>\n</tr>\n<tr>\n<td>Pseudomembranous colitis secondary to methotrexate therapy</td>\n</tr>\n<tr>\n<td>Kaposi's sarcoma</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72629 Version 1.0</div></div></div>"},"72631":{"type":"graphic_table","displayName":"Causes torsade de pointes","title":"Nonantiarrhythmic agents which may induce torsade de pointes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonantiarrhythmic agents which may induce torsade de pointes</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Psychiatric drugs</td></tr>\n\t\t\t\t\t\t<tr><td>Pheniothiazines - thioridazine, chlorpromazine</td></tr>\n\t\t\t\t\t\t<tr><td>Tricyclic antidepressants - amitriptyline</td></tr>\n\t\t\t\t\t\t<tr><td>Haloperidol</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Antibiotics</td></tr>\n\t\t\t\t\t\t<tr><td>Azithromycin</td></tr>\n\t\t\t\t\t\t<tr><td>Chloroquine</td></tr>\n\t\t\t\t\t\t<tr><td>Erythromycin</td></tr>\n\t\t\t\t\t\t<tr><td>Pentamidine</td></tr>\n\t\t\t\t\t\t<tr><td>Trimethoprim-sulfamethoxazole</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Toxins</td></tr>\n\t\t\t\t\t\t<tr><td>Arsenic</td></tr>\n\t\t\t\t\t\t<tr><td>Organophosphate insecticides</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Diuretics</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Antihistamines</td></tr>\n\t\t\t\t\t\t<tr><td>Terfenadine</td></tr>\n\t\t\t\t\t\t<tr><td>Astemizole</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Calcium channel blockers</td></tr>\n\t\t\t\t\t\t<tr><td>Bepridil</td></tr>\n\t\t\t\t\t\t<tr><td>Lidoflazine</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Antihyperlipidemics</td></tr>\n\t\t\t\t\t\t<tr><td>Probucol</td></tr>\n\t\t\t\t\t\t\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Other</td></tr>\n\t\t\t\t\t\t<tr><td>Amantadine</td></tr>\n\t\t\t\t\t\t<tr><td>Cisapride</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72631 Version 1.0</div></div></div>"},"72634":{"type":"graphic_picture","displayName":"Multiple actinic keratoses","title":"Multiple actinic keratoses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple actinic keratoses</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72634_Mult_actinic_keratoses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperkeratotic&nbsp;papules are present on the dorsal hands and forearms.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72634 Version 4.0</div></div></div>"},"72635":{"type":"graphic_picture","displayName":"Pathologic skin picking 2","title":"Acne excoriÃ©e","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne excoriÃ©e</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72635_Pathologic_skin_pick_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 13-year-old girl picked the comedones on her forehead, resulting in chronic erosions. Some of the erosions healed with scarring as new lesions appeared.</div><div class=\"graphic_reference\">Copyright Â© Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 72635 Version 7.0</div></div></div>"},"72636":{"type":"graphic_movie","displayName":"VSD closure device 2D and color","title":"VSD closure device 2D and color","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">VSD closure device 2D and color</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72636_VSDclosdeviccolormovie.mp4\" style=\"width:496px;height:400px\"></div><img style=\"width:545px; height:345px;\" src=\"images/CARD/72636_VSDclosdeviccolorposter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paired mid-esophageal apical four-chamber movie clips with and without color Doppler imaging from intraoperative transesophageal echocardiogram (TEE). The images show a relatively empty heart on cardiopulmonary bypass during intraoperative placement of an Amplatzer muscular VSD device. The device has been positioned using a perventricular approach, introducing the sheath and later the device through the right ventricular wall using TEE guidance. The device is well seated on the septum and remains attached to the delivery cable at this point in the procedure. Color Doppler imaging shows no significant residual shunting in the region of the VSD closure device.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; IVS: intraventricular septum; RV: right ventricle; LV: left ventricle; small arrows: Amplatzer VSD occluder device; large arrow: delivery cable.</div><div id=\"graphicVersion\">Graphic 72636 Version 5.0</div></div></div>"},"72637":{"type":"graphic_table","displayName":"Risk factors surgery obstructive jaundice","title":"Risk factors for morbidity and mortality in patients with obstructive jaundice undergoing surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for morbidity and mortality in patients with obstructive jaundice undergoing surgery</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Azotemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cholangitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hematocrit &#60; 30 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoalbulminemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malignant cause of biliary obstruction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Serum bilirubin level &#62; 11 mg/dL (188 &#181;mol/liter)</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29:1617. Copyright &#169; 1999 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 72637 Version 2.0</div></div></div>"},"72639":{"type":"graphic_figure","displayName":"Lateral thrust","title":"Lateral thrust","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Lateral thrust</div><div class=\"cntnt\"><img style=\"width:455px; height:650px;\" src=\"images/PEDS/72639_Lateral_thrust.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral thrust is a brief lateral shift at the head of the fibula and upper tibia during the stance phase of gait. It suggests incompetence of the knee ligaments with increased risk of progression.</div><div id=\"graphicVersion\">Graphic 72639 Version 1.0</div></div></div>"},"72640":{"type":"graphic_table","displayName":"MMR and VZV in immune globulin or blood product recipients","title":"Suggested interval between immune globulin or blood product and measles (MMR, MMRV) or VZV vaccine*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested interval between immune globulin or blood product and measles (MMR, MMRV) or VZV vaccine*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Product</td> <td class=\"subtitle1\">Interval (months)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intramuscular immune globulin (IG)</td> </tr> <tr> <td class=\"indent1\">Hepatitis A prophylaxis (IG)</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Measles prophylaxis (IG) for immunocompetent host (ie, standard measles prophylaxis)</td> <td>6&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tetanus IG</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Hepatitis B IG</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Rabies IG</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Varicella prophylaxis (as VariZIG)</td> <td>5</td> </tr> <tr> <td class=\"indent1\">RSV prophylaxis (palivizumab [Synagis])</td> <td>None</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Intravenous immune globulin (IVIG)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Replacement therapy (IVIG)</td> </tr> <tr> <td class=\"sublist2\">300 to 400 mg/kg</td> <td class=\"sublist_other\">8</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">For ITP (IVIG)</td> </tr> <tr> <td class=\"sublist2\">400 mg/kg</td> <td class=\"sublist_other\">8</td> </tr> <tr> <td class=\"sublist2\">1000 mg/kg</td> <td class=\"sublist_other\">10</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">For ITP or Kawasaki syndrome (IVIG)</td> </tr> <tr> <td class=\"sublist2\">1600 to 2000 mg/kg</td> <td class=\"sublist_other\">11</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus immune globulin</td> <td>6&nbsp;</td> </tr> <tr> <td class=\"indent1\">Botulinum immune globulin (as BabyBIG)</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Measles prophylaxis (as IVIG)</td> <td>8&nbsp;</td> </tr> <tr> <td class=\"indent1\">Varicella prophylaxis (as IVIG)&nbsp;</td> <td>8</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Blood products</td> </tr> <tr> <td class=\"indent1\">Washed RBCs</td> <td>0</td> </tr> <tr> <td class=\"indent1\">RBCs, adenine-saline added</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Packed RBCs</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Whole blood</td> <td>6</td> </tr> <tr> <td class=\"indent1\">Plasma or platelet products</td> <td>7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMR: measles, mumps, rubella vaccine; MMRV: measles, mumps, rubella, varicella vaccine; VZV: varicella zoster virus vaccine; RSV: respiratory syncytial virus; ITP: idiopathic thrombocytopenic purpura; RBCs: red blood cells.<br />* The information in this table does not apply to rubella nonimmune women&nbsp;who received anti-Rho(D)&nbsp;IG or any other blood product during the last trimester of pregnancy or at delivery. Such women should receive MMR vaccine immediately after delivery and should be tested at least three months later for evidence of immunity to rubella and measles. </div><div class=\"graphic_reference\">Data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Active immunization of people who recently received immune globulin and other blood products. Red Book: 2015 Report of the Committee on Infectious Diseases, 30<SUP>th</SUP> ed,&nbsp;Kimberlin DW, Brady MT, Jackson MA, Long SS&nbsp;(Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p. 38</LI>&#xD;&#xA;<LI>Kroger AT, Duchin J, VÃ¡zquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at:&nbsp;<A spellcheck=true href=\"http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>&nbsp;(Accessed on April 27, 2017). </LI></OL></div><div id=\"graphicVersion\">Graphic 72640 Version 13.0</div></div></div>"},"72642":{"type":"graphic_table","displayName":"WHO dehydration","title":"Clinical signs and symptoms of dehydration in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical signs and symptoms of dehydration in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">â&nbsp;</td> <td class=\"subtitle1\">No dehydration</td> <td class=\"subtitle1\">Moderate&nbsp;dehydration</td> <td class=\"subtitle1\">Severe dehydration</td> </tr> <tr> <td>Condition*</td> <td>Well, alert</td> <td>Restless, irritable</td> <td>Lethargic or unconscious</td> </tr> <tr> <td>Eyes<sup>&#182;</sup></td> <td>Normal</td> <td>Sunken</td> <td>Very sunken</td> </tr> <tr> <td>Tears</td> <td>Present</td> <td>Absent</td> <td>Absent</td> </tr> <tr> <td>Mouth and tongue<sup>&#916;</sup></td> <td>Moist</td> <td>Dry</td> <td>Very dry</td> </tr> <tr> <td>Thirst</td> <td>Drinks normally, not thirsty</td> <td>Thirsty, drinks eagerly</td> <td>Drinks poorly, or not able to drink</td> </tr> <tr> <td>Skin<sup>&#9674;</sup></td> <td>Springs back quickly</td> <td>Goes back slowly</td> <td>Goes back very slowly</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Being lethargic and sleepy are not the same. A lethargic child is not simply asleep: the child's mental state is dull and the child cannot be fully awakened; the child may appear to be drifting into unconsciousness.<br />Â¶ In some infants and children, the eyes normally appear somewhat sunken. It is helpful to ask the mother if the child's eyes are normal or more sunken than usual.<br />Î It is necessary to look inside the child's mouth. The mouth may be dry in a child who habitually breathes through the mouth. The mouth may be wet in a dehydrated child owing to recent vomiting or drinking.<br /><FONT class=lozenge>â</FONT> The skin turgor, as estimated by pinch, is less useful in infants or children with marasmus or kwashiorkor.</div><div class=\"graphic_reference\">Modified and reproduced with permission from: Treatment of diarrhea: A manual for physicians and other senior health workers. World Health Organization, Geneva, 2005. Copyright &copy; 2005 World Health Organization.</div><div id=\"graphicVersion\">Graphic 72642 Version 3.0</div></div></div>"},"72643":{"type":"graphic_figure","displayName":"Baby position PI","title":"Different baby positions in the uterus","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Different baby positions in the uterus</div><div class=\"cntnt\"><img style=\"width:479px; height:697px;\" src=\"images/PI/72643_Baby-positions-in-the-uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Before birth, babies lie in the uterus in different positions. Most babies lie with their head down and close to the vagina (as shown in A). Doctors also call this \"vertex\" or \"cephalic\" presentation.&nbsp;But some babies lie with their legs, buttocks, or shoulders down. Doctors call it \"breech\" if a baby's legs or buttocks are closest to the vagina (as shown in B).</div><div id=\"graphicVersion\">Graphic 72643 Version 3.0</div></div></div>"},"72644":{"type":"graphic_figure","displayName":"Principles of autofluorescence","title":"Principles of light-tissue interaction","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Principles of light-tissue interaction</div><div class=\"cntnt\"><img style=\"width:540px; height:203px;\" src=\"images/GAST/72644_Principles_of_autofluoresce.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several interactions are possible when a photon of light (excitation light) comes into contact with tissue. The photon may be reflected immediately, it may pass through the tissue for a certain distance to be absorbed by chromophores, or it can cause a light-tissue interaction resulting in a change in its wave-length, a phenomenon known as autofluorescence.</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &#169; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 72644 Version 1.0</div></div></div>"},"72645":{"type":"graphic_picture","displayName":"Torsion with salvageable ovary","title":"Ovarian and tubal torsion demonstrating marked vascular engorgement as well as increased size and distension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian and tubal torsion demonstrating marked vascular engorgement as well as increased size and distension</div><div class=\"cntnt\"><img style=\"width:432px; height:329px;\" src=\"images/OBGYN/72645_Torsionwithsalvageableov.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy was restored and both structures were salvaged despite non-viable appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72645 Version 15.0</div></div></div>"},"72646":{"type":"graphic_picture","displayName":"Adult T cell Leukemia","title":"Circulating tumor cells in adult T-cell leukemia/lymphoma (\"flower cells\")","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circulating tumor cells in adult T-cell leukemia/lymphoma (\"flower cells\")</div><div class=\"cntnt\"><img style=\"width:305px; height:287px;\" src=\"images/HEME/72646_Adult_T_cell_Leukemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This peripheral blood smear shows a number of lymphoid cells with hyperlobulated nuclei, often called &quot;flower cells.&quot;</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 72646 Version 2.0</div></div></div>"},"72647":{"type":"graphic_picture","displayName":"Aspiration olecranon bursa","title":"Aspiration of the olecranon bursa","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Aspiration of the olecranon bursa</div><div class=\"cntnt\"><img style=\"width:524px; height:381px;\" src=\"images/EM/72647_Aspiration_olecranon_bursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient is supine with the elbow flexed to 90 degrees and the forearm lying over the chest. Ethyl chloride or a comparable agent&nbsp;is applied to the skin for anesthesia. A 1.5 inch (3.75 cm), 16-gauge needle is inserted distally at the base of the bursa, nearly parallel to the ulna.&nbsp;0.5 mL of lidocaine is injected subcutaneously prior to aspiration of bursal fluid.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 72647 Version 4.0</div></div></div>"},"72648":{"type":"graphic_figure","displayName":"Function of C1 inhibitor","title":"Function of the C1 inhibitor","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Function of the C1 inhibitor</div><div class=\"cntnt\"><img style=\"width:540px; height:574px;\" src=\"images/ALLRG/72648_FunctionofC1inhibitor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">C1 inhibitor (a serpin or serine protease <FONT color=black>inhibitor)&nbsp;regulates the activation of the classical complement pathway by </FONT><FONT color=black><FONT color=black>binding to and inactivating the serine protease subcomponents of C1 (ie, the tetramer consisting of two C1r and two C1s proteins).</FONT> In this process,&nbsp;the C1 inhibitor complex dissociates from the C1q subcomponent of C1, which remains bound to the immune complex. Note that C1 inhibitor also regulates in the same manner the mannose-binding lectin-associated serine proteases (MASPs) that are the C1r/C1s equivalents in the lectin pathway of complement activation.</FONT></div><div class=\"graphic_footnotes\">Ab: antibody; Ag: antigen.</div><div id=\"graphicVersion\">Graphic 72648 Version 7.0</div></div></div>"},"72649":{"type":"graphic_diagnosticimage","displayName":"Retrograde urethrogram with severe stricture","title":"Retrograde urethrogram with severe stricture","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Retrograde urethrogram with severe stricture</div><div class=\"cntnt\"><img style=\"width:468px; height:418px;\" src=\"images/SURG/72649_Retro_urethro_sev_strict.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72649 Version 2.0</div></div></div>"},"72651":{"type":"graphic_table","displayName":"Cutaneous squamous cell carcinoma recurrence and metastasis","title":"Factors associated with increased risk for local recurrence and metastasis of cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors associated with increased risk for local recurrence and metastasis of cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor factors</td> <td class=\"subtitle1\">Rate of recurrence<br /> (percent)</td> <td class=\"subtitle1\">Rate of metastasis<br /> (percent)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Location</td> </tr> <tr> <td class=\"indent1\">Lip</td> <td class=\"centered\">2.3 to 22.2</td> <td class=\"centered\">3 to 20</td> </tr> <tr> <td class=\"indent1\">Ear</td> <td class=\"centered\">5.3 to 18.7</td> <td class=\"centered\">8.8 to 11.6</td> </tr> <tr> <td class=\"indent1\">Anogenital</td> <td class=\"centered\">14 to 15</td> <td class=\"centered\">15 to 74</td> </tr> <tr> <td class=\"indent1\">Chronic wound or scar</td> <td class=\"centered\">N/A</td> <td class=\"centered\">26.2 to 37.9</td> </tr> <tr> <td class=\"indent1\">Irradiated skin</td> <td class=\"centered\">N/A</td> <td class=\"centered\">20 to 26</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Size</td> </tr> <tr> <td class=\"indent1\">&#8805;2 cm</td> <td class=\"centered\">15.2</td> <td class=\"centered\">5.8 to 42.5</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Depth</td> </tr> <tr> <td class=\"indent1\">&#62;4 mm/Clark IV, V</td> <td class=\"centered\">17.2</td> <td class=\"centered\">30.4 to 51</td> </tr> <tr> <td class=\"indent1\">&#62;6 mm</td> <td class=\"centered\">N/A</td> <td class=\"centered\">15.6</td> </tr> <tr> <td>Recurrent tumor</td> <td class=\"centered\">10 to 27.5</td> <td class=\"centered\">16.3 to 30.3</td> </tr> <tr> <td>Poorly differentiated histology</td> <td class=\"centered\">28.6</td> <td class=\"centered\">32.8 to 57.9</td> </tr> <tr class=\"divider_bottom\"> <td>Perineural invasion</td> <td class=\"centered\">16 to 47.2</td> <td class=\"centered\">10 to 50</td> </tr> <tr> <td class=\"subtitle1\">Host factors</td> <td class=\"subtitle1\">Rate of recurrence<br /> (percent)</td> <td class=\"subtitle1\">Rate of metastasis<br /> (percent)</td> </tr> <tr> <td>CLL and SLL</td> <td class=\"centered\">25 to 100</td> <td class=\"centered\">18 to 100</td> </tr> <tr> <td>Organ transplantation</td> <td class=\"centered\">10 to 54</td> <td class=\"centered\">6 to 31</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: A systemic review of the English literature. Dermatol Surg 2006; 32:1309. DOI: <A spellcheck=true href=\"http://journals.lww.com/dermatologicsurgery/pages/articleviewer.aspx?year=2006&amp;issue=11000&amp;article=00001&amp;type=abstract\" target=_blank>10.1111/j.1524-4725.2006.32300.x</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright Â© 2006 American Society for Dermatologic Surgery. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 72651 Version 4.0</div></div></div>"},"72652":{"type":"graphic_diagnosticimage","displayName":"FAST pelvic view","title":"FAST: Pelvic (retrovesical) view","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Pelvic (retrovesical) view</div><div class=\"cntnt\"><img style=\"width:504px; height:421px;\" src=\"images/EM/72652_FAST_pelvic_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image, obtained during a FAST examination with the probe in a transverse orientation, reveals a full bladder but no free fluid surrounding bowel behind the bladder, indicating a negative study.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma; B: bladder.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 72652 Version 3.0</div></div></div>"},"72654":{"type":"graphic_figure","displayName":"Progression hep C by liver bx","title":"Progression of hepatitis C to cirrhosis according to baseline inflammation on initial liver biopsy","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Progression of hepatitis C to cirrhosis according to baseline inflammation on initial liver biopsy</div><div class=\"cntnt\"><img style=\"width:536px; height:326px;\" src=\"images/GAST/72654_Progression_hep_C_by_liver.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this study of 70 patients with chronic hepatitis C virus infection, those with mild inflammation (portal inflammation alone or with only focal periportal extension) and no fibrosis on the initial liver biopsy had only a 1.2 percent annual risk of progressing to cirrhosis (blue line). In comparison, patients with moderate chronic hepatitis (periportal inflammation usually involving more than 30 percent of the limiting plate) had a 4.6 percent annual risk of developing cirrhosis (green line), and those with severe inflammation or bridging fibrosis had a high risk of progression (red line); nearly all in the last group developed cirrhosis within ten years.</div><div class=\"graphic_reference\">Data from Yano, M, Kumada, H, Kage, M, et al, Hepatology 1996; 23:1334.</div><div id=\"graphicVersion\">Graphic 72654 Version 1.0</div></div></div>"},"72655":{"type":"graphic_diagnosticimage","displayName":"Chronic pancreatitis MRCP","title":"Chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:396px; height:254px;\" src=\"images/PEDS/72655_Chronic_pancreatitis_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiopancreatography showing a tortuous and markedly dilated pancreatic duct (arrow). There appears to be relative narrowing of the pancreatic duct just before its confluence with the common bile duct.</div><div class=\"graphic_reference\">Courtesy of Mohamed Miqdady, MD and Seiji Kitagawa, MD.</div><div id=\"graphicVersion\">Graphic 72655 Version 2.0</div></div></div>"},"72656":{"type":"graphic_diagnosticimage","displayName":"Apical pneumothorax","title":"Chest x-ray with apical pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest x-ray with apical pneumothorax</div><div class=\"cntnt\"><img style=\"width:450px; height:420px;\" src=\"images/PEDS/72656_Left_apical_pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The film demonstrates a small left apical spontaneous pneumothorax. The visceral pleural line is marked by the red arrows.</div><div id=\"graphicVersion\">Graphic 72656 Version 3.0</div></div></div>"},"72658":{"type":"graphic_figure","displayName":"Neuroblastoma incidence by age","title":"Age-specific neuroblastoma incidence rates by sex, all races, SEER 1976-84 and 1986-94","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Age-specific neuroblastoma incidence rates by sex, all races, SEER 1976-84 and 1986-94</div><div class=\"cntnt\"><img style=\"width:482px; height:544px;\" src=\"images/PEDS/72658_Neuroblastoma_incidence_by.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From Goodman, MT, Gurney, JG, Smith, MA, Olshan, AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, Ries, LA, Smith, MA, Gurney, JG, et al, National Cancer Institute, SEER Program. NIH Pub No. 99-4649; Bethesda, MD 1999. p. 66-67.</div><div id=\"graphicVersion\">Graphic 72658 Version 1.0</div></div></div>"},"72660":{"type":"graphic_diagnosticimage","displayName":"Tubal preg vs corpus luteum","title":"Tubal pregnancy versus corpus luteum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tubal pregnancy versus corpus luteum</div><div class=\"cntnt\"><img style=\"width:364px; height:504px;\" src=\"images/OBGYN/72660_Tubal_preg_vs_corpus_luteum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two examples of an ectopic pregnancy next to corpus luteal cysts. Note in both cases the ring around the ectopic pregnancy is more echogenic than the surrounding tissues of the corpus luteum.</div><div class=\"graphic_footnotes\">E: ectopic pregnancy; O: ovary.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 72660 Version 2.0</div></div></div>"},"72661":{"type":"graphic_picture","displayName":"White plaques of high-grade squamous intraepithelial lesions ","title":"White plaques of vulvar high-grade squamous intraepithelial lesions (HSIL)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">White plaques of vulvar high-grade squamous intraepithelial lesions (HSIL)</div><div class=\"cntnt\"><img style=\"width:288px; height:353px;\" src=\"images/OBGYN/72661_White_plaques_of_VIN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Raised whitish plaques as a manifestation of high-grade squamous intraepithelial lesions of the vulva (HSIL).</div><div class=\"graphic_reference\">Courtesy of Christine Holschneider, MD.</div><div id=\"graphicVersion\">Graphic 72661 Version 4.0</div></div></div>"},"72662":{"type":"graphic_picture","displayName":"Zellweger syndrome","title":"Four patients with Zellweger (cerebrohepatorenal syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Four patients with Zellweger (cerebrohepatorenal syndrome)</div><div class=\"cntnt\"><img style=\"width:396px; height:566px;\" src=\"images/PEDS/72662_Zellweger_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the high forehead, epicanthal folds, and hypoplasia of supraorbital ridges and midface.</div><div class=\"graphic_reference\">Courtesy of Hans Zellweger, MD. Reproduced with permission from: Behrman RE, Kliegman RM, Jenson HB (Eds). Nelson Textbook of Pediatrics, 17th Edition, Saunders 2004. p.439. Copyright Â© 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 72662 Version 3.0</div></div></div>"},"72664":{"type":"graphic_diagnosticimage","displayName":"Color Doppler of intraabdominal single umbilical artery","title":"Color Doppler of intraabdominal single umbilical artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color Doppler of intraabdominal single umbilical artery</div><div class=\"cntnt\"><img style=\"width:343px; height:514px;\" src=\"images/OBGYN/72664_Color_Doppler_intraabdom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler ultrasound depicting the intra-abdominal segment of the umbilical arteries running along side of the fetal bladder (B).<br> (Panel A) Normal two umbilical arteries in a fetus with a three-vessel cord.<br> (Panel B) Only a single artery is seen in a fetus with a two-vessel cord.</div><div id=\"graphicVersion\">Graphic 72664 Version 2.0</div></div></div>"},"72665":{"type":"graphic_figure","displayName":"Trochanteric bursa injection in children","title":"Trochanteric bursa injection in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trochanteric bursa injection in children</div><div class=\"cntnt\"><img style=\"width:378px; height:327px;\" src=\"images/ALLRG/72665_Trochant_bursa_inject_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trochanteric bursa injection, which may be multiple, not single as shown, may be made up of triamcinolone acetonide (1 mg/kg of 40 mg/mL suspension, maximum 40 mg) mixed with lidocaine without epinephrine (maximum 4.5 mg/kg, not to exceed 300 mg). After localizing the points of maximum tenderness by deep palpation, a 1.5- to 4-inch needle is used as a probe and the points of maximum tenderness are determined. The injection should be done by redirecting several places within the same coronal plane close to bone. The operator should not wander off the coronal plane of the maximal bony protuberance in order to be absolutely sure of avoiding neurovascular structures.</div><div class=\"graphic_reference\">Reproduced from: Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia, 1993. p.545.</div><div id=\"graphicVersion\">Graphic 72665 Version 1.0</div></div></div>"},"72666":{"type":"graphic_figure","displayName":"BAI and BDI cervical spine measurements","title":"BAI and BDI cervical spine measurements","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">BAI and BDI cervical spine measurements</div><div class=\"cntnt\"><img style=\"width:501px; height:515px;\" src=\"images/EM/72666_BAI-and-BDI-cervical-spine-measurements.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72666 Version 3.0</div></div></div>"},"72667":{"type":"graphic_diagnosticimage","displayName":"Right hemothorax ultrasound","title":"Hemothorax seen on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hemothorax seen on ultrasound</div><div class=\"cntnt\"><img style=\"width:504px; height:384px;\" src=\"images/EM/72667_Right_hemothorax_US_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dark (anechoic) area above the diaphragm in the lower left corner of this image, obtained during a FAST examination, indicates a hemothorax.</div><div class=\"graphic_footnotes\">K: kidney; L: liver; FAST: focused assessment with sonography for trauma.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 72667 Version 3.0</div></div></div>"},"72669":{"type":"graphic_diagnosticimage","displayName":"CT of renal stone","title":"CT of renal stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of renal stone</div><div class=\"cntnt\"><img style=\"width:356px; height:243px;\" src=\"images/RADIOL/72669_Staghorn_calculus_CT_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nephrolithiasis. Image of abdomen from a noncontrast CT shows a stone (arrow) in the right renal pelvis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Mark D Aronson, MD.</div><div id=\"graphicVersion\">Graphic 72669 Version 8.0</div></div></div>"},"72670":{"type":"graphic_table","displayName":"Paraneoplastic GI motor dysfunction","title":"Paraneoplastic gastrointestinal motor dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paraneoplastic gastrointestinal motor dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1\">Cancer</td>\n    <td class=\"subtitle1\">Autoantibodies</td>\n  </tr>\n  <tr>\n    <td>Breast cancer</td>\n    <td>PCA-1, ANNA-2</td>\n  </tr>\n  <tr>\n    <td>Hodgkin lymphoma</td>\n    <td>PCA-Tr, N-type Ca++Ab</td>\n  </tr>\n  <tr>\n    <td>Ovarian cancer</td>\n    <td>PCA-1, N-type Ca++Ab</td>\n  </tr>\n  <tr>\n    <td>Small cell lung cancer</td>\n    <td>ANNA-1</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">PCA-1: type 1 Purkinje cell cytoplasmic antibody, also called anti-Yo;<br> ANNA2: antineuronal nuclear antibody type 2, also called anti-Ri;<br> PCA-Tr: Purkinje cell cytoplasmic antibody type Tr;<br> N-type Ca++Ab: antineuronal calcium channel antibody of N-type specificity;<br> ANNA-1: antineuronal nuclear antibody type 1, also called anti-Hu.</div><div class=\"graphic_reference\">Data from: Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96:373.</div><div id=\"graphicVersion\">Graphic 72670 Version 3.0</div></div></div>"},"72672":{"type":"graphic_figure","displayName":"Subendocardial injury current with exercise","title":"Subendocardial ischemia during exercise testing as viewed from a V5 electrode","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Subendocardial ischemia during exercise testing as viewed from a V5 electrode</div><div class=\"cntnt\"><img style=\"width:478px; height:424px;\" src=\"images/CARD/72672_Injury_currents_with_exerci.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: At rest, a normal ECG results from the firing of hypothetical action potentials from subendocardial (Endo) and subepicardial (Epi) muscle cells. Panel B: A diastolic injury current from injured subendocardial cells causes TQ segment elevation (or &quot;pseudo&quot; ST depression). Panel C: Systolic and diastolic injury currents from injured subendocardial cells (panel C) causes TQ elevation and &quot;true&quot; ST depression.</div><div id=\"graphicVersion\">Graphic 72672 Version 3.0</div></div></div>"},"72673":{"type":"graphic_figure","displayName":"Abnormal mammograms","title":"Yield of abnormal screening mammograms according to patient age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Yield of abnormal screening mammograms according to patient age</div><div class=\"cntnt\"><img style=\"width:429px; height:485px;\" src=\"images/PC/72673_Abnormalmammograms.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Number of women without breast cancer for each woman diagnosed with breast cancer among women having an abnormal mammogram when screened for breast cancer.</div><div class=\"graphic_reference\">Data from: Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003; 138:168. Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright Â© 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72673 Version 11.0</div></div></div>"},"72674":{"type":"graphic_figure","displayName":"Orbital structures","title":"Structures associated with the orbit","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Structures associated with the orbit</div><div class=\"cntnt\"><img style=\"width:538px; height:511px;\" src=\"images/EM/72674_Orbital_structures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing illustrates structures that are associated with the orbit that can be damaged in orbital fracutres.</div><div id=\"graphicVersion\">Graphic 72674 Version 2.0</div></div></div>"},"72676":{"type":"graphic_table","displayName":"ACC AHA ESC anticoag cardiovert","title":"ACC/AHA/ESC guideline summary: Prevention of thromboembolism in patients with atrial fibrillation (AF) undergoing cardioversion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA/ESC guideline summary: Prevention of thromboembolism in patients with atrial fibrillation (AF) undergoing cardioversion</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class I - There is evidence and/or\ngeneral agreement that the following approaches are effective for the\nprevention of thromboembolism in patients with AF undergoing\ncardioversion</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; For AF duration of &#8805;48 hours or duration unknown, anticoagulation with a goal INR of 2.0 to 3.0 for at least three weeks before and four weeks after either electrical or pharmacologic cardioversion.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">&#8226;&nbsp; For AF duration of more than 48 hours that requires immediate cardioversion due to hemodynamic instability:</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">1. Unfractionated heparin should be given concurrently (unless contraindicated) by an initial intravenous bolus followed by a continuous infusion at a dose adjusted to prolong the activated partial thromboplastin time to 1.5 to 2.0 times control.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">2. Thereafter, oral anticoagulation with a goal INR of 2.0 to 3.0 for at least four weeks as in patients undergo elective cardioversion.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">3. Limited data support the use of subcutaneous low molecular weight heparin.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; For AF duration less than 48 hours associated with hemodynamic instability (as manifested by angina, myocardial infarction, shock, or pulmonary edema), immediate cardioversion should be performed with delay for prior initiation of anticoagulation.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Class IIa - The weight of evidence\nor opinion is in favor of the usefulness of the following approaches\nfor the prevention of thromboembolism in patients with AF undergoing\ncardioversion</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; During the 48 hours after the onset of AF, the need for anticoagulation before and after cardioversion may be based upon the patient's estimated risk of thromboembolism.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">&#8226;&nbsp; A reasonable alternative to anticoagulation prior to cardioversion is transesophageal echocardiography to look for thrombus in the left atrium or left atrial appendage:</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">1. If thrombus is not identified, cardioversion is reasonable after initiation of unfractionated heparin (intravenous bolus followed by infusion at a dose adjusted to prolong the activated partial thromboplastin time to 1.5 to 2.0 times control).</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Limited data support the use of subcutaneous low molecular weight heparin for this indication.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Heparin therapy is continued until oral anticoagulation with warfarin or other vitamin K antagonist has led to an INR &#8805;2.0.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist2\">Oral anticoagulation with a goal INR of 2.0 to 3.0 is continued for a total duration of anticoagulation of at least four weeks.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">2. If thrombus is present, oral anticoagulation with a goal INR of 2.0 to 3.0 for at least three weeks before and four weeks after restoration of sinus rhythm; a longer duration of anticoagulation may be appropriate even if cardioversion is successful, because the risk of thromboembolism often remains elevated.</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>&#8226;&nbsp; For patients with atrial flutter undergoing cardioversion, anticoagulation according to the recommendations for AF.</td>\n\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from: Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.</div><div id=\"graphicVersion\">Graphic 72676 Version 2.0</div></div></div>"},"72677":{"type":"graphic_picture","displayName":"Posterior subcapsular cataract","title":"Posterior subcapsular cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior subcapsular cataract</div><div class=\"cntnt\"><img style=\"width:289px; height:260px;\" src=\"images/PC/72677_Posterior_subcapsular_catar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit-lamp photo of a posterior subcapsular cataract reveals a \"frost-like\" haze just anterior to the posterior lens capsule (arrows), which is the back surface of the lens.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 72677 Version 2.0</div></div></div>"},"72678":{"type":"graphic_figure","displayName":"Innervation of lower airway","title":"The innervation of the lower airways depicted in a highly schematic diagram","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">The innervation of the lower airways depicted in a highly schematic diagram</div><div class=\"cntnt\"><img style=\"width:574px; height:435px;\" src=\"images/PULM/72678_Innervation_of_lower_airway.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the lower airways, two distinct parasympathetic pathways have been identified: cholinergic and noncholinergic. Cholinergic parasympathetic nerves mediate bronchospasm while noncholinergic parasympathetic nerves mediate bronchodilatation. Reflexes differentially regulate these distinct parasympathetic pathways. This differential regulation may be facilitated by the distinct origin of preganglionic parasympathetic nerves arising from regions of the nucleus ambiguous (nA) or the dorsal motor nucleus of the vagus nerves (dmnX), and perhaps through differential processing of afferent input through the nucleus tractus solitarius (nTS). Sympathetic-adrenergic innervation of airway smooth muscle in humans is sparse or nonexistent. Circulating catecholamines are thus likely to be the primary endogenous ligand for b-adrenoceptors on airway smooth muscle. Vagal afferent nerves regulate autonomic reflexes in the lower airways. Multiple subtypes of afferent nerves innervating the airways and lungs have been identified. These afferent nerves regulate autonomic nerve activity, respiration and defensive reflexes such as cough.</div><div class=\"graphic_reference\">Reproduced with permission from: Mazzone, SB, Canning, BJ. Central nervous system control of the airways: pharmacological implications. Curr Opin Pharmacol 2002; 2:220. Copyright &#169; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 72678 Version 1.0</div></div></div>"},"72679":{"type":"graphic_figure","displayName":"Survival pulmonary LCH","title":"Kaplan-Meier analysis of expected and observed survival among 102 adults with pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier analysis of expected and observed survival among 102 adults with pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:405px; height:256px;\" src=\"images/PULM/72679_Survival_pulmonary_LCH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The expected survival was defined as that for age- and sex-matched members of the general U.S. population.</div><div class=\"graphic_reference\">Data from Vassallo, R, Ryu, JH, Schroeder, DR, et al. N Engl J Med 2002; 346:484.</div><div id=\"graphicVersion\">Graphic 72679 Version 1.0</div></div></div>"},"72680":{"type":"graphic_picture","displayName":"Secondary syphilis - oral mucosa","title":"Secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72680_Sec_syphilis_oral_mucosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions (mucous patches) are present on the oral mucosa in this patient with secondary syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72680 Version 3.0</div></div></div>"},"72681":{"type":"graphic_picture","displayName":"Patulous eustachian tube catheter","title":"Left patulous eustachian tube catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left patulous eustachian tube catheter</div><div class=\"cntnt\"><img style=\"width:450px; height:343px;\" src=\"images/PC/72681_Left_pat_ET_cath2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72681 Version 1.0</div></div></div>"},"72682":{"type":"graphic_table","displayName":"Adverse reactions to patch testing","title":"Adverse reaction to patch testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse reaction to patch testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Active sensitization</td> <td>A negative reaction is followed by a late positive reaction after 10 to 20 days.</td> </tr> <tr> <td>\"Angry back\" or \"excites skin syndrome\"</td> <td>A few strong positive reactions cause a chain of multiple reactions to other patch tests that would otherwise be negative.</td> </tr> <tr> <td>Flare of dermatitis</td> <td>Usually it is not serious and helps to validate the positive reaction.</td> </tr> <tr> <td>Adhesive tape reaction</td> <td>Rare with the current acrylate-based adhesive tapes.</td> </tr> <tr> <td>Koebner phenomenon</td> <td>Can be seen in patients with active psoriasis and lichen planus<sup>[1]</sup>.</td> </tr> <tr> <td>Persistence of&nbsp;positive reaction</td> <td>Encountered more often with gold.</td> </tr> <tr> <td>Pigmentary alteration</td> <td>This includes postinflammatory hyper- and hypopigmentation.</td> </tr> <tr> <td>Pressure effect</td> <td>Imprint caused by pressure from the chamber or when testing a solid material.</td> </tr> <tr> <td>Bacterial and viral infections</td> <td>Higher risk (bacterial) when testing to plant substances.</td> </tr> <tr> <td>Necrosis/scar/keloid</td> <td>Risk of testing to unknown caustic substances that burn a hole in the skin<sup>[2]</sup>.</td> </tr> <tr> <td>Sarcoidal reaction</td> <td>Has been described with metals including palladium.</td> </tr> <tr> <td>Milia</td> <td>&nbsp;</td> </tr> <tr> <td>Anaphylactoid</td> <td>Extremely rare but potential risk with bacitracin, neomycin, and contact urticaria.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br> <ol> <li>Weiss G, Shemer A, Trau H. The Koebner phenomenon; review of the literature. JEADV 2002; 16:241. </li> <li>Thijs L, Deraedt K, Goosens A. Granuloma possibly induced by palladium after ear piercing. Dermatitis 2008; 19:E26. </li> </ol></div><div id=\"graphicVersion\">Graphic 72682 Version 4.0</div></div></div>"},"72685":{"type":"graphic_table","displayName":"Minimum reduction contaminants","title":"Determination of the minimum reduction required for each contaminant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determination of the minimum reduction required for each contaminant</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group</td> <td class=\"subtitle1\">Contaminant</td> <td class=\"subtitle1\">Feed water concentration (mg/L)</td> <td class=\"subtitle1\">ANSI/AAMI/ISO standard (mg/L)</td> <td class=\"subtitle1\">Reduction ratio</td> <td class=\"subtitle1\">Maximum reduction ratio for group</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"17\">A</td> <td>Arsenic</td> <td>0.004</td> <td>0.005</td> <td>0.8</td> <td>&nbsp;</td> </tr> <tr> <td>Antimony</td> <td>&#60;0.001</td> <td>0.006</td> <td>0</td> <td>&nbsp;</td> </tr> <tr> <td>Barium</td> <td>0.027</td> <td>0.1</td> <td>0.27</td> <td>&nbsp;</td> </tr> <tr> <td>Beryllium</td> <td>&#60;0.001</td> <td>0.004</td> <td>0</td> <td>&nbsp;</td> </tr> <tr> <td>Cadmium</td> <td>&#60;0.0001</td> <td>0.001</td> <td>0</td> <td>&nbsp;</td> </tr> <tr> <td>Chromium</td> <td>0.004</td> <td>0.014</td> <td>0.3</td> <td>&nbsp;</td> </tr> <tr> <td>Copper</td> <td>0.006</td> <td>0.1</td> <td>0.06</td> <td>&nbsp;</td> </tr> <tr> <td>Fluoride</td> <td>1.9</td> <td>0.2</td> <td>9.5</td> <td>9.5</td> </tr> <tr> <td>Lead</td> <td>0.004</td> <td>0.005</td> <td>0.8</td> <td>&nbsp;</td> </tr> <tr> <td>Nitrate (N)</td> <td>0.9</td> <td>2</td> <td>0.45</td> <td>&nbsp;</td> </tr> <tr> <td>Potassium</td> <td>1.9</td> <td>8</td> <td>0.24</td> <td>&nbsp;</td> </tr> <tr> <td>Selenium</td> <td>0.009</td> <td>0.09</td> <td>0.1</td> <td>&nbsp;</td> </tr> <tr> <td>Silver</td> <td>&#60;0.001</td> <td>0.005</td> <td>0</td> <td>&nbsp;</td> </tr> <tr> <td>Sodium</td> <td>8.0</td> <td>70</td> <td>0.1</td> <td>&nbsp;</td> </tr> <tr> <td>Sulfate</td> <td>48</td> <td>100</td> <td>0.5</td> <td>&nbsp;</td> </tr> <tr> <td>Thallium</td> <td>&#60;0.001</td> <td>0.002</td> <td>0</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Zinc</td> <td>&#60;0.01</td> <td>0.1</td> <td>0</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">B</td> <td>Mercury</td> <td>0.0001</td> <td>0.0002</td> <td>0.5</td> <td>0.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">C</td> <td>Aluminum</td> <td>0.04</td> <td>0.01</td> <td>4</td> <td>4</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"2\">D</td> <td>Calcium</td> <td>62</td> <td>2</td> <td>31</td> <td>31</td> </tr> <tr class=\"divider_bottom\"> <td>Magnesium</td> <td>12</td> <td>4</td> <td>3</td> <td>&nbsp;</td> </tr> <tr> <td class=\"centered\">E</td> <td>Total chlorine (free chlorine and chloramine)</td> <td>2.1</td> <td>0.1</td> <td>21</td> <td>21</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Organization of water contaminants (second column) in the ANSI/AAMI/ISO standard (fourth column) into five groups (A-E, first column) based upon similarities in the methods required for their removal. Once the expected maximum feed water concentration of each contaminant has been estimated by direct measurement in combination with information from the water supplier, the values are entered in the third column of the table (feed water concentration [mg/L]). The necessary minimum level of reduction for each contaminant is then calculated by dividing the feed water concentration by the ANSI/AAMI/ISO standard concentration, and this value is entered into the fifth column (reduction ratio). The maximum reduction ratio for each group is found and entered in the sixth column (maximum group reduction ratio). These values are used to select appropriate water treatment processes.</div><div class=\"graphic_footnotes\">ANSI: American National Standards Institute; AAMI: American Association for the Advancement of Medical Instrumentation; ISO: International Organization for Standardization.</div><div id=\"graphicVersion\">Graphic 72685 Version 6.0</div></div></div>"},"72687":{"type":"graphic_picture","displayName":"Palmar pits basal cell carcinoma nevus syndrome","title":"Palmar pits associated with nevoid basal cell carcinoma syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmar pits associated with nevoid basal cell carcinoma syndrome</div><div class=\"cntnt\"><img style=\"width:317px; height:318px;\" src=\"images/ONC/72687_PalmarpitsBCCnevussyndr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palmar surface of hand showing 1 to 2 mm, sharply marginated, depressed, red lesions (ie, palmar pits).</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas &amp; Synopsis of Clinical Dermatology. Common &amp; Serious Diseases. (4th Ed). McGraw-Hill, New York 2001. pgs. 268 &amp; 289. Copyright Â© 2001 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 72687 Version 4.0</div></div></div>"},"72688":{"type":"graphic_table","displayName":"CMT types 1, 2, X, 3, and 4","title":"Clinical features and genetics of Charcot-Marie-Tooth (CMT) disease types 1, 2, X, 3, and 4","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features and genetics of Charcot-Marie-Tooth (CMT) disease types 1, 2, X, 3, and 4</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Chromosome</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td colspan=\"3\"><strong>CMT1</strong></td> <td> <ul> <li>Onset in first or second decade </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT1A</td> <td>PMP22</td> <td>17p12</td> <td rowspan=\"6\"> <ul> <li>Motor symptoms predominate (clumsy walking) </li> <li>Gradual loss of proprioception and vibration </li> <li>Ambulation usually maintained </li> <li>Normal life expectancy </li> <li>Palpable enlargement of the peripheral nerves </li> <li>NCV slowed to &#60;60% normal </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT1B</td> <td>MPZ</td> <td>1q23.3</td> </tr> <tr> <td class=\"indent1\">CMT1C</td> <td>LITAF</td> <td>16p13.13</td> </tr> <tr> <td class=\"indent1\">CMT1D</td> <td>EGR2</td> <td>10q21.3</td> </tr> <tr> <td class=\"indent1\">CMT1E</td> <td>PMP22</td> <td>17p12</td> </tr> <tr> <td class=\"indent1\">CMT1F</td> <td>NEFL</td> <td>8p21</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Roussy-Levy</td> <td>MPZ</td> <td>1q23.3</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>CMT1 features plus: <ul> <li>Postural tremor and gait ataxia </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>PMP22</td> <td>17p12</td> </tr> <tr> <td colspan=\"3\"><strong>CMT2</strong></td> <td> <ul> <li>Onset in second or third decade </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT2A</td> <td>MFN2</td> <td>1p36.2</td> <td rowspan=\"9\"> <ul> <li>Sensory symptoms predominate </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT2B</td> <td>RAB7</td> <td>3q21.3</td> </tr> <tr> <td class=\"indent1\">CMT2C</td> <td>TRPV4</td> <td>12q24.1</td> </tr> <tr> <td class=\"indent1\">CMT2D</td> <td>GARS</td> <td>7p15</td> </tr> <tr> <td class=\"indent1\">CMT2E</td> <td>NEFL</td> <td>8p</td> </tr> <tr> <td class=\"indent1\">CMT2F</td> <td>HSPB1</td> <td>7q11.23</td> </tr> <tr> <td class=\"indent1\">CMT2I</td> <td>MPZ</td> <td>1q22</td> </tr> <tr> <td class=\"indent1\">CMT2K</td> <td>GDAP1</td> <td>8q21.11</td> </tr> <tr> <td class=\"indent1\">CMT2L</td> <td>HSPB8</td> <td>12q24.23</td> </tr> <tr> <td class=\"indent1\">CMT2M</td> <td>DNM2</td> <td>19p13.2</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">CMT2P</td> <td>LRSAM1</td> <td>9q33.3-q34.1</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">CMT2S</td> <td>IGHMBP2</td> <td>11q13.3</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">CMT2T</td> <td>MME</td> <td>3q25.2</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Early onset</td> <td>&nbsp;</td> <td>Not known</td> <td> <ul> <li>Onset before age 5 years </li> <li>Rapid progression of weakness below the knee </li> <li>Loss of ambulation by mid-teens </li> <li>NCV normal or mildly reduced </li> </ul> </td> </tr> <tr> <td colspan=\"3\"><strong>CMTX</strong></td> <td> <ul> <li>X-linked </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMTX1</td> <td>GJB1</td> <td>Xq13.1</td> <td> <ul> <li>CMT1 features plus: <ul> <li>Symptoms more prominent in males </li> <li>Symptomatic in second decade </li> <li>Loss of ankle reflexes </li> <li>NCV moderately slowed </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMTX2</td> <td>Not known</td> <td>Xp22</td> <td> <ul> <li>Affects males only </li> <li>Infantile onset with risk of intellectual disability </li> <li>May have both axonal and demyelinating physiology </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMTX3</td> <td>78kb insertion from chromosome 8</td> <td>Xq27.1</td> <td> <ul> <li>Affects males only </li> <li>Juvenile onset </li> <li>Prominent sensory symptoms </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>CMTX4</p> (Cowchock syndrome) </td> <td>AIFM1</td> <td>Xq26</td> <td> <ul> <li>Affects primarily males, who have infantile onset axonal neuropathy with deafness and intellectual disability </li> <li>Females have mild symptoms </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMTX5</td> <td>PRPS1</td> <td>Xq22.3</td> <td> <ul> <li>Affects males only </li> <li>Deafness and optic neuropathy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">CMTX6</td> <td>PDK3</td> <td>Xp22.11</td> <td> <ul> <li>Affects primarily males </li> <li>Predominantly axonal sensorimotor polyneuropathy </li> </ul> </td> </tr> <tr> <td colspan=\"3\"><strong>CMT3</strong></td> <td> <ul> <li>Severe, early onset </li> </ul> </td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Dejerine-Sottas syndrome</td> <td>PMP22</td> <td>17p12</td> <td rowspan=\"3\"> <ul> <li>Hypotonia in early infancy </li> <li>Delayed motor development </li> <li>Initial sensory loss and distal weakness </li> <li>Ataxia </li> <li>NCV profoundly slowed (10 m/second) </li> </ul> </td> </tr> <tr> <td>MPZ</td> <td>1q23.3</td> </tr> <tr> <td>EGR2</td> <td>10q21.3</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Congenital hypomyelinating neuropathy</td> <td>PMP22</td> <td>17p12</td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>Profound hypotonia and contractures at birth </li> <li>Feeding difficulties </li> <li>Respiratory distress </li> <li>Death in infancy </li> <li>NCV extremely slowed or absent </li> </ul> </td> </tr> <tr> <td>MPZ</td> <td>1q23.3</td> </tr> <tr class=\"divider_bottom\"> <td>EGR2</td> <td>10q21.3</td> </tr> <tr> <td colspan=\"4\"><strong>CMT4</strong></td> </tr> <tr> <td class=\"indent1\">CMT4A</td> <td>GDAP1</td> <td>8q21.11</td> <td> <ul> <li>Onset in early childhood </li> <li>Distal weakness </li> <li>Mild sensory loss </li> <li>Rapidly progressive </li> <li>Incapacity in first decade </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4B1</td> <td>MTMR2</td> <td>11q21</td> <td> <ul> <li>Onset at age 2 to 4 years </li> <li>Distal and proximal weakness </li> <li>Moderate sensory loss </li> <li>Frequent involvement of cranial nerves </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4B2</td> <td>SBF2</td> <td>11p15.4</td> <td> <ul> <li>Onset in first two decades </li> <li>Initial distal weakness </li> <li>Proximal weakness after several years </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4B3</td> <td>SBF1</td> <td>22q13.33</td> <td> <ul> <li>Onset mean age 8 years </li> <li>Slowly progressive leg weakness and gait difficulty </li> <li>Areflexia and sensory loss (vibration/position affected more than pain/temperature) </li> <li>Pes planus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4C</td> <td>SH3TC2</td> <td>5q32</td> <td> <ul> <li>Severe spinal deformities and weakness </li> <li>Onset in childhood and adolescence </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4D</td> <td>NDRG1</td> <td>8q24.22</td> <td> <ul> <li>Early onset neuropathy </li> <li>Muscle weakness and wasting </li> <li>Skeletal deformities </li> <li>Sensory loss </li> <li>Neural deafness in second or third decade </li> <li>NCV severely reduced </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4E</td> <td>EGR2</td> <td>10q21.3</td> <td> <ul> <li>Distal weakness at birth </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4F</td> <td>PRX</td> <td>19q13.2</td> <td> <ul> <li>Onset in early childhood </li> <li>Distal muscle weakness </li> <li>Severe sensory loss </li> <li>Absent sensory and motor evoked response on NCV </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4H</td> <td>FGD4</td> <td>12p11.21</td> <td> <ul> <li>Severe demyelinating neuropathy </li> <li>Unsteady gait </li> </ul> </td> </tr> <tr> <td class=\"indent1\">CMT4J</td> <td>FIG4</td> <td>6q21</td> <td> <ul> <li>Childhood or adult onset </li> <li>Widespread denervation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NCV: nerve conduction velocity.</div><div id=\"graphicVersion\">Graphic 72688 Version 8.0</div></div></div>"},"72689":{"type":"graphic_picture","displayName":"Stasis dermatitis petechiae","title":"Petechiae in stasis dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Petechiae in stasis dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72689_Stasis_dermatitis_petechiae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous petechiae are present on the lower leg in this patient with stasis dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72689 Version 3.0</div></div></div>"},"72690":{"type":"graphic_picture","displayName":"Pemphigoid gestationis bullae","title":"Pemphigoid gestationis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigoid gestationis</div><div class=\"cntnt\"><img style=\"width:432px; height:351px;\" src=\"images/DERM/72690_Pemphigoid_gestationis_bull.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense bullae on skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72690 Version 5.0</div></div></div>"},"72691":{"type":"graphic_diagnosticimage","displayName":"Ultrasound neck vessels","title":"Ultrasound of normal neck vessels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of normal neck vessels</div><div class=\"cntnt\"><img style=\"width:317px; height:494px;\" src=\"images/EM/72691_US_neck_vessels.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse ultrasound images of the right neck demonstrate normal anatomy, including the internal jugular vein (blue arrow), common carotid artery (red arrow), sternocleidomastoid muscle (SCM), and thyroid gland (T). B shows collapse of the internal jugular vein when compression is applied with the transducer. The carotid artery is not easily compressed with light probe pressure.</div><div class=\"graphic_reference\">Courtesy of Lauren W Averill, MD.</div><div id=\"graphicVersion\">Graphic 72691 Version 5.0</div></div></div>"},"72692":{"type":"graphic_table","displayName":"ERCP for pancreatic disorders in children","title":"Potential indications for ERCP for pancreatic disease in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential indications for ERCP for pancreatic disease in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">- Nonresolving acute</td> </tr> <tr> <td class=\"indent1\">- Idiopathic recurrent</td> </tr> <tr> <td class=\"indent1\">- Chronic</td> </tr> <tr> <td>Evaluation of abnormalities on ultrasound, CT or MRCP</td> </tr> <tr> <td>Pancreatic pseudocysts</td> </tr> <tr> <td>Pancreatic trauma</td> </tr> <tr> <td>Pancreatic ascites</td> </tr> <tr> <td>Pancreatic duct leaks</td> </tr> <tr> <td>Pancreatic duct obstruction (eg, stone or stricture)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ERCP: endoscopic retrograde cholangiopancreatography; CT: computerized tomography; MRCP: magnetic resonance cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 72692 Version 7.0</div></div></div>"},"72694":{"type":"graphic_picture","displayName":"CLL and AIHA marrow","title":"Chronic lymphocytic leukemia with erythroid hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic lymphocytic leukemia with erythroid hyperplasia</div><div class=\"cntnt\"><img style=\"width:426px; height:288px;\" src=\"images/HEME/72694_CLL_and_AIHA_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia with bone marrow erythroid hyperplasia. The small lymphocytes (black arrows) have a dense nucleus with a thin rim of blue cytoplasm. The nucleated red cells have an irregularly clumped nucleus with a greater amount of cytoplasm, which can range from basophilic to polychromatophilic, to eosinophilic (red arrows). (Wright- Giemsa).</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 72694 Version 1.0</div></div></div>"},"72695":{"type":"graphic_diagnosticimage","displayName":"Pancreas divisum with dilation of the dorsal duct","title":"Pancreas divisum with dilation of the dorsal duct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreas divisum with dilation of the dorsal duct</div><div class=\"cntnt\"><img style=\"width:433px; height:504px;\" src=\"images/PEDS/72695_Panc_divisum_dilated_dd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) of a patient with pancreas divisum shows abnormal dilation of the dorsal duct, consistent with chronic pancreatitis. Patients with ductal dilation are less likely to respond to endoscopic therapy than those with pancreas divisum alone.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright Â©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 72695 Version 3.0</div></div></div>"},"72698":{"type":"graphic_diagnosticimage","displayName":"Pulmonary histiocytosis X CT","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:324px; height:304px;\" src=\"images/PULM/72698_Pulmonary_histiocytosis_X_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT with thin section shows the cysts in pulmonary Langerhans cell histiocytosis (PLCH), which vary markedly in size and may be larger than 10 mm. The cysts are bizarre in shape, often closely related to pulmonary arteries, and mimic bronchiectasis. Few nodules are present in this case.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 72698 Version 4.0</div></div></div>"},"72699":{"type":"graphic_picture","displayName":"Nail bed splint","title":"Nail bed repair: Splinting of the nail bed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail bed repair: Splinting of the nail bed</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/72699_Nail_bed_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The repaired nail bed is protected by placing the original nail back into the proximal fold (eponychium) and securing it with or wound adhesive (eg, Dermabond, Surgiseal, Histoacryl Blue, or Periacryl) or nonabsorbable suture. The nail should undergo trephination prior to replacement to permit drainage. If the nail cannot be used, trimmed sterile foil from the suture pack, a single thickness of nonadherent gauze, or a 0.2 inch silicon sheeting may be placed instead.</div><div class=\"graphic_reference\">Courtesy of Richard A Saladino, MD.</div><div id=\"graphicVersion\">Graphic 72699 Version 5.0</div></div></div>"},"72700":{"type":"graphic_table","displayName":"Heterozygous complement defects","title":"Inherited partial (heterozygous) defects and polymorphisms of complement proteins leading to human disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Inherited partial (heterozygous) defects and polymorphisms of complement proteins leading to human disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Defective protein(s)</td> <td class=\"subtitle1\">Associated illnesses</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td>Factor H*</td> <td>AMD; aHUS; HELLP; C3G</td> <td>Excessive AP activation (LOF)</td> </tr> <tr> <td>Factor I*</td> <td>AMD; aHUS; HELLP; C3G</td> <td>Excessive AP activation (LOF)</td> </tr> <tr> <td>MCP (CD46)*</td> <td>aHUS; HELLP; C3G</td> <td>Excessive AP activation (LOF)</td> </tr> <tr> <td>Factor B<sup>&#182;</sup></td> <td>aHUS; AMD</td> <td>Excessive AP activation (GOF)</td> </tr> <tr> <td>C3<sup>&#182;</sup></td> <td>aHUS, AMD; C3G</td> <td>Excessive AP activation (GOF)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AMD: age-related macular degeneration; aHUS: atypical hemolytic uremic syndrome; HELLP: hemolytic anemia, elevated liver enzymes and low platelet count; C3G: C3 glomerulopathies; AP: alternative pathway; LOF: loss-of-function; MCF: membrane cofactor protein; GOF: gain-of-function.<br />* Decreased regulatory activity secondary to being haploinsufficient (lack of protein production or a functionally-deficient protein).<br />Â¶&nbsp;GOF mutations lead to increased&nbsp;AP activity.</div><div class=\"graphic_reference\">Courtesy of&nbsp;M Kathryn Liszewski, BA&nbsp;and John P Atkinson, MD.</div><div id=\"graphicVersion\">Graphic 72700 Version 9.0</div></div></div>"},"72702":{"type":"graphic_diagnosticimage","displayName":"Brain MRI of PML in HIV infection","title":"Brain MRI of PML in a patient with HIV infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain MRI of PML in a patient with HIV infection</div><div class=\"cntnt\"><img style=\"width:299px; height:342px;\" src=\"images/NEURO/72702_PML_in_AIDS_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sharply demarcated hyperintense lesion without mass effect is seen in this T2-weighted image in the subcortical right frontal white matter.</div><div class=\"graphic_footnotes\">PML: progressive multifocal leukoencephalopathy; MRI: magnetic resonance imaging; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 72702 Version 3.0</div></div></div>"},"72703":{"type":"graphic_table","displayName":"Strategies for assisting adolescents with smoking cessation","title":"Strategies for assisting adolescent patients with smoking cessation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies for assisting adolescent patients with smoking cessation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Action\n   </td>\n   <td  class=\"subtitle1\">\n   Strategies for implementation\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Help the patient with a quit plan\n   </td>\n   <td>Set a quit date. Ideally, the quit date should be within two weeks. For patients who have difficulty with this type of \"all-or-nothing\" approach, it is reasonable to develop a strategy of cutting down gradually, in anticipation of a quit date further in the future.</td>\n   </tr>\n   <tr>\n   <td>Tell family, friends, and coworkers about quitting and request understanding and support.</td>\n   </tr>\n   <tr>\n   <td>Anticipate challenges to planned quit attempt, particularly during the critical first few weeks. These include nicotine withdrawal symptoms.</td>\n   </tr>\n   <tr>\n   <td>Remove tobacco products from your environment. Prior to quitting, avoid smoking in places where you spend a lot of time (eg, work, home, car).</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Provide practical counseling (problem solving/training)\n   </td>\n   <td>Abstinence - Total abstinence is essential. \"Not even a single puff after the quit date.\"</td>\n   </tr>\n   <tr>\n   <td>Past quit experience - Review past quit attempts including identification of what helped during the quit attempt and what factors contributed to relapse.</td>\n   </tr>\n   <tr>\n   <td>Anticipate triggers or challenges in upcoming attempt - Discuss challenges/triggers (such as school pressures, parties, or feelings of boredom or depression) and how patient will successfully overcome them.</td>\n   </tr>\n   <tr>\n   <td>Alcohol, marijuana, and other drugs - Because these can cause relapse, the patient should consider limiting/abstaining from their use while quitting. Health care providers should discuss the use/abuse of these substances and plans for changing behavior.</td>\n   </tr>\n   <tr>\n   <td>Other smokers in the household - Quitting is more difficult when there is another smoker in the household. Patients should encourage family members or roommates to quit with them or not smoke in their presence.</td>\n   </tr>\n   <tr>\n   <td>Provide intra-treatment social support</td>\n   <td>Provide a supportive clinical environment while encouraging the patient in his or her quit attempt. \"My office staff and I are available to assist you.\"</td>\n   </tr>\n   <tr>\n   <td>Help the patient obtain extra-treatment social support</td>\n   <td>Help the patient develop social support for his or her quit attempt in his or her environments outside of treatment. \"Ask your boyfriend/girlfriend, friends, and family to support you in your quit attempt.\"</td>\n   </tr>\n   <tr>\n   <td>Recommend the use of approved pharmacotherapy, except in special circumstances</td>\n   <td>Recommend the use of pharmacotherapies found to be effective. Explain how these medications increase smoking cessation success and reduce withdrawal symptoms. Discuss the proper use of these medications; review their use at future visits.</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Provide supplementary materials\n   </td>\n   <td>Sources - Federal agencies, nonprofit agencies, or local/state health departments, eg, 1-800-QUITNOW (1800quitnow.cancer.gov), www.notobacco.org, or www.tobaccofree.org/children.htm.</td>\n   </tr>\n   <tr>\n   <td>Type - Have printed materials on hand in clinical setting; provide web addresses or Quitline phone numbers. Materials should be culturally, racially, educationally and age-appropriate for the patient.</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from: Flore, MC, Bailey, WC, Cohen, SJ, et al. Treating Tobacco Use and Dependence. Public Health Service, US Dept of Health and Human Services, 2000.</div><div id=\"graphicVersion\">Graphic 72703 Version 2.0</div></div></div>"},"72705":{"type":"graphic_table","displayName":"Properties of opioid receptors","title":"Properties of opioid receptors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of opioid receptors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Mu</td> </tr> <tr> <td class=\"sublist2_start\">Mu1</td> </tr> <tr> <td class=\"indent2\">Supraspinal analgesia</td> </tr> <tr> <td class=\"indent2\">Bradycardia</td> </tr> <tr> <td class=\"indent2\">Sedation</td> </tr> <tr> <td class=\"sublist2_start\">Mu2</td> </tr> <tr> <td class=\"indent2\">Respiratory depression</td> </tr> <tr> <td class=\"indent2\">Euphoria</td> </tr> <tr> <td class=\"indent2\">Physical dependence</td> </tr> <tr> <td class=\"subtitle1_single\">Delta</td> </tr> <tr> <td class=\"indent1\">Spinal analgesia</td> </tr> <tr> <td class=\"indent1\">Respiratory depression</td> </tr> <tr> <td class=\"subtitle1_single\">Kappa</td> </tr> <tr> <td class=\"indent1\">Spinal analgesia</td> </tr> <tr> <td class=\"indent1\">Respiratory depression</td> </tr> <tr> <td class=\"indent1\">Sedation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72705 Version 3.0</div></div></div>"},"72706":{"type":"graphic_diagnosticimage","displayName":"Cystic bronchiectasis CT","title":"Cystic bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic bronchiectasis</div><div class=\"cntnt\"><img style=\"width:369px; height:279px;\" src=\"images/PULM/72706_Cystic_bronchiectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-tuberculous bronchiectasis characterized by marked destruction of the right upper lobe with cylindrical and cystic bronchiectasis and cicatrization atelectasis. These findings explain the ipsilateral rotational shift of the mediastinum. Cylindrical and varicose bronchiectasis is present in the left upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72706 Version 2.0</div></div></div>"},"72708":{"type":"graphic_figure","displayName":"Theophylline effect in asthma","title":"Lack of effect of theophylline during hospitalization for acute asthma ","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Lack of effect of theophylline during hospitalization for acute asthma </div><div class=\"cntnt\"><img style=\"width:479px; height:274px;\" src=\"images/PULM/72708_Theophylline_effect_in_asth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Change in total asthma score during hospital stay in patients treated with theophylline or placebo, showing the mean regression line of the asthma score until the time that discharge criteria were achieved (asthma score = 2). There was no difference between the two groups.</div><div class=\"graphic_reference\">From DiGiulio, GA, Kercsmar, CM, Krug, SE, et al, J Pediatr 1993; 122:464.</div><div id=\"graphicVersion\">Graphic 72708 Version 2.0</div></div></div>"},"72709":{"type":"graphic_figure","displayName":"Basic shoulder anatomy anterior view","title":"Anterior view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Anterior view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:600px; height:436px;\" src=\"images/RHEUM/72709_Shoulder_anatomy_ant_muscle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72709 Version 3.0</div></div></div>"},"72710":{"type":"graphic_figure","displayName":"Epigastric hernia","title":"Epigastric hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epigastric hernia</div><div class=\"cntnt\"><img style=\"width:316px; height:334px;\" src=\"images/SURG/72710_Epigastric_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An epigastric hernia occurs when bowel protrudes through a weakness in the linea alba. The small bulge appears midline between the xiphoid process and the umbilicus. It may be discovered only on palpation.</div><div class=\"graphic_reference\">Reproduced with permission from: Weber, J, Kelley, J. Health Assessment in Nursing, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72710 Version 1.0</div></div></div>"},"72711":{"type":"graphic_picture","displayName":"Leukoplakia - tongue","title":"Leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukoplakia</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/72711_Leukoplakia_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white plaque is present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72711 Version 3.0</div></div></div>"},"72712":{"type":"graphic_figure","displayName":"T3 resin test TBG excess","title":"T3-resin test in TBG excess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T3-resin test in TBG excess</div><div class=\"cntnt\"><img style=\"width:285px; height:386px;\" src=\"images/ENDO/72712_T3_resin_test_TBG_excess.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiolabeled T3 (*T3) is able to bind to the excess binding sites on TBG; as a result, the amount left over to bind to the resin is lower than normal. The serum total T4 is high; the T3-resin uptake and THBR are low, and the serum free T4 index is normal.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine: TBG: thyroxine-binding globulin; THBR: thyroid hormone binding ratio.</div><div id=\"graphicVersion\">Graphic 72712 Version 2.0</div></div></div>"},"72714":{"type":"graphic_picture","displayName":"Acute osteomyelitis light microscopy","title":"Acute osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute osteomyelitis</div><div class=\"cntnt\"><img style=\"width:306px; height:214px;\" src=\"images/ID/72714_Acute_osteomyelitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of acute osteomyelitis of the tibia shows many disconnected bony trabeculae in a sea of inflammatory cells (red arrow) and a single multinucleated giant cell (black arrow). The surfaces of the trabeculae (white arrows) have a few undifferentiated, spindle-shaped connective tissue elements. There is little evidence of active bone formation or bone resorption.</div><div class=\"graphic_reference\">Courtesy of Jon Mader, MD.</div><div id=\"graphicVersion\">Graphic 72714 Version 3.0</div></div></div>"},"72716":{"type":"graphic_table","displayName":"Opportunistic infections and cancers affecting endocrine glands","title":"Opportunistic infections and cancersÂ affecting endocrine glands","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opportunistic infections and cancers&nbsp;affecting endocrine glands</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Adrenal</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td><em>Cryptococcus neoformans</em></td> </tr> <tr> <td><em>Mycobacterium avium intracellulare</em></td> </tr> <tr> <td><em>M. tuberculosis</em></td> </tr> <tr> <td><em>Toxoplasmosis gondii</em></td> </tr> <tr> <td><em>Pneumocystis jirovecii</em></td> </tr> <tr> <td><em>Histoplasma capsulatum</em></td> </tr> <tr> <td>Kaposi sarcoma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Gonads</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td><em>T. gondii</em></td> </tr> <tr> <td><em>M. avium intracellulare</em></td> </tr> <tr> <td>Kaposi sarcoma</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Pancreas</td> </tr> <tr> <td><em>M. tuberculosis</em></td> </tr> <tr> <td><em>M. avium intracellulare</em></td> </tr> <tr> <td><em>P. jirovecii</em></td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td><em>T. gondii</em></td> </tr> <tr> <td>Kaposi sarcoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Parathyroid</td> </tr> <tr> <td><em>P. jirovecii</em></td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td class=\"subtitle1_single\">Pituitary</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td><em>P. jirovecii</em></td> </tr> <tr> <td><em>T. gondii</em></td> </tr> <tr> <td>Herpetic meningoencephalitis</td> </tr> <tr> <td>Lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Thyroid</td> </tr> <tr> <td><em>P. jirovecii</em></td> </tr> <tr> <td>Cytomegalovirus</td> </tr> <tr> <td><em>C. neoformans</em></td> </tr> <tr> <td><em>Aspergillus fumigatus</em></td> </tr> <tr> <td><em>Rhodococcus equi</em></td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> </tr> <tr> <td><em>Microsporidia</em></td> </tr> <tr> <td><em>H. capsulatum</em></td> </tr> <tr> <td><em>Paracoccidiodes brasiliensis</em></td> </tr> <tr> <td><em>M. avium intracellulare</em></td> </tr> <tr> <td><em>M. tuberculosis</em></td> </tr> <tr> <td>Kaposi sarcoma</td> </tr> <tr> <td>Lymphoma</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72716 Version 2.0</div></div></div>"},"72717":{"type":"graphic_figure","displayName":"ACEI vs Ca blocker in CRF","title":"ACE inhibitor and calcium blocker therapy protect against progressive glomerulosclerosis in rats by different mechanisms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor and calcium blocker therapy protect against progressive glomerulosclerosis in rats by different mechanisms</div><div class=\"cntnt\"><img style=\"width:368px; height:239px;\" src=\"images/NEPH/72717_ACEI_vs_Ca_blocker_in_CRF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Beneficial effect of antihypertensive therapy with the calcium channel blocker nifedipine and the angiotensin-converting enzyme inhibitor enalapril in rats with subtotal nephrectomy. At eight weeks, both drugs lowered the blood pressure to an equivalent degree and were associated with better maintenance of the glomerular filtration rate (GFR) and a lesser degree of glomerulosclerosis than untreated rats. However, the mechanism of protection appeared to be different: enalapril lowered the glomerular capillary pressure (PGC), while nifedipine minimized glomerular hypertrophy as manifested by a reduction in glomerular volume.</div><div class=\"graphic_reference\">Data from: Dworkin LD, Burstein JA, Parker M, et al. Kidney Int 1993; 43:808.</div><div id=\"graphicVersion\">Graphic 72717 Version 2.0</div></div></div>"},"72718":{"type":"graphic_figure","displayName":"Parous and nonparous cervix","title":"Parous and nonparous cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parous and nonparous cervix</div><div class=\"cntnt\"><img style=\"width:390px; height:494px;\" src=\"images/OBGYN/72718_Parousandnonparouscervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal nulligravid cervix. The external os is a small, smooth circular opening.<br />(B) Normal parous cervix. The external os is a large, transverse, stellate slit.</div><div class=\"graphic_reference\">Modified from: Pritchard JA, MacDonald PC. Williams Obstetrics, 16th ed, Appleton-Century-Crofts, Prentice Hall, New York 1981. p.23.</div><div id=\"graphicVersion\">Graphic 72718 Version 4.0</div></div></div>"},"72720":{"type":"graphic_figure","displayName":"Percutaneous suprapubic catheter placement","title":"Percutaneous suprapubic catheter placement","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Percutaneous suprapubic catheter placement</div><div class=\"cntnt\"><img style=\"width:524px; height:712px;\" src=\"images/SURG/72720_Suprapubic_cath_insertion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percutaneous suprapubic catheters are placed using sterile technique with local anesthesia, and sedation if needed. Ultrasound is used to verify full bladder distension prior to the procedure. The lower abdominal skin is prepared and lidocaine is injected in the midline, 2 centimeters above the symphysis pubis. The catheter is placed through a small skin incision into the bladder either with a direct puncture or Seldinger technique. For the direct puncture technique, a mushroom catheter is straightened with a stylet and advanced into the bladder. Once the catheter is confirmed within the bladder, the stylet is removed. For the Seldinger technique, a needle is inserted until urine is aspirated. A guidewire is placed through the needle into the bladder and the needle is removed. A dilator is advanced over the wire enlarging the tract. The dilator is then replaced with a sheath, the guidewire removed, and the catheter placed through the sheath which is then peeled away. The catheter balloon is inflated and the catheter gently withdrawn until slight tension is felt. The catheter is then connected to the catheter drainage system and secured to the patient.</div><div id=\"graphicVersion\">Graphic 72720 Version 2.0</div></div></div>"},"72722":{"type":"graphic_table","displayName":"AB subgroups KPD","title":"AÎ² subgroups of ketosis-prone diabetes mellitus: Clinical characteristics and natural history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AÎ² subgroups of ketosis-prone diabetes mellitus: Clinical characteristics and natural history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">A+&#946;-</td> <td class=\"subtitle1\">A-&#946;-</td> <td class=\"subtitle1\">A+&#946;+</td> <td class=\"subtitle1\">A-&#946;+</td> <td class=\"subtitle1\">P</td> </tr> <tr> <td>Number</td> <td>18 (17 percent)</td> <td>23 (22 percent)</td> <td>11 (11 percent)</td> <td>51 (50 percent)</td> <td>&nbsp;</td> </tr> <tr> <td>Age</td> <td>34 &#177; 17</td> <td>38 &#177; 15</td> <td>43 &#177; 14</td> <td>42 &#177; 13</td> <td>0.1 </td> </tr> <tr> <td>Age at diagnosis</td> <td>25 &#177; 17</td> <td>26 &#177; 12</td> <td>42 &#177; 12</td> <td>39 &#177; 12</td> <td>&#60;0.0001</td> </tr> <tr> <td>Years with diabetes</td> <td>9.1 &#177; 10.4</td> <td>9.8 &#177; 8.7</td> <td>0.9 &#177; 3.0</td> <td>3.0 &#177; 4.8</td> <td>&#60;0.0001</td> </tr> <tr> <td>Family history of diabetes</td> <td>9 (50 percent)</td> <td>19 (83 percent)</td> <td>9 (82 percent)</td> <td>45 (88 percent)</td> <td>0.01 </td> </tr> <tr> <td>BMI </td> <td>24.5 &#177; 3.9</td> <td>23.0 &#177; 2.8</td> <td>30.6 &#177; 7.6</td> <td>29.4 &#177; 8.3</td> <td>0.0003 </td> </tr> <tr> <td class=\"sublist1_start\">Weight category</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#60;0.0001</td> </tr> <tr> <td class=\"sublist1\">Lean</td> <td class=\"sublist_other\">11 (61 percent)</td> <td class=\"sublist_other\">17 (74 percent)</td> <td class=\"sublist_other\">2 (18 percent)</td> <td class=\"sublist_other\">17 (33 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Overweight</td> <td class=\"sublist_other\">5 (28 percent)</td> <td class=\"sublist_other\">6 (26 percent)</td> <td class=\"sublist_other\">4 (36 percent)</td> <td class=\"sublist_other\">13 (26 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Obese</td> <td class=\"sublist_other\">2 (11 percent)</td> <td class=\"sublist_other\">0 </td> <td class=\"sublist_other\">5 (46 percent)</td> <td class=\"sublist_other\">21 (41 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td>New onset diabetes</td> <td>3 (17 percent)</td> <td>2 (9 percent)</td> <td>10 (91 percent)</td> <td>26 (51 percent)</td> <td>&#60;0.0001</td> </tr> <tr> <td>Male:female ratio </td> <td>1:1</td> <td>1.3:1</td> <td>0.6:1</td> <td>1.7:1</td> <td>0.4</td> </tr> <tr> <td class=\"sublist1_start\">Ethnicity </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>0.02 </td> </tr> <tr> <td class=\"sublist1\">African-American</td> <td class=\"sublist_other\">13 (72 percent)</td> <td class=\"sublist_other\">9 (39 percent)</td> <td class=\"sublist_other\">4 (36.4 percent)</td> <td class=\"sublist_other\">14 (27 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Hispanic-American</td> <td class=\"sublist_other\">2 (11 percent)</td> <td class=\"sublist_other\">9 (39 percent)</td> <td class=\"sublist_other\">4 (36.4 percent)</td> <td class=\"sublist_other\">30 (59 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Caucasian-American</td> <td class=\"sublist_other\">2 (11 percent)</td> <td class=\"sublist_other\">5 (22 percent)</td> <td class=\"sublist_other\">3 (27.2 percent)</td> <td class=\"sublist_other\">6 (12 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Asian-American</td> <td class=\"sublist_other\">1 (6 percent)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">1 (2 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td>Recurrent DKA episodes</td> <td>7 (39 percent)</td> <td>7 (30 percent)</td> <td>1 (9 percent)</td> <td>1 (2 percent)</td> <td>&#60;0.0001</td> </tr> <tr> <td>Insulin discontinued by&nbsp;six months</td> <td>0 (0 percent)</td> <td>0 (0 percent)</td> <td>5 (45 percent)</td> <td>26 (51 percent)</td> <td>&#60;0.0001 </td> </tr> <tr> <td class=\"sublist1_start\">Anti-diabetic regimen at 12 months</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&#60;0.0001 </td> </tr> <tr> <td class=\"sublist1\">Insulin only</td> <td class=\"sublist_other\">17 (94 percent)</td> <td class=\"sublist_other\">23 (100 percent)</td> <td class=\"sublist_other\">3 (27 percent)</td> <td class=\"sublist_other\">17 (33 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Insulin&nbsp;and oral hypoglycemics</td> <td class=\"sublist_other\">1 (6 percent)</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">3 (27 percent)</td> <td class=\"sublist_other\">8 (16 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Oral hypoglycemics only</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">3 (27 percent)</td> <td class=\"sublist_other\">21 (41 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Diet and exercise only</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">2 (19 percent)</td> <td class=\"sublist_other\">5 (10 percent)</td> <td class=\"sublist_other\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index; DKA: diabetic ketoacidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev 2008; 29:292. Copyright Â© 2008 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 72722 Version 10.0</div></div></div>"},"72724":{"type":"graphic_figure","displayName":"Brooke end ileostomy","title":"End ileostomy (Brooke ileostomy)","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">End ileostomy (Brooke ileostomy)</div><div class=\"cntnt\"><img style=\"width:542px; height:404px;\" src=\"images/SURG/72724_Brooke_end_ileostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Absorbable sutures are placed full thickness through the distal end of the bowel, 2 cm proximally through the seromuscular layer, and then through subcuticular space.<br> (B) During the tying of the sutures, the distal end is everted unto itself.<br> (C) The matured, everted, Brooke end ileostomy with the sutures at the mucocutaneous junction.</div><div id=\"graphicVersion\">Graphic 72724 Version 5.0</div></div></div>"},"72725":{"type":"graphic_table","displayName":"Nutritional deficiency IBD","title":"Laboratory evidence of nutritional deficiences reported in adults with inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evidence of nutritional deficiences reported in adults with inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td>Hypoalbuminemia</td> <td>25&nbsp;to 80</td> </tr> <tr> <td>Anemia</td> <td>60 to 80</td> </tr> <tr> <td>Iron deficiency</td> <td>39 to 81</td> </tr> <tr> <td>Vitamin B12 deficiency<sup>&#182;</sup></td> <td>20 to 60</td> </tr> <tr> <td>Folic acid deficiency</td> <td>36 to 54</td> </tr> <tr> <td>Calcium deficiency</td> <td>13</td> </tr> <tr> <td>Magnesium deficiency</td> <td>14 to 33</td> </tr> <tr> <td>Potassium deficiency</td> <td>6 to 20</td> </tr> <tr> <td>Vitamin A deficiency</td> <td>11</td> </tr> <tr> <td>Vitamin D deficiency</td> <td>75</td> </tr> <tr> <td>Vitamin E deficiency</td> <td>*</td> </tr> <tr> <td>Vitamin K deficiency</td> <td>*</td> </tr> <tr> <td>Zinc deficiency</td> <td>40 to 50</td> </tr> <tr> <td>Copper deficiency</td> <td>*</td> </tr> <tr> <td>Vitamin C deficiency</td> <td>*</td> </tr> <tr> <td>Vitamin B1 (thiamine) deficiency<sup>[1]</sup></td> <td>32</td> </tr> <tr> <td>Niacin deficiency</td> <td>*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cases reported but prevalence not described.<br />Â¶ Frequency of vitamin B12 deficiency depends on extent of ileal involvement or ileal resection.</div><div class=\"graphic_reference\">Adapted from: Perkal MF, Seashore JH. Nutrition and inflammatory bowel disease. Gastroenterol Clin N Am 1989; 18(3):567.&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis 2012; 18:1961.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72725 Version 4.0</div></div></div>"},"72727":{"type":"graphic_picture","displayName":"Dermoid cyst","title":"Dermoid cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoid cyst</div><div class=\"cntnt\"><img style=\"width:356px; height:285px;\" src=\"images/PC/72727_Dermoid_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section 8, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 72727 Version 1.0</div></div></div>"},"72728":{"type":"graphic_table","displayName":"Screening and prevention, adults younger than 65 years","title":"Screening and prevention, adults younger than 65 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening and prevention, adults younger than 65 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Priority health problem</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Preventive intervention(s)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular disease</td> </tr> <tr> <td class=\"indent1\">Risk assessment</td> <td>Patients &#8805;20 years</td> <td>CVD risk assessment every&nbsp;three to five&nbsp;years</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td>All patients</td> <td>Blood pressure screening/control</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hyperlipidemia</td> <td>Patients between 17 and 21 years</td> <td>One-time screening for dyslipidemia</td> </tr> <tr> <td> <p>Risk factors: Women &#8805;35 years, men &#8805;25 years</p> Without risk factors: Women &#8805;45 years, men &#8805;35 years</td> <td>Dyslipidemia screening/control</td> </tr> <tr> <td class=\"indent1\">Obesity</td> <td>All patients</td> <td> <p>Screen with BMI</p> Select patients for treatment based on risk factors</td> </tr> <tr> <td class=\"indent1\">Physical activity</td> <td>All patients</td> <td>Counseling to exercise</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Diabetes mellitus</td> <td>Adults with hypertension or hyperlipidemia</td> <td>Screen for diabetes mellitus </td> </tr> <tr class=\"divider_bottom\"> <td>Adults aged 40 to 70 years with BMI &#8805;25 kg/m<sup>2</sup> </td> <td>Screen for diabetes mellitus as part of cardiovascular risk assessment </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cancer</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Breast cancer</td> <td>Concerning family history</td> <td>Refer for genetic counseling/testing</td> </tr> <tr> <td>Hereditary breast and ovarian syndrome</td> <td>Screen per recommendations</td> </tr> <tr> <td>Women &#62;40</td> <td>Discuss screening, individual decision; if screening desired, screen with mammography every&nbsp;two years</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Cervical cancer</td> <td>Women 21 to 29 years</td> <td>Pap smear every&nbsp;three years</td> </tr> <tr> <td>Women &#8805;30 years</td> <td> <p>Pap smear every&nbsp;three years</p> <p>Or</p> Pap smear + HPV testing every&nbsp;five years</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Colorectal cancer</td> <td>Patients with risk factors</td> <td>Screen per recommendations</td> </tr> <tr> <td>Patients &#8805;50 years without risk factors</td> <td>Screening (decide among colonoscopy, flexible sigmoidoscopy, fecal occult blood test)</td> </tr> <tr> <td class=\"indent1\">Lung cancer</td> <td>Patients 55 to 74 years, &#8805;30 pack-year smoking history and either currently smoking or quit in the past 15 years</td> <td>Consider screening with low-dose helical CT scan</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Prostate cancer</td> <td>High-risk men 40 to 45 years</td> <td>Discuss screening, individual decision</td> </tr> <tr> <td>Men &#8805;50 years without risk factors</td> <td>Discuss screening, individual decision</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Melanoma</td> <td>High-risk patients</td> <td>Periodic skin exam</td> </tr> <tr class=\"divider_bottom\"> <td>Average-risk patients</td> <td>Remain vigilant for suspicious lesions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Immunizations</td> </tr> <tr> <td class=\"indent1\">Influenza</td> <td>All patients</td> <td>Annual influenza vaccination</td> </tr> <tr> <td class=\"indent1\">Tdap/Td</td> <td>All patients</td> <td> <p>Tdap at least once</p> Td every 10 years</td> </tr> <tr> <td class=\"indent1\">Varicella</td> <td>Patients without evidence of immunity</td> <td>Varicella vaccine</td> </tr> <tr> <td class=\"indent1\">HPV</td> <td> <p>Women until 26 years</p> <p>Men until 21 years</p> MSM until 26 years</td> <td>HPV vaccine</td> </tr> <tr> <td class=\"indent1\">Zoster</td> <td>Patients &#8805;50 years</td> <td>Zoster vaccine</td> </tr> <tr> <td class=\"indent1\">Pneumococcal disease</td> <td>Patients with risk factors</td> <td>Pneumococcal vaccine*</td> </tr> <tr> <td class=\"indent1\">Meningococcal disease</td> <td>Patients with risk factors</td> <td>Meningococcal vaccine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hepatitis B</td> <td> <p>Patients with risk factors</p> Patients with diabetes &#60;60 years and consider if &#8805;60 years&nbsp;if risk factors</td> <td>Hepatitis B vaccine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Sexually transmitted infections/blood-borne infections</td> </tr> <tr> <td class=\"indent1\">Chlamydia</td> <td> <p>Women &#60;25 years</p> <p>Women &#8805;25 at increased risk</p> Men at increased risk</td> <td>Screening for chlamydia</td> </tr> <tr> <td class=\"indent1\">Gonorrhea</td> <td> <p>Women at increased risk (including sexually-active women &#60;25 years)</p> <p>Men at increased risk </p> </td> <td>Screening for gonorrhea</td> </tr> <tr> <td class=\"indent1\">Hepatitis B</td> <td>Patients with risk factors</td> <td>Screening for hepatitis B</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Hepatitis C</td> <td>Patients born in the United States between 1945 and 1965</td> <td>One-time screening for hepatitis C</td> </tr> <tr> <td>Patients with risk factors</td> <td>Screening for hepatitis C</td> </tr> <tr> <td class=\"indent1\">HIV</td> <td>All patients</td> <td>One-time screening</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Syphilis</td> <td>Patients with risk factors</td> <td>Screening for syphilis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Psychosocial health concerns</td> </tr> <tr> <td class=\"indent1\">Depression</td> <td>All patients</td> <td>Brief screening</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> <td>All patients</td> <td>Screen for alcohol misuse</td> </tr> <tr> <td class=\"indent1\">Tobacco</td> <td>Smokers and tobacco users</td> <td>Smoking/tobacco cessation</td> </tr> <tr> <td class=\"indent1\">Other drug use</td> <td>All patients</td> <td>Assess for unhealthy drug use</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"2\">Intimate partner violence</td> <td> <p>All patients&nbsp;&nbsp;</p> </td> <td> <p>Screen for intimate partner violence on initial visit</p> </td> </tr> <tr class=\"divider_bottom\"> <td>Concerning history or physical exam findings</td> <td>Screening for intimate partner violence </td> </tr> <tr> <td><strong>Osteoporosis</strong></td> <td> <p>Postmenopausal women &#60;65 years with risk factors</p> Men with clinical manifestations of low bone mass</td> <td>BMD screening</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to individual UpToDate topics for more detailed discussions of screening and preventive counseling.</div><div class=\"graphic_footnotes\">CVD: cardiovascular disease; BMI: body mass index; HPV: human papillomavirus; CT: computed tomography; Tdap: tetanus, diphtheria, and acellular pertussis vaccination; Td: tetanus, diphtheria vaccine; MSM: men who have sex with men; HIV: human immunodeficiency virus; BMD: bone mineral density.<br />* The pneumococcal vaccine (23-valent polysaccharide vaccine or 13-valent conjugate vaccine) and schedule varies depending upon the risk factor. Refer to UpToDate topic on pneumococcal vaccination in adults for details.</div><div id=\"graphicVersion\">Graphic 72728 Version 13.0</div></div></div>"},"72731":{"type":"graphic_figure","displayName":"Use of metered dose inhaler","title":"Use of metered dose inhaler","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of metered dose inhaler</div><div class=\"cntnt\"><img style=\"width:446px; height:316px;\" src=\"images/PULM/72731_Use_of_metered_dose_inhaler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient holds the MDI between the thumb and index finger and closes his mouth around the spacer's mouthpiece.</div><div id=\"graphicVersion\">Graphic 72731 Version 2.0</div></div></div>"},"72733":{"type":"graphic_diagnosticimage","displayName":"Duplex collecting system","title":"Left duplex collecting system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left duplex collecting system</div><div class=\"cntnt\"><img style=\"width:320px; height:241px;\" src=\"images/OBGYN/72733_Duplex_collecting_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 72733 Version 2.0</div></div></div>"},"72735":{"type":"graphic_table","displayName":"Med mgmt gastroparesis","title":"Medical management of gastroparesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical management of gastroparesis</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Drug </td>\r\n                    <td class=\"subtitle1\">Mechanism(s) of action </td>\r\n                    <td class=\"subtitle1\">Dosage </td>\r\n                    <td class=\"subtitle1\">Adverse reactions </td>\r\n                    <td class=\"subtitle1\">Availability in US </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Prokinetic agents </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Metoclopramide </td>\r\n                    <td>Dopamine antagonist; promotes gastric emptying by sensitizing tissues to the action of acetylcholine</td>\r\n                    <td>5 to 10 mg IV every&nbsp;six hours or 5 to 10 mg&nbsp;orally before meals and at night (increase to 20 mg if no improvement)</td>\r\n                    <td>Drowsiness, restlessness, acute dystonic reactions, arrhythmia (rare), galactorrhea, gynecomastia; long-standing metoclopramide therapy, over three months has a risk of irreversible tardive dyskinesia, in 1 to 10 percent</td>\r\n                    <td>Yes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Erythromycin </td>\r\n                    <td>Motilin agonist; induces gastric peristalsis</td>\r\n                    <td>150 to 250 mg&nbsp;orally&nbsp;three times daily or 100 mg IV&nbsp;three times daily</td>\r\n                    <td>Arrhythmias (rare), headache, nausea, vomiting, diarrhea, cholestasis; tachyphylaxis is common; rarely effective beyond one month</td>\r\n                    <td>Yes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Domperidone </td>\r\n                    <td>Dopamine antagonist similar to metoclopramide but does not cross the blood brain barrier</td>\r\n                    <td>10 to 20 mg three times daily before meals and at night</td>\r\n                    <td>Arrhythmia, galactorrhea, gynecomastia</td>\r\n                    <td>Available only through an IND, limited-access program</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Tegaserod </td>\r\n                    <td>Serotonin 5-HT<sub>4</sub> receptor agonist; increases the peristaltic reflex predominantly in small bowel</td>\r\n                    <td>6 mg&nbsp;orally 30 mins before meals&nbsp;three times daily</td>\r\n                    <td>Headache, abdominal pain, nausea, diarrhea; rare: angina, ischemic colitis, increased transaminase levels</td>\r\n                    <td>No longer approved in the US</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Cisapride </td>\r\n                    <td>Increases acetylcholine by stimulating serotonin receptors and stimulates gastrointestinal motility</td>\r\n                    <td>10 mg&nbsp;orally four&nbsp;times daily before meals</td>\r\n                    <td>Serious: ventricular arrhythmia and prolonged QT interval; rash, abdominal pain, diarrhea, headache</td>\r\n                    <td>Available only through an IND, limited-access program</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\" colspan=\"5\">Antiemetic agents </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Ondansetron </td>\r\n                    <td>Serotonin 5-HT<sub>3</sub> receptor antagonist; acts peripherally by selectively binding to 5-HT<sub>3</sub> receptors on the vagus nerve and centrally in the area postrema of the chemoreceptor trigger zone</td>\r\n                    <td>8 mg&nbsp;orally or IV every&nbsp;eight hours</td>\r\n                    <td>Constipation, xerostomia, fatigue, dizziness; rare: arrhythmia, increased transaminase levels</td>\r\n                    <td>Yes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Prochlorperazine </td>\r\n                    <td>Acts centrally by inhibiting dopamine receptors in the medullary chemoreceptor trigger zone and peripherally by blocking the vagus nerve</td>\r\n                    <td>5 to 10 mg orally or IV every&nbsp;six hours</td>\r\n                    <td>Hypotension, galactorrhea, gynecomastia, weight gain, drowsiness, dystonic reaction; rare: neuroleptic malignant syndrome, prolonged QT interval</td>\r\n                    <td>Yes</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_lgnd\">Tricyclic antidepressants, such as nortriptyline (10 to 75 mg every night), or investigational drugs, such as mirtazapine and dronabinol (Marinol), can be considered for refractory malignant gastroparesis.</div><div class=\"graphic_footnotes\">US: United States; IV: intravenous; IND: investigational new drug; 5-HT<SUB>4</SUB>: 5-hydroxytryptamine-4; FDA: US Food and Drug Administration; 5-HT<SUB>3</SUB>: 5-hydroxytryptamine-3.</div><div class=\"graphic_reference\">Reproduced with permission from: Donthireddy K, Ailawadhi S, Nasser E, et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 72735 Version 3.0</div></div></div>"},"72737":{"type":"graphic_picture","displayName":"Ectropion","title":"Ectropion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectropion</div><div class=\"cntnt\"><img style=\"width:432px; height:261px;\" src=\"images/PC/72737_Ectropion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Outward turning of the lower eyelid with increased exposure of the ocular surface and sensitive mucous membrane of the inner lid, as well as disruption of normal tear drainage patterns.</div><div id=\"graphicVersion\">Graphic 72737 Version 1.0</div></div></div>"},"72738":{"type":"graphic_picture","displayName":"Alopecia areata eyelash","title":"Alopecia areata involving the eyelashes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata involving the eyelashes</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72738_Alopecia_areata_eyelash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral eyelashes are absent in this patient with alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72738 Version 4.0</div></div></div>"},"72739":{"type":"graphic_figure","displayName":"Lateral skull anatomy","title":"Lateral skull anatomy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lateral skull anatomy</div><div class=\"cntnt\"><img style=\"width:576px; height:523px;\" src=\"images/EM/72739_Skull_anat_lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the adult skull in the anatomical position.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed.). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72739 Version 2.0</div></div></div>"},"72741":{"type":"graphic_table","displayName":"Diagnosis of cystic fibrosis","title":"Criteria for the diagnosis of cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for the diagnosis of cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"sublist1_start\">One or more typical phenotypic features of CF:</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Chronic sinopulmonary disease</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Characteristic gastrointestinal and nutritional abnormalities</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Salt loss syndromes</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Obstructive azoospermia</td>\n</tr>\n<tr>\n<td><strong>or</strong></td>\n</tr>\n<tr>\n<td>A history of cystic fibrosis in a sibling</td>\n</tr>\n<tr>\n<td><strong>or</strong></td>\n</tr>\n<tr>\n<td>A positive newborn screening test</td>\n</tr>\n<tr>\n<td><strong>PLUS</strong></td>\n</tr>\n<tr>\n<td>An elevated sweat chloride concentration on two or more occasions</td>\n</tr>\n<tr>\n<td><strong>or</strong></td>\n</tr>\n<tr>\n<td>Identification of mutations in each CFTR gene known to cause CF</td>\n</tr>\n<tr>\n<td><strong>or</strong></td>\n</tr>\n<tr>\n<td>In vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Rosenstein BJ, Cutting GR. J Pediatr 1998; 132:589.</div><div id=\"graphicVersion\">Graphic 72741 Version 2.0</div></div></div>"},"72742":{"type":"graphic_picture","displayName":"Pleural mesothelial cell layer","title":"Pleural mesothelial cell layer","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Pleural mesothelial cell layer</div><div class=\"cntnt\"><img style=\"width:480px; height:289px;\" src=\"images/PULM/72742_Pleural_mesothelial_cell_la.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both pleurae are lined by a continuous mesothelial cell layer. The mesothelial cell is a flat cell one to 4 Âµm thick with a variable covering of microvilli (up to 3 Âµm long).</div><div class=\"graphic_reference\">Courtesy of V Courtney Broaddus, MD.</div><div id=\"graphicVersion\">Graphic 72742 Version 2.0</div></div></div>"},"72743":{"type":"graphic_diagnosticimage","displayName":"RUL atelectasis II","title":"Right upper lobe atelectasis with juxtaphrenic peak","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right upper lobe atelectasis with juxtaphrenic peak</div><div class=\"cntnt\"><img style=\"width:385px; height:356px;\" src=\"images/PULM/72743_RUL_atelectasis_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right upper lobe atelectasis with veil of opacity in the right upper lung region. A juxtaphrenic peak is present (arrow); this finding indicates loss of volume in the upper lobe and can be a helpful sign of upper lobe atelectasis.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72743 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"72745":{"type":"graphic_table","displayName":"TEE factors for embolism AF","title":"Indicators of thromboembolic risk on transesophageal echocardiography in patients with atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indicators of thromboembolic risk on transesophageal echocardiography in patients with atrial fibrillation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Left atrial appendage size and function</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left atrial size and function</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spontaneous echo contrast</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Left atrial or atrial appendage thrombus</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intraatrial septal aneurysm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Patent foramen ovale</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aortic atherosclerosis with plaque in ascending aorta</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72745 Version 1.0</div></div></div>"},"72750":{"type":"graphic_table","displayName":"DCIS versus LCIS","title":"Comparative features of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparative features of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">DCIS</td>\n\n      <td class=\"subtitle1\">LCIS</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Presentation</td>\n\n      <td>Incidental finding, mammographic abnormality, occasionally palpable, unifocal</td>\n\n      <td>Incidental finding, often multifocal</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Predominant location</td>\n\n      <td>Ducts</td>\n\n      <td>Lobules</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cell size</td>\n\n      <td>Medium or large</td>\n\n      <td>Small</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pattern</td>\n\n      <td>Comedo, cribriform, micropapillary, papillary, solid </td>\n\n      <td>Solid</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Calcifications</td>\n\n      <td>Yes or no</td>\n\n      <td>Usually no</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Risk of subsequent invasive cancer</td>\n\n      <td>Higher</td>\n\n      <td>Lower</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Location of subsequent invasive cancer</td>\n\n      <td>Ipsilateral</td>\n\n      <td>Ipsilateral or contraleteral</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72750 Version 1.0</div></div></div>"},"72751":{"type":"graphic_picture","displayName":"Lifting techniques PI","title":"Lifting techniques","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Lifting techniques</div><div class=\"cntnt\"><img style=\"width:509px; height:282px;\" src=\"images/PI/72751_Lifting_techniques_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Improper lifting techniques (left panel) contribute to the high incidence of back injuries in the workplace. Keeping the knees straight while reaching out to pick up a heavy object significantly increases the forces on the spine. Proper lifting techniques (right panel) use good body mechanics to protect the spine. The patient should squat and keep the weight close to the body during the lifting process; the thigh muscles are used for power.</div><div id=\"graphicVersion\">Graphic 72751 Version 2.0</div></div></div>"},"72752":{"type":"graphic_diagnosticimage","displayName":"Periostitis in congenital syphilis","title":"Congenital syphilis: Periostitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis: Periostitis</div><div class=\"cntnt\"><img style=\"width:250px; height:586px;\" src=\"images/PEDS/72752_Periostitis_cong_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solid periosteal reaction (arrows) in a patient with congenital syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72752 Version 3.0</div></div></div>"},"72754":{"type":"graphic_algorithm","displayName":"Management of knee dislocation","title":"Management of knee (tibiofemoral) dislocation","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Management of knee (tibiofemoral) dislocation</div><div class=\"cntnt\"><img style=\"width:530px; height:432px;\" src=\"images/EM/72754_Knee_dislocation_algo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72754 Version 2.0</div></div></div>"},"72755":{"type":"graphic_picture","displayName":"Ramp position","title":"Ramp position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ramp position</div><div class=\"cntnt\"><img style=\"width:315px; height:442px;\" src=\"images/EM/72755_RAMP_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In the supine patient, access to the airway is obstructed. <br />(B) With the patient propped on linens in the ramp position, access to the airway is improved. In this position, an imaginary horizontal line can be drawn from the external auditory meatus to the sternal notch.</div><div class=\"graphic_reference\">Reproduced with permission from: Wiser SH, Zane RD. The Morbidly Obese Patient. In: Manual of Emergency Airway Management, 3rd ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72755 Version 11.0</div></div></div>"},"72757":{"type":"graphic_waveform","displayName":"Advanced case 10","title":"Advanced case 10","html":"<div class=\"graphic normal\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Advanced case 10</div><div class=\"cntnt\"><img style=\"width:519px; height:352px;\" src=\"images/CARD/72757_Advanced_case_10.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72757 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"72758":{"type":"graphic_figure","displayName":"Control of lipids decreases the progression of SVG disease","title":"Aggressive control of lipids decreases the progression of saphenous vein graft disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aggressive control of lipids decreases the progression of saphenous vein graft disease</div><div class=\"cntnt\"><img style=\"width:393px; height:319px;\" src=\"images/CARD/72758_Lipids_saphenous_graft_dise.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Post Coronary Artery Bypass Graft trial of 1353 patients, aggressive treatment of low density lipoprotein (LDL) cholesterol with lovastatin and, if needed, cholestyramine to achieve an LDL &lt;100 mg/dL (2.6 mmol/L) reduced the progression of saphenous vein graft disease, regardless of the number of coronary heart disease (CHD) risk factors. All of the differences were significant except for an almost significant trend in patients with no CHD risk factors (p = 0.07).</div><div class=\"graphic_reference\">Data from Campeau L, Hunninghake DB, Knatterud GL, et al, and Post CABG Trial Investigators. Circulation 1999; 99:3241.</div><div id=\"graphicVersion\">Graphic 72758 Version 3.0</div></div></div>"},"72763":{"type":"graphic_figure","displayName":"Pendulum exercises","title":"Pendulum exercises","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pendulum exercises</div><div class=\"cntnt\"><img style=\"width:278px; height:330px;\" src=\"images/RHEUM/72763_Pendulum_exercises.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arm is hung downward and rotated in large circles in order to regain shoulder range of motion.</div><div id=\"graphicVersion\">Graphic 72763 Version 5.0</div></div></div>"},"72765":{"type":"graphic_diagnosticimage","displayName":"Exencephaly first trimester","title":"Exencephaly","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Exencephaly</div><div class=\"cntnt\"><img style=\"width:517px; height:681px;\" src=\"images/OBGYN/72765_Exencephaly_first_trimester.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal view of a first-trimester fetus with exencephaly. The head is wide and bilobed (\"Mickey Mouse\" sign).<br />(B) An oblique view of an exencephalic fetus. Normal facial bones are seen, but no cranial vault surrounds the exposed brain.<br />(C) Three-dimensional surface rendering demonstrating the bilobed brain.</div><div id=\"graphicVersion\">Graphic 72765 Version 3.0</div></div></div>"},"72766":{"type":"graphic_picture","displayName":"Lichen sclerosus with lichen simplex chronicus","title":"Lichen sclerosus with lichen simplex chronicus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus with lichen simplex chronicus</div><div class=\"cntnt\"><img style=\"width:285px; height:360px;\" src=\"images/OBGYN/72766_LS_LSC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure 8 involvement of vulvar&nbsp;lichen sclerosus&nbsp;with scarring of the vulva and loss of all the normal architecture. All areas are lichenified with fissuring of the thick periclitoral area and labiocrural fold.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 72766 Version 4.0</div></div></div>"},"72767":{"type":"graphic_algorithm","displayName":"FISH for HER2 status","title":"Algorithm for FISH in assessment of HER2 status","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Algorithm for FISH in assessment of HER2 status</div><div class=\"cntnt\"><img style=\"width:523px; height:354px;\" src=\"images/ONC/72767_FISH.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* HER2: human epidermal growth factor receptor 2; FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; CEP17: chromosome 17 centromere.</div><div class=\"graphic_reference\">Revised with information from:<br /><OL>&#xD;&#xA;<LI>Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013. DOI: JCO.2013.50.9984.</LI></OL>Modified from: Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Onc 2007; 25:118. Copyright Â© 2007 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 72767 Version 5.0</div></div></div>"},"72768":{"type":"graphic_waveform","displayName":"ECG interpolated VPB tutorial","title":"Single lead electrocardiogram (ECG) showing an interpolated ventricular premature beat (VPB)","html":"<div class=\"graphic normal\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing an interpolated ventricular premature beat (VPB)</div><div class=\"cntnt\"><img style=\"width:461px; height:141px;\" src=\"images/CARD/72768_Interpolated_VPB_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The third beat is a ventricular premature beat (VPB). It is called an interpolated VPB since it does not alter the underlying sinus RR interval.</div><div id=\"graphicVersion\">Graphic 72768 Version 3.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"72769":{"type":"graphic_table","displayName":"ACCESS criteria sarcoid B","title":"ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACCESS study criteria for organ involvement in patients with biopsy-confirmed sarcoidosis - II</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Organ</td>\n\n      <td class=\"subtitle1\">Definite</td>\n\n\n      <td class=\"subtitle1\">Probable</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Nonthoracic lymph node</td>\n\n      \n\n      <td colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n\n      \n\n      <td>1. New palpable node above waist</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      \n\n      \n\n      <td>2. Lymph node &#62;2 cm by computed tomographic (CT) scan</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Parotid/salivary glands</td>\n\n      \n\n      <td>1. Symmetrical parotitis with syndrome of mumps</td>\n\n      \n\n      <td colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n\n    </tr>\n\n\n    <tr>\n\n\n      \n      <td>2. Positive gallium scan (\"Panda sign\")</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Renal</td>\n\n      \n      <td>1. Treatment responsive renal failure</td>\n\n      \n\n      <td>1. Steroid responsive renal failure in patient with diabetes and/or hypertension</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Liver</td>\n\n      \n\n      <td colspan=\"1\" rowspan=\"2\">1. Liver function tests &#62; three times normal</td>\n\n      \n\n      <td>1. Compatible computed tomographic (CT) scan</td>\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n      \n\n      \n\n      <td>2. Elevated alkaline phosphatase</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Spleen</td>\n\n      \n\n      <td colspan=\"1\" rowspan=\"4\" class=\"sublist1_start\">&nbsp;</td>\n\n      \n\n      <td class=\"sublist1_start\">1. Enlargement by:</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      \n\n      \n\n      <td class=\"sublist1\">Exam</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      \n\n      \n\n      <td class=\"sublist1\" colspan=\"1\">Computed tomographic (CT) scan</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      \n\n      \n\n      <td class=\"sublist1\">Radioisotope scan</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"3\">Bone marrow</td>\n\n      \n\n      <td>1. Unexplained anemia</td>\n\n      \n\n      <td colspan=\"1\" rowspan=\"3\">&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>2. Leukopenia</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n\n      \n\n      <td>3. Thrombocytopenia</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td>Bone/joints</td>\n\n      \n      <td>1. Cystic changes on hand or feet phalanges</td>\n\n      \n\n      <td>1. Asymmetric painful clubbing</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Ears/Nose/Throat</td>\n\n      \n\n      <td colspan=\"1\">1. Unexplained hoarseness with exam consistent with granulomatous involvement</td>\n      \n\n      <td>&nbsp;</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Muscles</td>\n\n      \n\n      <td>1. Increased creatine phosphokinase (CK) aldolase which decreases with treatment</td>\n\n      \n\n      <td>1. Increased creatine, phosphokinase (CK)/aldolase</td>\n\n    </tr>\n\n\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Judson, MA, RP Baughman, AS. Teirstein, ML Terrin, and H Yeager, Jr. 1999. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 16:75-86. Copyright &#169; 1999 Sarcoidosis, Vasculitis, and Diffuse Lung Diseases.</div><div id=\"graphicVersion\">Graphic 72769 Version 1.0</div></div></div>"},"72771":{"type":"graphic_figure","displayName":"Normal shoulder lig PI","title":"Normal shoulder ligaments","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Normal shoulder ligaments</div><div class=\"cntnt\"><img style=\"width:536px; height:438px;\" src=\"images/PI/72771_Normal_shoulder_lig_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72771 Version 3.0</div></div></div>"},"72772":{"type":"graphic_table","displayName":"Features of hemorrhage I","title":"Clinical features of major causes of immune or idiopathic alveolar hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of major causes of immune or idiopathic alveolar hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Extrapulmonary features</td> <td class=\"subtitle1\">Serology</td> <td class=\"subtitle1\">Essential diagnostic criteria</td> </tr> <tr> <td rowspan=\"2\">ABMA disease</td> <td>GN &#62;90%</td> <td rowspan=\"2\">+ABMA</td> <td>+Serum ABMA</td> </tr> <tr> <td>Extrarenal disease rare</td> <td>Linear IgG in glomeruli</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">SLE</td> <td>GN &#62;90%</td> <td rowspan=\"2\">+ANA</td> <td rowspan=\"2\">Clinical features, +ANA, immune complexes in glomeruli by IF, EM</td> </tr> <tr> <td>Extrarenal disease common (arthritis, serositis, purpura, photosensitivity)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">WG</td> <td class=\"sublist1_start\">GN &#62;90% extrarenal disease</td> <td rowspan=\"3\">+ANCA</td> <td rowspan=\"3\"> <p>Necrotizing granulomatous vasculitis in upper airway or lung biopsy</p> <p>or</p> <p>Pauci-immune necrotizing GN with extensive upper airway disease or cavitary lung nodules</p> </td> </tr> <tr> <td class=\"sublist1\">Distinctive: upper airway disease, pulmonary nodules&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Nonspecific (arthritis, purpura, mononeuropathy)</td> </tr> <tr class=\"divider_top\"> <td>Nonspecific systemic necrotizing vasculitis (microscopic polyarteritis, polyangiitis, overlap syndrome)</td> <td>GN &#62;90% extrarenal disease variably present (arthritis, purpura, mononeuropathy)</td> <td>&#177;ANCA (usually + if include p-ANCA)</td> <td>Necrotizing, crescentic GN (or pathologic evidence of vasculitis elsewhere) and exclude WG to extent possible</td> </tr> <tr class=\"divider_top\"> <td>Idiopathic pulmonary hemosiderosis</td> <td>None</td> <td>None</td> <td>Exclusion of all other causes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABMA: antibasement membrane antibody; GN: glomerulonephritis; SLE: systemic lupus erythematosus; ANA: antinuclear antibody; IF: immunofluorescence; EM: electron microscopy; WG: granulomatosis with polyangiitis (Wegener's); ANCA: antineutrophil cytoplasmic antibody; p-ANCA: perinuclear ANCA; %: percent.</div><div class=\"graphic_reference\">Redrawn from: Leatherman JL. In: Immunologically Mediated Pulmonary Diseases, Lynch JP, DeRemee RA (Eds), JB Lippincott, Philadelphia, 1991, p.490.</div><div id=\"graphicVersion\">Graphic 72772 Version 3.0</div></div></div>"},"72774":{"type":"graphic_table","displayName":"Poultry related antigens in HP","title":"Hypersensitivity pneumonitides associated with birds and poultry handling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides associated with birds and poultry handling</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Environmental source</td>\n<td class=\"subtitle1\">Major causative antigen</td>\n</tr>\n<tr>\n<td>Bird fancier's lung (parakeets, budgerigars, pigeons)</td>\n<td>Droppings, feathers, serum proteins</td>\n</tr>\n<tr>\n<td>Poultry worker's lung (feather plucker's disease) </td>\n<td>Serum proteins (chicken products)</td>\n</tr>\n<tr>\n<td>Turkey handling disease</td>\n<td>Serum proteins (turkey products)</td>\n</tr>\n<tr>\n<td>Canary fancier's lung </td>\n<td>Serum proteins</td>\n</tr>\n<tr>\n<td>Duck fever</td>\n<td>Feathers, serum proteins</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72774 Version 1.0</div></div></div>"},"72775":{"type":"graphic_figure","displayName":"Right ventricular tracing","title":"Right ventricular pressure tracing","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Right ventricular pressure tracing</div><div class=\"cntnt\"><img style=\"width:453px; height:313px;\" src=\"images/PULM/72775_Right_ventricular_tracing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the different components of the right ventricular pressure tracing. A simultaneous ECG is shown to demonstrate the timing of the different components. Right ventricular end diastolic pressure is measured after the a wave, just prior to the systolic upstroke.</div><div class=\"graphic_reference\">Redrawn from Gore, JM, Alpert, JS, Benotti, JR, et al. Handbook of hemodynamic monitoring, 1st ed, Boston, Little Brown &amp; Co, 1985.</div><div id=\"graphicVersion\">Graphic 72775 Version 1.0</div></div></div>"},"72777":{"type":"graphic_diagnosticimage","displayName":"Thoracic aortic plaque","title":"Thoracic aortic plaque","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Thoracic aortic plaque</div><div class=\"cntnt\"><img style=\"width:547px; height:229px;\" src=\"images/CARD/72777_Thoracic_aortic_plaque.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three transesophageal echocardiograms of the thoracic aorta: left: normal; middle: moderate (3 mm) plaque; and right: severe (7 mm) plaque.</div><div class=\"graphic_reference\">Reproduced with permission from: Tunick, PA, Kronzon, I. Atheroembolism. In: Vascular Medicine. A Companion to Braunwald's Heart Disease, 1st edition, Dzau, VJ, Creager, M, Loscalzo, J, et al (Eds), WB Saunders 2005. Copyright Â© 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 72777 Version 2.0</div></div></div>"},"72780":{"type":"graphic_table","displayName":"Aphasia syndromes","title":"Aphasia syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aphasia syndromes</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Syndrome\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Flu\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Rep\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Comp\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Read\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Write\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Localization\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Wernicke-Lichtheim model\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Broca's</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>\"Broca's\" area- left inferior frontal, often anterior MCA branch occlusion</td>\r\n  \r\n   <td>1</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Wernicke's</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>\"Wernicke's\" area- left superior temporal and inferior parietal region, often posterior MCA branch occlusion</td>\r\n  \r\n   <td>8</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Anomic</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>&#177;</td>\r\n  \r\n   <td>&#177;</td>\r\n  \r\n   <td>Temporal, parietal, and occipital regions of cortex outside of classical language areas</td>\r\n  \r\n   <td>6</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Conduction</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>&#177;</td>\r\n  \r\n   <td>Superior temporal gyrus, inferior parietal region adjacent to temporal lobe; classically in arcuate fasciculus</td>\r\n  \r\n   <td>5</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transcortical motor</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Left mesial frontal, especially supplementary motor area; anterior cerebral artery occlusion</td>\r\n  \r\n   <td>4</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transcortical sensory</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Left posterior watershed zone between MCA and PCA territories</td>\r\n  \r\n   <td>7</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transcortical mixed</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Anterior and posterior watershed zones, effectively disconnecting perisylvian cortex from other cortical regions</td>\r\n  \r\n   <td>4,7</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Global</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Large MCA or left carotid inclusions infarcting a vast region of the left hemisphere</td>\r\n  \r\n   <td>4,5,7</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pure word deafness</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>Left or bilateral superior temporal gyrus lesions</td>\r\n  \r\n   <td>10</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pure alexia</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>Left occipital lobe with involvement of splenium of corpus callosum</td>\r\n  \r\n   <td>9</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aphemia</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>Motor cortex outflow to articulators</td>\r\n  \r\n   <td>2</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pure agraphia</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>+</td>\r\n  \r\n   <td>-</td>\r\n  \r\n   <td>Left inferior frontal region</td>\r\n  \r\n   <td>3</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">Language disorders acquired through brain injury. The first eight rows are aphasic syndromes. Numbers in the column labeled 'Wernicke-Lichtheim model' refer to lesion labels on Figure 1.</div><div class=\"graphic_footnotes\">Flu: fluency; Rep: repetition; Comp: comprehension; Read: reading; Write: writing; +: relatively spared; -: impaired; ACA: anterior cerebral artery; MCA: middle cerebral artery; PCA: posterior cerebral artery.</div><div class=\"graphic_reference\">Data from: Mendez, MF, Clark, DG. Neuropsychiatric aspects of aphasia and related disorders. In: The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences, 5th ed, Yudofsky, SC, Hales, RH (Eds), American Psychiatric Publishing, Washington, DC 2007. p.522.</div><div id=\"graphicVersion\">Graphic 72780 Version 1.0</div></div></div>"},"72781":{"type":"graphic_picture","displayName":"Condyloma acuminatum2","title":"Vulvar condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:400px; height:345px;\" src=\"images/OBGYN/72781_Condyloma_acuminatum2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72781 Version 6.0</div></div></div>"},"72783":{"type":"graphic_diagnosticimage","displayName":"Craniopharyngioma MRI I","title":"Craniopharyngioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Craniopharyngioma</div><div class=\"cntnt\"><img style=\"width:286px; height:360px;\" src=\"images/ONC/72783_Craniopharyngioma_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging in a patient with craniopharyngioma reveals hyperintense mass relative to gray matter (arrow) with the epicenter in the sella turcica and extending superiorly to displace hypothalmic stalk.</div><div class=\"graphic_reference\">Courtesy of Lawrence Recht, MD.</div><div id=\"graphicVersion\">Graphic 72783 Version 2.0</div></div></div>"},"72784":{"type":"graphic_diagnosticimage","displayName":"Normal biceps tendon sonogr","title":"Normal biceps tendon sonogram","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Normal biceps tendon sonogram</div><div class=\"cntnt\"><img style=\"width:504px; height:385px;\" src=\"images/RHEUM/72784_Normal_biceps_tendon_sonogr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This transverse sonogram of a normal bicipital tendon in the bicipital groove of the proximal humerus shows a round cross section and multiple echogenic dots.</div><div class=\"graphic_reference\">Courtesy of George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 72784 Version 2.0</div></div></div>"},"72786":{"type":"graphic_picture","displayName":"Lichen planus tongue","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:396px; height:281px;\" src=\"images/DERM/72786_Lichen_planus_tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient has lichen planus which in this case is clinically indistinguishable from leukoplakia.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72786 Version 2.0</div></div></div>"},"72787":{"type":"graphic_picture","displayName":"Macintosh laryngoscope blade","title":"Macintosh laryngoscope blade","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Macintosh laryngoscope blade</div><div class=\"cntnt\"><img style=\"width:432px; height:308px;\" src=\"images/EM/72787_Macintoshlaryngoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Orebaugh SL. Retraction blades for direct laryngoscopy. In: Atlas of Airway Management: Techniques and Tools, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright Â© 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72787 Version 10.0</div></div></div>"},"72790":{"type":"graphic_figure","displayName":"Low dose warfarin high risk AF","title":"Low-dose warfarin plus aspirin is not optimal in high risk AF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low-dose warfarin plus aspirin is not optimal in high risk AF</div><div class=\"cntnt\"><img style=\"width:359px; height:264px;\" src=\"images/CARD/72790_Low_dose_warfarin_high_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative event rate of patients with atrial fibrillation (AF) at high risk for thromboembolism in the SPAF III trial. High risk was defined as the presence of at least one of the following: previous thromboembolism, female older than 75 years of age, heart failure or severe left ventricular systolic dysfunction, and systolic pressure &gt;160 mmHg. There was a much lower incidence of events with standard adjusted-dose warfarin therapy (INR 2 to 3) compared to treatment with aspirin and low-dose warfarin (INR 1.2 to 1.5) (p &lt;0.0001).</div><div class=\"graphic_reference\">Data from Stroke Prevention in Atrial Fibrillation Investigators. Lancet 1996; 348:633.</div><div id=\"graphicVersion\">Graphic 72790 Version 2.0</div></div></div>"},"72792":{"type":"graphic_table","displayName":"Heparin protocol II","title":"Example of a non-weight-based intravenous heparin protocol: Part II titration based upon the activated partial thromboplastin time","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of a non-weight-based intravenous heparin protocol: Part II titration based upon the activated partial thromboplastin time</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">IV infusion</td> </tr> <tr> <td class=\"subtitle2\">aPTT</td> <td class=\"subtitle2\">Rate change, mL/hour*</td> <td class=\"subtitle2\">Dose change, units/24-hour</td> <td class=\"subtitle2\">Additional action</td> </tr> <tr> <td>&#8804;45</td> <td>+6</td> <td>+5760</td> <td>Repeated aPTT<sup>&#182;</sup> in 4 to 6 hours</td> </tr> <tr> <td>46 to 54</td> <td>+3</td> <td>+2880</td> <td>Repeated aPTT in 4 to 6 hours</td> </tr> <tr> <td>55 to 85</td> <td>0</td> <td>0</td> <td>None<sup>&#916;</sup></td> </tr> <tr> <td>86 to 110</td> <td>&ndash;3</td> <td>&ndash;2880</td> <td>Stop heparin sodium treatment for 1 hour; repeated aPTT 4 to 6 hours after restarting heparin treatment</td> </tr> <tr> <td>&#62;110</td> <td>&ndash;6</td> <td>&ndash;5760</td> <td>Stop heparin treatment for 1 hour; repeated aPTT 4 to 6 hours after restarting heparin treatment</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: This table reflects the original aPTT ranges, bolus sizes, and suggested changes in infusion rate that were present at the time this study was performed. The therapeutic ranges (ie, relationship between the aPTT and anti-factor Xa activity), initial and subsequent bolus sizes, and sizes of the infusion rate changes, as well as dosing differences depending on the disorder under treatment (eg, venous thromboembolism, stroke, acute coronary syndrome) should be established separately for each institution.</div><div class=\"graphic_footnotes\">aPTT: activated partial thromboplastin time; IV: intravenous.<br />* Heparin sodium concentration, 20,000 units in 500 mL = 40 units/mL.<br />&para; With the use of Actin-FS thromboplastin reagent (Dade, Mississauga, Ontario).<br />&Delta; During the first 24 hours, repeated aPTT in 4 to 6 hours. Thereafter, the aPTT will be determined once daily, unless subtherapeutic.</div><div class=\"graphic_reference\">Redrawn from: Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152:1589.</div><div id=\"graphicVersion\">Graphic 72792 Version 10.0</div></div></div>"},"72793":{"type":"graphic_table","displayName":"Likelihood ratios","title":"Likelihood ratios","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Likelihood ratios</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Likelihood ratio (LR)\n   </td>\n   <td  class=\"subtitle1\">\n   Calculation\n   </td>\n   <td  class=\"subtitle1\">\n   Change in probability of success or failure\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   LR positive\n   </td>\n   <td  rowspan=\"4\">\n   Sensitivity/(1-specificity)\n   </td>\n   <td>LR = 1-2, none/minimal</td>\n   </tr>\n   <tr>\n   <td>LR = 2-5, small</td>\n   </tr>\n   <tr>\n   <td>LR = 5-10, moderate</td>\n   </tr>\n   <tr>\n   <td>LR &#62;10 = large</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   LR negative\n   </td>\n   <td  rowspan=\"4\">\n   (1-sensitivity)/specificity\n   </td>\n   <td>LR = 0.5-1, none/minimal</td>\n   </tr>\n   <tr>\n   <td>LR = 0.3-0.5, small</td>\n   </tr>\n   <tr>\n   <td>LR = 0.1-0.3, moderate</td>\n   </tr>\n   <tr>\n   <td>LR &#60;0.1 = large</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">LR: likelihood ratio.</div><div id=\"graphicVersion\">Graphic 72793 Version 1.0</div></div></div>"},"72794":{"type":"graphic_picture","displayName":"PVOD septal thickening","title":"Longitudinal section of lobular septa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal section of lobular septa</div><div class=\"cntnt\"><img style=\"width:382px; height:269px;\" src=\"images/PULM/72794_PVOD_septal_thickening.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows demonstrate septal thickening due to interstitial edema and fibrosis. Hematoxylin-eosin; original magnification: x4.</div><div class=\"graphic_reference\">Reproduced with permission from: Mandel, J, Mark, E, Hales, C. Pulmonary veno- occlusive disease. Am J Respir Crit Care Med 2000; 162:1964. Official Journal of the American Thoracic Society Â© American Lung Association.</div><div id=\"graphicVersion\">Graphic 72794 Version 2.0</div></div></div>"},"72797":{"type":"graphic_figure","displayName":"Malaria map â Western Hemisphere","title":"Malaria-endemic countries in the Western Hemisphere","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Malaria-endemic countries in the Western Hemisphere</div><div class=\"cntnt\"><img style=\"width:547px; height:806px;\" src=\"images/ID/72797_Malaria_map_West_Hem_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this map, countries with areas endemic for malaria are shaded completely even if transmission occurs only in a small part of the country. For more specific within-country malaria transmission information, see the Yellow Fever &amp; Malaria Information, by Country section in chapter 3 of <em>CDC Health Information for International Travel 2018</em>.</div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 72797 Version 8.0</div></div></div>"},"72798":{"type":"graphic_form","displayName":"Birth center consent 1","title":"Birth center consent form","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Birth center consent form</div><div class=\"cntnt\"><img style=\"width:603px; height:749px;\" src=\"images/OBGYN/72798_Birth_center_consent_1.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: the American Association of Birth Centers. Copyright Â©2007.</div><div id=\"graphicVersion\">Graphic 72798 Version 2.0</div></div></div>"},"72799":{"type":"graphic_table","displayName":"Probability RDS by FLM and GA","title":"Absolute risk ofÂ respiratory distress syndromeÂ based on TDx FLM II ratio (mg/g) and gestational age*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Absolute risk of&nbsp;respiratory distress syndrome&nbsp;based on TDx FLM II ratio (mg/g) and gestational age*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">FLM</td> <td class=\"subtitle1\" colspan=\"11\">Gestational age, weeks</td> </tr> <tr> <td class=\"subtitle2\">29</td> <td class=\"subtitle2\">30</td> <td class=\"subtitle2\">31</td> <td class=\"subtitle2\">32</td> <td class=\"subtitle2\">33</td> <td class=\"subtitle2\">34</td> <td class=\"subtitle2\">35</td> <td class=\"subtitle2\">36</td> <td class=\"subtitle2\">37</td> <td class=\"subtitle2\">38</td> <td class=\"subtitle2\">39</td> </tr> <tr> <td>10</td> <td>98%</td> <td>97%</td> <td>96%</td> <td>95%</td> <td>92%</td> <td>89%</td> <td>85%</td> <td>80%</td> <td>73%</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>20</td> <td>94%</td> <td>92%</td> <td>89%</td> <td>85%</td> <td>80%</td> <td>73%</td> <td>65%</td> <td>57%</td> <td>47%</td> <td>38%</td> <td>&nbsp;</td> </tr> <tr> <td>30</td> <td>85%</td> <td>79%</td> <td>73%</td> <td>65%</td> <td>56%</td> <td>47%</td> <td>38%</td> <td>30%</td> <td>23%</td> <td>17%</td> <td>12%</td> </tr> <tr> <td>40</td> <td>64%</td> <td>55%</td> <td>46%</td> <td>37%</td> <td>29%</td> <td>22%</td> <td>17%</td> <td>12%</td> <td>8.7%</td> <td>6.2%</td> <td>4.4%</td> </tr> <tr> <td>50</td> <td>37%</td> <td>29%</td> <td>22%</td> <td>16%</td> <td>12%</td> <td>8.5%</td> <td>6.1%</td> <td>4.3%</td> <td>3.0%</td> <td>2.1%</td> <td>1.5%</td> </tr> <tr> <td>60</td> <td>16%</td> <td>12%</td> <td>8.4%</td> <td>6.0%</td> <td>4.2%</td> <td>3.0%</td> <td>2.1%</td> <td>1.4%</td> <td>1.0%</td> <td>0.70%</td> <td>0.49%</td> </tr> <tr> <td>70</td> <td>5.8%</td> <td>4.1%</td> <td>2.9%</td> <td>2.0%</td> <td>1.4%</td> <td>0.98%</td> <td>0.68%</td> <td>0.47%</td> <td>0.33%</td> <td>0.23%</td> <td>0.16%</td> </tr> <tr> <td>80</td> <td>2.0%</td> <td>1.4%</td> <td>0.96%</td> <td>0.67%</td> <td>0.46%</td> <td>0.32%</td> <td>0.22%</td> <td>0.16%</td> <td>0.11%</td> <td>0.07%</td> <td>0.05%</td> </tr> <tr> <td>90</td> <td>&nbsp;</td> <td>0.45%</td> <td>0.31%</td> <td>0.22%</td> <td>0.15%</td> <td>0.11%</td> <td>0.07%</td> <td>0.05%</td> <td>0.04%</td> <td>0.02%</td> <td>0.02%</td> </tr> <tr> <td>100</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>0.10%</td> <td>0.07%</td> <td>0.05%</td> <td>0.03%</td> <td>0.02%</td> <td>0.02%</td> <td>0.01%</td> <td>&#60;0.01%</td> <td>&#60;0.01%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These risk estimates reflect the prevalence pattern of&nbsp;respiratory distress syndrome&nbsp;across the&nbsp;gestational age&nbsp;range observed in the current study data. The overall prevalence of&nbsp;respiratory distress syndrome&nbsp;in a clinical setting depends on both the prevalence of&nbsp;respiratory distress syndrome&nbsp;at each gestational age&nbsp;and on the distribution of gestational ages encountered.</div><div class=\"graphic_reference\">Reproduced with permission from: Parvin CA, Kaplan LA, Chapman JF, et al. Predicting respiratory distress syndrome using gestational age and fetal lung maturity by fluorescent polarization. Am J Obstet Gynecol 2005; 192:199. Copyright Â© 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 72799 Version 3.0</div></div></div>"},"72801":{"type":"graphic_table","displayName":"Pharmacologic Rx GH excess","title":"Pharmacologic treatment of growth hormone excess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic treatment of growth hormone excess</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Route of administration</td> <td class=\"subtitle1\">Side effects</td> </tr> <tr> <td>Bromocriptine</td> <td>Dopamine agonist</td> <td>Oral</td> <td>Headaches, nausea, dizziness</td> </tr> <tr> <td>Octreotide</td> <td>Long-acting somatostatin analog</td> <td> <p>Multiple daily subcutaneous injections</p> <p>-- or --</p> <p>Continuous subcutaneous infusion</p> </td> <td> <p>Mild&nbsp;gastrointestinal complaints</p> <p>Increased risk of gallstones</p> </td> </tr> <tr> <td>Lanreotide</td> <td>Sustained-release long- acting somatostatin analog</td> <td>Intramuscular injection&nbsp;every 2 to 4 weeks</td> <td> <p>Mild&nbsp;gastrointestinal complaints</p> <p>Increased risk of gallstones</p> </td> </tr> <tr> <td>Pegvisomant</td> <td>Growth hormone&nbsp;receptor antagonist</td> <td>Daily subcutaneous injection</td> <td> <p>Injection site reactions</p> <p>Elevated liver enzymes? (one patient)</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72801 Version 5.0</div></div></div>"},"72805":{"type":"graphic_table","displayName":"IVF GIFT ZIFT TET","title":"Assisted reproductive technologies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assisted reproductive technologies</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   In vitro fertilization (IVF)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aspiration of one or more oocytes from ovarian follicles, fertilization in vitro, and then transfer of the embryo(s) into the uterus. This is the most common procedure using assisted reproductive technology.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Intracytoplasmic sperm injection (ICSI) is a specialized technique for couples with severe sperm abnormalities. It is performed in conjunction with IVF whereby fertilization is accomplished by injecting a single sperm directly into the egg.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Gamete intrafallopian transfer (GIFT)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>A laparoscope is used to aspirate one or more mature oocytes from ovarian follicles and then transfer the oocytes and sperm to the fallopian tube.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>GIFT, although more invasive than IVF, may be an appropriate choice in patients who, for religious or personal reasons, do not wish to have embryos in the laboratory. It is also appropriate for those who have failed donor insemination or require laparoscopy for other reasons. The success rate is similar to those with IVF.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Zygote intrafallopian transfer (ZIFT) or tubal embryo transfer (TET)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>This procedure involves placement of fertilized eggs (zygotes) or embryos into the fallopian tube.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>ZIFT is analogous to GIFT in that laparoscopy is needed to place the zygotes in the fallopian tubes.  Whereas overall success rates are similar to IVF, ZIFT may offer some advantages to patients with difficult trans-cervical embryo transfer, uterine abnormalities (such as those caused by DES exposure), or recurrent failture with standard IVF</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from Meldrum, DR. Assisted Reproductive Technology: Clinical Aspects. In: Essentials of Reproductive Medicine. Hillier, SG, Kitchener, HC, Neilson, JP (eds) WB Saunders, Philadelphia,1996.</div><div id=\"graphicVersion\">Graphic 72805 Version 1.0</div></div></div>"},"72806":{"type":"graphic_figure","displayName":"Alveoli COPD PI","title":"Alveoli anatomy in COPD","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Alveoli anatomy in COPD</div><div class=\"cntnt\"><img style=\"width:458px; height:430px;\" src=\"images/PI/72806_Alveoli_COPD_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows normal and damaged alveoli. Alveoli that are damaged make it harder for oxygen and carbon dioxide to pass between the lungs and the blood stream.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Co., Pulmonary Disorders. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72806 Version 4.0</div></div></div>"},"72809":{"type":"graphic_table","displayName":"Risk classific exercise class C","title":"Risk classification for exercise training: class C: those at moderate-to-high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk classification for exercise training: class C: those at moderate-to-high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">This classification includes individuals with any of the following diagnoses:</td> </tr> <tr> <td class=\"indent1\">1. Coronary artery disease with the clinical characteristics outlined below.</td> </tr> <tr> <td class=\"indent1\">2. Valvular heart disease, excluding severe valvular stenosis or regurgitation with the clinical characteristics as outlined below.</td> </tr> <tr> <td class=\"indent1\">3. Congenital heart disease; risk stratification for patients with congenital heart disease should be guided by the 27<sup>th</sup> Bethesda Conference recommendations.</td> </tr> <tr> <td class=\"indent1\">4. Cardiomyopathy: ejection fraction &#60;30 percent; includes stable patients with heart failure with clinical characteristics as outlined below but not hypertrophic cardiomyopathy or recent myocarditis.</td> </tr> <tr> <td class=\"indent1\">5. Complex ventricular arrhythmias not well controlled.</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical characteristics (any of the following):</td> </tr> <tr> <td class=\"indent1\">1. NYHA class 3 or 4.</td> </tr> <tr> <td class=\"sublist2_start\">2. Exercise test results</td> </tr> <tr> <td class=\"sublist2\">Exercise capacity &#60;6 METs</td> </tr> <tr> <td class=\"sublist2\">Angina or ischemic ST depression at a workload &#60;6 METs</td> </tr> <tr> <td class=\"sublist2\">Fall in systolic blood pressure below resting levels during exercise</td> </tr> <tr> <td class=\"sublist2\">Nonsustained ventricular tachycardia with exercise</td> </tr> <tr> <td class=\"indent1\">3. Previous episode of primary cardiac arrest (ie, cardiac arrest that did not occur in the presence of an acute myocardial infarction or during a cardiac procedure).</td> </tr> <tr> <td class=\"indent1\">4. A medical problem that the clinician believes may be life-threatening.</td> </tr> <tr> <td class=\"subtitle1_single\">Activity guidelines:</td> </tr> <tr> <td class=\"indent1\">1. Activity should be individualized, with exercise prescription provided by qualified individuals and approved by primary health care provider.</td> </tr> <tr> <td class=\"subtitle1_single\">Supervision</td> </tr> <tr> <td class=\"indent1\">1. Medical supervision during all exercise sessions until safety is established.</td> </tr> <tr> <td class=\"subtitle1_single\">ECG and blood pressure monitoring:</td> </tr> <tr> <td class=\"indent1\">1. Continuous during exercise sessions until safety is established, usually &#8805;12 sessions.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NYHA: New York Heart Association; METs: metabolic equivalents: ECG: electrocardiogram.<br />* Class C patients who have successfully completed a series of supervised exercise sessions may be reclassified to Class B providing that the safety of exercise at the prescribed intensity is satisfactorily established by appropriate medical personnel and that the patient has demonstrated the ability to self-monitor.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 72809 Version 6.0</div></div></div>"},"72810":{"type":"graphic_figure","displayName":"Craniovertebral joints and ligaments","title":"Craniovertebral joints and ligaments","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Craniovertebral joints and ligaments</div><div class=\"cntnt\"><img style=\"width:610px; height:720px;\" src=\"images/EM/72810_Craniovertejointsligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ligaments of the atlanto-occipital and atlantoaxial joints. The tectorial membrane and the right side of the cruciate ligament of the atlas have been removed to show the attachment of the right alar ligament to the dens of vertebra C2 (axis).<br> (B) The hemisected craniovertebral region shows the median joints and membranous continuities of the ligamenta flava and longitudinal ligaments in the craniovertebral region.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72810 Version 10.0</div></div></div>"},"72811":{"type":"graphic_figure","displayName":"Technique of below-knee amputation with long posterior flap","title":"Technique of below-knee amputation with long posterior flap","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Technique of below-knee amputation with long posterior flap</div><div class=\"cntnt\"><img style=\"width:508px; height:676px;\" src=\"images/SURG/72811_BKA-long-posterior-flap.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72811 Version 2.0</div></div></div>"},"72812":{"type":"graphic_picture","displayName":"Gram-positive cocci clusters 2","title":"Gram-positive cocci clusters","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gram-positive cocci clusters</div><div class=\"cntnt\"><img style=\"width:418px; height:299px;\" src=\"images/ID/72812_Gram_pos_cocci_clusters_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram-positive cocci (<EM>Staphylococcus aureus</EM>) in pus (large, dark-red globules are white cell nuclei).</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright Â© 2008.</div><div id=\"graphicVersion\">Graphic 72812 Version 4.0</div></div></div>"},"72813":{"type":"graphic_picture","displayName":"Fibrillary vs immunotactoid glomerulonephritis EM","title":"Fibrillary glomerulonephritis versus immunotactoid glomerulopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrillary glomerulonephritis versus immunotactoid glomerulopathy</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/72813_Fibrillary_GN_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrographs showing the two different fibrillar patterns in fibrillary glomerulonephritis: true fibrils, which are 2 to 4 times larger than those seen in amyloidosis (left panel); and immunotactoids, which appear as microtubules with a hollow center (right panel).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 72813 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"72814":{"type":"graphic_picture","displayName":"Early papilledema","title":"Early papilledema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early papilledema</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/NEURO/72814_Early_papilledema.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 72814 Version 1.0</div></div></div>"},"72815":{"type":"graphic_diagnosticimage","displayName":"Asystole","title":"Induced fetal demise: Post-procedure asystole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Induced fetal demise: Post-procedure asystole</div><div class=\"cntnt\"><img style=\"width:360px; height:327px;\" src=\"images/OBGYN/72815_Asystole.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pericardial effusion is also present.</div><div id=\"graphicVersion\">Graphic 72815 Version 3.0</div></div></div>"},"72817":{"type":"graphic_picture","displayName":"High arched palate","title":"High arched palate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High arched palate</div><div class=\"cntnt\"><img style=\"width:396px; height:280px;\" src=\"images/PEDS/72817_High_arched_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palate with a high and narrow maxillary arch in a patient with obstructive sleep apnea. The tongue cannot fit into the narrow palate. Therefore, the tongue tends to move backward when the patient is supine, blocking the airway.</div><div class=\"graphic_reference\">Courtesy of Rafael Pelayo, MD.</div><div id=\"graphicVersion\">Graphic 72817 Version 2.0</div></div></div>"},"72818":{"type":"graphic_picture","displayName":"Airtraq device","title":"Airtraq optical laryngoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airtraq optical laryngoscope</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/EM/72818_Airtraq_device.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Optical laryngoscopes use lenses to provide a high quality view of the anterior glottis. The devices are an inexpensive, durable, and portable tool for difficult airway management.</div><div class=\"graphic_reference\">Reproduced with permission from: Prodol Meditec S.A. Copyright &#169;2008 Prodol Meditec S.A.</div><div id=\"graphicVersion\">Graphic 72818 Version 1.0</div></div></div>"},"72821":{"type":"graphic_picture","displayName":"Psammoma body FNA","title":"Psammoma body: Appearance on fine needle aspirate of the thyroid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psammoma body: Appearance on fine needle aspirate of the thyroid</div><div class=\"cntnt\"><img style=\"width:360px; height:244px;\" src=\"images/ENDO/72821_Psammoma_body_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate of a papillary carcinoma of the thyroid showing a psammoma body. The laminations can best be appreciated under the microscope by moving the depth of focus.</div><div id=\"graphicVersion\">Graphic 72821 Version 2.0</div></div></div>"},"72822":{"type":"graphic_table","displayName":"Geriatric depression scale","title":"Yesavage geriatric depression scale (short form)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Yesavage geriatric depression scale (short form)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t\t\t<tr>\n\t\t\t\t<td>1. Are you basically satisfied with your life?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>2. Have you dropped many of your activities and interests?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>3. Do you feel that your life is empty?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>4. Do you often get bored?</td>\n\t\t\t\t<td>Y </td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>5. Are you in good spirits most of the time?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>6. Are you afraid that something bad is going to happen to you?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>7. Do you feel happy most of the time?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>8. Do you often feel helpless?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>9. Do you prefer to stay at home, rather than going out and doing new things?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>10. Do you feel you have more problems with memory than most?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>11. Do you think it is wonderful to be alive now?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>12. Do you feel pretty worthless the way you are now?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>13. Do you feel full of energy?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>14. Do you feel that your situation is hopeless?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>15. Do you think that most people are better off than you are?</td>\n\t\t\t\t<td>Y</td>\n\t\t\t\t<td>N</td>\n\t\t\t</tr>\n\t\t\t\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle1_left\" colspan=\"3\">Score 1 point for each \"depressed\" answer (no on 1, 5, 7, 11, 13; yes on others)</td>\n\n\t\t\t</tr>\n\t\t\t\n\t\t\t<tr>\n\t\t\t\t<td colspan=\"2\">Normal</td>\n\t\t\t\t<td>3&plusmn;2</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td colspan=\"2\">Mildly depressed</td>\n\t\t\t\t<td>7&plusmn;3</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td colspan=\"2\">Very depressed</td>\n\t\t\t\t<td>12&plusmn;2</td>\n\t\t\t</tr>\n\t\t</table></div><div class=\"graphic_reference\">Adapted from Sheikh, JI, Yesavage, JA, Brooks, JO 3d, et al. Int Psychogeriatr 1991; 3:23.</div><div id=\"graphicVersion\">Graphic 72822 Version 1.0</div></div></div>"},"72824":{"type":"graphic_waveform","displayName":"Biphasic arterial Doppler waveform","title":"Biphasic arterial Doppler waveform","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Biphasic arterial Doppler waveform</div><div class=\"cntnt\"><img style=\"width:464px; height:274px;\" src=\"images/SURG/72824_Biph_art_Doppler_wave.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biphasic signal has a rapid upstroke, sharp peak, and&nbsp;fairly rapid downstroke, with a short period of antegrade flow in diastole (there is no flow below baseline).<br /></div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 72824 Version 1.0</div></div></div>"},"72825":{"type":"graphic_picture","displayName":"Acute GVHD palm","title":"Palmar involvement in acute graft-versus-host disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palmar involvement in acute graft-versus-host disease</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/DERM/72825_Acute_GVHD_palm2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous erythematous macules are present on the palm.</div><div id=\"graphicVersion\">Graphic 72825 Version 1.0</div></div></div>"},"72826":{"type":"graphic_figure","displayName":"Atriocaval shunting procedure to control liver bleeding","title":"Atriocaval shunting procedure to control liver bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atriocaval shunting procedure to control liver bleeding</div><div class=\"cntnt\"><img style=\"width:447px; height:707px;\" src=\"images/SURG/72826_Atriocaval-shunting-procedure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrial-caval shunts divert caval and hepatic venous blood flow away from the liver to provide a bloodless field where injuries to these structures can be repaired. A variety of shunting conduits are available for use.</div><div id=\"graphicVersion\">Graphic 72826 Version 3.0</div></div></div>"},"72828":{"type":"graphic_picture","displayName":"X and V factors","title":"Test for utilization of X and V factors","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Test for utilization of X and V factors</div><div class=\"cntnt\"><img style=\"width:362px; height:240px;\" src=\"images/ID/72828_XandVfactors.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On brain-heart infusion agar, which lacks both X and V factors, <EM>Haemophilus influenzae</EM> grows only where both factors have diffused between the paper strips.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 72828 Version 5.0</div></div></div>"},"72831":{"type":"graphic_figure","displayName":"Disease prog CA vs CD","title":"Disease progression in cancer versus chronic diseases","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Disease progression in cancer versus chronic diseases</div><div class=\"cntnt\"><img style=\"width:465px; height:268px;\" src=\"images/ONC/72831_Disease_prog_CA_vs_CD.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Lynn J. Living long in fragile health: the new demographics shape end of life care. Improving end of life care: why has it been so difficult? Hastings Center Special Report 2005; 35(6): S14-8.</div><div id=\"graphicVersion\">Graphic 72831 Version 1.0</div></div></div>"},"72833":{"type":"graphic_picture","displayName":"Dry eye conjunctival vessels","title":"Dry eye disease with prominent conjunctival vessels indicating irritation of ocular surface","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Dry eye disease with prominent conjunctival vessels indicating irritation of ocular surface</div><div class=\"cntnt\"><img style=\"width:513px; height:231px;\" src=\"images/PC/72833_Dry_eye_conjunctivl_vessels.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72833 Version 2.0</div></div></div>"},"72834":{"type":"graphic_picture","displayName":"Dividing apple extraction","title":"Rectal foreign body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectal foreign body</div><div class=\"cntnt\"><img style=\"width:432px; height:354px;\" src=\"images/GAST/72834_Dividing_apple_extraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An apple has been divided so that it can be removed using a transanal approach.</div><div class=\"graphic_reference\">Courtesy of Scott Steele, MD.</div><div id=\"graphicVersion\">Graphic 72834 Version 1.0</div></div></div>"},"72835":{"type":"graphic_picture","displayName":"Lymphoblasts of ALL","title":"Lymphoblasts in acute lymphoblastic leukemia ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoblasts in acute lymphoblastic leukemia </div><div class=\"cntnt\"><img style=\"width:429px; height:288px;\" src=\"images/HEME/72835_L1_lymphoblasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow aspirate from a patient with acute lymphoblastic leukemia in the World Health Organization classification. The blast cells have a high nuclear to cytoplasmic ratio; many cells have only a thin rim of deep blue cytoplasm. The nucleus may have several distinct and/or indistinct nucleoli. (Wright-Giemsa stain)</div><div class=\"graphic_reference\">Courtesy of David S Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 72835 Version 3.0</div></div></div>"},"72836":{"type":"graphic_table","displayName":"Risk VTE multiple defects","title":"Risk of venous thromboembolism associated with use of oral contraceptives, factor V leiden, and/or prothrombin gene mutation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of venous thromboembolism associated with use of oral contraceptives, factor V leiden, and/or prothrombin gene mutation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">OC Use*</td> <td class=\"subtitle1\">Factor V Leiden</td> <td class=\"subtitle1\">Factor II G20210A</td> <td class=\"subtitle1\">Odds ratio<sup>&#182;</sup></td> </tr> <tr> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>1</td> </tr> <tr> <td>+</td> <td>&ndash;</td> <td>&ndash;</td> <td>2.3</td> </tr> <tr> <td>&ndash;</td> <td>&ndash;</td> <td>+</td> <td>3.2</td> </tr> <tr> <td>&ndash;</td> <td>+</td> <td>&ndash;</td> <td>5.9</td> </tr> <tr> <td>+</td> <td>&ndash;</td> <td>+</td> <td>7.1</td> </tr> <tr> <td>+</td> <td>+</td> <td>&ndash;</td> <td>10.2</td> </tr> <tr> <td>&ndash;</td> <td>+</td> <td>+</td> <td>14.7</td> </tr> <tr> <td>+</td> <td>+</td> <td>+</td> <td>17</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Oral contraceptives; factor II is prothrombin.<br />Â¶ Crude odds ratio for risk of venous thromboembolism given the combination of risks (â: risk not present; +: risk present).</div><div class=\"graphic_reference\">Adapted from: Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809.</div><div id=\"graphicVersion\">Graphic 72836 Version 3.0</div></div></div>"},"72837":{"type":"graphic_table","displayName":"Funct level scale for Meniere disease","title":"Functional level scale for Meniere disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional level scale for Meniere disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Regarding my current state of overall function, not just during attacks (check the ONE that best applies):</td> </tr> <tr> <td>1. My dizziness has no effect on my activities at all.</td> <td>&nbsp;</td> </tr> <tr> <td>2. When I am dizzy I have to stop what I am doing for a while, but it soon passes and I can resume activities. I continue to work, drive, and engage in any activity I choose without restriction. I have not changed any plans or activities to accommodate my dizziness.</td> <td>&nbsp;</td> </tr> <tr> <td>3. When I am dizzy I have to stop what I am doing for a while, but it does pass and I can resume activities. I continue to work, drive, and engage in most activities I choose, but I have had to change some plans and make some allowance for my dizziness.</td> <td>&nbsp;</td> </tr> <tr> <td>4. I am able to work, drive, travel, take care of a family, or engage in most essential activities, but I must exert a great deal of effort to do so. I must constantly make adjustments in my activities and budget my energies. I am barely making it.</td> <td>&nbsp;</td> </tr> <tr> <td>5. I am unable to work, drive, or take care of a family. I am unable to do most of the active things that I used to. Even essential activities must be limited. I am disabled.</td> <td>&nbsp;</td> </tr> <tr> <td>6. I have been disabled for one year or longer and/or I receive compensation (money) because of my dizziness or balance problem.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995; 113:181. Copyright Â©1995 American Academy of Otolaryngology-Head and Neck Surgery.</div><div id=\"graphicVersion\">Graphic 72837 Version 3.0</div></div></div>"},"72838":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CT III","title":"Paratracheal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratracheal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:255px;\" src=\"images/PULM/72838_Med_bronchogen_cyst_CT_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan displays a non-enhancing right paratracheal mass.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72838 Version 4.0</div></div></div>"},"72841":{"type":"graphic_figure","displayName":"Bone composition and anatomical location","title":"Bone composition and anatomical location","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone composition and anatomical location</div><div class=\"cntnt\"><img style=\"width:432px; height:337px;\" src=\"images/SURG/72841_Bone_comp_anat_location.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Midshaft proximal phalangeal fractures need 6 to 10 weeks and midshaft middle phalangeal fractures require 10 to 14 weeks for complete bony healing. These long healing times are due to the bony composition of the midshaft of the phalanges, which is hard cortical bone.</div><div id=\"graphicVersion\">Graphic 72841 Version 2.0</div></div></div>"},"72842":{"type":"graphic_figure","displayName":"Androgen levels in PCOS","title":"Serum androgen concentrations are high in women with PCOS","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Serum androgen concentrations are high in women with PCOS</div><div class=\"cntnt\"><img style=\"width:496px; height:315px;\" src=\"images/ENDO/72842_Androgen_levels_in_PCOS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean serum concentrations of testosterone (pg/mL), androstenedione (pg/mL), and DHEA-sulfate (mcg/mL) in 10 normal women between days 2 to 4 of their menstrual cycle and 19 women with PCOS. The mean serum concentration of each androgen was high in the women with PCOS, but there was substantial overlap between the two groups and many women with PCOS had normal values for one or more androgens.</div><div class=\"graphic_footnotes\">DHEA: dehydroepiandrosterone; PCOS: polycystic ovary syndrome.</div><div class=\"graphic_reference\">Data from: DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.</div><div id=\"graphicVersion\">Graphic 72842 Version 3.0</div></div></div>"},"72843":{"type":"graphic_movie","displayName":"Anterior wall dyskinesis post MI four chamber echo","title":"Anterior wall myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior wall myocardial infarction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72843_4chantdyconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:259px; height:448px;\" src=\"images/CARD/72843_4chantdy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-chamber view from a 2D echocardiogram shows a large dyskinetic region of the apex and anterior wall of a dilated left ventricle as a result of a large anterior wall infarction. The anterior wall and interventricular septum are thin and do not thicken during systole.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 72843 Version 3.0</div></div></div>"},"72845":{"type":"graphic_figure","displayName":"Reactive nonstress test","title":"Reactive nonstress test performed eight days before the patient's estimated delivery date","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Reactive nonstress test performed eight days before the patient's estimated delivery date</div><div class=\"cntnt\"><img style=\"width:540px; height:303px;\" src=\"images/OBGYN/72845_Reactive_nonstress_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reactive nonstress test. The baseline fetal heart rate is between 130 and 140 beats per minute. There are two accelerations &gt;15 beats per minute; one peaks at approximately 170 beats per minute and the other peaks at approximately 160 beats per minute. The duration of each acceleration exceeds 20 seconds. Variability is moderate (6 to 25 beats per minute).<br />The top tracing is the fetal heart rate. The y-axis reflects the fetal heart rate measured in beats per minute. The x-axis reflects time; each of the smallest divisions represents 10 seconds with one minute between bold vertical lines.<br />The bottom tracing shows the frequency and duration of uterine contractions.</div><div id=\"graphicVersion\">Graphic 72845 Version 6.0</div></div></div>"},"72846":{"type":"graphic_picture","displayName":"Palpating plantar fascia PI","title":"Palpating the plantar fascia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpating the plantar fascia</div><div class=\"cntnt\"><img style=\"width:363px; height:282px;\" src=\"images/PI/72846_Palpating_plantar_fascia_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The toes are grasped and dorsiflexed with one hand, while the other hand palpates the plantar aspect of the foot, particularly the bands compressing the plantar fascia.</div><div class=\"graphic_reference\">Courtesy of Robert P Sheon, MD.</div><div id=\"graphicVersion\">Graphic 72846 Version 1.0</div></div></div>"},"72847":{"type":"graphic_picture","displayName":"Potters syndrome","title":"Facial appearance of a patient with Potter's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Facial appearance of a patient with Potter's syndrome</div><div class=\"cntnt\"><img style=\"width:270px; height:432px;\" src=\"images/PEDS/72847_Potters_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical facial appearance observed in Potter's syndrome. Characteristic abnormalities include pseudoepicanthus, recessed chin, posteriorly rotated, flattened ears, and flattened nose.</div><div id=\"graphicVersion\">Graphic 72847 Version 2.0</div></div></div>"},"72848":{"type":"graphic_table","displayName":"Resiliency strategies LD","title":"Strategies to enhance resilience and success in children and adolescents with learning disabilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Strategies to enhance resilience and success in children and adolescents with learning disabilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Exhibit belief in the child's or adolescent's positive attributes</td> </tr> <tr> <td>Find words to describe the attributes of the child or adolescent in positive terms</td> </tr> <tr> <td>Identify the child's or adolescent's areas of strength and highlight those skills and their contribution to the family's well-being<sup>[1]</sup></td> </tr> <tr> <td>Accept the unique pattern of the child's or adolescent's strengths and weaknesses</td> </tr> <tr> <td>Emphasize effort rather than achievement</td> </tr> <tr> <td>Emphasize the value of education</td> </tr> <tr> <td class=\"subtitle1_single\">Establish realistic expectations</td> </tr> <tr> <td>Praise success and avoid frustration by matching tasks to the child's or adolescent's level of functioning and interests</td> </tr> <tr> <td>Align expectations with child's or adolescent's capabilities, considering personal temperament, moral development, and learning style</td> </tr> <tr> <td>Communicate realistic expectations and celebrate effort to achieve a skill or goal</td> </tr> <tr> <td>Prepare the child or adolescent for new situations to ensure success</td> </tr> <tr> <td>Match expectations to child's or adolescent's temperament</td> </tr> <tr> <td>Teach socially acceptable methods of requesting information or stating personal desires</td> </tr> <tr> <td>Recognize the individual's unique learning style</td> </tr> <tr> <td>Monitor books that the child chooses to read independently to prevent undue frustration; helping the child to choose books at his or her \"independent\" reading level (99 percent accuracy); reading the age-appropriate books that are beyond the child's independent reading level aloud to the child<sup>[2]</sup></td> </tr> <tr> <td>Use many senses to assist a child to learn information</td> </tr> <tr> <td class=\"subtitle1_single\">Provide the child or adolescent with the opportunity to assume responsibility</td> </tr> <tr> <td>Encourage independence (in situations where the child or adolescent is likely to be successful) to enhance self-esteem</td> </tr> <tr> <td>Give the individual household and personal tasks that are within the ability of the individual</td> </tr> <tr> <td>Permit the individual to experience the management of money, considering age and ability to self-regulate</td> </tr> <tr> <td>Assist children and adolescents to manage their modes of transportation independently, as appropriate for age and level of self-regulation</td> </tr> <tr> <td>Encourage decision-making</td> </tr> <tr> <td class=\"subtitle1_single\">Improve social skills and provide opportunities for successful social interaction</td> </tr> <tr> <td>Keep children abreast of current events</td> </tr> <tr> <td>Involve children in community service</td> </tr> <tr> <td>Encourage activities of interest rather than age outside of home and school</td> </tr> <tr> <td>Avoid intensive competition</td> </tr> <tr> <td class=\"subtitle1_single\">Be consistent about rules and limits</td> </tr> <tr> <td>Keep rules to a minimum</td> </tr> <tr> <td>Seek to educate and negotiate rather than dictate</td> </tr> <tr> <td>Apply logical consequences</td> </tr> <tr> <td>Use positive reinforcement</td> </tr> <tr> <td>Use rewards only when needed</td> </tr> <tr> <td>Reward effort and initiative, as well as achievement</td> </tr> <tr> <td class=\"subtitle1_single\">Enhance family dynamics</td> </tr> <tr> <td>Permit parents to provide support for each other as they navigate educational decisions, school communication, advocate for their child, and make social decisions</td> </tr> <tr> <td>Use a team approach to parenting, including shared responsibility for decision-making and child management<sup>[2]</sup></td> </tr> <tr> <td>Give siblings adequate time and attention</td> </tr> <tr> <td class=\"sublist1_start\">Listen to feelings </td> </tr> <tr> <td class=\"sublist1\">Look for outside support when necessary</td> </tr> <tr> <td class=\"sublist1\">Parent support groups</td> </tr> <tr> <td class=\"sublist1\">Individual, marriage, and family counseling</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Smith C, Strick L. Strategies for Promoting Personal Success. In: Learning Disabilities: A to Z: A parent's complete guide to learning disabilities from preschool to adulthood, The Free Press, a division of Simon &amp; Schuster, Inc., New York 1997. p.257.<br /><ol><li>Lock RH, Janas M. Build Resiliency. Intervention in School & Clinic 2002; 38:117.</li>&#xD;&#xA;<li>Lerner J. Learning Disabilities: Theories, Diagnosis, and Teaching Strategies, Houghton Mifflin Company, Boston 2000.</li></ol></div><div id=\"graphicVersion\">Graphic 72848 Version 2.0</div></div></div>"},"72850":{"type":"graphic_figure","displayName":"BG in postprandial hypoglycemia","title":"Lack of correlation between symptoms and plasma glucose in postprandial hypoglycemia","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Lack of correlation between symptoms and plasma glucose in postprandial hypoglycemia</div><div class=\"cntnt\"><img style=\"width:534px; height:442px;\" src=\"images/ENDO/72850_BG_in_postprandial_hypoglyc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma glucose concentrations and possible hypoglycemic symptoms in a patient with postprandial symptoms who was studied after oral glucose administration (dashed blue curve) and a more physiologic mixed meal (red curve). After oral glucose, symptoms occurred at both the peak and nadir of the plasma glucose responses. Similar symptoms occurred after the mixed meal even though there were no episodes of hypoglycemia. These observations indicate that the postprandial symptoms were not due to hypoglycemia. To convert plasma glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Data from: Hogan MJ, Service FJ, Sharbrough FW, Gerich JE. Oral glucose tolerance test compared with a mixed meal in the diagnosis of reactive hypoglycemia. A caveat on stimulation. Mayo Clin Proc 1983; 58:491.</div><div id=\"graphicVersion\">Graphic 72850 Version 3.0</div></div></div>"},"72854":{"type":"graphic_table","displayName":"Comparison of modalities","title":"Comparison of argon plasma coagulation, electrocautery, and cryotherapy via flexible bronchoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of argon plasma coagulation, electrocautery, and cryotherapy via flexible bronchoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Argon plasma coagulation</td>\n<td class=\"subtitle1\">Electrocautery</td>\n<td class=\"subtitle1\">Cryotherapy</td>\n</tr>\n\n<tr>\n<td>Immediate effect</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n\t\n<tr>\n<td>Hemoptysis control</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>Yes</td>\n</tr>\n\n<tr>\n<td>Fire risk</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n\n<tr>\n<td>Foreign body removal</td>\n<td>No</td>\n<td>No</td>\n<td>Yes</td>\n</tr>\n\n<tr>\n<td>Mucous plug removal</td>\n<td>No</td>\n<td>No</td>\n<td>Yes</td>\n</tr>\n\n<tr>\n<td>Effect on bronchial wall</td>\n<td>Scar</td>\n<td><p>Scar</p><p>Stricture</p></td>\n<td>No</td>\n</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72854 Version 2.0</div></div></div>"},"72855":{"type":"graphic_table","displayName":"Selected food sources of folate and folic acid","title":"Selected food sources of folate and folic acid","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected food sources of folate and folic acid</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Micrograms (&#181;g)</td> </tr> <tr> <td>Breakfast cereals fortified with 100 percent of the DV, &#190; cup*</td> <td>400</td> </tr> <tr> <td>Beef liver, cooked, braised, 3 ounces</td> <td>185</td> </tr> <tr> <td>Cowpeas (blackeyes), immature, cooked, boiled, &#189; cup</td> <td>105</td> </tr> <tr> <td>Breakfast cereals, fortified with 25 percent of the DV, &#190; cup*</td> <td>100</td> </tr> <tr> <td>Spinach, frozen, cooked, boiled, &#189; cup</td> <td>100</td> </tr> <tr> <td>Great Northern beans, boiled, &#189; cup</td> <td>90</td> </tr> <tr> <td>Asparagus, boiled, 4 spears</td> <td>85</td> </tr> <tr> <td>Rice, white, long-grain, parboiled, enriched, cooked, &#189; cup*</td> <td>65</td> </tr> <tr> <td>Vegetarian baked beans, canned, 1 cup</td> <td>60</td> </tr> <tr> <td>Spinach, raw, 1 cup</td> <td>60</td> </tr> <tr> <td>Green peas, frozen, boiled, &#189; cup</td> <td>50</td> </tr> <tr> <td>Broccoli, chopped, frozen, cooked, &#189; cup</td> <td>50</td> </tr> <tr> <td>Egg noodles, cooked, enriched, &#189; cup*</td> <td>50</td> </tr> <tr> <td>Broccoli, raw, 2 spears (each 5 inches long)</td> <td>45</td> </tr> <tr> <td>Avocado, raw, all varieties, sliced, &#189; cup sliced</td> <td>45</td> </tr> <tr> <td>Peanuts, all types, dry roasted, 1 ounce</td> <td>40</td> </tr> <tr> <td>Lettuce, Romaine, shredded, &#189; cup</td> <td>40</td> </tr> <tr> <td>Wheat germ, crude, 2 tablespoons</td> <td>40</td> </tr> <tr> <td>Tomato Juice, canned, 6 ounces</td> <td>35</td> </tr> <tr> <td>Orange juice, chilled, includes concentrate, &#190; cup</td> <td>35</td> </tr> <tr> <td>Turnip greens, frozen, cooked, boiled, &#189; cup</td> <td>30</td> </tr> <tr> <td>Orange, all commercial varieties, fresh, 1 small</td> <td>30</td> </tr> <tr> <td>Bread, white, 1 slice*</td> <td>25</td> </tr> <tr> <td>Bread, whole wheat, 1 slice*</td> <td>25</td> </tr> <tr> <td>Egg, whole, raw, fresh, 1 large</td> <td>25</td> </tr> <tr> <td>Cantaloupe, raw, &#188; medium</td> <td>25</td> </tr> <tr> <td>Papaya, raw, &#189; cup cubes</td> <td>25</td> </tr> <tr> <td>Banana, raw, 1 medium</td> <td>20</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=78718&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* Items marked with an asterisk (*) are fortified with folic acid as part of the Folate Fortification Program.</div><div class=\"graphic_reference\">Reproduced from: US Department of Agriculture, Agricultural Research Service 2003. USDA National Nutrient Database for Standard Reference, Release 16. Nutrient Data Laboratory Home Page, http://www.nal.usda.gov/fnic/cgi-bin/nut_search.pl.</div><div id=\"graphicVersion\">Graphic 72855 Version 2.0</div></div></div>"},"72857":{"type":"graphic_table","displayName":"ATS Dyspnea Treatment Guidelines","title":"American Thoracic Society Guidelines for the treatment of dyspnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Thoracic Society Guidelines for the treatment of dyspnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mild dyspnea</td> <td class=\"subtitle1\">Moderate dyspnea</td> <td class=\"subtitle1\">Severe dyspnea</td> </tr> <tr> <td> <p>Treat underlying disease*</p> Treat psychosocial factors<sup>&#182;</sup></td> <td> <p>Treat underlying disease</p> <p>Treat psychosocial factors</p> <p>Pulmonary rehabilitation<sup>&#916;</sup></p> Consider anxiolytic </td> <td> <p>Treat underlying disease</p> <p>Treat psychosocial factors</p> <p>Pulmonary rehabilitation</p> <p>Facial cooling (by use of fan)</p> <p>Opioids<sup>&#9674;</sup></p> <p>Anxiolytics</p> Noninvasive ventilation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Treat underlying disease includes anemia, pleural effusions, congestive heart failure, reversible airway obstruction, hypoxemia, main stem bronchial compression or obstruction.<br />Â¶ Treat psychosocial factors: For anxiety, use relaxation techniques, distraction, activity modifications, behavior modifications, and breathing strategies. For depression, use cognitive therapy, antidepressants, or a combination of both.<br />Î Pulmonary rehabilitation includes exercise training, psychosocial support, nutritional therapy, and self-management education, including breathing strategies, use of supplemental oxygen, pharmacologic therapy (to relieve airways obstruction), and panic control.<br /><FONT class=lozenge>â</FONT> Evidence indicates that they do not cause premature death in end-of-life patients when titrated to relieve pain or dyspnea.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2008 American Thoracic Society. Lanken PN, Terry PB, DeLisser HM, et al. An Official American Thoracic Society Clinical Policy Statement: Palliative Care for Patients with Respiratory Diseases and Critical Illnesses. American Journal of Respiratory Critical Care Medicine 2008; 177:912. Official Journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 72857 Version 4.0</div></div></div>"},"72858":{"type":"graphic_diagnosticimage","displayName":"MRI extranodal NK-T cell lymphoma nasal type","title":"Magnetic resonance imaging of extranodal NK/T cell lymphoma, nasal type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of extranodal NK/T cell lymphoma, nasal type</div><div class=\"cntnt\"><img style=\"width:380px; height:466px;\" src=\"images/HEME/72858_MRIextranodalNKTL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nuclear magnetic resonance scan showing NK-cell lymphoma in the midline nasal cavity.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Jaffe ES, Liang RH, et al. Mature nodal and extranodal T-cell and natural killer-cell lymphomas. In: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 72858 Version 9.0</div></div></div>"},"72859":{"type":"graphic_picture","displayName":"Side leg raise exercise","title":"Strength exercise: Side leg raise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Side leg raise</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/72859_Side_leg_raise_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise strengthens hips, thighs, and buttocks. For an added challenge, you can modify the exercise to improve your balance.   <OL>  <LI>Stand behind a sturdy chair with feet slightly apart, holding on for balance. Breathe in slowly. </LI>  <LI>Breathe out and slowly lift one leg out to the side. Keep your back straight and your toes facing forward. The leg you are standing on should be slightly bent. </LI>  <LI>Hold position for one second. </LI>  <LI>Breathe in as you slowly lower your leg. </LI>  <LI>Repeat 10 to 15 times. </LI>  <LI>Repeat 10 to 15 times with other leg. </LI>  <LI>Repeat 10 to 15 more times with each leg. </LI></OL>As you progress, you may want to add ankle weights.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 72859 Version 3.0</div></div></div>"},"72862":{"type":"graphic_movie","displayName":"Hyperopia farsightedness","title":"Hyperopia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperopia</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72862_hyperopconv.mp4\" style=\"width:336px;height:226px\"></div><img style=\"width:334px; height:209px;\" src=\"images/CARD/72862_hyperop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperopia is also known as farsightedness. The image of an object twenty feet or more away (optical infinity) is focused behind the retina resulting in blurry near vision.</div><div class=\"graphic_reference\">Reproduced with permission from: The University of Michigan Kellogg Eye Center, www.kellogg.umich.edu.</div><div id=\"graphicVersion\">Graphic 72862 Version 4.0</div></div></div>"},"72863":{"type":"graphic_waveform","displayName":"ECG third degree or complete AV block","title":"Single-lead electrocardiogram (ECG) showing sinus rhythm with third degree (complete) AV block","html":"<div class=\"graphic normal\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing sinus rhythm with third degree (complete) AV block</div><div class=\"cntnt\"><img style=\"width:527px; height:141px;\" src=\"images/CARD/72863_Complete_heart_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm with third degree (complete) heart block. There is independent atrial (as shown by the P waves) and ventricular activity, with respective rates of 83 and 43 beats per minute. The wide QRS complexes may represent a junctional escape rhythm with underlying bundle branch block or an idioventricular pacemaker.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 72863 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"72864":{"type":"graphic_picture","displayName":"Contact dermatitis eyelids","title":"Contact dermatitis of the periorbital skin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis of the periorbital skin</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/ALLRG/72864_Contactdermeyelidsedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intense erythema and edema with vesiculation in this patient with allergic contact dermatitis of the eyelids.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72864 Version 7.0</div></div></div>"},"72865":{"type":"graphic_table","displayName":"Rx recs antiemetic IV chemo","title":"Recommended antiemetic prophylaxis for intravenously administered chemotherapy in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended antiemetic prophylaxis for intravenously administered chemotherapy in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Dosing on day of chemotherapy</td> <td class=\"subtitle1\">Dosing on subsequent days</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"17\"> <p><strong>High emetic risk</strong>*<br /> (&#62;90 percent)</p> <p class=\"indent1\"><em><strong>Option 1</strong></em></p> </td> <td colspan=\"3\"><strong>NK<sub>1</sub>R antagonist (one of following)</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Aprepitant </li> </ul> </td> <td>125 mg oral</td> <td>80 mg oral daily; days 2 and 3</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Fosaprepitant </li> </ul> </td> <td>150 mg IV</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Rolapitant </li> </ul> </td> <td>180 mg oral or 166.5 mg IV</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><em><strong>PLUS</strong></em></td> </tr> <tr> <td colspan=\"3\"><strong>5-HT<sub>3</sub> antagonist (one of following)</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Granisetron </li> </ul> </td> <td>2 mg oral; 1 mg or 0.01 mg/kg IV; 10 mg SQ</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Ondansetron </li> </ul> </td> <td>8 mg oral twice daily; 8 mg or 0.15 mg/kg IV</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Palonosetron </li> </ul> </td> <td>0.5 mg oral; 0.25 mg IV</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Dolasetron </li> </ul> </td> <td>100 mg oral ONLY</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Tropisetron </li> </ul> </td> <td>5 mg oral; 5 mg IV</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Ramosetron </li> </ul> </td> <td>0.3 mg IV</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><em><strong>PLUS</strong></em></td> </tr> <tr> <td colspan=\"3\"><strong>Glucocorticoid</strong><sup>&#182;</sup></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Dexamethasone </li> </ul> </td> <td>12 mg oral or IV (20 mg orally if using rolapitant)</td> <td>8 mg oral or IV daily; days 2 to 4<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><em><strong>PLUS</strong></em></td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Olanzapine </li> </ul> </td> <td>5 to 10 mg<sup>&#9674;</sup></td> <td>5 to 10 mg daily; days 2 to 4<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"> <p><strong>High emetic risk</strong>*<br /> (&#62;90 percent)</p> <p class=\"indent1\"><em><strong>Option 2</strong></em></p> </td> <td><strong>NEPA</strong> (netupitant plus palonosetron)</td> <td>Once</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><em><strong>PLUS</strong></em></td> </tr> <tr> <td colspan=\"3\"><strong>Glucocorticoid</strong><sup>&#182;</sup></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Dexamethasone </li> </ul> </td> <td>12 mg oral or IV</td> <td>8 mg oral daily on days 2 to 4 (cisplatin only<sup>&#167;</sup>)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><em><strong>PLUS</strong></em></td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Olanzapine </li> </ul> </td> <td>5 to 10 mg<sup>&#9674;</sup></td> <td>5 to 10 mg daily; days 2 to 4<sup>&#9674;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Moderate emetic risk</strong><sup>&#165;</sup><sup>&#135;</sup><br /> (31 to 90 percent)</td> <td colspan=\"3\"><strong>5-HT<sub>3</sub> antagonist</strong></td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Palonosetron<sup>&#134;</sup> </li> </ul> </td> <td>0.5 mg oral; 0.25 mg IV</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"><em><strong>PLUS</strong></em></td> </tr> <tr> <td colspan=\"3\"><strong>Glucocorticoid</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Dexamethasone </li> </ul> </td> <td>8 mg oral or IV</td> <td>8 mg oral or IV daily; days 2 and 3<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Low emetic risk</strong><br /> (10 to 30 percent)</td> <td colspan=\"3\"><strong>Glucocorticoid</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Dexamethasone </li> </ul> </td> <td>4 to 8 mg oral or IV</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Minimal emetic risk</strong><br /> (&#60;10 percent)</td> <td>None</td> <td>None</td> <td>None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NK<SUB>1</SUB>R: neurokinin 1 receptor; IV: intravenous; 5-HT<SUB>3</SUB>: 5-hydroxytryptamine-3; SQ: subcutaneous.<br />* Includes combination of an anthracycline and cyclophosphamide.<br />Â¶ The dexamethasone dose is for patients who are receiving the recommended regimen that contains an NK<SUB>1</SUB>R antagonist for highly emetic chemotherapy. If patients do not receive an NK<SUB>1</SUB>R antagonist, the dexamethasone dose should be adjusted to 20 mg on day 1 and 16 mg daily&nbsp;on days 2 to 4.<br />Î For patients receiving anthracycline/cyclophosphamide for breast cancer or a carboplatin-containing regimen, delete day 2 to 3 of dexamethasone.<br /><FONT class=lozenge>â</FONT> 5 mg dose of olanzapine preferred for most patients because of less sedation.<br />Â§ When NEPA is used on day 1, multiday administration of glucocorticoids is only used in the delayed phase period with cisplatin. For anthracycline/cyclophosphamide combinations, administer glucocorticoids on day 1 only. If a first-generation 5-HT<SUB>3</SUB> antagonist is used on day 1 rather than palonosetron, treatment with a first-generation 5-HT<SUB>3</SUB> antagonist alone on days 2 and 3 is an acceptable alternative.<br />Â¥ Clinicians who choose to use an NK<SUB>1</SUB>R antagonist for a moderate risk regimen should follow recommendations for high emetic risk chemotherapy regimens. Importantly, corticosteroid is only given on day 1; the dexamethasone dose is lower (12 mg).<br />â¡ Also appropriate for anthracycline/cyclophosphamide-containing chemotherapy in diseases other than breast cancer.<br />â  If palonosetron is not available, substitute a first-generation 5-HT<SUB>3</SUB> antagonist, preferably granisetron or ondansetron.</div><div class=\"graphic_reference\">Modified from:<br /><OL>&#xD;&#xA;<LI>Hesketh P, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update&nbsp;J Clin Oncol 2017.</LI>&#xD;&#xA;<LI>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 72865 Version 17.0</div></div></div>"},"72866":{"type":"graphic_picture","displayName":"Bullous pemphigoid multiple lesions","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/72866_Bullous_pemphigoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous plaques, bullae, erosions, and crusts on the trunk and extremity skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.&nbsp;&nbsp;</div><div id=\"graphicVersion\">Graphic 72866 Version 4.0</div></div></div>"},"72867":{"type":"graphic_table","displayName":"Complementary therapies","title":"Complementary and alternative therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complementary and alternative therapies</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Acupuncture</td>\n   </tr>\n   <tr>\n   <td>Ayurveda</td>\n   </tr>\n   <tr>\n   <td>Biofeedback</td>\n   </tr>\n   <tr>\n   <td>Chelation</td>\n   </tr>\n   <tr>\n   <td>Chiropractic</td>\n   </tr>\n   <tr>\n   <td>Energy healing/Reiki</td>\n   </tr>\n   <tr>\n   <td>Folk medicine</td>\n   </tr>\n   <tr>\n   <td>Herbs</td>\n   </tr>\n   <tr>\n   <td>High dose vitamins</td>\n   </tr>\n   <tr>\n   <td>Homeopathy</td>\n   </tr>\n   <tr>\n   <td>Hypnosis</td>\n   </tr>\n   <tr>\n   <td>Massage</td>\n   </tr>\n   <tr>\n   <td>Naturopathy</td>\n   </tr>\n   <tr>\n   <td>Qigong</td>\n   </tr>\n   <tr>\n   <td>Relaxation techniques</td>\n   </tr>\n   <tr>\n   <td>Special diets</td>\n   </tr>\n   <tr>\n   <td>Tai Chi</td>\n   </tr>\n   <tr>\n   <td>Yoga</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in the use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005; 11:42.</div><div id=\"graphicVersion\">Graphic 72867 Version 2.0</div></div></div>"},"72868":{"type":"graphic_table","displayName":"Comparison of reconstructive materials","title":"Comparison of reconstructive materials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of reconstructive materials</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Graft type</td>\n\t\t\t\t\t<td class=\"subtitle1\">Advantages</td>\n\t\t\t\t\t<td class=\"subtitle1\">Disadvantages</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Synthetic</td>\n\t\t\t\t\t<td><p>Accessible: easy to manufacture and obtain</p>\n\t\t\t\t\t\t<p>Consistent: materials are reproducible</p>\n\t\t\t\t\t\t<p>Durable</p>\n\t\t\t\t\t\t<p>Cost-effective: less expensive to produce than allo- and xenografts</p></td>\n\t\t\t\t\t<td><p>Infection: microporous and multifilament grafts in particular</p>\n\t\t\t\t\t\t<p>Erosion: may erode into vagina or viscus</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Autograft</td>\n\t\t\t\t\t<td><p>Host response: no risk of rejection</p>\n\t\t\t\t\t\t<p>No erosion risk: although permanent sutures used to secure may erode</p>\n\t\t\t\t\t\t<p>Cost-effective</p></td>\n\t\t\t\t\t<td><p>Limited tissue quantity and quality possible</p>\n\t\t\t\t\t\t<p>Morbidity: tissue harvest required</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Allograft</td>\n\t\t\t\t\t<td><p>Accessible: larger quantities available than autografts, but depends on donor supply</p>\n\t\t\t\t\t\t<p>No harvest morbidity</p>\n\t\t\t\t\t\t<p>Low erosion risk</p></td>\n\t\t\t\t\t<td><p>Infection: theoretical risk of transmission of host pathogens</p>\n\t\t\t\t\t\t<p>Host response: potential for rejection</p>\n\t\t\t\t\t\t<p>Inconsistent graft strength</p>\n\t\t\t\t\t\t<p>Limited durability: processing may weaken material</p>\n\t\t\t\t\t\t<p>Limited ability to compare among materials</p>\n\t\t\t\t\t\t<p>Expensive</p></td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Xenograft</td>\n\t\t\t\t\t<td><p>Accessible: larger quantities available than autografts</p>\n\t\t\t\t\t\t<p>No harvest morbidity</p>\n\t\t\t\t\t\t<p>Low erosion risk</p></td>\n\t\t\t\t\t<td><p>Infection: theoretical risk of transmission of host pathogens</p>\n\t\t\t\t\t\t<p>Host response: potential for rejection given nonhuman source</p>\n\t\t\t\t\t\t<p>Inconsistent graft strength</p>\n\t\t\t\t\t\t<p>Limited durability: processing may weaken material</p>\n\t\t\t\t\t\t<p>Cultural issues with porcine or bovine products</p>\n\t\t\t\t\t\t<p>Expensive</p></td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72868 Version 2.0</div></div></div>"},"72870":{"type":"graphic_picture","displayName":"Congenital cholesteatoma","title":"Congenital cholesteatoma of the anterosuperior quadrant (right ear)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital cholesteatoma of the anterosuperior quadrant (right ear)</div><div class=\"cntnt\"><img style=\"width:396px; height:371px;\" src=\"images/ALLRG/72870_Congenitalcholesteatoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital cholesteatoma of the anterosuperior quadrant. A white mass (arrows) behind an intact drum.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 120, Pages 603-8, Copyright Â© 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 72870 Version 16.0</div></div></div>"},"72871":{"type":"graphic_waveform","displayName":"Recordings suck swallow","title":"Simultaneous recordings of suction, expression, swallowing, and respiration from an eight-day-old term infant","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Simultaneous recordings of suction, expression, swallowing, and respiration from an eight-day-old term infant</div><div class=\"cntnt\"><img style=\"width:517px; height:200px;\" src=\"images/PEDS/72871_Recordings_suck_swallow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time markers are in seconds.</div><div class=\"graphic_reference\">Reproduced with permission from: Lau C, Schanler RJ. Oral motor function in the neonate. Clin Perinatol 1996; 23:161. Copyright Â© 1996 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 72871 Version 4.0</div></div></div>"},"72872":{"type":"graphic_table","displayName":"Types of moisturizers","title":"Types of moisturizers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of moisturizers</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Action</td>\r\n                    <td class=\"subtitle1\">Mechanism of action</td>\r\n                    <td class=\"subtitle1\">Indication</td>\r\n                    <td class=\"subtitle1\">Examples</td>\r\n                    <td class=\"subtitle1\">Comments</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Occulsive</td>\r\n                    <td>Blocks transepidermal water loss<br />\r\n                    Barrier</td>\r\n                    <td>Xerosis<br />\r\n                    Atopic dermatitis<br />\r\n                    Prevention of irritant contact dermatitis</td>\r\n                    <td>Petrolatum<br />\r\n                    Zinc oxide<br />\r\n                    Lanolin<br />\r\n                    Mineral oil<br />\r\n                    Silicones</td>\r\n                    <td>Messy, comedogenic<br />\r\n                    Cosmetically unacceptable<br />\r\n                    May cause folliculitis (mineral oil) or contact dermatitis (lanolin)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Humectant</td>\r\n                    <td>Attracts water to stratum corneum</td>\r\n                    <td>Xerosis<br />\r\n                    Icthyosis</td>\r\n                    <td>Urea<br />\r\n                    Alpha hydroxy acids<br />\r\n                    Glycerin<br />\r\n                    Sorbital<br />\r\n                    Lactic acid</td>\r\n                    <td>May cause irritation (urea, lactic acid)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Emollient</td>\r\n                    <td>Smooths skin</td>\r\n                    <td>Decrease skin roughness</td>\r\n                    <td>Cholesterol<br />\r\n                    Squalene<br />\r\n                    Fatty acids</td>\r\n                    <td>Not always effective</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Replacement of deficiencies in \"raw materials\" of the intact stratum corneum</td>\r\n                    <td>Claims to replenish essential skin components</td>\r\n                    <td>Possibly skin rejuvenation</td>\r\n                    <td>\r\n                    <p>Ceramides, natural moisturizing factor</p>\r\n                    </td>\r\n                    <td>May improve skin moisturization and barrier function, but unproven</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=56703&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">Adapted from Lynde CW. Moisturizers: what they are and how they work. Skin Therapy Lett 2001; 6:3.</div><div id=\"graphicVersion\">Graphic 72872 Version 3.0</div></div></div>"},"72874":{"type":"graphic_figure","displayName":"Anatomy of the anal canal and rectum","title":"Anatomy of the anal canal and rectum","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Anatomy of the anal canal and rectum</div><div class=\"cntnt\"><img style=\"width:530px; height:540px;\" src=\"images/SURG/72874_ARF_anal_region_anat_edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the anatomy of the rectum and anal canal. Note the anal crypts and glands; 90 percent of anorectal fistulas originate in a cryptoglandular abscess. Also note the relationship of the crypts and glands to the internal and external sphincters.</div><div id=\"graphicVersion\">Graphic 72874 Version 5.0</div></div></div>"},"72875":{"type":"graphic_picture","displayName":"Tuberous xanthoma","title":"Tuberous xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberous xanthoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/72875_Tuberous_xanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow papules on the elbow in a case of tuberous xanthoma.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72875 Version 4.0</div></div></div>"},"72877":{"type":"graphic_movie","displayName":"Phonocardiogram of bicuspid AS at apex","title":"Carotid artery pulse tracing and phonocardiogram of aortic stenosis with bicuspid AS","html":"<div class=\"graphic normal\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Carotid artery pulse tracing and phonocardiogram of aortic stenosis with bicuspid AS</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/72877_asbapexconv.mp4\" style=\"width:564px;height:378px\"></div><img style=\"width:561px; height:221px;\" src=\"images/CARD/72877_asbapex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid artery pulse tracing and phonocardiogram of aortic stenosis as heard at the apex. S1 (mitral and tricuspid valve closure) is followed by an ejection click from the opening of the stenotic aortic valve. A faint mid systolic murmur of aortic stenosis is heard. S2 is single as a result of delayed aortic valve closure which occurs simultaneously with closure of the pulmonic valve.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 72877 Version 4.0</div></div></div>"},"72878":{"type":"graphic_waveform","displayName":"Defibrillation waveforms","title":"Defibrillation waveforms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Defibrillation waveforms</div><div class=\"cntnt\"><img style=\"width:333px; height:495px;\" src=\"images/CARD/72878_Defibrillation_waveforms.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission by Mittal, S, Ayati, S, Stein, KM, et al, Circulation 2000; 101:1282.</div><div id=\"graphicVersion\">Graphic 72878 Version 2.0</div></div></div>"},"72880":{"type":"graphic_diagnosticimage","displayName":"Proximal cholangiocarcinoma MRCP","title":"Hilar cholangiocarcinoma as seen on MRCP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hilar cholangiocarcinoma as seen on MRCP</div><div class=\"cntnt\"><img style=\"width:245px; height:281px;\" src=\"images/ONC/72880_Proximal_cholangioCA_MRCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This magnetic resonance cholangiopancreatography (MRCP) image depicts an intrabiliary filling defect (arrow) due to a hilar papillary cholangiocarcinoma.</div><div id=\"graphicVersion\">Graphic 72880 Version 3.0</div></div></div>"},"72881":{"type":"graphic_waveform","displayName":"ECG anomalous left coronary","title":"An electrocardiogram obtained from a patient with anomalous left main coronary artery arising from the pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An electrocardiogram obtained from a patient with anomalous left main coronary artery arising from the pulmonary artery</div><div class=\"cntnt\"><img style=\"width:337px; height:303px;\" src=\"images/PEDS/72881_ECG_anomalous_left_coronary.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a pattern of anterolateral infarction with deep wide Q waves in the anterior (I, aVL) and lateral (V5, V6) leads. There are T wave inversions in these leads as well.</div><div class=\"graphic_reference\">Courtesy of Robert L Geggel, MD.</div><div id=\"graphicVersion\">Graphic 72881 Version 3.0</div></div></div>"},"72882":{"type":"graphic_diagnosticimage","displayName":"Crohn abscess CT","title":"Right lower quadrant abscess in Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right lower quadrant abscess in Crohn disease</div><div class=\"cntnt\"><img style=\"width:376px; height:289px;\" src=\"images/GAST/72882_Crohns_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single axial CT scan of the lower abdomen demonstrates an abscess (arrowheads) extending from the markedly thickened and inflamed terminal ileum (arrow). The presence of contrast material within the abscess confirms a communication with the adjacent ileum.</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 72882 Version 3.0</div></div></div>"},"72883":{"type":"graphic_figure","displayName":"Continent colon pouch","title":"Continent colon pouch for pelvic exenteration","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Continent colon pouch for pelvic exenteration</div><div class=\"cntnt\"><img style=\"width:546px; height:456px;\" src=\"images/OBGYN/72883_Continent_colon_pouch.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72883 Version 2.0</div></div></div>"},"72887":{"type":"graphic_figure","displayName":"Nerve supply to leg","title":"Bony relationships of the nerve supply to the leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bony relationships of the nerve supply to the leg</div><div class=\"cntnt\"><img style=\"width:357px; height:519px;\" src=\"images/PC/72887_Nerve_supply_to_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission by Patten, J. Neurological Differential Diagnosis, 2nd ed, Springer, London 1996.</div><div id=\"graphicVersion\">Graphic 72887 Version 1.0</div></div></div>"},"72888":{"type":"graphic_figure","displayName":"Pravastatin is more effective in reducing MACE in women than men","title":"Pravastatin is more effective in reducing major adverse cardiac events in women than in men","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Pravastatin is more effective in reducing major adverse cardiac events in women than in men</div><div class=\"cntnt\"><img style=\"width:489px; height:275px;\" src=\"images/CARD/72888_Pravastatin_men_v_women_CAR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the CARE trial of patients with a recent history of myocardial infarction and average lipid levels, women had a greater reduction in coronary events (coronary death, nonfatal infarction, need for revascularization with angioplasty or surgery) with pravastatin, compared with placebo, than men (46 versus 20% reduction in men, p = 0.001 for both sexes).</div><div class=\"graphic_reference\">Redrawn from: Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32:140.</div><div id=\"graphicVersion\">Graphic 72888 Version 5.0</div></div></div>"},"72889":{"type":"graphic_figure","displayName":"Elbow ligaments and capsule","title":"Elbow ligaments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elbow ligaments</div><div class=\"cntnt\"><img style=\"width:333px; height:565px;\" src=\"images/EM/72889_Elbowligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The capsule and ligaments give stability to the elbow.</div><div class=\"graphic_reference\">Reproduced with permission from: Pring ME, Wenger DR, Rang M. Elbow: Proximal radius and ulna. In: Rang's Children's Fractures, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright Â© 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72889 Version 8.0</div></div></div>"},"72890":{"type":"graphic_figure","displayName":"Fall hazards PI","title":"How to avoid falling at home","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">How to avoid falling at home</div><div class=\"cntnt\"><img style=\"width:530px; height:551px;\" src=\"images/PI/72890_Fall-hazards-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows some of the things that can cause a fall in your home. Look around and remove any loose rugs, electrical cords, clutter, or furniture that could trip you.</div><div id=\"graphicVersion\">Graphic 72890 Version 1.0</div></div></div>"},"72892":{"type":"graphic_table","displayName":"Accuracy of cholangioscopy","title":"Cholangioscopy for malignant diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cholangioscopy for malignant diseases</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">PTBD (n)</td>\n<td class=\"subtitle1\">PTCS (n)</td>\n<td class=\"subtitle1\">Biopsy (n)</td>\n<td class=\"subtitle1\">Sensitivity (percent)</td>\n</tr>\n<tr>\n<td>Bile duct cancer</td>\n<td>270</td>\n<td>155</td>\n<td>141</td>\n<td>96</td>\n</tr>\n<tr>\n<td>Pancreatic cancer</td>\n<td>160</td>\n<td>81</td>\n<td>67</td>\n<td>67</td>\n</tr>\n<tr>\n<td>Gallbladder cancer</td>\n<td>134</td>\n<td>76</td>\n<td>63</td>\n<td>76</td>\n</tr>\n<tr>\n<td>Papillary cancer</td>\n<td>44</td>\n<td>34</td>\n<td>30</td>\n<td>90</td>\n</tr>\n<tr>\n<td>Liver cancer</td>\n<td>17</td>\n<td>11</td>\n<td>10</td>\n<td>90</td>\n</tr>\n<tr>\n<td>Recurrent and other cancers</td>\n<td>48</td>\n<td>28</td>\n<td>17</td>\n<td>35</td>\n</tr>\n<tr>\n<td class=\"subtitle2_left\">Total</td>\n<td>671</td>\n<td>385</td>\n<td>328</td>\n<td>82</td>\n</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">Results in 671 patients treated for hepatobiliary or pancreatic malignancies at Nagoya University Hospital from April 1977 to April 1997. All patients underwent percutaneous biliary drainage (PTBD) and 385 had percutaneous transhepatic cholangioscopy (PTCS) with biopsies. The sensitivity values refer to the yield of the biopsies obtained during PTCS, using the histopathology obtained during later surgery or repeat biopsy or the clinical course as the gold standard. The overall sensitivity of PTCS was 82 percent.</div><div class=\"graphic_reference\">Data from: Nimura Y, Kamiya J. Endoscopy 1998; 30:182.</div><div id=\"graphicVersion\">Graphic 72892 Version 2.0</div></div></div>"},"72893":{"type":"graphic_picture","displayName":"Haemophilus influenzae in sputum","title":"<em>Haemophilus influenzae</em> in sputum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Haemophilus influenzae</em> in sputum</div><div class=\"cntnt\"><img style=\"width:364px; height:240px;\" src=\"images/ID/72893_Haemophilus1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of sputum (x1000) shows inflammatory cells and very small gram-negative coccobacilli. <EM>Haemophilus influenzae </EM>grew from this specimen on chocolate agar and was shown to utilize X and V factors.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 72893 Version 4.0</div></div></div>"},"72897":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis femur","title":"Osteomyelitis of the femur","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis of the femur</div><div class=\"cntnt\"><img style=\"width:523px; height:485px;\" src=\"images/PEDS/72897_Osteomyelitis_femur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Plain radiograph of the pelvis demonstrates destructive lesion of the metaphysis of the proximal left femur.<br />(B,C) Magnetic resonance imaging demonstrates high signal in this area, indicative of osteomyelitis.</div><div class=\"graphic_reference\">Courtesy of the Department of Diagnostic Imaging, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 72897 Version 3.0</div></div></div>"},"72898":{"type":"graphic_algorithm","displayName":"Admin PCN to patient with immediate rxn ceph","title":"Administration of penicillin to a patient with a history of an immediate allergic reaction to a cephalosporin ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Administration of penicillin to a patient with a history of an immediate allergic reaction to a cephalosporin </div><div class=\"cntnt\"><img style=\"width:296px; height:213px;\" src=\"images/ALLRG/72898_Admin_pen_pt_hx_ceph.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Figure 1 in Ann Allergy Asthma Immunol 1999; 83: Suppl. Copyright &#169;1999 American College of Allergy, Asthma and Immunology.</div><div id=\"graphicVersion\">Graphic 72898 Version 2.0</div></div></div>"},"72899":{"type":"graphic_figure","displayName":"Esophageal acid clearance","title":"Esophageal acid clearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal acid clearance</div><div class=\"cntnt\"><img style=\"width:384px; height:397px;\" src=\"images/GAST/72899_Esophageal_acid_clearance.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Results of an acid clearance test performed with radiolabeled 0.1 N HCl. The calculation of bolus volume within the esophagus is derived from scintiscanning over the chest. DS denotes dry swallows. Although all but about 1 mL of the infused fluid is cleared from the esophagus by the first peristaltic contraction, the distal esophageal pH initially is still reduced. Stepwise increases in distal esophageal pH occur with subsequent swallows due in part to the delivery of salivary secretions.</div><div class=\"graphic_reference\">Data from: Helm JF, Dodds WJ, Pelc LR, et al. N Engl J Med 1984; 310:284.</div><div id=\"graphicVersion\">Graphic 72899 Version 3.0</div></div></div>"},"72901":{"type":"graphic_table","displayName":"ECOG performance scale","title":"Eastern Cooperative Oncology Group (ECOG, Zubrod, World Health Organization) performance scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eastern Cooperative Oncology Group (ECOG, Zubrod, World Health Organization) performance scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Performance status</td> <td class=\"subtitle1_single\">Definition</td> </tr> <tr> <td class=\"indent1\">0</td> <td>Fully active; no performance restrictions.</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Strenuous physical activity restricted; fully ambulatory and able to carry out light work.</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Capable of all self-care but unable to carry out any work activities. Up and about &#62;50% of waking hours.</td> </tr> <tr> <td class=\"indent1\">3</td> <td>Capable of only limited self-care; confined to bed or chair &#62;50% of waking hours.</td> </tr> <tr> <td class=\"indent1\">4</td> <td>Completely disabled; cannot carry out any self-care; totally confined to bed or chair.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649.</div><div id=\"graphicVersion\">Graphic 72901 Version 10.0</div></div></div>"},"72902":{"type":"graphic_table","displayName":"Medications for subacute or chronic low back pain","title":"Medications for subacute or chronic low back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications for subacute or chronic low back pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Net benefit*</td> <td class=\"subtitle1\">Graded recommendation<sup>&#182;</sup></td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Acetaminophen</td> <td>Small to none</td> <td>Suggested as alternative therapy in patients who cannot tolerate NSAIDs, although evidence of efficacy is&nbsp;lacking<strong> (2C)</strong></td> <td>Asymptomatic increased liver function tests at therapeutic doses</td> </tr> <tr> <td>Antiepileptic drugs</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2C)</strong></td> <td>Gabapentin, pregabalin,&nbsp;and topiramate evaluated in short-term trials, primarily in patients with radiculopathy</td> </tr> <tr> <td>Benzodiazepines&nbsp;</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Duloxetine&nbsp;</td> <td>Small</td> <td>Suggested as alternative regimen for patients with chronic low back pain who do not respond to NSAIDs <strong>(2B)</strong>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Nonbenzodiazepine skeletal muscle relaxants&nbsp;</td> <td>Unable to estimate</td> <td>Suggested&nbsp;as&nbsp;adjunctive therapy&nbsp;for patients with subacute low back pain who to not respond to NSAIDs<strong> (2C)</strong>&nbsp;</td> <td>Cyclobenzaprine is most the commonly prescribed drug</td> </tr> <tr> <td>NSAIDs</td> <td>Moderate</td> <td>Suggested as first-line therapy <strong>(2B)</strong></td> <td> <p>May cause serious gastrointestinal and cardiovascular adverse events</p> Insufficient evidence to judge benefits and harms of aspirin or celecoxib for low back pain</td> </tr> <tr> <td>Opioids</td> <td>Unable to estimate</td> <td>Suggest not using as first-line therapy <strong>(2C)</strong></td> <td>No reliable data on risks of abuse or addiction</td> </tr> <tr> <td>Tramadol&nbsp;</td> <td>Small to moderate</td> <td>Suggested as alternative therapy for patients with chronic low back pain&nbsp;who do not respond to NSAIDs <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Tricyclic antidepressants</td> <td>Unable to estimate</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs.<br />* Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5 to 10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1 to 2 points on the Roland Morris Disability Questionnaire (RDQ), 10 to 20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2 to 0.5. Moderate benefit defined as 10 to 20 points on a VAS for pain, 2 to 5 points on the RDQ, 10 to 20 points on the ODI, or a SMD of 0.5 to 0.8. Large benefit defined as &gt;20 points on a 100-point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.<br />Â¶ Grading:<br /><STRONG>1A</STRONG> - Strong recommendation. High-quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.<br /><STRONG>1B</STRONG> - Strong recommendation. Moderate-quality evidence. Strong recommendation, likely to apply to most patients.<br /><STRONG>1C</STRONG> - Strong recommendation. Low-quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.<br /><STRONG>2A</STRONG> - Weak recommendation. High-quality evidence. Weak recommendation, best action may differ depending on circumstances or patients or societal values.<br /><STRONG>2B</STRONG> - Weak recommendation. Moderate-quality evidence. Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.<br /><STRONG>2C</STRONG> - Weak recommendation. Low-quality evidence. Very weak recommendation; other alternatives may be equally reasonable.<br />Â§ Due to safety profile.</div><div id=\"graphicVersion\">Graphic 72902 Version 7.0</div></div></div>"},"72905":{"type":"graphic_figure","displayName":"Numeric pain scale 0 to 10","title":"Numeric pain scale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Numeric pain scale</div><div class=\"cntnt\"><img style=\"width:430px; height:117px;\" src=\"images/SURG/72905_Numeric_pain_scale.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numeric pain scale allows patients to rate the pain on a scale of 0 to 10, with 10 as the worst possible pain.</div><div id=\"graphicVersion\">Graphic 72905 Version 2.0</div></div></div>"},"72906":{"type":"graphic_figure","displayName":"Bunion PI","title":"Bunion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bunion</div><div class=\"cntnt\"><img style=\"width:443px; height:569px;\" src=\"images/PI/72906_Bunion-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bunion is a bony, often painful bump on the outer edge of the big toe.</div><div id=\"graphicVersion\">Graphic 72906 Version 1.0</div></div></div>"},"72907":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus histopathology","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/72907_paraneo_pemphigus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suprabasal acantholysis in paraneoplastic pemphigus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72907 Version 3.0</div></div></div>"},"72911":{"type":"graphic_table","displayName":"Clin finding 22q11 deletion","title":"Nonimmunologic clinical findings in patients with chromosome 22q11.2 deletion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonimmunologic clinical findings in patients with chromosome 22q11.2 deletion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nonimmunologic clinical findings</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td>Palatal anomalies&nbsp;</td> <td>69 to 100</td> </tr> <tr> <td>Speech delay</td> <td>79 to 90</td> </tr> <tr> <td>Learning disabilities</td> <td>45 to 90</td> </tr> <tr> <td>Cardiac abnormalities</td> <td>49 to 83</td> </tr> <tr> <td>Developmental delay</td> <td>75</td> </tr> <tr> <td>Ophthalmologic abnormalities</td> <td>7 to 70</td> </tr> <tr> <td>Hypocalcemia</td> <td>17 to 60</td> </tr> <tr> <td>Psychiatric disorders</td> <td>9 to 60</td> </tr> <tr> <td>Skeletal abnormalities</td> <td>17 to 45</td> </tr> <tr> <td>Renal abnormalities</td> <td>31 to 37</td> </tr> <tr> <td>Short stature</td> <td>20</td> </tr> <tr> <td>Neurologic </td> <td>8</td> </tr> <tr> <td>Dental</td> <td>2.5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: J Med Genet 1997; 34:798; Am J Med Genet 1992; 42:141; J Med Genet 1997; 34:453; Am J Med Genet 1999; 85:127; J Pediatr 1999; 134:193; Am J Med Genet 1998; 81:41; Genet Couns 1999; 10:3; Dev Med Child Neurol 2000; 42:422; Genet Couns 1999; 10:11; J Pediatr 1993; 123:406; J Pediatr 2011; 159:332.</div><div id=\"graphicVersion\">Graphic 72911 Version 2.0</div></div></div>"},"72913":{"type":"graphic_table","displayName":"2010 TNM staging colorectal CA","title":"TNM staging for colorectal cancer, 7th edition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging for colorectal cancer, 7th edition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Primary tumor (T)</td> </tr> <tr> <td>TX</td> <td colspan=\"5\">Primary tumor cannot be assessed</td> </tr> <tr> <td>T0</td> <td colspan=\"5\">No evidence of primary tumor</td> </tr> <tr> <td>Tis</td> <td colspan=\"5\">Carcinoma in situ: intraepithelial or invasion of lamina propria*</td> </tr> <tr> <td>T1</td> <td colspan=\"5\">Tumor invades submucosa</td> </tr> <tr> <td>T2</td> <td colspan=\"5\">Tumor invades muscularis propria</td> </tr> <tr> <td>T3</td> <td colspan=\"5\">Tumor invades through the muscularis propria into pericolorectal tissues</td> </tr> <tr> <td>T4a</td> <td colspan=\"5\">Tumor penetrates to the surface of the visceral peritoneum<sup>&#182;</sup></td> </tr> <tr> <td>T4b</td> <td colspan=\"5\">Tumor directly invades or is adherent to other organs or structures<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Regional lymph node (N)<sup>&#9674;</sup></td> </tr> <tr> <td>NX</td> <td colspan=\"5\">Regional lymph nodes cannot be assessed</td> </tr> <tr> <td>N0</td> <td colspan=\"5\">No regional lymph node metastasis</td> </tr> <tr> <td class=\"sublist1_start\">N1</td> <td class=\"sublist_other_start\" colspan=\"5\">Metastasis in&nbsp;one to three&nbsp;regional lymph nodes</td> </tr> <tr> <td class=\"sublist1\">N1a</td> <td class=\"sublist_other\" colspan=\"5\">Metastasis in one regional lymph node</td> </tr> <tr> <td class=\"sublist1\">N1b</td> <td class=\"sublist_other\" colspan=\"5\">Metastasis in&nbsp;two to three&nbsp;regional lymph nodes</td> </tr> <tr> <td class=\"sublist1\">N1c</td> <td class=\"sublist_other\" colspan=\"5\">Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional nodal metastasis</td> </tr> <tr> <td>N2</td> <td colspan=\"5\">Metastasis in four or more regional lymph nodes</td> </tr> <tr> <td class=\"sublist1\">N2a</td> <td class=\"sublist_other\" colspan=\"5\">Metastasis in&nbsp;four to six&nbsp;regional lymph nodes</td> </tr> <tr> <td class=\"sublist1\">N2b</td> <td class=\"sublist_other\" colspan=\"5\">Metastasis in seven or more regional lymph nodes</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Distant metastasis (M)</td> </tr> <tr> <td>M0</td> <td colspan=\"5\">No distant metastasis</td> </tr> <tr> <td class=\"sublist1_start\">M1</td> <td class=\"sublist_other_start\" colspan=\"5\">Distant metastasis</td> </tr> <tr> <td class=\"sublist1\">M1a</td> <td class=\"sublist_other\" colspan=\"5\">Metastasis confined to one organ or site (eg, liver, lung, ovary, nonregional node)</td> </tr> <tr> <td class=\"sublist1\">M1b</td> <td class=\"sublist_other\" colspan=\"5\">Metastases in more than one organ/site or the peritoneum</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Anatomic stage/prognostic groups<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle2\">Stage</td> <td class=\"subtitle2\">T</td> <td class=\"subtitle2\">N</td> <td class=\"subtitle2\">M</td> <td class=\"subtitle2\">Dukes<sup>&#165;</sup></td> <td class=\"subtitle2\">MAC<sup>&#165;</sup></td> </tr> <tr> <td>0</td> <td>Tis</td> <td>N0</td> <td>M0</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td rowspan=\"2\">I</td> <td>T1</td> <td>N0</td> <td>M0</td> <td>A</td> <td>A</td> </tr> <tr> <td>T2</td> <td>N0</td> <td>M0</td> <td>A</td> <td>B1</td> </tr> <tr> <td>IIA</td> <td>T3</td> <td>N0</td> <td>M0</td> <td>B</td> <td>B2</td> </tr> <tr> <td>IIB</td> <td>T4a</td> <td>N0</td> <td>M0</td> <td>B</td> <td>B2</td> </tr> <tr> <td>IIC</td> <td>T4b</td> <td>N0</td> <td>M0</td> <td>B</td> <td>B3</td> </tr> <tr> <td rowspan=\"2\">IIIA</td> <td>T1 to T2</td> <td>N1/N1c</td> <td>M0</td> <td>C</td> <td>C1</td> </tr> <tr> <td>T1</td> <td>N2a</td> <td>M0</td> <td>C</td> <td>C1</td> </tr> <tr> <td rowspan=\"3\">IIIB</td> <td>T3 to T4a</td> <td>N1/N1c</td> <td>M0</td> <td>C</td> <td>C2</td> </tr> <tr> <td>T2 to T3</td> <td>N2a</td> <td>M0</td> <td>C</td> <td>C1/C2</td> </tr> <tr> <td>T1 to T2</td> <td>N2b</td> <td>M0</td> <td>C</td> <td>C1</td> </tr> <tr> <td rowspan=\"3\">IIIC</td> <td>T4a</td> <td>N2a</td> <td>M0</td> <td>C</td> <td>C2</td> </tr> <tr> <td>T3 to T4a</td> <td>N2b</td> <td>M0</td> <td>C</td> <td>C2</td> </tr> <tr> <td>T4b</td> <td>N1 to N2</td> <td>M0</td> <td>C</td> <td>C3</td> </tr> <tr> <td>IVA</td> <td>Any T</td> <td>Any N</td> <td>M1a</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>IVB</td> <td>Any T</td> <td>Any N</td> <td>M1b</td> <td>&ndash;</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa.<br />Â¶ Direct invasion in T4 includes invasion of other organs or other segments of the colorectum as a result of direct extension through the serosa, as confirmed on microscopic examination (for example, invasion of the sigmoid colon by a carcinoma of the cecum) or, for cancers in a retroperitoneal or subperitoneal location, direct invasion of other organs or structures by virtue of extension beyond the muscularis propria (ie, respectively, a tumor on the posterior wall of the descending colon invading the left kidney or lateral abdominal wall; or a mid- or distal rectal cancer with invasion of prostate, seminal vesicles, cervix, or vagina).<br />Î Tumor that is adherent to other organs or structures, grossly, is classified cT4b. However, if no tumor is present in the adhesion microscopically, the classification should be pT1-4a depending on the anatomical depth of wall invasion. The V and L classifications should be used to identify the presence or absence of vascular or lymphatic invasion whereas the PN site-specific factor should be used for perineural invasion.<br /><FONT class=lozenge>â</FONT> A satellite peritumoral nodule in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule may represent discontinuous spread, venous invasion with extravascular spread (V1/2), or a totally replaced lymph node (N1/2). Replaced nodes should be counted separately as positive nodes in the N category, whereas discontinuous spread or venous invasion should be classified and counted in the Site-Specific Factor category Tumor Deposits (TD).<br />Â§ cTNM is the clinical classification, pTNM is the pathologic classification. The y prefix is used for those cancers that are classified after neoadjuvant pretreatment (eg, ypTNM). Patients who have a complete pathologic response are ypT0N0cM0 that may be similar to Stage Group 0 or I. The r prefix is to be used for those cancers that have recurred after a disease-free interval (rTNM).<br />Â¥ Dukes B is a composite of better (T3 N0 M0) and worse (T4 N0 M0) prognostic groups, as is Dukes C (Any TN1 M0 and Any T N2 M0). MAC is the modified Astler-Coller classification.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 72913 Version 17.0</div></div></div>"},"72915":{"type":"graphic_diagnosticimage","displayName":"Esophageal tumor staging EUS","title":"Esophageal tumor staging with endoscopic ultrasound (EUS)","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Esophageal tumor staging with endoscopic ultrasound (EUS)</div><div class=\"cntnt\"><img style=\"width:530px; height:406px;\" src=\"images/GAST/72915_Esophageal_tumor_staging_EU.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Superficial esophageal carcinoma (T1b tumor) extending into the submucosa (third hyperechoic layer), but not into the muscularis propria (fourth layer).<br />Panel B: Esophageal tumor going into the muscularis propria (fourth hypoechoic layer) but not through, defining a T2 lesion by EUS criteria.<br />Panel C: Carcinoma of the esophagus extending through the esophageal wall and invading the adventitia (fifth layer) (T3 tumor).<br />Panel D: EUS image of an esophageal tumor going through the esophageal wall and extending into the pleural space, defining the tumor as a T4a lesion.</div><div class=\"graphic_reference\">Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 72915 Version 5.0</div></div></div>"},"72916":{"type":"graphic_picture","displayName":"Thrombosed external hemorrhoid","title":"Thrombosed external hemorrhoids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thrombosed external hemorrhoids</div><div class=\"cntnt\"><img style=\"width:300px; height:252px;\" src=\"images/GAST/72916_Thrombosed_external_hemorrh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph shows a swollen external hemorrhoid (arrows).</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Colon and Rectal Surgeons.</div><div id=\"graphicVersion\">Graphic 72916 Version 2.0</div></div></div>"},"72917":{"type":"graphic_figure","displayName":"Genetic basis for donor selection HCT","title":"Genetic basis for donor selection for hematopoietic cell transplantation","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Genetic basis for donor selection for hematopoietic cell transplantation</div><div class=\"cntnt\"><img style=\"width:530px; height:499px;\" src=\"images/HEME/72917_Donor_selection_HCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The above figure represents the genetic basis for donor selection. Every person has two sets of&nbsp;HLAs (haplotypes), which are located on chromosome 6; one set is derived from the father and one from the mother. These are shown in different colors, reflecting the vast HLA diversity among human subjects.<br />For any given mother and father there are four equally possible sets of HLA antigens in their children. On average, only one out of every four siblings (25%) will be fully HLA-matched with the patient requiring the transplantation, here shown in the black box. Two out of every four siblings (50%) will be haplotype matches only.<br />Note that all of the patient's children and both of the patient's parents will only be haplotype matches. It is unlikely that any of the patient's parents, children, or first cousins will be full HLA matches unless the involved families happen to have very common haplotypes or there has been intermarrying among their families.</div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Figure supplied by Dr. Robert S. Negrin, Stanford University School of Medicine.</div><div id=\"graphicVersion\">Graphic 72917 Version 5.0</div></div></div>"},"72919":{"type":"graphic_picture","displayName":"Convergence insufficiency","title":"Convergence insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Convergence insufficiency</div><div class=\"cntnt\"><img style=\"width:376px; height:520px;\" src=\"images/PEDS/72919_Convergence_insufficiency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) The patient is fixing on a near target with both eyes and single vision. B) When the target is moved a bit closer (too close for the patient to converge on the target), the left eye drifts, with resultant diplopia. The patient has a remote near point of convergence.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72919 Version 2.0</div></div></div>"},"72921":{"type":"graphic_algorithm","displayName":"Unconjugated bilirubin no anemia child","title":"Approach to the child with unconjugated hyperbilirubinemia who does not have anemia or hemolysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to the child with unconjugated hyperbilirubinemia who does not have anemia or hemolysis</div><div class=\"cntnt\"><img style=\"width:354px; height:293px;\" src=\"images/PEDS/72921_Unconj_bili_no_anem.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Mandl KD. Jaundice-Unconjugated Hyperbilirubinemia. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006.</div><div id=\"graphicVersion\">Graphic 72921 Version 11.0</div></div></div>"},"72922":{"type":"graphic_picture","displayName":"Silver nitrate cautery of anterior epistaxis","title":"Silver nitrate cautery of anterior epistaxis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Silver nitrate cautery of anterior epistaxis</div><div class=\"cntnt\"><img style=\"width:442px; height:308px;\" src=\"images/EM/72922_Silver_nitrate_cautery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Kesselbach's plexus is hyperemic with a slight suggestion of oozing. Note that the area for cauterization is dry.<br> (B) Successful cauterization of the area which now has a white eschar.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 72922 Version 2.0</div></div></div>"},"72923":{"type":"graphic_diagnosticimage","displayName":"Liver metastases on somatostatin receptor scintigraphy","title":"Liver metastases demonstrating high-grade radiotracer uptake on somatostatin receptor scintigraphy fused with SPECT/CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver metastases demonstrating high-grade radiotracer uptake on somatostatin receptor scintigraphy fused with SPECT/CT scan</div><div class=\"cntnt\"><img style=\"width:420px; height:315px;\" src=\"images/ONC/72923_Liver_metastases_OctreoScan.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SPECT: single photon emission computed tomography; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 72923 Version 4.0</div></div></div>"},"72924":{"type":"graphic_picture","displayName":"Glomus tumor subungual 2","title":"Subungual glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subungual glomus tumor</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/72924_Glom_tum_sunbung_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bluish-red flush of the nail induced by a glomus tumor of the nail bed.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 72924 Version 3.0</div></div></div>"},"72926":{"type":"graphic_picture","displayName":"S pneumoniae in CSF","title":"<em>Streptococcus pneumoniae</em> in cerebrospinal fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Streptococcus pneumoniae</em> in cerebrospinal fluid</div><div class=\"cntnt\"><img style=\"width:369px; height:240px;\" src=\"images/ID/72926_SpneumoniaeCSF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of cerebrospinal fluid (x1000) shows inflammatory cells and gram-positive diplococci. <EM>Streptococcus pneumoniae </EM>grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 72926 Version 5.0</div></div></div>"},"72928":{"type":"graphic_picture","displayName":"Pemphigoid gestationis 2","title":"Pemphigoid gestationis (herpes gestationis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigoid gestationis (herpes gestationis)</div><div class=\"cntnt\"><img style=\"width:432px; height:302px;\" src=\"images/OBGYN/72928_Pemphigoid_gestationis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The multiple urticarial plaques on the abdomen of this patient closely resemble the polymorphic eruption of pregnancy (PEP), also called pruritic urticarial papules and plaques of pregnancy (PUPPP).</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72928 Version 2.0</div></div></div>"},"72931":{"type":"graphic_table","displayName":"Immune defects and trauma","title":"Immune defects associated with trauma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immune defects associated with trauma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Lymphocytes</td> </tr> <tr> <td>Lymphopenia</td> </tr> <tr> <td>Cutaneous anergy</td> </tr> <tr> <td>Decreased CD4+ T cell count</td> </tr> <tr> <td>Inverted CD4/CD8 ratio</td> </tr> <tr> <td>Decreased mitogen-induced proliferation</td> </tr> <tr> <td>Decreased cytokine production</td> </tr> <tr> <td>Decreased natural killer cell activity</td> </tr> <tr> <td class=\"subtitle1_single\">Monocytes/macrophages</td> </tr> <tr> <td>Decreased expression of MHC class II and complement receptors</td> </tr> <tr> <td>Increased production of prostaglandin E<sub>2</sub> (suppressive for lymphocytes and neutrophils)</td> </tr> <tr> <td class=\"subtitle1_single\">Neutrophils</td> </tr> <tr> <td>Decreased chemotaxis</td> </tr> <tr> <td>Decreased phagocytosis</td> </tr> <tr> <td>Decreased respiratory burst</td> </tr> <tr> <td>Decreased expression of integrins</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MHC: major histocompatibility complex.</div><div class=\"graphic_reference\">Adapted from Faist E, Schinkel C, Zimmer S. World J Surg 1996; 20:454.</div><div id=\"graphicVersion\">Graphic 72931 Version 2.0</div></div></div>"},"72932":{"type":"graphic_table","displayName":"Endotracheal tube size formula","title":"Age-based formula for selecting endotracheal tube size (internal diameter in mm)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-based formula for selecting endotracheal tube size (internal diameter in mm)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Uncuffed tube </td> <td class=\"subtitle1\">Cuffed tube*</td> </tr> <tr> <td>4 + (age in years/4)</td> <td>3.5 + (age in years/4) </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Additional tubes one size larger and one size smaller than calculated should also be available. </div><div class=\"graphic_footnotes\">*Use formula for children 2 years of age and older. Use 3.5 mm internal diameter&nbsp;cuffed endotracheal tube for children 1 to &lt;2 years of age and a 3.0 mm internal diameter&nbsp;cuffed endotracheal tube&nbsp;for children &lt;1 year of age. </div><div class=\"graphic_reference\">Formula for cuffed tubes from:<br />Litman R, Fiadjoe J, Stricker P, et al. The pediatric airway. In: Cote C, Lerman J, Anderson B (Eds). A Ptractice of Anesthesia for Infants and Children, 5th ed. Saunders-Elsevier, Philadelphia 2013. p 237.</div><div id=\"graphicVersion\">Graphic 72932 Version 4.0</div></div></div>"},"72935":{"type":"graphic_diagnosticimage","displayName":"Negative remodeling IVUS","title":"Example of negative remodeling","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of negative remodeling</div><div class=\"cntnt\"><img style=\"width:403px; height:253px;\" src=\"images/CARD/72935_Negative_remodeling_IVUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravascular ultrasound images of the proximal reference and lesion site are shown. The remodeling ratio (EEM area lesion/EEM area proximal reference) is 0.71. </div><div class=\"graphic_footnotes\">EEM: external elastic membrane.</div><div class=\"graphic_reference\">Reprinted with permission from: Schoenhagen P, Ziada KM, Vince DG, et al. J Am Coll Cardiol 2001; 38:297. Copyright &copy; 2001 American College of Cardiology.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 72935 Version 6.0</div></div></div>"},"72937":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM CT II","title":"Arteriovenous malformation in right lower lobe in patient who developed a stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation in right lower lobe in patient who developed a stroke</div><div class=\"cntnt\"><img style=\"width:360px; height:286px;\" src=\"images/PULM/72937_Pulm_AVM_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan confirms a tangle of vessels in right lower lobe and draining vein coursing towards left atrium.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 72937 Version 3.0</div></div></div>"},"72938":{"type":"graphic_table","displayName":"Risk factors for smoking initiation","title":"Selected risk factors for tobacco use in children and adolescents that are potentially modifiable","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected risk factors for tobacco use in children and adolescents that are potentially modifiable</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Individual factors</td> <td class=\"subtitle1\">Family/social factors</td> </tr> <tr> <td>Depression</td> <td>Parent/household smokers</td> </tr> <tr> <td>Poor academic performance or learning disability</td> <td>No home smoking restriction policy</td> </tr> <tr> <td>Nicotine dependence (which develops in some individuals after smoking as few as 100 cigarettes)</td> <td>Lack of parental supervision/family management issues</td> </tr> <tr> <td>Antisocial behavior</td> <td>Family conflict and communication issues</td> </tr> <tr> <td>Alcohol or other substance abuse</td> <td>Adverse experiences (eg, parental separation or divorce, abuse)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72938 Version 3.0</div></div></div>"},"72939":{"type":"graphic_picture","displayName":"Laparoscopic primary repair of hiatal defect","title":"Laparoscopic primary repair of hiatal defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic primary repair of hiatal defect</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/SURG/72939_Lapar_prim_repair_hiatal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the primary repair of the hiatal defect. The crura of the diaphragm are sutured posterior to the esophagus, as indicated by the arrow.</div><div class=\"graphic_reference\">Courtesy of Michael Rosen, MD.</div><div id=\"graphicVersion\">Graphic 72939 Version 1.0</div></div></div>"},"72940":{"type":"graphic_picture","displayName":"Esophageal lichen planus","title":"Esophageal lichen planus","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Esophageal lichen planus</div><div class=\"cntnt\"><img style=\"width:546px; height:527px;\" src=\"images/DERM/72940_Esophageal_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Endoscopy showing erosions.<br> (B) Stricture and erosions.<br> (C) Stricture.<br> (D) Bulla formation in the esophagus.</div><div class=\"graphic_reference\">Copyright Â© Grant Anhalt, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 72940 Version 4.0</div></div></div>"},"72943":{"type":"graphic_diagnosticimage","displayName":"Ultrasound images of vasa previa","title":"Ultrasound images of vasa previa","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Ultrasound images of vasa previa</div><div class=\"cntnt\"><img style=\"width:514px; height:231px;\" src=\"images/OBGYN/72943_Vasa_previa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound images showing a posteriorÂ placenta with an anterior succinturiate lobe complicated by vasa previa.</div><div class=\"graphic_reference\">Courtesy of The Division of Maternal Fetal Medicine at The Valley Hospital, Ridgewood New Jersey.</div><div id=\"graphicVersion\">Graphic 72943 Version 3.0</div></div></div>"},"72944":{"type":"graphic_figure","displayName":"Gamma knife LINAC radiosu","title":"The use of multiple, overlapping isocenters in Gamma Knife and LINAC radiosurgery","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">The use of multiple, overlapping isocenters in Gamma Knife and LINAC radiosurgery</div><div class=\"cntnt\"><img style=\"width:478px; height:271px;\" src=\"images/ONC/72944_Gamma_knife_LINAC_radiosu.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overlapping multiple isocenters of different sizes (left) allows for conformal radiation of irregularly shaped lesions (right). However, this is achieved at the expense of dose homogeneity.</div><div id=\"graphicVersion\">Graphic 72944 Version 1.0</div></div></div>"},"72945":{"type":"graphic_waveform","displayName":"Intermediate case 2","title":"Intermediate case 2","html":"<div class=\"graphic normal\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Intermediate case 2</div><div class=\"cntnt\"><img style=\"width:530px; height:155px;\" src=\"images/CARD/72945_Intermediate_case_2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72945 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"72946":{"type":"graphic_algorithm","displayName":"Pediatric sore throat initial approach","title":"Pediatric sore throat: Initial approach","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Pediatric sore throat: Initial approach</div><div class=\"cntnt\"><img style=\"width:609px; height:557px;\" src=\"images/PEDS/72946_Algo_sore_throat_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis.<br />* Common conditions that can cause referred pain to the pharynx include cervical adenitis, acute otitis media, and dental abscess.</div><div id=\"graphicVersion\">Graphic 72946 Version 5.0</div></div></div>"},"72947":{"type":"graphic_figure","displayName":"Pyloric stenosis PI","title":"Upper digestive tract in a baby","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Upper digestive tract in a baby</div><div class=\"cntnt\"><img style=\"width:462px; height:407px;\" src=\"images/PI/72947_Pyloric-stenosis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the upper digestive tract in a baby. The pylorus is the opening between the stomach and the first part of the small intestine.</div><div id=\"graphicVersion\">Graphic 72947 Version 1.0</div></div></div>"},"72948":{"type":"graphic_figure","displayName":"Follicle number and age","title":"Declining follicle number with age","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Declining follicle number with age</div><div class=\"cntnt\"><img style=\"width:590px; height:374px;\" src=\"images/ENDO/72948_Follicle_number_and_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comparison of the relationship between age and primordial follicle number in Block's study of 44 girls and women aged 7 to 44 years with that of Gougeon's study of women aged 45 to 55 years. Follicle depletion appears to accelerate in the decade preceding menopause.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages. Acta Anat 1952; 14:108.</li>&#xD;&#xA;    <li>Gougeon A. Caract&egrave;res qualitatifs et quantitatifs de la population folliculaire dans l&oacute;vaire humain adulte. Contr Fert Sex 1984; 12:527.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72948 Version 3.0</div></div></div>"},"72949":{"type":"graphic_figure","displayName":"Structure of the TSH receptor","title":"Structure of the TSH receptor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Structure of the TSH receptor</div><div class=\"cntnt\"><img style=\"width:415px; height:254px;\" src=\"images/ENDO/72949_Structure_of_the_TSH_recept.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypothetical structure of the TSH receptor. Stimulating (in Graves' disease) and blocking (in Hashimoto's thyroiditis) anti-TSH receptor antibodies may bind to different regions of the extracellular.</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 72949 Version 2.0</div></div></div>"},"72950":{"type":"graphic_figure","displayName":"Effect of globin charge on hemoglobin assembly","title":"Effect of charge of the mutant Î²-globin chain on in vitro assembly of the abnormal hemoglobin","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Effect of charge of the mutant &#946;-globin chain on in vitro assembly of the abnormal hemoglobin</div><div class=\"cntnt\"><img style=\"width:496px; height:525px;\" src=\"images/HEME/72950_Mutant_hemoglobin_assembly.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In these in vitro experiments, equal amounts of normal and mutant beta chains were incubated with limiting quantities of normal alpha chains. The fraction of total hemoglobin represented by the abnormal hemoglobin is plotted here versus the net charge of the mutant beta chain. Separate experiments for 72 stable beta globin variants are each represented by a single open circle. The normal beta chain, which has a net charge of -2.5 at pH 7.2, is shown as the red circle at the 50 percent point. Under the same conditions, the normal alpha chain has a net charge of +2.4.</div><div class=\"graphic_reference\">Data from Bunn, HF. Blood 1987; 69:1.</div><div id=\"graphicVersion\">Graphic 72950 Version 2.0</div></div></div>"},"72951":{"type":"graphic_table","displayName":"Predisposing factors MDS","title":"Myelodysplastic syndromes: predisposing factors and epidemiologic associations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Myelodysplastic syndromes: predisposing factors and epidemiologic associations</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Heritable predisposition\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Constitutional genetic disorders\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Down syndrome (trisomy 21)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Trisomy 8 mosaicism\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Familial monosomy 7\n   </td>\n   </tr>\n   <tr>\n   <td>Neurofibromatosis 1</td>\n   </tr>\n   <tr>\n   <td>Germ cell tumors (embryonal dysgenesis)</td>\n   </tr>\n   <tr>\n   <td>Congenital neutropenia (Kostmann's or Shwachman-Diamond syndrome)</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   DNA repair deficiencies\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Fanconi's anemia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Ataxia telangiectasia\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Bloom's syndrome\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Xeroderma pigmentosum\n   </td>\n   </tr>\n   <tr>\n   <td>Mutagen-detoxification (GSTq1-null)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acquired\n   </td>\n   </tr>\n   <tr>\n   <td>Senescence</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Mutagen exposure\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Genotoxic therapy\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Alkylators\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Topoisomerase II interactive agents\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Beta-emitters (eg, radioactive P-32)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist2\">\n   Hematopoietic cell transplantation\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Environmental/occupational (eg, benzene)\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Tobacco use\n   </td>\n   </tr>\n   <tr>\n   <td>Aplastic anemia</td>\n   </tr>\n   <tr>\n   <td>Paroxysmal nocturnal hemoglobinuria (PNH)</td>\n   </tr>\n   <tr>\n   <td>\t<p>Polycythemia vera</p>\n\t<p>Obesity</p>\n</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">5/23/2002 -perm requested -jm; perm granted, gave to chris &amp;amp; ajeah -jm 6/2/2003 renewal requested 7/18/2003 emailed follow up 7/23/2003 renewal granted should be no fee 6/4/2004 renewal requested 6/29/2004 granted 6/3/2005 renewal requested 8/3/2005 granted 7/25/2006 renewal requested 8/21/2006 bugged 9/12/2006 granted 8/6/2007 -renewal requested.mn 9/24/2007 - bugged.mn 10/2/2007 -granted. mn 8/13/2008--Requested renewal (JD). 9/29/2008--Renewal granted (JD). 9/13/2009--Requested renewal (JD). 10/7/2009--Renewal granted (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26336&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Predisposing_factors_MDS.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: List AF, Sandberg AA, Doll DC. Myelodysplastic Syndromes. Wintrobe's Clinical Hematology, 12th edition, Greer JP (Ed), Lippincott Williams &amp; Wilkins, Baltimore 2008. Copyright Â© 2008 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 72951 Version 12.0</div></div></div>"},"72952":{"type":"graphic_table","displayName":"Actions extraocular muscles","title":"Actions of extraocular muscles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Actions of extraocular muscles</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Nerve and muscle</td>\n\n      <td class=\"subtitle1\">Primary action</td>\n\n      <td class=\"subtitle1\">Secondary action</td>\n\n      <td class=\"subtitle1\">Tertiary action</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Cranial nerve III&nbsp;</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Superior rectus</td>\n\n      <td>Elevation (maximal on lateral gaze)</td>\n\n      <td>Intorsion</td>\n\n      <td>Adduction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Inferior rectus</td>\n\n      <td>Depression (maximal on lateral gaze)</td>\n\n      <td>Extorsion</td>\n\n      <td>Adduction</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Medial rectus</td>\n\n      <td>Adduction</td>\n\n      <td>None</td>\n\n      <td>None</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Inferior oblique</td>\n\n      <td>Excyclotorsion</td>\n\n      <td>Elevation (maximal on medial gaze)</td>\n\n      <td>Abduction</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Cranial nerve IV</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Superior oblique</td>\n\n      <td>Incyclotorsion</td>\n\n      <td>Depression (maximal on medial gaze)</td>\n\n      <td>Abduction</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td colspan=\"4\" rowspan=\"1\" class=\"subtitle2_left\">Cranial nerve VI</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Lateral rectus</td>\n\n      <td>Abduction</td>\n\n      <td>None</td>\n\n      <td>None</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 72952 Version 1.0</div></div></div>"},"72953":{"type":"graphic_table","displayName":"Asthma peak flow instruct","title":"Asthma daily diary II instructions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Asthma daily diary II instructions</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   To do a peak flow measurement:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Take a deep breath, seal your lips around the mouthpiece, blow as hard and as quickly as you can (like blowing out a candle), check the number, re-set the pointer to zero and repeat.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Generally, the best of three peak flow values is the one to record on the chart.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Record the date at the top of the chart.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Use an <strong> <sup>o</sup> </strong> for first morning values.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Use a &#8226; for afternoon or evening values.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Use a &#916; for before exercise.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; Use an <strong>x</strong> for after exercise or with symptoms.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   &#8226; If your peak flow is lower than normal, check your action plan or call your asthma care provider.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from: Woolcock Institute of Medical Research, 2006.</div><div id=\"graphicVersion\">Graphic 72953 Version 1.0</div></div></div>"},"72955":{"type":"graphic_figure","displayName":"Oxidized LDL endothelial injury","title":"Linkage between lipid infiltration and endothelial injury in atherosclerosis","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Linkage between lipid infiltration and endothelial injury in atherosclerosis</div><div class=\"cntnt\"><img style=\"width:485px; height:244px;\" src=\"images/CARD/72955_Oxidized_LDL_endothelial_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oxidized LDL in atherosclerosis. Postulated linkage between oxidized LDL and endothelial injury in the pathogenesis of atherosclerosis. Lipid- infiltration may be sufficient to account for fatty streaks (left column), while endothelial injury (right column) may account for progression of the fatty streak to more advanced lesions.</div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein.</div><div class=\"graphic_reference\">Redrawn from Steinberg, D, Parthasarathy, S, Carew, TE, et al, N Engl J Med 1989; 320:915.</div><div id=\"graphicVersion\">Graphic 72955 Version 2.0</div></div></div>"},"72956":{"type":"graphic_figure","displayName":"Collateral circulation right lower extremity","title":"Collateral circulation right lower extremity","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Collateral circulation right lower extremity</div><div class=\"cntnt\"><img style=\"width:506px; height:691px;\" src=\"images/SURG/72956_Collateral_circ_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The collateral circulation of the right lower extremity is&nbsp;shown. It&nbsp;provides blood flow around regions of arterial obstruction due to atherosclerosis, which commonly affects the superficial femoral artery, thrombosed arterial aneurysm (eg, femoral, popliteal), or thromboembolism.</div><div class=\"graphic_footnotes\">a: artery.</div><div id=\"graphicVersion\">Graphic 72956 Version 7.0</div></div></div>"},"72957":{"type":"graphic_table","displayName":"AAST-OIS for the esophagus","title":"American Association for the Surgery of Trauma Organ Injury Severity Score (AAST-OIS) for the esophagus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Association for the Surgery of Trauma Organ Injury Severity Score (AAST-OIS) for the esophagus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury description</td> </tr> <tr> <td class=\"centered\">I</td> <td>Contusion; hematoma; partial thickness laceration</td> </tr> <tr> <td class=\"centered\">II</td> <td>Laceration &#8804;50 percent of circumference</td> </tr> <tr> <td class=\"centered\">III</td> <td>Laceration &#62;50 percent of circumference</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Segmental loss or devascularization of &#8804;2 cm</td> </tr> <tr> <td class=\"centered\">V</td> <td>Segmental loss or devascularization of &#62;2 cm</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">20</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=94065&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">* Advance one grade for multiple lesions up to grade III.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore EE, Jurkovich GJ, Knudson M, et al. Organ injury scaling VI: Extrahepatic biliary, esophagus, stomach, vulva, uterus (nonpregnant), uterus (pregnant), fallopian tube, and ovary. J Trauma 1995; 39:1069. Copyright Â© 1995 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72957 Version 6.0</div></div></div>"},"72961":{"type":"graphic_figure","displayName":"Cerebral veins and sinuses","title":"Major cerebral veins and sinuses","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Major cerebral veins and sinuses</div><div class=\"cntnt\"><img style=\"width:542px; height:609px;\" src=\"images/NEURO/72961_Cerebral_veins_and_sinuses.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72961 Version 2.0</div></div></div>"},"72963":{"type":"graphic_picture","displayName":"Well different beta catenin","title":"Well differentiated (intestinal type) gastric adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Well differentiated (intestinal type) gastric adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:277px;\" src=\"images/ONC/72963_Well_different_beta_catenin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Beta-catenin stain is prominent in the tumor cell membranes.</div><div id=\"graphicVersion\">Graphic 72963 Version 1.0</div></div></div>"},"72964":{"type":"graphic_picture","displayName":"Acanthosis nigricans on neck","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:504px; height:410px;\" src=\"images/DERM/72964_Acanthosis_Nigricans_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A velvety, slightly verrucous plaque is present on the neck.</div><div id=\"graphicVersion\">Graphic 72964 Version 1.0</div></div></div>"},"72965":{"type":"graphic_table","displayName":"Revised Bethesda criteria","title":"The revised Bethesda guidelines for testing colorectal tumors for microsatellite instability (MSI)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The revised Bethesda guidelines for testing colorectal tumors for microsatellite instability (MSI)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tumors from individuals should be tested for MSI in the following situations: </td> </tr> <tr> <td>1. Colorectal cancer diagnosed in a patient who is less than 50 years of age.</td> </tr> <tr> <td>2. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors<sup>*</sup>, regardless of age. </td> </tr> <tr> <td>3. Colorectal cancer with the MSI-H<sup>&#182;</sup>-like histology<sup>&#916;</sup> diagnosed in a patient who is less than 60 years of age<sup>&#9674;</sup>. </td> </tr> <tr> <td>4. Colorectal cancer diagnosed in a patient with one or more first-degree relatives with an HNPCC-related tumor, with one of the cancers being diagnosed under age 50 years. </td> </tr> <tr> <td>5. Colorectal cancer diagnosed in a patient with two or more first- or second-degree relatives with HNPCC-related tumors, regardless of age. </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HNPCC: hereditary nonpolyposis colorectal cancer; MSI-H: microsatellite instability-high.<br />* HNPCC-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratocanthomas in Muir-Torre syndrome, and carcinoma of the small bowel.<br />Â¶&nbsp;MSI-H in tumors refers to changes in two or more of the five National Cancer Institute-recommended panels of microsatellite markers.<br />Î Presence of tumor infiltrating lymphocytes. Crohn's-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.<br />â There was no consensus among the Workshop participants on whether to include the age criteria in guideline 3 above; participants voted to keep less than 60 years of age in the guidelines.</div><div class=\"graphic_reference\">Reproduced with permission from Umar A, et al. J Natl Cancer Inst 2004; 96:261. Copyright Â© 2004 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 72965 Version 5.0</div></div></div>"},"72966":{"type":"graphic_picture","displayName":"Radical vulvectomy2","title":"Radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/72966_Radical_vulvectomy2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The specimen has been dissected laterally and off the symphysis pubis. The suspensory ligament is seen attached to the symphysis.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 72966 Version 2.0</div></div></div>"},"72968":{"type":"graphic_picture","displayName":"EBUS tissue core","title":"Endobronchial ultrasound (EBUS) tissue core","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial ultrasound (EBUS) tissue core</div><div class=\"cntnt\"><img style=\"width:432px; height:241px;\" src=\"images/PULM/72968_EBUS_tissue_core.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue core obtained by endobronchial ultrasound-guided sampling.</div><div id=\"graphicVersion\">Graphic 72968 Version 3.0</div></div></div>"},"72970":{"type":"graphic_picture","displayName":"Umbilical hernia","title":"Umbilical hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical hernia</div><div class=\"cntnt\"><img style=\"width:311px; height:360px;\" src=\"images/SURG/72970_Umbilical_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Berg, D, Worzala, K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright Â© 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72970 Version 2.0</div></div></div>"},"72971":{"type":"graphic_table","displayName":"Conventional approach to cardioversion","title":"Advantages and disadvantages of the conventional approach to cardioversion (one month of pretreatment with warfarin) in patients with atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of the conventional approach to cardioversion (one month of pretreatment with warfarin) in patients with atrial fibrillation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Use of warfarin for one month before cardioversion may lower the stroke rate from 5.6 percent to a very low stroke rate of &#60;2 percent.</td> <td>Delaying cardioversion to normal sinus rhythm for one month potentially decreases functional capacity.</td> </tr> <tr> <td>Relatively easy to administer with regular monitoring of INRs. </td> <td>Prolonging treatment for&nbsp;seven to&nbsp;eight weeks one month prior to and one month after cardioversion increases the risk of bleeding complications.</td> </tr> <tr> <td>Suitable for community hospitals.</td> <td>Not followed by routine clinical practice, especially in the elderly.</td> </tr> <tr> <td>The conventional approach has withstood the \"test of time\" since the 1960s.</td> <td>Patients who are at the highest risk for developing systemic embolization who should receive more prolonged or intensive anticoagulation are not routinely identified.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from the American College of Cardiology. J Am Coll Cardiol 2001; 37:691. <A spellcheck=true href=\"https://www.journals.elsevier.com/jacc-journal-of-the-american-college-of-cardiology\" target=_blank>https://www.journals.elsevier.com/jacc-journal-of-the-american-college-of-cardiology</A>.</div><div id=\"graphicVersion\">Graphic 72971 Version 5.0</div></div></div>"},"72972":{"type":"graphic_picture","displayName":"Lichen sclerosus in sites of friction","title":"Extragenital lichen sclerosus developing in sites of friction","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus developing in sites of friction</div><div class=\"cntnt\"><img style=\"width:583px; height:413px;\" src=\"images/DERM/72972_Lich_sclerosus_sites_frict.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of lichen sclerosus in sites of friction. Note the porcelain white color (arrow), telangiectasias, peripheral hyperpigmentation, and erythema (which likely signifies disease activity).</div><div id=\"graphicVersion\">Graphic 72972 Version 2.0</div></div></div>"},"72973":{"type":"graphic_table","displayName":"CMV effects in transplantation","title":"Effects of cytomegalovirus in transplant recipients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of cytomegalovirus in transplant recipients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Direct effects</td> </tr> <tr> <td>Asymptomatic viral shedding and/or seroconversion</td> </tr> <tr> <td>Acute \"viral syndromes\" - flu-like or mono-like illness (fever, myalgia)</td> </tr> <tr> <td>Leukopenia, thrombocytopenia, fever</td> </tr> <tr> <td class=\"sublist1_start\">Pneumonitis</td> </tr> <tr> <td class=\"sublist1_start\">Infection of allograft</td> </tr> <tr> <td class=\"sublist1\">Hepatitis</td> </tr> <tr> <td class=\"sublist1\">Pneumonitis</td> </tr> <tr> <td class=\"sublist1\">Nephritis</td> </tr> <tr> <td class=\"sublist1\">Myocarditis</td> </tr> <tr> <td class=\"sublist1\">Pancreatitis</td> </tr> <tr> <td class=\"sublist1_start\">Infection of native tissues</td> </tr> <tr> <td class=\"sublist1\">Retina</td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal tract</td> </tr> <tr> <td class=\"sublist1\">Pancreas</td> </tr> <tr> <td class=\"sublist1\">Encephalitis</td> </tr> <tr> <td class=\"sublist1\">Adrenalitis and insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Indirect effects</td> </tr> <tr> <td>Bacterial and fungal superinfection</td> </tr> <tr> <td>Activation or accelerated infection due to other viruses (HCV, EBV, HHV6, HSV)</td> </tr> <tr> <td>Allograft injury and rejection</td> </tr> <tr> <td class=\"sublist1_start\">Oncogenesis and Proliferative Syndromes</td> </tr> <tr> <td class=\"sublist1\">EBV-associated PTLD</td> </tr> <tr> <td class=\"sublist1\">Accelerated atherogenesis (cardiac)</td> </tr> <tr> <td class=\"sublist1\">Bronchiolitis obliterans (lungs)</td> </tr> <tr> <td>Toxicities of therapy</td> </tr> <tr> <td>Cost of prophylaxis and therapy</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">HCV: hepatitis C virus; EBV: Epstein-Barr virus; HHV: human herpesvirus; HSV: herpes simplex virus; PTLD: posttransplant lymphoproliferative disorder.</div><div id=\"graphicVersion\">Graphic 72973 Version 3.0</div></div></div>"},"72974":{"type":"graphic_table","displayName":"Pharmacokinetics and drug interactions of fluoroquinolones","title":"Pharmacokinetics and drug interactions of systemic fluoroquinolones in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics and drug interactions of systemic fluoroquinolones in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"8%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Bioavailability</td> <td class=\"subtitle1\">Clearance</td> <td class=\"subtitle1\">Metabolism</td> <td class=\"subtitle1\">Inhibition or induction<br /> of metabolism</td> <td class=\"subtitle1\">Elimination half-life</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>Ciprofloxacin</td> <td> <p>70% (range 50 to 85%).</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> <p>May be taken with most foods or on an empty stomach.</p> However, avoid taking with milk or dairy products: decreased bioavailability up to 40%.<sup><sub></sub>[1]</sup></td> <td>Oral administration: <ul class=\"decimal_heading\"> <li>30 to 50% renally cleared<sup>&#182;</sup> </li> <li>15% metabolized </li> <li>30% presystemic clearance (hepatobiliary and fecal) </li> </ul> IV administration: <ul class=\"decimal_heading\"> <li>70% renally cleared<sup>&#182;</sup> </li> <li>10% metabolized </li> </ul> </td> <td>Hepatic metabolism is poorly characterized; some metabolites are active.</td> <td> <p>Inhibitor of CYP1A2.</p> Can increase blood levels of CYP1A2 substrate drugs (eg, clozapine, erlotinib, ibrutinib, ropinirole, theophylline, tizanidine); refer to Lexicomp drug interactions program for detail.</td> <td> <p>3 to 5 hours.</p> Prolonged in older adults and in renal impairment (up to 8 hours in advanced chronic kidney disease).</td> <td>Some drug interactions require dose adjustment or avoidance of certain combinations; refer to Lexicomp drug interactions program for detail.</td> </tr> <tr> <td>Delafloxacin</td> <td> <p>59%.</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> May be taken with or without food. </td> <td>Oral administration: <ul class=\"decimal_heading\"> <li>50% renally cleared<sup>&#182;</sup> </li> <li>1% metabolized </li> <li>48% fecal clearance </li> </ul> IV administration: <ul class=\"decimal_heading\"> <li>65% renally cleared<sup>&#182;</sup> </li> <li>1% metabolized </li> <li>28% fecal clearance </li> </ul> </td> <td>Does not undergo CYP450 metabolism. Minimally metabolized via glucuronidation.</td> <td>Does not inhibit or induce hepatic CYP450 enzymes to a clinically relevant extent.</td> <td> <p>IV: 3.7 hours; oral: 4.2 to 8.5 hours.</p> Prolonged in renal impairment.</td> <td>IV formulation contains cyclodextrin vehicle, which accumulates in renal impairment. IV form is not recommended in patients with eGFR of &#60;15 mL/minute/1.73 m<sup>2</sup>.</td> </tr> <tr> <td>Gemifloxacin<sup>&#916;</sup><br /> (oral only)</td> <td> <p>71%.</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> May be taken with or without food.</td> <td>Oral administration: <ul class=\"decimal_heading\"> <li>36% renally cleared<sup>&#182;</sup> </li> <li>&#60;10% metabolized </li> <li>61% fecal clearance </li> </ul> </td> <td>Does not undergo CYP450 metabolism. Metabolized via glucuronidation.</td> <td>Does not inhibit or induce hepatic CYP450 enzymes.</td> <td> <p>7 hours (range 4 to 12 hours).</p> Prolonged in renal impairment.</td> <td>&nbsp;</td> </tr> <tr> <td>Levofloxacin</td> <td> <p>99%.</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> May be taken with or without food.</td> <td>Oral/IV administration: <ul class=\"decimal_heading\"> <li>87% renally cleared<sup>&#182;</sup> </li> <li>&#60;1% metabolized </li> <li>&#60;4% fecal clearance </li> </ul> </td> <td>Does not undergo CYP450 metabolism. Minimally metabolized via glucuronidation.</td> <td>Does not inhibit or induce hepatic CYP450 enzymes.</td> <td> <p>6 to 8 hours.</p> Prolonged up to 35 hours in advanced chronic kidney disease.</td> <td>&nbsp;</td> </tr> <tr> <td>Moxifloxacin</td> <td> <p>90%.</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> May be taken with or without food.</td> <td>Oral/IV administration: <ul class=\"decimal_heading\"> <li>20% renally cleared </li> <li>52% metabolized </li> <li>25% fecal clearance </li> </ul> </td> <td>Does not undergo CYP450 metabolism. Metabolized via glucuronidation and sulfate conjugation.</td> <td>Does not inhibit or induce hepatic CYP450 enzymes.</td> <td>10 to 14 hours.</td> <td>&nbsp;</td> </tr> <tr> <td>Norfloxacin<sup>&#916;</sup><br /> (oral only)</td> <td> <p>30 to 40%.</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> <p>May be taken with most foods or on an empty stomach, but food may delay absorption.</p> However, avoid taking with milk or dairy products: decreased bioavailability up to 40%.<sup>[2]</sup></td> <td>Oral administration: <ul class=\"decimal_heading\"> <li>30% renally cleared<sup>&#182;</sup> </li> <li>5 to 8% metabolized </li> <li>30% fecal clearance </li> </ul> </td> <td>Undergoes modest hepatic metabolism; however, its metabolism has not been well characterized.</td> <td> <p>Can increase blood levels of theophylline.<sup>[3]</sup></p> May alter cyclosporine levels; monitoring suggested.<sup>[4]</sup> Refer to Lexicomp drug interactions program for detail.</td> <td> <p>3 to 4 hours.</p> Prolonged up to 6.5 hours in advanced chronic kidney disease.</td> <td>Some drug interactions require dose adjustment or avoidance of certain combinations; refer to Lexicomp drug interactions program for detail.</td> </tr> <tr> <td>Ofloxacin</td> <td> <p>&#62;90%.</p> <p>Avoid taking with most antacids, mineral supplements, and certain oral medications: Decreased bioavailability in some cases by &#62;90%.*</p> May be taken with or without food.</td> <td>Oral/IV administration: <ul class=\"decimal_heading\"> <li>80% renally cleared<sup>&#182;</sup> </li> <li>4% metabolized </li> <li>4 to 8% fecal clearance </li> </ul> </td> <td>Does not undergo CYP450 metabolism. Metabolized via glucuronidation.</td> <td>Does not inhibit or induce hepatic CYP450 enzymes.</td> <td> <p>5 to 7.5 hours.</p> Prolonged in renal impairment.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Data on clearance and metabolism are provided to assess potential for pharmacokinetic drug interactions and risk of drug accumulation in organ failure. This table does not address potential pharmacodynamic interactions of fluoroquinolones with other drugs (eg, additive QTc prolongation). Refer to Lexicomp drug interactions program included with UpToDate for specific drug interactions.</LI>&#xD;&#xA;<LI>Patients receiving warfarin should have INR monitored when treated with a fluoroquinolone; an increased risk of bleeding has been observed.<SUP>[5]</SUP></LI></UL></div><div class=\"graphic_footnotes\">IV: intravenous; CYP450: cytochrome P450 hepatic metabolism; eGFR: estimated glomerular filtration rate; INR: International normalized ratio<br />* Fluoroquinolones form chelation complexes with medications containing multivalent cations that can significantly impair absorption resulting in subtherapeutic serum concentrations and treatment failure. Examples include but are not limited to: Aluminum, magnesium, and calcium-containing antacids, mineral supplements (calcium, iron, magnesium, zinc), phosphate binders (eg, sevelamer, lanthanum), sodium polystyrene sulfonate, sucralfate, and buffered didanosine. Administering oral fluoroquinolones at least 2 to 4 hours before or 3 to 8 hours after these medications or supplements may minimize but not eliminate these interactions. Enteral nutrition formulas may also impair absorption of fluoroquinolones depending upon tube terminus placement and timing of administration. H<SUB>2</SUB> receptor antagonists and proton pump inhibitors do not appear to significantly alter absorption of fluoroquinolones.<SUP>[1]</SUP><br />Â¶ Requires dose adjustment in renal impairment.<br />Î Not available in the United States; in most countries where it is available, only an oral formulation is marketed.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bolhuis MS, Panday PN, Pranger AD, et al. Pharmacokinetic drug interactions of antimicrobial drugs: A systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams. Pharmaceutics 2011; 3:865.</LI>&#xD;&#xA;<LI>Kivisto KT, Ojala-Karlsson P, Neuvonen PJ. Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother 1992; 36:489.</LI>&#xD;&#xA;<LI>Tierney MG, Ho G, Dales RE. Effect of norfloxacin on theophylline pharmacokinetics. Clin Pharmacol Ther 1988, 43:156.</LI>&#xD;&#xA;<LI>McLellan RA, Drobitch RK, McLellan H, et al. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995, 58:322.</LI>&#xD;&#xA;<LI>Baillargeon J, Holmes HM, Lin YL, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med 2012; 125:183.</LI></OL>Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US Food &amp; Drug Administration prescribing information. Available at: <A href=\"https://www.accessdata.fda.gov/scripts/cder/daf/\" target=_blank>https://www.accessdata.fda.gov/scripts/cder/daf/</A> (Accessed on October 19, 2017).</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright Â© 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 72974 Version 6.0</div></div></div>"},"72975":{"type":"graphic_table","displayName":"Neurologic manifestations of hypothyroidism","title":"Summary of the neurologic manifestations of hypothyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the neurologic manifestations of hypothyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cardinal features</td> <td class=\"subtitle1\">Relative frequency</td> </tr> <tr> <td><strong>Myxedema coma</strong></td> <td>Decreased mental status, bradycardia, hypothermia, hypotension, others</td> <td>Rare</td> </tr> <tr> <td><strong>Cognitive impairment</strong></td> <td>Slowed mentation, poor concentration and short-term memory</td> <td>Common in overt hypothyroidism; uncertain in subclinical hypothyroidism</td> </tr> <tr> <td><strong>Cerebellar ataxia</strong></td> <td>Gait most often affected, limb and speech involvement can occur</td> <td>Uncertain; early studies suggest 10 to 30 percent</td> </tr> <tr> <td><strong>Carpal tunnel syndrome</strong></td> <td>Pain, numbness, weakness in median nerve distribution</td> <td>Common 25 to 33 percent</td> </tr> <tr> <td><strong>Peripheral neuropathy</strong></td> <td>Predominantly sensory, often painful</td> <td>Common, but rarely the presenting symptom</td> </tr> <tr> <td><strong>Myopathy</strong></td> <td>Ranges from asymptomatic serum CK elevation to cramps and myalgias to more disabling proximal muscle weakness</td> <td>Common in at least one form</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72975 Version 3.0</div></div></div>"},"72976":{"type":"graphic_picture","displayName":"Retinal vein occlusion","title":"Retinal vein occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal vein occlusion</div><div class=\"cntnt\"><img style=\"width:432px; height:312px;\" src=\"images/NEURO/72976_Retinal_vein_occlusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 72976 Version 1.0</div></div></div>"},"72978":{"type":"graphic_table","displayName":"Common foods and drugs that can cause the stool to appear bloody","title":"Common foods and drugs that can cause the stool to appear bloody","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common foods and drugs that can cause the stool to appear bloody</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Red coloration, similar to fresh blood</td> </tr> <tr> <td class=\"indent1\">Certain antibiotics*</td> </tr> <tr> <td class=\"indent1\">Beets</td> </tr> <tr> <td class=\"indent1\">Flavored gelatin (red colored)</td> </tr> <tr> <td class=\"indent1\">Kool-Aid or fruit punch (red colored)</td> </tr> <tr> <td class=\"indent1\">Red licorice</td> </tr> <tr> <td class=\"indent1\">Red-dyed snack foods (eg, spicy \"red-hot\" snacks)</td> </tr> <tr> <td class=\"subtitle1_single\">Black coloration, similar to melena</td> </tr> <tr> <td class=\"indent1\">Bismuth preparations (Pepto-Bismol, Maalox, Kaopectate)</td> </tr> <tr> <td class=\"indent1\">Activated charcoal</td> </tr> <tr> <td class=\"indent1\">Chocolate</td> </tr> <tr> <td class=\"indent1\">Blueberries</td> </tr> <tr> <td class=\"indent1\">Iron supplements<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Large quantities of some dark green foods</td> </tr> <tr> <td class=\"subtitle1_single\">False-positive results to fecal occult blood test</td> </tr> <tr> <td class=\"indent1\">Rare red meat</td> </tr> <tr> <td class=\"indent1\">Peroxidase-containing vegetables (turnips, horseradish, broccoli, cauliflower, and cantaloupe)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Several reports have described cases of very red-appearing stools associated with cefdinir, apparently caused by an interaction with iron supplements or iron-containing infant formula.<SUP>[1-3]</SUP> Rifampin can cause orange discoloration of stools as well as urine. Other antibiotics in red vehicles (eg, cherry syrup) may cause a red tint to the stool, especially in infants or others with a fast transit time. Antibiotics can also trigger true gastrointestinal bleeding (Clostridium difficile [C. difficile] colitis). Therefore, red-appearing stools should be evaluated with guaiac or other tests for blood.<br />Â¶ Whether iron supplements cause false-positive results for fecal occult blood testing is controversial.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lancaster J, Sylvia LM, Schainker E. Nonbloody, red stools from coadministration of cefdinir and iron-supplemented infant formulas. Pharmacotherapy 2008; 28:678.</li>&#xD;&#xA;    <li>Roath MC, Di Palma JA. Cefdinir and red stool. Gastroenterology and Hepatology 2013; 9:338.</li>&#xD;&#xA;    <li>Graves R, Weaver SP. Cefdinir-associated \"bloody stools\" in an infant. J Am Board Fam Med 2008; 21:246.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 72978 Version 6.0</div></div></div>"},"72979":{"type":"graphic_table","displayName":"GnRH agonists for CPP","title":"Long-acting gonadotropin-releasing hormone (GnRH) agonists for treatment of central (gonadotropin-dependent)Â precocious puberty","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Long-acting gonadotropin-releasing hormone (GnRH) agonists for treatment of central (gonadotropin-dependent)&nbsp;precocious puberty</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">GnRH agonist</td> <td class=\"subtitle1\">Trade names and availability</td> <td class=\"subtitle1\">Dose, frequency, and method of administration</td> </tr> <tr> <td>Histrelin acetate subcutaneous implant</td> <td>Supprelin LA (US)</td> <td>Subcutaneous implant. Children &#8805;2 years: 50 mg implant surgically inserted every 12 months. Releases approximately 65 mcg per day over 12 months.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Leuprolide acetate(leuprorelin)</td> <td> <p>Lupron Depot-Ped (1 month) (US)</p> <p>Lupron Depot CPP (CAN)</p> <p>Eligard, Lucrin (EU, AU, SA, elsewhere)</p> </td> <td>Intramuscular depot injection, given every 28 days:<br /> <ul> <li>Patients weighing &#8804;25 kg: 7.5 mg </li> <li>Patients weighing&nbsp;&#62;25&nbsp;kg: 11.25 mg </li> </ul> Titrate dose upward by 3.75 mg every 4 weeks (increase of approximately 10 mcg/kg/day) as needed to achieve clinical response. Starting doses in Europe are typically lower (eg, 3.75 mg/dose).</td> </tr> <tr> <td>Lupron Depot-Ped (3 month)</td> <td>Intramuscular depot injection, given every 12 weeks:<br /> <ul> <li>11.25, 22.5,&nbsp;or 30 mg </li> </ul> Criteria for selection of the 11.25 mg versus&nbsp;other dosages have not been established.</td> </tr> <tr class=\"divider_top\"> <td>Goserelin acetate</td> <td>Zoladex (US, CAN, UK, EU, SA, elsewhere)</td> <td>Subcutaneous implant injected into the anterior abdominal wall:<br /> <ul> <li>The 3.6 mg preparation is given once every 28 days </li> <li>The 10.8 mg preparation is given once every 12 weeks </li> </ul> More frequent injections may be needed in some individuals.</td> </tr> <tr class=\"divider_top\"> <td>Triptorelin pamoate</td> <td>Gonapeptyl (UK, EU, SA, elsewhere)</td> <td>Intramuscular depot injection. Initial dose by body weight:<br /> <ul> <li>Patients weighing &#60;20 kg: 1.875 mg </li> <li>Patients weighing 20 to 30 kg: 2.5 mg </li> <li>Patients weighing &#62;30 kg: 3.75 mg </li> </ul> Initial three doses given at 14-day intervals with further doses every four weeks. More frequent injections may be needed in some individuals. An 11.25 mg intramuscular depot injection given every 12 weeks is available in some countries.</td> </tr> <tr class=\"divider_top\"> <td>Triptorelin pamoate</td> <td>Triptodur (US)*&nbsp;</td> <td>Intramuscular depot injection, given once every 24 weeks:<br /> <ul> <li>Children &#62;2&nbsp;years and adolescents: 22.5 mg<sup>&#182;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Approval of these GnRH agonists for use in central precocious puberty (CPP), dosing, and schedules of administration vary between products in different countries. Consult local product information. Short-acting GnRH preparations requiring daily subcutaneous injections or multiple daily dosing nasal spray (such as nafarelin) are not recommended due to compliance difficulty; use of these products usually is limited to patients with sterile abscesses from depot injections. Note that the doses used to treat CPP in children are substantially higher than those used in adults for other indications, such as prostate cancer and endometriosis.</div><div class=\"graphic_footnotes\">US: United States; CAN: Canada; EU: European Union; AU: Australia; SA: South America; UK: United Kingdom.<br />* This formulation is also available under the trade name of Decapeptyl in the UK and Diphereline in AU. However, use of these medications for the treatment of central precocious puberty is not an approved indication in these countries (as of 2017).<br />Â¶&nbsp;For Triptodur, 22.5 mg is equivalent to 31 mg triptorelin pamoate.</div><div id=\"graphicVersion\">Graphic 72979 Version 13.0</div></div></div>"},"72980":{"type":"graphic_diagnosticimage","displayName":"Midshaft clavicle fracture with shortening","title":"Midshaft clavicle fracture with shortening","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Midshaft clavicle fracture with shortening</div><div class=\"cntnt\"><img style=\"width:504px; height:182px;\" src=\"images/EM/72980_Clav_mid3_fx_short.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows complete displacement of a middle-third fracture of the left clavicle, with marked shortening (over 4 cm). Note the overlap of the proximal and distal fragments. Surgical referral is needed for patients with&nbsp;severe fracture&nbsp;displacement.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 72980 Version 3.0</div></div></div>"},"72981":{"type":"graphic_table","displayName":"Digit reduction","title":"Digit dislocation reduction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Digit dislocation reduction</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Preparation</td>\n</tr>\n <tr>\n <td>1. Remove all rings from the affected hand or foot.</td>\n </tr>\n <tr>\n <td>2. Assure no fractures or open joints are present on AP, true lateral, and oblique plain radiographs.</td>\n </tr>\n <tr>\n <td class=\"sublist1_start\">3. Assemble all necessary materials:</td>\n </tr>\n <tr>\n <td class=\"sublist2\">Latex free gloves</td>\n </tr>\n <tr>\n <td class=\"sublist2\">1 percent buffered lidocaine without epinephrine (one part of 1 mEq/mL of sodium bicarbonate to 9 or 10 parts of 1 percent lidocaine)</td>\n </tr>\n <tr>\n <td class=\"sublist2\">Syringes (3 mL or 5 mL) and needles (25 or 27 gauge)</td>\n </tr>\n <tr>\n <td class=\"sublist2\">Povidone iodine solution (eg, Betadine&#174;) and alcohol</td>\n </tr>\n <tr>\n <td class=\"sublist2\">Scissors</td>\n </tr>\n <tr>\n <td class=\"sublist2\">White surgical tape</td>\n </tr>\n <tr>\n <td class=\"sublist2\">Splinting materials depend on the affected joint:</td>\n </tr>\n <tr>\n <td class=\"sublist3\">- Finger interphalangeal dislocations: padded, malleable, aluminum digital splint </td>\n </tr>\n <tr>\n <td class=\"sublist3\">- Metacarpal (thumb) dislocations: water, bucket, prefabricated splinting material (eg, plaster of Paris or fiberglass) <strong>OR</strong> Webril&#174;, plaster of Paris, and stockinette to fashion a thumb spica splint</td>\n </tr>\n <tr>\n <td>4. Provide appropriate analgesia as determined by the patient's age and degree of pain.</td>\n </tr>\n <tr>\n <td class=\"subtitle1_single\">Interphalangeal reduction </td>\n </tr>\n <tr>\n <td>Have an assistant brace the hand or foot.</td>\n </tr>\n <tr>\n <td class=\"sublist1_start\">Reduce the dislocation using one of the following methods:</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>Dorsal dislocation:</strong> Provide longitudinal traction; <strong>gently</strong> hyperextend the joint while pushing the base of the dislocated phalanx into place.</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>Volar dislocation:</strong> Provide longitudinal traction; <strong>gently</strong> hyperflex while pushing the base of the dislocated phalanx into place.</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>Lateral dislocation:</strong> Provide longitudinal traction; <strong>gently</strong> hyperextend the joint while correcting the ulnar or radial deformity.</td>\n </tr>\n <tr>\n <td>Test joint stability throughout full range of motion of the digit to ensure that the joint will recover well with splinting alone.</td>\n </tr>\n <tr>\n <td>Obtain a post-reduction plain radiograph, including a true lateral view of the digit.</td>\n </tr>\n <tr>\n <td class=\"subtitle1_single\">Interphalangeal immobilization</td>\n </tr>\n <tr>\n <td class=\"sublist1_start\">Immobilize the digit based on the location and type of dislocation:</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>DIP dorsal or lateral finger dislocation:</strong> Splint the DIP in full extension while allowing full range of motion of the PIP joint.</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>PIP dorsal or lateral finger dislocation:</strong> Apply a dorsal splint with the PIP in 20 to 30 degrees of flexion.</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>Volar finger dislocation:</strong> Splint the PIP and DIP in full extension.</td>\n </tr>\n <tr>\n <td class=\"sublist1\"><strong>DIP or PIP toe dislocation:</strong> Buddy tape the affected digit to its neighbor.</td>\n </tr>\n <tr>\n <td class=\"subtitle1_single\">Simple metacarpophalangeal dislocation</td>\n </tr>\n <tr>\n <td class=\"subtitle2_left\">Reduction:</td>\n </tr>\n <tr>\n <td class=\"indent1\">Have an assistant brace the hand and flex the wrist.</td>\n </tr>\n <tr>\n <td class=\"indent1\"><strong>Avoid</strong> excessive hyperextension or distraction that can convert a simple dislocation into a complex dislocation.</td>\n </tr>\n <tr>\n <td class=\"indent1\"><strong>Gently</strong> distract the affected thumb or digit and apply volar pressure to the base of the dislocated proximal phalanx.</td>\n </tr>\n <tr>\n <td class=\"indent1\">Test joint stability throughout the full range of thumb or finger motion to ensure that the joint will recover well with splinting alone.</td>\n </tr>\n <tr>\n <td class=\"subtitle2_left\">Immobilization</td>\n </tr>\n <tr>\n <td class=\"indent1\"><strong>Finger dislocation:</strong> Splint the digit in 90 degrees of flexion.</td>\n </tr>\n <tr>\n <td class=\"indent1\"><strong>Thumb dislocation:</strong> Apply a thumb spica splint with the MCP joint in 20 degrees of flexion.</td>\n </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=11040&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Digit_reduction.htm</title></head></div><div id=\"graphicVersion\">Graphic 72981 Version 1.0</div></div></div>"},"72984":{"type":"graphic_table","displayName":"Histology of vaginal cancer","title":"Incidence of histologic subtypes of primary vaginal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of histologic subtypes of primary vaginal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Histology</td>\n\n      <td class=\"subtitle1\">Number of patients</td>\n\n      <td class=\"subtitle1\">Incidence</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Squamous cell</td>\n\n      <td>627</td>\n\n      <td>83.4</td>\n\n    </tr>\n\n    <tr>\n      <td>Adenocarcinoma</td>\n      <td>70</td>\n      <td>9.3</td>\n    </tr>\n    <tr>\n      <td>Sarcoma</td>\n      <td>20</td>\n      <td>2.6</td>\n    </tr>\n    <tr>\n      <td>Melanoma</td>\n      <td>2</td>\n      <td>2.6</td>\n    </tr>\n    <tr>\n      <td>Undifferentiated</td>\n      <td>8</td>\n      <td>1.0</td>\n    </tr>\n    <tr>\n      <td>Small cell</td>\n      <td>5</td>\n      <td>0.7</td>\n    </tr>\n    <tr>\n      <td>Lymphoma</td>\n      <td>2</td>\n      <td>0.3</td>\n    </tr>\n    <tr>\n      <td>Carcinoid</td>\n      <td>1</td>\n      <td>0.1</td>\n    </tr>\n    <tr>\n\n      <td><strong>Total</strong></td>\n\n      <td>753</td>\n\n      <td>100.0</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Berek JS, Hacker NF (Eds). Practical Gynecologic Oncology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia, 2000.</div><div id=\"graphicVersion\">Graphic 72984 Version 2.0</div></div></div>"},"72985":{"type":"graphic_table","displayName":"Findings neonatal sepsis","title":"Clinical findings in neonatal sepsis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in neonatal sepsis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Finding</td> <td class=\"subtitle1\">Frequency*</td> </tr> <tr> <td>Hyperthermia</td> <td>+++</td> </tr> <tr> <td>Respiratory distress</td> <td>+++</td> </tr> <tr> <td>Tachycardia</td> <td>+++</td> </tr> <tr> <td>Lethargy</td> <td>++</td> </tr> <tr> <td>Poor feeding</td> <td>++</td> </tr> <tr> <td>Apnea</td> <td>++</td> </tr> <tr> <td>Bradycardia</td> <td>++</td> </tr> <tr> <td>Poor perfusion/hypotension</td> <td>++</td> </tr> <tr> <td>Vomiting</td> <td>++</td> </tr> <tr> <td>Jaundice</td> <td>++</td> </tr> <tr> <td>Hepatomegaly</td> <td>++</td> </tr> <tr> <td>Cyanosis</td> <td>+</td> </tr> <tr> <td>Hypothermia</td> <td>+</td> </tr> <tr> <td>Irritability</td> <td>+</td> </tr> <tr> <td>Seizures</td> <td>+</td> </tr> <tr> <td>Abdominal distension</td> <td>+</td> </tr> <tr> <td>Diarrhea</td> <td>+</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* +++: commonly associated (â¥50 percent of cases); ++: frequently associated (25 to 50 percent); +: occasionally associated (&lt;25 percent).</div><div class=\"graphic_reference\">References: <br />Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious Diseases of the Fetus and Newborn Infant, 7<SUP>th</SUP> ed, Remington JS, et al (Eds), Elsevier Saunders, Philadelphia 2010. p.244.<br />âStoll BJ, Hansen NI, SÃ¡nchez PJ, et al. Early onset neonatal sepsis: The burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011; 127:817.</div><div id=\"graphicVersion\">Graphic 72985 Version 5.0</div></div></div>"},"72986":{"type":"graphic_figure","displayName":"Homocysteine metabolism","title":"Pathways of homocysteine metabolism","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Pathways of homocysteine metabolism</div><div class=\"cntnt\"><img style=\"width:539px; height:459px;\" src=\"images/PC/72986_Homocysteine_metabolism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Homocysteine is metabolized by one of two divergent pathways: transsulfuration and remethylation. The transsulfuration of homocysteine to cysteine is catalyzed by cystathionine-Î²-synthase (CBS), a process that requires pyridoxal phosphate (vitamin B6) as a cofactor. Remethylation of homocysteine produces methionine. This reaction is catalyzed either by methionine synthase or by betaine-homocysteine methyltransferase. Vitamin B12 (cobalamin) is the precursor of methylcobalamin, which is the cofactor for methionine synthase.</div><div id=\"graphicVersion\">Graphic 72986 Version 4.0</div></div></div>"},"72987":{"type":"graphic_table","displayName":"Pt selection laser surgery","title":"Patient selection criteria for laser refractive surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient selection criteria for laser refractive surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Age 18 years or older with appropriate expectations</td> </tr> <tr> <td>Stable refraction at least one year</td> </tr> <tr> <td>Myopia between -.50 and -12.00 diopters</td> </tr> <tr> <td>Astigmatism &#8804;5.00 diopters</td> </tr> <tr> <td>Hyperopia &#60;+6.00 diopters</td> </tr> <tr> <td class=\"sublist1_start\">Absence of ocular contraindications:</td> </tr> <tr> <td class=\"sublist1\">Keratoconus, pellucid marginal degeneration, keratoglobus</td> </tr> <tr> <td class=\"sublist1\">Herpetic keratitis</td> </tr> <tr> <td class=\"sublist1\">Progressive myopia</td> </tr> <tr> <td class=\"sublist1\">Corneal disease*</td> </tr> <tr> <td class=\"sublist1\">Glaucoma*</td> </tr> <tr> <td class=\"sublist1\">Cataract*</td> </tr> <tr> <td class=\"sublist1\">Any other preexisting pathology of the cornea or anterior segment, including scarring, lagophthalmos, severe dry eye and blepharitis*</td> </tr> <tr> <td class=\"sublist1_start\">Absence of medical contraindications</td> </tr> <tr> <td class=\"sublist1\">Uncontrolled vascular disease</td> </tr> <tr> <td class=\"sublist1\">Autoimmune disease</td> </tr> <tr> <td class=\"sublist1\">Immunosuppressed/immunocompromised</td> </tr> <tr> <td class=\"sublist1\">Pregnant or nursing</td> </tr> <tr> <td class=\"sublist1\">History of keloids</td> </tr> <tr> <td class=\"sublist1\">Diabetes mellitus</td> </tr> <tr> <td>Absence of use of systemic medication such as isotretinoin, amiodarone</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Determined by ophthalmologist.</div><div id=\"graphicVersion\">Graphic 72987 Version 3.0</div></div></div>"},"72988":{"type":"graphic_picture","displayName":"Lung biopsy cellular NSIP in systemic sclerosis","title":"Histopathology in nonspecific interstitial pneumonia associated with systemic sclerosis (scleroderma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathology in nonspecific interstitial pneumonia associated with systemic sclerosis (scleroderma)</div><div class=\"cntnt\"><img style=\"width:382px; height:254px;\" src=\"images/PULM/72988_Cellular_infiltrate_in_SD_l.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung biopsy from a patient with&nbsp;systemic sclerosis&nbsp;and ground glass opacification on high resolution&nbsp;computed tomography (CT)&nbsp;showing marked interstitial cellular (lymphocytic) infiltration. These changes are consistent with cellular nonspecific interstitial pneumonia (NSIP).</div><div class=\"graphic_reference\">Courtesy of Professor B Corrin, Royal Brompton and National Heart Hospital, London, UK.</div><div id=\"graphicVersion\">Graphic 72988 Version 3.0</div></div></div>"},"72989":{"type":"graphic_table","displayName":"Lasers in dermatology","title":"Clinically used lasers in dermatology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically used lasers in dermatology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Wavelength (nm)</td> <td class=\"subtitle1\">Laser</td> <td class=\"subtitle1\">Indications</td> </tr> <tr> <td>308 (UVB)</td> <td>Excimer (pulsed)</td> <td>Psoriasis, vitiligo, hypopigmentation</td> </tr> <tr> <td>488; 514 (blue-green)</td> <td>Argon (continuous)</td> <td>Telangiectasias, thick PWS in adults, epidermal pigmented lesions</td> </tr> <tr> <td>504-690 (green-yellow-red)</td> <td>Argon-pumped tunable dye (continuous)</td> <td>Telangiectasias, thick PWS in adults, epidermal pigmented lesions, photodynamic therapy</td> </tr> <tr> <td>510 (green)</td> <td>Flashlamp-pumped dye (short-pulsed)</td> <td>Epidermal pigmented lesions, red tattoos</td> </tr> <tr> <td>511 (green)</td> <td>Copper vapor/bromide (pseudo-continuous)</td> <td>Epidermal pigmented lesions</td> </tr> <tr> <td>521; 531 (green)</td> <td>Krypton (continuous)</td> <td>Epidermal pigmented lesions</td> </tr> <tr> <td>532 (green)</td> <td>KTP (pseudo-continuous)</td> <td>Telangiectasias, thick PWS in adults, epidermal pigmented lesions</td> </tr> <tr> <td>532 (green)</td> <td>KTP (long-pulsed)</td> <td>Telangiectasias, PWS in adults, epidermal pigmented lesions</td> </tr> <tr> <td>532 (green)</td> <td>Frequency-doubled Q-switched Nd:YAG (pulsed)</td> <td>Epidermal pigmented lesions, red tattoos</td> </tr> <tr> <td>568 (yellow)</td> <td>Krypton (continuous)</td> <td>Telangiectasias, thick PWS in adults</td> </tr> <tr> <td>578 (yellow)</td> <td>Copper vapor/bromide (pseudo-continuous)</td> <td>Telangiectasias, thick PWS in adults</td> </tr> <tr> <td>585-600 (yellow)</td> <td>Flashlamp-pumped dye (long-pulsed)</td> <td>PWS, PWS in children, telangiectasias, warts, hypertrophic scars, striae</td> </tr> <tr> <td>694 (red)</td> <td>Q-switched ruby (short-pulsed)</td> <td>Epidermal and dermal pigmented lesions; blue, black and green tattoos</td> </tr> <tr> <td>694 (red)</td> <td>Ruby (long-pulsed)</td> <td>Hair removal, dermal pigmented lesions</td> </tr> <tr> <td>755 (near infrared)</td> <td>Q-switched alexandrite (short-pulsed)</td> <td>Epidermal and dermal pigmented lesions; blue, black and green tattoos</td> </tr> <tr> <td>755 (near infrared)</td> <td>Alexandrite (long-pulsed)</td> <td>Hair removal, thick vascular lesions</td> </tr> <tr> <td>800; 810 (near infrared)</td> <td>Diode (long-pulsed)</td> <td>Hair removal</td> </tr> <tr> <td>1064 (near infrared)</td> <td>Q-switched Nd:YAG (short-pulsed)</td> <td>Dermal pigmented lesions; blue and black tattoos</td> </tr> <tr> <td>1064 (near infrared)</td> <td>Nd:YAG (pulsed)</td> <td>Hair removal, vascular lesions, leg veins, laser-assisted liposuction</td> </tr> <tr> <td>1064 (near infrared)</td> <td>Nd:YAG (continuous)</td> <td>Deep coagulation of tissue</td> </tr> <tr> <td>1320 (near infrared)</td> <td>Nd:YAG (pulsed)</td> <td>Skin rejuvenation, acne scars (subtle)</td> </tr> <tr> <td>1450 (near infrared)</td> <td>Diode (pulsed)</td> <td>Sebaceous hyperplasia, acne</td> </tr> <tr> <td>2940 (mid-infrared)</td> <td>Er:YAG (pulsed)</td> <td>Skin resurfacing, tissue ablation</td> </tr> <tr> <td>10,600 (far infrared)</td> <td>Carbon dioxide (continuous; pulsed)</td> <td>Coagulation, vaporization and cutting of tissue; skin resurfacing</td> </tr> <tr> <td>500+ (visible to near infrared)</td> <td>Intense pulsed light (pulsed)</td> <td>Vascular lesions, epidermal pigmented lesions, hair removal, photorejuvenation</td> </tr> <tr> <td>810; 940; 980; 1064; 1320 (near infrared)</td> <td>Endovenous Laser Therapy</td> <td>Varicose vein destruction, especially greater saphenous vein </td> </tr> <tr> <td>1320; 1440; 1540; 1550</td> <td>Fractionated, non-ablative</td> <td>Photorejuvenation, scars, striae</td> </tr> <tr> <td>2790; 2940; 10,600</td> <td>Fractionated, ablative</td> <td>Photorejuvenation, wrinkles, scars</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 72989 Version 1.0</div></div></div>"},"72990":{"type":"graphic_diagnosticimage","displayName":"CT of a peripheral 2 cm nonmucinous adenocarcinoma in situ","title":"CT of a peripheral 2 cm nonmucinous adenocarcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of a peripheral 2 cm nonmucinous adenocarcinoma in situ</div><div class=\"cntnt\"><img style=\"width:442px; height:277px;\" src=\"images/ONC/72990_CT_periph_2_cm_nonmuc_AIS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial CT section.<br />(B) Coronal maximal intensity projection (MIP) image shows a pure ground-glass nodule in the left lower lobe. Vessels and lung architecture are seen through the nodule.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72990 Version 10.0</div></div></div>"},"72994":{"type":"graphic_figure","displayName":"Correct position forceps","title":"Correct placement of the forceps blades on the fetal head","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Correct placement of the forceps blades on the fetal head</div><div class=\"cntnt\"><img style=\"width:454px; height:319px;\" src=\"images/OBGYN/72994_Correct_position_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Scott JR, Gibbs RS. Danforth's Obstetrics and Gynecology,&nbsp;9<SUP innerHtml>th</SUP> ed,&nbsp;Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 72994 Version 2.0</div></div></div>"},"72996":{"type":"graphic_picture","displayName":"Hamartoma with fat","title":"Pulmonary hamartoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hamartoma</div><div class=\"cntnt\"><img style=\"width:414px; height:270px;\" src=\"images/PULM/72996_Hamartoma_with_fat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows a pulmonary hamartoma composed largely of fat. An elongated cleft lined by respiratory epithelium (arrow) is visible at the left.</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 72996 Version 1.0</div></div></div>"},"72997":{"type":"graphic_waveform","displayName":"Advanced case 6","title":"Advanced case 6","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 6</div><div class=\"cntnt\"><img style=\"width:540px; height:319px;\" src=\"images/CARD/72997_Advanced_case_6.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 72997 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75Â°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"72998":{"type":"graphic_diagnosticimage","displayName":"Lymphoma colon CT","title":"Colonic involvement with lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Colonic involvement with lymphoma</div><div class=\"cntnt\"><img style=\"width:407px; height:251px;\" src=\"images/HEME/72998_Lymphoma_colon_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography scan of the lower abdomen (with oral contrast, arrow) in a patient with B-cell non-Hodgkin lymphoma shows an area of asymmetric bowel wall thickening (arrowhead) secondary to lymphomatous involvement.</div><div class=\"graphic_reference\">Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.</div><div id=\"graphicVersion\">Graphic 72998 Version 4.0</div></div></div>"},"72999":{"type":"graphic_picture","displayName":"Red blood cell EM","title":"Normal red blood cell","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal red blood cell</div><div class=\"cntnt\"><img style=\"width:302px; height:252px;\" src=\"images/HEME/72999_Red_blood_cell_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron microphotograph of a normal adult human red blood cell. Note the biconcave disc shape, which gives the cell more surface area than a sphere of identical volume. The normal red cell is thinnest in the center, resulting in the central pallor seen on the peripheral smear.</div><div class=\"graphic_reference\">Courtesy of Stanley L Schrier, MD.</div><div id=\"graphicVersion\">Graphic 72999 Version 1.0</div></div></div>"}};